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Introduction: Guidelines for the use of flow
cytometry in immunology
The marriage between immunology and cytometry is one of the
most stable and productive in the recent history of science. A
rapid search in PubMed shows that, as of July 2017, using “flow
cytometry immunology” as a search term yields more than 68 000
articles, the first of which, interestingly, is not about lymphocytes.
It might be stated that, after a short engagement, the exchange
of the wedding rings between immunology and cytometry offi-
cially occurred when the idea to link fluorochromes to monoclonal
antibodies came about. After this, recognizing different types of
cells became relatively easy and feasible not only by using a sim-
ple fluorescence microscope, but also by a complex and sometimes
esoteric instrument, the flow cytometer that is able to count hun-
dreds of cells in a single second, and can provide repetitive results
in a tireless manner. Given this, the possibility to analyse immune
phenotypes in a variety of clinical conditions has changed the use
of the flow cytometer, which was incidentally invented in the late
1960s to measure cellular DNA by using intercalating dyes, such
as ethidium bromide.
The epidemics of HIV/AIDS in the 1980s then gave a dra-
matic impulse to the technology of counting specific cells, since it
became clear that the quantification of the number of peripheral
blood CD4+ T cells was crucial to follow the course of the infec-
tion, and eventually for monitoring the therapy. As a consequence,
the development of flow cytometers that had to be easy-to-use in
all clinical laboratories helped to widely disseminate this technol-
ogy. Nowadays, it is rare to find an immunological paper or read a
conference abstract in which the authors did not use flow cytom-
etry as the main tool to dissect the immune system and identify
its fine and complex functions. Of note, recent developments have
created the sophisticated technology of mass cytometry, which is
able to simultaneously identify dozens of molecules at the single
cell level and allows us to better understand the complexity and
beauty of the immune system.
However, the moon has a dark side. The main strengths of this
technology, i.e. the fact that it is relatively easy to use and that
often only a brief training is sufficient to use a flow cytometer and
start producing data, is also its main weakness. Indeed, in sev-
eral (too many) papers, the eye of a well-trained cytometrist can
identify aspects that would need, to be polite, a “little” improve-
ment. Not to mention the cases in which technical mistakes are
performed, involving, among others, the use of (in)adequate con-
trols, the (lack of appropriate) compensation, sorting strategies,
or even the description of the methods used.
For this reason, the editorial team of the European Journal of
Immunology feels it is worthwhile to offer our community guide-
lines for the correct use of cytometric techniques in the field of
immunology. Thus, starting at the European Congress of Immunol-
ogy (ECI 2015) in Vienna (Austria) and under the guidance of
Professor Andreas Radbruch, we asked colleagues and friends, all
renowned in this field, to contribute by sharing their knowledge in
their particular areas of expertise, in order to present a collection
of protocols of great interest. Such information includes, among
others, suggestions and tricks regarding how to study cell pheno-
types, the type or amount of molecules produced or secreted after
stimulation by a cell population of interest, signalling processes,
differentiation, proliferation or cell death, cytotoxic activities, cell-
cell interactions, activity of intracellular organelles such as mito-
chondria, different types of response induced against tumours or
by anticancer or immunosuppressive drugs, transcription factor
activity, the quantification of soluble molecules, drug uptake, and
rare events.
Today’s challenges also involve the choice of reagents, the
preparation and eventual storage of the cells under analysis, the
overall experimental plan and, last but not least, data analyses.
We are no longer limited by complex instrumentation, but by our
creativity to ask the critical questions.
These “Guidelines for the use of flow cytometry and cell sorting
in immunological studies” thus represent a community effort to
collect the currently accepted best methods for monitoring most
of the variation of the major players of immune system (along
with their organelles and functionality) and include standards for
data interpretation, as well as cautions about technical issues.
One aspect of the guidelines concerns data reproducibility, a topic
that has recently attracted considerable attention. Therefore, the
guidelines are meant to help researchers avoid potential pitfalls
that could drastically alter the interpretation of their data.
While preparing the guidelines, feedback was received that
we feel should be highlighted in this Introduction. Firstly, “FACS”
(fluorescence activated cell sorting) should only be used for Becton
Dickinson (BD) technologies as it is a BD trademark (FACSTM); the
more general term “flow cytometry cell sorting” should be used to
be company agnostic. Secondly, CD mAbs and not anti-CD mAbs
(in other words CD1 mAb and not anti-CD1 mAb, for example)
should be used. This is because the CD nomenclature is primarily a
system to cluster/characterize mAbs and it was only later accepted
to use this system to also describe the respective CD molecules.
Thirdly, although the guidelines are as comprehensive as possible,
there are naturally limitations e.g. only a subset of antibodies and
antigens are shown and, at times, only certain reagents/companies
are used as examples.
It is our opinion that all efforts must be improved—this is how
science works! Thus, we would be glad to receive from readers of
the European Journal of Immunology critical comments, new ideas,
and even suggestions for new articles for possible future updates of
the Guidelines. Before closing, we would like to thank four people
who played a major role in ensuring that Andreas Radbruch’s
and Andrea Cossarizza’s vision became a reality. These are Hyun-
Dong Chang and Ute Hoffman, both at the DRFZ, and Karen Chu,
former Associate Editor, and Cate Livingstone, Managing Editor
of the European Journal of Immunology. Together this core team
coordinated author invitations, and the submission, peer review
and revision of all the sections and proofs, as well as ensuring
that community feedback was sought and incorporated. We would
also like to thank the full editorial team of the European Journal
of Immunology for their invaluable work on this project.
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I. Cytometry equipment
1. Fluidic system of a flow cytometer
1.1 Purposes of the fluidic system of a flow cytometer
To accurately measure optical properties of cells with a flow
cytometer, cells have to pass through the uniformly bright cen-
ter of focused laser beams. Light collection optics is focused on
the intersection point of cells with the laser beams to pick up fluo-
rescence and scattered light from cells. This is the sensing zone of
a flow cytometer, here the measurements of cell parameters are
taken. In a stream-in-air cell sorters, the sensing zone is located
around 0.3 mm under the nozzle tip, in other cytometers it is
located inside a cuvette.
One purpose of the fluidic system is to move the cells one by
one precisely through the sensing region in a liquid stream in such
a way that each cell is illuminated by the same amount of light
from the lasers.
In cytometers with sort capabilities or cell sorters, the fluidic
system has to establish a stable break off of the liquid stream in
small uniform droplets. Droplets containing the cells of interest
can be charged and deflected in an electric field for sorting.
This kind of cell sorting technique was invented by Mack
J. Fulwyler in 1965 at Los Alamos National Laboratory [1].
Mack Fulwyler needed a machine for testing the performance
of Coulter counters, so the first particle separator was used
for sorting of particles with different Coulter volumes. Len
Herzenberg was interested in a machine that can sort living
cells on the basis of fluorescence, he got the design plans of
the particle separator from Mack Fulwyler and found a little
group at Stanford University to build the first FACS in the late
1960s (see the video Inventing the Cell Sorter, Herzenberg Lab,
https://www.youtube.com/watch?v=Ro8P3w9BPhg).
1.2 Hydrodynamic focusing
For precise positioning of cells in a liquid jet the hydrodynamic
focusing technique is used in most cytometers and cell counters
[2].
The cells in suspension are injected by a thin tubing in a laminar
flow of a sheath fluid that enters from a wide tubing into a narrow
tubing or small orifice. The sheath flow speeds up when it enters
the narrow tubing and the diameter of sheath and sample flow
(sample core) is decreased (Fig. 1). Crosland-Taylor described
this technique first in Nature 1953 [3] and used it in a device for
counting small particles suspended in a fluid. Some years before in
1947, F.T. Gucker used a similar technique for detecting bacteria
in a laminar sheath stream of air [4].
The hydrodynamic focusing takes place in the so-called flow
chamber or flow cell of a cytometer. A detailed description of
an optimized flow chamber for a stream-in-air cell sorter can be
found in the patent applications from Gerrit van den Engh [5, 6]
Figure 1. Sample core after hydrodynamic focussing by laminar sheath
flow in a flow chamber.
and a flow chamber of a cuvette system is found in another patent
application from BD [7].
In addition to flow chambers for laser based cytometers,
flow chambers with hydrodynamic focusing for cytometers with
an arc lamp light source were developed. These early cytome-
ters are based on a standard fluorescence microscope with epi-
fluorescence setup. Here the same microscope lens is used to bring
excitation light to the cells and take fluorescence emission from
the cells. Excitation and emission light is separated by a dichroic
mirror and special filters. With an immersion microscope lens of
high numerical aperture, a stabilized arc lamp and optimized stain-
ing protocol, DNA histograms with coefficient of variations (CVs)
lower than 1% (0.50–0.7%) were achieved [8, 9].
With the hydrodynamic focusing technique, cells can be aligned
to a precision of one micrometer. With high sample flow rates the
sample core is increased, however, and cells in the sample core
can move out of the focus center of the laser. Thus, not all cells
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Figure 2. Intensity profile of a focus spot of a gaussian laser beam. Note: if a cell is out of the center of the laser focus by 10 μm (20 μm sample
core), laser intensity goes down about 5% with a 60 μm diameter laser focus.
get the same amount of laser illumination. This means that the
accuracy of measurements is lost.
To avoid loss of measurement precision when the sample core
increases and to maintain laser intensity, cytometers use elliptical
laser focus spots. Typical sizes of focus spot are 60–150 microme-
ters horizontally and 5–20 micrometers vertically. Recently, beam
shaping optics for flat top focused laser beams were introduced
in flow cytometers by the manufacturer. The intensity profile of
a gaussian laser beam with 60 100, and 150 micrometer focus
diameters is shown in Fig. 2.
An approximation of the sample core diameter d in microme-
ters is given in [10]:
d = 1.13 ∗ 1000 ∗ 2
√
u/nv
with u = particle measurement rate in particle per second, n =
particle concentration in particle/mL, and v = jet velocity in m/s.
An approximation of the jet velocity is given by
v = 3,7 ∗ 2
√
delta P
with v in m/s and delta P, the sheath pressure drop at the nozzle
in psi (in practise around the pressure on the sheath container
minus 1 to 3 psi pressure drop on tubings and sterile filter).
The approximation of the sample core diameter calculation
shows that for a ten times lower sample concentration a more
than three times bigger sample core diameter is necessary to keep
the particle measurement rate.
For the sheath fluid, PBS (phosphate buffered saline) filtered
through a 0.22 or 0.1 micrometer filter is often used. The sheath
fluid should be compatible with cells or species that have to be
sorted.
1.3 Acoustic focusing of particles in a liquid stream
An acoustic focusing technology was developed by Gregory
Kaduchak and co-workers at the Los Alamos National Laboratory
in 2001 and introduced to flow cytometry [11, 12]. Recently,
the acoustic focusing technique was implemented into a flow
cytometer to support hydrodynamic focusing. This technique helps
to increase measurement precision in particular if wide sample
cores are used. According to the manufacturer, cytometers with
acoustic-assisted hydrodynamic focusing can run samples with low
concentrations of cells up to 10 times faster as compared with
cytometers without and still maintain the precision of themeasure-
ments. The fundamentals of acoustic cytometry are given in [13].
1.4 Droplet generation of a cell sorter
Based on the invention from Richard Sweet [14], droplet forma-
tion of the liquid jet of a cell sorter is stabilized by vibrations of
an ultrasonic transducer.
Little disturbances on the surface of the liquid jet at the exit
of the nozzle orifice are generated by the transducer. The distur-
bances grow exponentially and lead to break up of the jet in little
droplets [2, 10]. A cell of interest that should be sorted is measured
at the sensing zone and moves down the stream to the breakoff
point. During the separation of the droplet with the cell in it from
the liquid jet, a voltage pulse is given to the liquid jet. So electrons
are caught with the cell in a droplet and cannot go back when the
droplet is separated from the liquid stream and the voltage pulse is
shut off. The droplet with the cell is charged and can be deflected
in a static electric field of two deflection plates for sorting (Fig. 3).
It is important for the sorting process that the cell of interest is
at the right place when a voltage pulse is given to the liquid jet to
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Figure 3. Liquid stream of a jet in air sensing cell sorter. Depending
of abort settings of the cell sorter, cells that are too close together are
aborted from sorting. Reproduced with permission from [15].
charge a droplet. The delay from the measurements of cell param-
eters to the charging pulse is determined by the cell sorter operator
or by the cell sorter electronics. This is done with the help of fluo-
rescence beads and a laser beam under the deflection plates. The
laser beam illuminates the streams of deflected and un-deflected
droplets. The fluorescence beads are sorted all in one direction,
and with a camera, the fluorescence in the droplet streams is
observed on a monitor. During observation of the fluorescence
spots the drop delay is changed so that the brightness of the flu-
orescence spot of the deflected droplet stream is maximized and
the brightness of the fluorescence spot of the un-deflected droplet
stream is minimized. The distance from the sensing zone to the
break off point is controlled by a microscope and held constant.
The delay setting is fixed during sorting and in general the
break off distance is kept constant by the operator. If the velocity
of the liquid jet is constant during sorting the sorting works fine,
but in practice this is not always the case. Small changes of sheath
pressure for example due to partial clogging of the sheath filter
can alter jet velocity during sorting. Timothy Petersen and Gerrit
van den Engh have examined the problem and showed how little
variations of sheath pressure can disturb the sorting process and
how the operator can handle it [16]. Toralf Kaiser examined how
temperature changes of sheath fluid alters sorting performance
and gives a solution for stabilizing sheath fluid temperature [17].
A schematic of a typical fluid system of a cell stream-in-air
sorter is shown in Fig. 4.
2. Optics and electronics
2.1 Introduction
From a technical point of view a flow cytometer is a light detection
device capable of detecting photons of different wavelengths over
a high dynamic range. In order to achieve a high dynamic range,
the optics, signal detection, and processing units must be carefully
designed.
2.2 Optics
2.2.1 Lenses. In flow cytometers, lenses are used to collect light
emitted from the cell of interest, i.e. due to their spatial resolu-
tion they collect light only from the point of interest. Furthermore,
they are used to make the collected light parallel in order to direct
it through the optical bench to the detectors. A flow cytometer
employs collection and collimation lenses. Collection lenses (con-
vex lenses) are used to focus the light from the interrogation point
either to the end of an optical fiber or directly to a collimation lens
(e.g. aspheric condenser lenses). Some instruments use optical
fibers to route the detected light to detectors which are installed
in an octagon. In this case a collimation lens is installed at the
other end of the fiber to ensure that all light is routed parallel
through the octagon. Inside the octagon another collimation lens
is placed in front of each detector to focus the parallel light onto
the photocathode. In instruments without fiber optics the parallel
light is routed through the optical bench and then focused onto
the photocathode by a collimation lens.
2.2.2 Optical filter. The photodetectors used in flow cytometers
are spectrally broadband and therefore unable to generate a signal
exclusively from specific wavelengths and thus specific markers.
To add specificity, optical filters and dichroic mirrors are used in
a well defined manner to route the light to the detectors.
Optical filters are designed as band pass (BP), long pass (LP),
or short pass (SP) filters and are mostly installed in front of the
light detectors. The common property of the filters is that they
transmit light only within a spectral range. A BP filter trans-
mits light in a certain range. For example, if the BP is named
as 660/20, this means that light between 650 and 670 nm will
pass through the filter to the photomultiplier tube and all other
wavelengths will be reflected to the next filter set within the spec-
ified laser configuration. SP filters will pass short wavelengths and
block longer ones whereas LP filters will do the opposite meaning
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Figure 4. Schematics of fluidics of a jet in air sensing cell sorter.
that SP and LP filters transmit light below (SP) or above (LP) a
certain wavelength. For example, a LP of 660 nm will transmit
all light above 660 nm. Due to aging, quality of coating, and
contamination, the actual parameter of an optical filter can
differ from the technical description. Therefore, it is recommended
to check the transmission spectra of new filters provided by the
manufacturer and always keep filters dust free.
Sometimes mirrors (usually silver mirrors) are used in the opti-
cal bench of a flow cytometer in order to deflect light for geomet-
rical or constructive reasons. These filters are >99%, reflective
over a wide range of wavelengths. In contrast, a dichroic mirror
deflects light of a certain wavelength while the rest pass-through.
The effect of the dichroic is dependent on the operating angle. In
some instruments, the dichroics employed have a working angle
of 45° whereas others have a working angle of 12.5°.
2.2.3 Dispersing elements. Recently, commercial cytometers
have become available which use spatially dispersing elements
instead of or in combination with optical filters in order to deflect
light wavelength specific to a detector array. The rationale behind
this is the measurement of the entire emission spectra of a cell
(see Section I.3: Flow cytometry, including flow cytometry cell
sorting). A dispersing element can be a dispersive prism or a grat-
ing. Prisms have a higher light efficiency over gratings and they
are not sensitive for polarized light. This maybe the reason why
they are employed in the spectral flow cytometer from Sony.
A dispersing element is installed between the interrogation
point and a detector array.
2.2.4 Laser. Lasers employed for flow cytometers are mainly
solid-state, continuous wave lasers. Such lasers have a small foot-
print and a typical output power range from 20 to 100 mW. Lasers
are coherent light sources which allow a high photon density at
the illumination point, and therefore an efficient energy transfer
to the fluorochrome. Modern cytometers are equipped with up to
seven different lasers in a typical laser line ranging from 355 to
650 nm. This gives high flexibility in choosing the fluorophores.
2.3 Electronics
As a flow cytometer measures the biological information of a par-
ticle (e.g. a cell) via photons, this light needs to be converted to
electrons and processed by an amplifier, filter, analog to digital
converter (ADC), and baseline restorer in order to visualize and
store the biological information of the cells or other particles. In
this section, the main components of cytometer electronics are
briefly described.
2.3.1 Detectors. From a technical point of view, the detection
of cell related light is difficult due to (i) the low light level, (ii)
the high analysis rate, and (iii) the high dynamic range of the
light level. Photomultiplier tubes (PMTs) meet these requirements
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Figure 5. Typical electronic signal processing of a flow cytometer. The
signal coming from a PMT or photo diode is amplified by a preamp and
a main amp. The analogue signals are then digitized by an ADC board.
A personal computer (PC) is used for further data processing and HV
controlling.
and are therefore employed in almost all flow cytometers. PMTs
are vacuum tubes containing a photocathode, electron focusing
electrodes, and a series of dynodes for electron multiplication.
The photocathode converts photons to photoelectrons which are
then multiplied by a series of dynodes driven by a high voltage
(Fig. 5). Photocathodes of PMTs employed in flow cytometers are
made from bialkali material which determines the spectral quan-
tum efficiency η of the PMT, which is the ratio of emitted electrons
to incident photons. The quantum efficiency of the photocathode
is always 0< η <1 and is a function of the light quantum energy
(h*f). A typical PMT (R9220, Hamamatsu) of a cytometer has a
quantum efficiency η = 0.2 at 500 nm and η = 0.09 at 700 nm
which is a reduction in sensitivity of about 7 dB. This means that
the detection of PE-Cy7 is always less sensitive as the detection
of FITC, for example. In many applications, PMTs are increasingly
being replaced, e.g. by avalanche photodiodes due to their higher
quantum efficiency. However, in flow cytometry, only one com-
mercial instrument (CytoFlex, Beckman Coulter) employs APDs in
order to improve the sensitivity for wavelengths >700 nm [18].
2.3.2 Amplifier and signal processing. Amplifiers in a flow
cytometer can be grouped as pre and main amplifiers. Pre-
amplifiers are either voltage (VA) or transimpedance (TIA) ampli-
fiers which are used to amplify the voltage amplitude of a PMT
(VA) or to convert a signal current of a photodiode to a voltage
(TIA). Furthermore, pre-amplifiers perform operations, such as:
 impedance matching
 filtering and pulse shaping
 bandwidth limiting
All amplifiers in a cytometer are analogue hardware devices
which must be very well designed for optimal signal to noise ratios
(SNRs). In a typical cytometer such amplifiers have an SNR of>86
dB. Once the signals are processed by the pre-amplifiers, the main
amplifier moves the signal level to a suitable range for the ADC
(Fig. 5).
In modern cytometers, the conversion of the continuous ana-
log voltage signal into discrete digital values is done by ADCs
which are defined by their sampling frequency and sample res-
olution. The required dynamic detection range (DNR) of a flow
cytometer can be defined as the intensity range of stained and
unstained cells, for example. A stained cell can be 10 000 times
brighter than an unstained cell which gives a DNR of 4 log or 80
dB (DNR[dB]=20log(104)). The DNR of an ideal ADC is given by:
DNR = 6.02*N + 1.76 dB [19].
This means that in theory an ADC with N = 14 bit will have a
DNR of 86.04 dB. In practice, the effective number of bits of an
ADC is, due to noise and distortion of the circuit, some decibels
below the theoretical value (e.g. the ADC AD9240AS of the BD
Diva electronic has 78.5 dB [20]). This limits the dynamic range to
less than 4 decades and, more importantly, shrinks the resolution
of dim signals.
The sampling frequency of the AD9240AS is 10 MHz which
results in 30 samples per measured pulse of a high speed cell sorter
(pulse length = 3 μs). This results in a peak detection error of 1–
2% [21]. Modern ADCs have a resolution of 16 bit and a sampling
frequency of 250 MHz which allows the design of flow cytometers
with dynamic range of >4 decades and a peak detection error of
<0.1%.
In the digital domain the signals are processed by filters, base-
line restorer, pulse height, pulse width algorithms, and trigger (see
Section I.3: Flow cytometry, including flow cytometry cell sort-
ing). Filtering is done to smoothen the raw PMT signal in order to
improve the SNR. The resulting signal consists of an unwanted DC
part due to laser scatter light and electronic noise (among others)
and a specific AC part. Hence, the DC part is subtracted by baseline
restorers to increase the SNR and the DNR of the cytometer. The
baseline restorer attempts to keep the baseline at zero. In practise
however, baseline restoring is not perfect and can lead to negative
values on the histogram axis or introduce a slight distortion of
low signals and therefore to a increased CV of dim signals. After
baseline restoring, the pulse parameters (height, width, and area)
are extracted and converted into a *.fcs file.
Taken together, the analogue and digital components of a flow
cytometer in combination with the baseline and pulse shaping
algorithms need to be well adjusted in order to maximize SNR
and DNR.
3. Flow cytometry, including flow cytometry cell
sorting
3.1 Convention, or fluorescence-activated flow cytometry
and sorting
Since the invention of the first prototype of a Fluorescence Acti-
vated Cell Sorter in 1968 at Stanford University, the technology
has become a powerful tool to analyze and sort individual cells
based on their functional status. Moreover, flow cytometry pro-
vides a robust statistic of thousands of individual cells and can
detect rare events at a frequency below 10–4 cells. The sample
uptake by the instrument can be done from tubes or multi-well
plates at an acquisition rate of thousands of cells per second.
In a typical cytometer, the sensitivity decreases with increasing
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flow rate due to the increasing diameter of the cell stream within
the flow cell. Alternatively, the AttuneNXT (ThermoFisher) uses
acoustic-assisted hydrodynamic focusing which helps keeping the
core stream tight and therefore gives accurate results even at a
much higher sample throughput. Furthermore, the serial acqui-
sition of multiple cell samples can be automated by using high-
throughput platforms (HyperCyt R©).
Today, instruments are available designed to detect up to 27
different bio-markers on an individual cell. Typically thesemarkers
are fluorescently tagged antibodies, molecular sensors, as well as
genetically encoded reporters. For instance, the FACSymphonyTM
(Becton Dickinson) is technically capable of detecting up to 50
parameters of an individual cell. In practice, this high number of
parameters is not achievable because at the moment the range of
appropriate fluorescent dyes is limited.
Technical limitations regarding the maximum number of
detectable markers are also given by the overlap of the emission
spectra of the different fluorescent tags, since each fluorescence
detection channel is correlated to a biological marker. To over-
come this, fluorescent tags became available which have different
excitation wavelengths. Currently, up to seven lasers with emis-
sion wavelengths from 325 to 650 nm are used in order to achieve
a high flexibility in the choice of the fluorescent tags. Furthermore,
tunable lasers are used for special applications like fluorescent life
time measurements (FLIMs).
Flow cytometers use either photomultipliers (PMTs) or
avalanche diodes to convert the emitted or scattered light into
amplified electrical pulses which are processed by appropriate
electronics to extract information like pulse height, area, length,
and time. The electronics of the cytometer consist basically of
a preamp circuit, baseline restoration circuit, and an analog
to digital converter (ADC). In most modern cytometers, the
data post-processing (i.e. pulse integration, compensation, log-
transformation) and data analysis is done in a computer by soft-
ware. All components together must have a low noise level (i.e.
a high SNR) to achieve high instrument sensitivity (Q) and low
background (B) detection.
Avalanche diodes have better detection efficiency in long wave-
lengths and thus a better SNR in that range over PMTs. Fur-
thermore, they open new possibilities for the application of flu-
orescent tags with long-wave emission spectra. Avalanche diodes
are implemented in the CytoFLEX (Beckman Coulter) cytometer.
Within this instrument, the emitted fluorescence light is divided
by a wavelength division multiplexer (WDM) through a series of
band pass filters and integrated optics, onto an array of avalanche
diodes which enables a high sensitivity in the detection of e.g.
PE-Cy7.
Avalanche diodes or PMTs itself are light detectors which are
unsuitable for wavelength detection, hence the fluorescent light
needs to be filtered by optical filters andmirrors. These filters must
be carefully chosen because a multiparameter experiment, i.e. an
experiment in which multiple parameters (markers) are analyzed,
requires that multiple fluorophores are used simultaneously; a
consequence of this is spectral overlap or spillover (see Section
III.1: Compensation).
Conventional flow cytometers circumvent this problem by com-
pensation (see Section III.1: Compensation) in order to accurately
correlate the physical light properties with the biological proper-
ties of the cell. Following this, the data are analyzed in a multi-
variate fashion in combination with a hierarchical gating strategy
(see Section VI.1: Data analysis—An overview, and Section VI.2:
Data analysis—Automated analysis: Automated flow cytometry
cell population identification and visualization).
It is essential to adapt the combination of fluorescent tags to the
given optical, laser, and electronic setup of the instrument to min-
imize spillover, increase Q, and lower B signals. For instance, by
choosing the right concentration of a certain reagent (see Section
IV.2: Titration—Determining optimal reagent concentration), the
fluorochrome related B can be optimized such that it contributes
ideally nothing to the B given by the instrument. This can help to
increase the separation (the distance between themeans) between
a blank and a fluorescent population which is a function of Q and
B. Thus, it requires the characterization of Q and B of the used
instrument.
Mostly polystyrene particles (beads) are used for this purpose
in combination with software based protocols implemented in the
instruments e.g. MACSQuant, Fortessa, Yeti, Cytoflex to name just
a few. Beads are small particles and so to say “cell dummies” of
well defined fluorescent intensity and sizes which also can be used
for PMT voltage optimization, compensation setup, cell counting,
scale calibration and so on.
Scale calibration is an especially useful approach to mea-
sure absolute values (e.g. number of binding antibodies, amount
of fluorescent molecules or photoelectrons) instead of relative
mean fluorescent intensities (MFIs) which leads to quantitative
flow cytometry (see Section VII: Cytometric parameters). Beside
beads, scale calibration can also be achieved by using LED light
pulses. Recently, the quantiFlashTM (APE) tool has become avail-
able which provides ultra stable LED light pulses. Furthermore, by
using this tool, instruments can be compared within or between
labs regarding their Q and B values.
Up to this point, analytical cytometers have been described but
cells can, in addition, be sorted based on specific marker expres-
sion for downstream analysis (molecular biology, sequencing, etc.)
or cell culture (see Section II: Cell sorting).
3.2 Spectral flow cytometry: Principles and evolution
For spectral flow cytometry, the “one detector, one marker”
paradigm is changed. After excitation (A in Fig. 6), the complete
emitted light of a marker (B in Fig. 6) is spectrally dispersed either
by refraction within a prism or by diffraction within a grating (C
in Fig. 6) over a highly sensitive photo detector array (D in Fig. 6).
Gratings are susceptible for polarized light. As polarization occurs
frequently in flow cytometry [22], the total efficiency of a grat-
ing may be reduced. In fact, prisms are better suited for spectral
light dispersion because they have a better light transmission and
are also stable for polarized light. Unfortunately, the dispersion
of a prism is not linear with regard to the wavelength, which
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Figure 6. Principle of a spectral flow cytometer. (A)
Excitation light source (laser), (B) labeled cell, (C)
dispersing element, (D]multichannel light detector
(CCD or multichannel PMT).
makes it difficult to use linear detector arrays such as multianode
PMTs [23].
As mentioned above, multianode PMTs or charge-coupled
devices (CCDs) can be used as detector arrays. CCDs have a high
quantum efficiency of 80–90% in the visible range (500–800 nm)
and a relative long readout time which limits the acquisition rate.
On the other hand, this in combination with high spectral resolu-
tion allows the spectral detection of Raman scattering which is a
characteristic spectrum of molecular vibrations, much narrower
than fluorescence spectra. This allows the application of new
biological markers, such as surface enhanced Raman scattering
tags or near infrared fluorescent dyes [24, 25].
Spectral flow cytometry was introduced in 1979 [26], when
the cytometric measurement of FITC- and PI-labelled mouse cells
was demonstrated using a video camera tube as a detector. More
recently, Robinson et al. developed a single cell spectral flow
cytometer based on a grating and PMT array [27–30]. This instru-
ment created single cell spectra and demonstrated a spectral flow
cytometer based on a 32-channel PMT array detector using a holo-
graphic grating and showed the detection and analysis of labelled
lymphocytes and microspheres in hyperspectral space. Goddard
et al. [31] employed a grating spectrograph attached to an intensi-
fied CCD for measuring microspheres and cells. This spectrograph
was implemented in the optical pathway of a conventional flow
cytometer and was able to take spectra of single cells and micro-
spheres as well as to discriminate free versus bound propidium
iodide.
The first commercially available spectral flow cytometer, the
SP6800, was developed by Sony [32]. This instrument employs a
prism array to disperse the collected light over a 32-channel mul-
tianode PMT. Moreover, the instrument is equipped with 3 lasers
(405, 488, and 638 nm), which allows for full spectral detection of
the resulting emission spectra. The measured spectra from single
cells are subsequently unmixed by using reference spectra of all
used dyes and the autofluorescence spectrum. Least Square Fitting
algorithms are used to calculate the most accurate fit for all refer-
ence spectra, leading to an accurate determination of which dyes
are present on each cell and at which intensity. Using this method,
a complete fluorescence emission is used instead of only a small
portion of emitted light entering a dedicated detector through a
specific set of mirrors and optical filters. This is a major advantage
over conventional flow cytometry, in which light that is lost out-
side of the optical filters also contaminates other channels with
unwanted light which has to be corrected by a subtractive method
(see Section III.1: Compensation). Since dyes frequently used in
flow cytometry have rather broad emission spectra and large spec-
tral overlaps, spectral unmixing can help mitigate this problem.
Therefore, applications for spectral flow cytometry are similar to
those performed on conventional flow cytometers with the addi-
tional benefit of spectral unmixing, which allows spectrally over-
lapping dyes to be measured, and auto-fluorescence subtraction
to be included. Moreover, control of reagents (especially tandem
dyes) is paramount with the increased need for standardization.
Given that spectral flow cytometry shows full spectrum unbiased
data, quality control is more or less integrated.
In this fashion, spectral flow cytometers are designed to mea-
sure the biological information across multiple detection channels,
where the optical configuration can be fixed for all experiments,
giving the added benefit of instrument stability, sensitivity [33],
and easier standardization across instruments, aided by the lack
of individual PMTs and individual optical filters and mirrors.
4. Imaging flow cytometry
4.1 Introduction
Imaging flow cytometers combine conventional flow cytometry
with the additional benefit of imaging each individual cell. By
utilizing the speed and phenotyping ability of flow cytometry
with the imagery of microscopy, it allows a broad range of
applications to be studied that would be impossible using either
technique alone. Imaging flow cytometers are manufactured by
MerckMillipore using technology originally developed by Amnis R©.
Peer review publications using Imaging flow cytometers have
rapidly increased and, with the third generation of the Amnis R©
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Figure 7. Amnis R© ImageStream assays on
immune cells. Autophagy assay on human
peripheral blood mononuclear cells (PBMCs)
showing (A) LC3 puncta in CD8+ PBMCs. (B)
Autolysosome formation by co-localisation of
LC3 and LysoID from untreated cells (con-
trol), cells treated with an autophagy inducer
(Rapamycin) or inhibitor (Chloroquin), is fur-
ther quantified as percentage of cells with a
bright detail similarity (BDS) of >1.5 or >2.
BDS is a feature in IDEAS software that com-
pares the bright detail image detail of two
images to quantify co-localization. (C) Immune
synapse detection between mouse CD90+ T
cells and CD11b+ dendritic cells (DCs) cultured
in vitro. An anti-mouse phalloidin-FITC anti-
body was used to detect synapse formation.
(D) Phagocytosis of FITC-conjugated beads in
humanCD14+ macrophages. (E) Differentiation
of mouse bonemarrow Ly6G+ neutrophils. Cell
were stained with a fixable live dead violet
marker (L/D), anti-mouse Ly6G FITC antibody
andDRAQ5 nuclear stain. Nuclearmorphology,
shown by DRAQ5 staining, indicates the neu-
trophil maturation state.
ImageStream released into the market, the use of the technology
is expected to expand rapidly. Each generation has become faster
with higher resolution, and the addition of a benchtop model has
made imaging flow cytometry more accessible to researchers.
4.2 Imaging flow cytometers
Currently, two platforms are on the market, Amnis R© FlowSight R©
and Amnis R© ImageStream R©X Mark II (Merck Millipore). Both cap-
ture 12 images of each cell, of which 10 can be fluorescent. The
ImageStream R©X Mark II is the larger and more powerful of the
two instruments, with higher resolution, up to ×60 magnification
and seven laser options, compared with ×20 magnification and
the four lasers of the FlowSight R©.
The high throughput cell imaging of these instruments allows
cellular functions, which are often only otherwise measurable by
microscopy, to be investigated. It is very time consuming and user
biased to analyze large number of cells by microscopy, and near
impossible for rare cell types. In addition, the Amnis R© instruments
have been successfully used to investigate many important bio-
logical questions specific for immunology research. Examples of
biological measurements achieved by the ImageStreams include
spot count and co-localization features such as that between LC3
puncta and LysolD to measure autophagy in human peripheral
PBMCs [34] (Fig. 7A and B); identifying and quantifying immune
synapses by the presence of phalloidin in a mask created at the
junction of a DC and T-cell doublet [35] (Fig. 7C); phagocy-
tosis of monocytes measured by quantification of the uptake
of FITC-conjugated beads using a spot count analysis feature
(Fig. 7D); and identification of the differentiation stages in neu-
trophil maturation using nuclear morphology to detect banded
neutrophils through to the fully mature segmented neutrophils
(Fig. 7E).
4.3 Experimental set-up
The antibody panel design guidelines for conventional flow cyto-
metric analysis also apply to Amnis R© instruments. An antibody
panel appropriate for the biological question should be chosen
and selection of the fluorochrome conjugates should take into
account the expression level of the molecules while avoiding
excessive compensation. The software on the Amnis R© instruments
(INSPIRE) and the analysis software (IDEAS) both compensate
effectively; however, fluorochromes requiring little or no compen-
sation should be used to detect proteins in similar locations (for
further information see Section III.1: Compensation). Web based
software can aid in the panel design, such as BD fluorescence
spectrum viewer and Biolegend fluorescence spectra analyzer.
For optimal results, and as for conventional flow cytometry,
antibodies should be titrated when used for the first time on
Amnis R© instruments (more detail in Section IV.2: Titration—
Determining optimal reagent concentration). Since the laser pow-
ers frequently differ from conventional flow cytometers, even
antibodies, which provide optimal cell detection in conventional
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flow cytometry require titration. The imaging component helps
to determine the appropriate concentration and ensures that the
protein is detected in the expected cell compartment.
As for conventional flow cytometry, correct controls (positive
and negative) need to be included, i.e. single-stained cells (or
compensation beads) for compensation, and unstained cells to
determine levels of autofluorescence (more detail found in Sec-
tion IV.1: Controls: Determining positivity by eliminating false
positives). Positive experimental controls are also vital to assist in
the generation of the best analysis strategy. For example to investi-
gate NFκB translocation, untreated and LPS-treated cells are ideal
negative and positive controls. LPS causes a translocation of NFκB
from the cytoplasm to the nucleus, and hence is an ideal control
to determine and validate the analysis method. After acquisition,
the machines return unused sample, and this could be useful when
setting up a new assay allowing direct comparison of imaging flow
cytometer data to an established technique (i.e. flow cytometry or
fluorescent microscopy).
4.4 Acquisition
The power of each laser can be adjusted on the INSPIRE software
which will alter the signal level. Therefore, when performing titra-
tion experiments, it is important to test antibodies from the same
panel at the same laser power. For example, FITC and PE are both
excited by the 488 nm laser and should be titrated at the same
laser power. This prevents saturation of bright stains when they
are used in combination with dim stains. Data quality is enhanced
when the brightness levels of all probes excited off a single laser
are balanced within one log scale of fluorescence intensity.
Due to long acquisition times and the lack of temperature con-
trol of the machines, fixation of cells is recommended (for further
information see Section IV.6: Cell fixation and permeabilization
for flow cytometric analyses). As cell number is also vital, it is
recommended to run no less than 1×106 cells in 50 μL/sample.
On the ImageStream R©X Mark II, this will produce running speeds
of 400 cells/s on low speed, whereas the Mark II can achieve
speeds of 5 000 cells/s, and maximum acquisition speed of the
FlowSight R© is 4 000 cells/s.
File sizes which are generated after acquisition can be very
large, for example 500 MB for a 10 000 event file. To investigate
rare cell populations several 100 000s of cells may need to be
acquired. Here it would be beneficial to collect data only from the
cells of interest. Thus, the file size becomes manageable and the
analysis is sped up, as it needs to be remembered that the software
is slow when handling large data files.
4.5 Data analysis
Analysis is usually performed using IDEAS, a personal computer-
based free software downloadable from Amnis R© Millipore. FCS
Express (DeNovo software) can be used as an alternative analysis
programme. FCS files and the associated images, in .tif format,
can be exported from IDEAS into FCS Express. The FCS files alone
can also be exported into other data analysis software for flow
cytometry, but would only provide information about fluorescence
intensity and not imaging.
Analysis of a new experiment can be very time consuming, but
once optimized, for example the optimal mask and feature have
been determined, it can be quickly applied to future experiments.
IDEAS has many features to aid new users with analysis, as
well as user defined features for advanced users. The first step
is compensation. Compensation files generated in INSPIRE can
be imported or new ones created using single stained controls.
IDEAS guides the user through the process automatically, select-
ing what it considers as positive events for each channel. This can
be inaccurate, and therefore it is important to check that the cor-
rect population has been selected by clicking on the values in the
compensation matrix and if necessary adjusting the gating in the
compensation graphs.
The simplest way to generate a new analysis method is to use
one of several built-in wizards, such as spot count, internalization,
and co-localization. These guide the user step by step through the
analysis. If no analysis wizard exists, the feature finder wizard is a
useful tool to determine the best feature to use. If this also does not
lead to a useful strategy, one can determine masks and features
manually from the 85 features/channel and 14 function masks
that are available and described in the IDEAS handbook. If several
features are an option for the read-out of interest, the method that
gives greatest separation between positive and negative controls
should be chosen.
Once an analysis method has been developed, samples can
be batch analysed. One should be aware that each sample might
require a different gating. A treatment or activation may change
the properties of the cell e.g. shape and size. Therefore, the anal-
ysis should be checked ensuring the gating is still valid for each
treatment and adjust if necessary. Following analysis, a statistics
report can be then generated of the parameters of interest.
Useful for presentation/publication is the ability to tailor the
image gallery to create the most suitable images/composites
for presentations/publication. The brightness and contrast can
be manipulated for each channel and any background staining
removed. Importantly, changing the way the images are viewed
does not alter the raw data or analysis.
In summary, the Amnis R© technology is a very powerful tool
allowing the combination of imaging and flow cytometry. How-
ever, slow running and long complicated analysis should be taken
into consideration when opting for this technique over conven-
tional flow cytometry.
5. Mass cytometry
5.1 Introduction
Since its introduction in 2009 [36], mass cytometry (or Cytometry
by Time-Of-Flight technology, CyTOF) has pioneered a new era
of high-dimensional single-cell analysis, surpassing the limits set
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Figure 8. Schematic overview of a mass cytometric measurement.
by the availability of spectrally resolvable fluorochromes in con-
ventional flow cytometry [37, 38]. The innovative concept of mass
cytometry is the use of stable rare earth metal isotopes of very high
isotopic purity coupled to antibodies or other target-specific probes
for labeling of single-cell suspensions. These probes are character-
ized by and detected based on the metals’ mass/charge ratios by
inductively-coupled plasma time of flight mass spectrometry [39].
Thereby, it is comparatively easy to perform single-cell cytometric
experiments with currently approx. 40 parameters in a single mea-
surement without the typical obstacles inherent to fluorescence-
based cytometry, such as spectral overlap/compensation and auto-
fluorescence.
5.2 Mass cytometry in biological research
Mass cytometry is ideally applied to research requiring high
parametrization at single-cell resolution, e.g. for resolving cellu-
lar heterogeneity in complex mixtures of cells (such as blood or
tissue cells); complex phenotypes of isolated cell types (such as
T-cell subsets according to intracellular cytokine expression and
chemokine receptor expression) [40–42]; or when a maximum of
information is to be extracted from a given, limited sample, such
as from certain cell cultures, fluids, tissue biopsies, children’s or
certain patients’ blood samples [43–46]. Lanthanide-labeled anti-
bodies used in mass cytometry largely resist the methanol treat-
ment that is used for permeabilization of cells in order to detect
phosphorylated states of intracellular signaling mediators. There-
fore, mass cytometry is a sought-after tool in cell signaling stud-
ies. Mass cytometry also facilitates large-scale immune monitoring
and drug screening in clinical/translational research and systems
immunology.
To date, mass cytometry has been performed not only on
leukocytes from different species including mouse, man, and non-
human primates [47], but also on cell lines and bacteria [48, 49],
and has been used to track metal nanoparticles [49, 50]. Metal-
containing polystyrene beads [51] are used as internal stan-
dards in mass cytometry measurements and could potentially
be modified to work as capture beads for serological analysis
using the CyTOF platform, similar to fluorescence-based Luminex
technology.
5.3 The mass cytometer: Cell introduction and signal
detection
The mass cytometer combines a cell introduction system with a
mass spectrometer consisting of three basic components: the ion
source, the ion analyzer, and the ion detector. Essential parts and
steps of the measurement are summarized in Fig. 8.
During a CyTOF measurement, single cells labeled with metal-
tagged probes suspended in water are injected at a flow rate of
45 μL/min into a nebulizer. Using argon as a carrier gas, the
nebulizer creates an aerosol that is guided into the ion source.
The nebulizer’s orifice of about 80–150 μm diameter limits the
size of cells or particles measurable by mass cytometry.
The ion source of the CyTOF instrument is an inductively cou-
pled argon plasma. At a plasma temperature of approx. 8 000 K,
injected cells are vaporized, and entirely disintegrate into their
atomic, ionized constituents. Thus, each cell generates an ion
cloud that expands by diffusion and enters the vacuum. From
these ion clouds, uncharged materials are depleted by an elec-
trostatic deflector, and low-weight ions, including those of ele-
ments abundant in organic material such as C, O, H, N, and
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Ar (atomic mass less than 80 Da), as well as ions carrying
multiple charges, are filtered out by a quadrupole ion guide,
leaving only heavy-weight single-charged ions to pass on to the
detector.
The ion analyzer of the CyTOF instrument is a time-of-flight
(TOF) analyzer. Ions are accelerated by an electric field of a known
strength, resulting in ions receiving the same energy. Since the ions
all have the same charge, the ions can be separated by their mass
difference. The velocity of lighter ions is higher and they reach
the detector first, followed by heavier (and slower) ions, in the
sequence of increasing ion mass.
The ion cloud of a given cell is measured in small portions,
termed pushes. The CyTOF instrument performs 76 800 measure-
ments (pushes) per second, which means that one mass spectrum
is captured every 13 microseconds. Since the CyTOF technology
focuses on metal isotopes with high atomic mass, only the seg-
ment of the spectrum corresponding to atomic masses higher than
80 Da is taken in consideration. Typically, a single ion cloud is
captured by approximately 10–40 spectra. An electron multiplier
is used for ion detection and consists of a series of dynodes main-
tained at increasing potentials, resulting in serial amplification
of the original signal. The output signal of the detector is fur-
ther amplified and subsequently digitized by an analog-to-digital
converter.
The spectra are then analyzed by two successive integration
steps, to obtain information about the amount of metal associ-
ated with each ion cloud corresponding to a single event. The first
integration is an area under curve calculated over an around 19–
26 nanosecond interval according to the region of a given mass
spectrum and represents the intensity of the peak for a given iso-
tope. The region used for the first integration is determined during
the instrument setup procedure termed mass calibration, using a
tuning solution. The second integration summarizes consecutive
positive peaks corresponding to a single (cell) event. The signal
withmaximumnumber of consecutive spectra is taken as reference
to identify the spectra contributing to an ion cloud representing a
single-cell event.
Finally, the integrated signal intensities obtained for one cell
in the different mass channels are converted into flow cytometry
standard (FCS) 3.0 format files. Thus, mass cytometric data can be
viewed and analyzedmanually using standard flow cytometry soft-
ware packages. However, considering the high complexity of mass
cytometric data, manual data analysis is time-consuming, subjec-
tive, andmaymiss much information contained inmass cytometric
data. It is advisable to employ automated cell clustering, popula-
tion identification and dimensionality reduction techniques such
as principal component analyses (PCA) or t-stochastic neighbor
embedding (t-SNE)-based methods (reviewed in [53–56]) for the
analysis of high-content mass cytometry data (see also Section
VI.1: Data analysis: An overview; and Section VI.5: Data reposi-
tories: Sharing your data). An important point to consider is that
data analyses of a given study more and more often employ sev-
eral algorithms organized in an analysis pipeline, very similar to an
experimental procedure that needs to be described and annotated
in appropriate detail [57].
5.4 Instrumentation
At present, Fluidigm Corp. is the only commercial provider of mass
cytometry instruments and of almost all mass cytometry-tailored
reagents. Mass cytometers can be run in a high-throughput man-
ner by employing either an autosampler suitable for consecutive
measurements of larger number of samples of limited sample size
(from a 96-well plate), or an add-on device which permits acqui-
sition of larger samples of any volume (Supersampler, Victorian
Airship LLC), which is ideally used in combination with sample
barcoding approaches (for more detail see Section IV.7: Barcoding
in cytometric assays). The latest mass cytometer version (“Helios”)
can sample volumes of up to 5 mL.
More recently, mass cytometry has been used for imaging of
tissue sections stained with metal-conjugated antibodies, similar
to those used in immunofluorescence microscopy. The stained sec-
tion is dissected into a series of vaporized samples corresponding
to μm-sized tissue section spots by high-resolution laser ablation;
these tissue section spots are then consecutively analyzed on a
CyTOF instrument [58]. The data of each spot reveal the amount
of metal isotopes that was bound to the spot when the tissue sec-
tion was stained with metal-tagged antibodies. By plotting the
data so that the single-spot data are next to each other in the
order they were originally sampled from the entire tissue section,
highly multiplexed images of the tissue sections are reconstructed.
Similar data can be generated using an alternative approach i.e.
multiplexed ion beam imaging (MIBI) that, does not rely on the
mass cytometry equipment discussed here [59, 60].
More recent mass cytometer versions (CyTOF version 2 and
Helios) do not necessarily require in-depth technical knowledge of
mass spectrometry, as the daily tuning and instrument alignment is
largely performed automatically. However, it is advisable to have
the instrument maintained and managed by an expert operator.
The installation of a mass cytometry platform usually requires the
additional set-up of air conditioning, an exhaust system, argon gas
supply and an IT infrastructure suitable to store and manage mass
cytometry data.
5.5 Bottlenecks in mass cytometry
While the advantages of mass cytometry are striking for various
applications, it should be noted that due to the destruction of
the cells in the argon plasma, CyTOF instruments cannot recover
the original cell sample for subsequent experiments. Instrument
sensitivity, cell throughput and recovery should be taken in con-
sideration when planning a study involving mass cytometry.
Cells labeled with metal-conjugated antibodies usually deliver
signal intensities sufficient for gating and quantitative analyses.
At least later-generation mass cytometers have a manufacturer-
specified dynamic range of 4.5 orders of magnitude, which is com-
parable to fluorescence-based flow cytometry. The variability in
sensitivity for the detection of different reporters is lower in mass
cytometry compared with that in flow cytometry. However, mass
cytometry currently lacks reporters which provide a specifically
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“bright” signal such as PE in conventional flow cytometry [38], due
to an upper limit of metal ions which can currently be loaded onto
a probe (140 lanthanide ions per antibody using MAXPAR label-
ing kits [61]). In addition, of any 10 000 heavy metal ions of the
CyTOF detectionmass range injected, only about 3–10 are counted
by the instrument [62]. These limitations are in part compensated
for by the lack of inherent biological background (no “autofluo-
rescence”) and the absence of compensation of signal spillover,
which both can negatively impact fluorescent flow cytometry
data. However, this principally does not protect from background
signals due to unspecific binding of metal-labeled probes to cells.
Significant background binding of MAXPAR-labeled antibodies
has been reported for fixed eosinophils, which could be eliminated
by pre-incubation with heparin [63]. In theory, sensitivity could
be improved by hardware design, allowing for the detection of
more of the injected target ions, and by the use of probes that carry
more metal per specific probe, such as heavy metal nanoparticles
[64–66].
The volume of a single-cell derived ion cloud expands by dif-
fusion to approximately 2 mm in size, restricting the instrument’s
throughput to1000 cells per second. A lower throughput (<500
events per second) usually delivers data comprising fewer doublet
events. Thus, in contrast to most fluorescence-based flow cytome-
ters with event acquisition rates of usually up to 10 000 events
per second, acquisition times in mass cytometry are significantly
longer and might necessitate pre-enrichment of target cells prior
to mass cytometric analysis [67]. In addition, a CyTOF measure-
ment recovers data for about 30–50% of the injected cells, while
the remaining sample is lost, e.g. by accumulating on the walls of
the spray chamber.
Mass cytometers need to be set up and tuned daily (procedure
detailed in [68]). Although the tuning process is designed to con-
fer stable instrument performance during day-to-day operations,
slight differences in e.g. oxide formation can remain and in theory
cause batch effects. The impact on data of such signal variability in
datasets can be counteracted by data normalization using metal-
containing beads as an internal standard spiked into cell sam-
ples [69], and by sample barcoding (described in greater detail
in Section IV.7: Barcoding in cytometric assays) [70–72], which
effectively minimizes technical variability between barcoded and
pooled samples [71].
5.6 Experimental workflow, reagents, and controls
The experimental workflow for preparing mass cytometry
assays is typically very similar to that for conventional flow
cytometry, except for the strict requirement of cell fixation and
their resuspension in water prior to acquisition on the CyTOF
instrument. Briefly, cells are subjected to cell surface staining
and optional dead cell label incubation, fixed, (usually using
formaldehyde), permeabilized, stained for intracellular antigens
and DNA content, and finally resuspended in water (optionally
supplemented with normalization beads) for injection into the
mass cytometer. Cell-surface and intracellular sample barcoding
solutions are available and can be applied prior to surface staining
or after permeabilization, respectively.
Protocols are available for in-depth surface marker-based
immune phenotyping [73–75], intracellular cytokine staining
[40], tetramer-based detection of antigen-specific T cells [40, 41],
cell signaling analyses based on the detection of phosphorylated
signaling mediators [37, 44, 70], in vitro proliferation assays [76]
and the detection of RNA in single cells [77]. Functional probes
available for mass cytometry include 5-Iodo-2′-deoxyuridine for
assessing cell proliferation [76] and a tellurium-based hypoxia
probe [78].
Mass cytometers do not measure the light scatter parameters
usually employed in flow cytometry for detection of cell events
and separation of cell aggregates. In mass cytometry, cells are
solely detected by the metal associated with them. Nucleated cells
are typically revealed by rhodium- or iridium-based DNA interca-
lators [79], and probes specific to characteristic cell antigens can
be envisaged to reveal non-nucleated cells such as erythrocytes or
platelets. Doublet events can be minimized counteracted in mass
cytometry by (i) filtering cells prior to injection, (ii) avoiding high
cell densities in the injected sample, (iii) excluding cell events with
high DNA signal and/or high “cell length” parameter value by gat-
ing, or (iv) sample barcoding using a restricted barcoding scheme
filtering out doublet events formed between cell of differently
barcoded samples very efficiently [71, 72]. Finally, DNA interca-
lators, cisplatin [80], or metal-loaded DOTA-maleimide [75, 81],
are used for cell viability staining. A typical gating strategy is pro-
vided in Fig. 9.
A central part of any mass cytometry experiment is antibody
panel design, for which various mass tagged-antibodies and pre-
designed panels are commercially available. Antibodies can be
labeled in-house using commercial kits for lanthanides and indium
isotopes or with isotopes of palladium [71] and platinum [61].
Moreover, metal-containing nanoparticles such as Qdots contain-
ing cadmium [40, 82] and silver nanoparticles [64] have been
successfully employed as mass tags for reporting binding of spe-
cific probes to cells. The design of mass cytometry panels is gen-
erally easier as compared to flow cytometric panels of similar
marker capacity, since signal spillover and sensitivity differences
are comparably minor issues [38]. However, the mere number of
parameters and the implementation of quality control for antibod-
ies [74] both make panel design a significant effort. Panel design
includes optimizing the pairing of specific probes with unique
heavy metal isotopes considering instrument sensitivity for that
particular isotope mass, target antigen abundance, and addition-
ally potential signal spillover. Signal spillover in mass cytometry
can arise from isotopic and elemental impurities of mass tags,
and between adjacent mass channels at high signal abundance
(usually M±1 spillover), and because of metal oxide formation
(M+16 spillover) [52, 74]. A careful panel design, an optimally
tuned instrument and highly pure reagents, however, can mini-
mize these spillovers to very low levels that are orders of magni-
tude lower than fluorescent spectral overlaps.
Isotype and fluorescence-minus-one (FMO) controls are
typically used in conventional flow cytometry experiments to
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Figure 9. Typical gating strategy for PBMC analyzed by mass cytometry. Intact cells are identified by staining of DNA. Normalization beads elicit
high signals in defined channels such as 140Ce in the present example. Cells (unless stained with 140Ce conjugated antibodies) do not elicit high
140Ce signals, and beads do not elicit high DNA/iridium signals. Events that appear in the upper right are cell-bead doublets, which could be
either physical aggregates, or due to timely overlapping acquisition of two ion clouds with one cloud representing a cell, and the other one a bead
event. Events not stained in either channel (lower left) are usually debris associated with metal amounts sufficient to be detected by the CyTOF
instrument (first dotplot). Cell events are further restricted to events showing strongly correlating DNA signals according to their 193Ir and 191Ir
staining. Both Ir isotopes almost equally contribute to the natural abundance iridium used in the DNA intercalator. Thus, signals are expected to
correlate. Events with high iridium staining intensity are excluded since the DNAhigh fraction is enriched for cell doublets. This procedure does
not fully eliminate doublets but reliably reduces their presence when barcoding was not used to filter out doublets. However, backgating should
be used to confirm that target cells are not excluded in this step (second dotplot). Gating according to “cell length” or “event length” is often
employed in order to minimize the presence of doublets. The “length” parameters corresponds to the number of spectra which belong to a given
event. Events labeled with large amounts of metal (and doublets) tend to show higher, and those with little metal tend to show lower “length”
values. Upper and lower cell length boundaries are defined in the acquisition software. The length parameter is not indicative of cell size. Again,
backgating should be employed to ensure that target cells are not excluded (third dotplot). Next, dead cells are excluded by gating on 103Rhlow/–
cell events. High 103Rh signals result from stronger labeling of dead cells by 103Rh-mDOTA compared to live cells. PBMC identity is confirmed by
CD45 staining (in-house Pd104 conjugate, fourth dotplot), and CD36 and CD20 staining differentiate betweenmonocytes/dendritic cells and B cells,
respectively (in-house conjugates, fifth dotplot).
distinguish between specific and background signal (for fur-
ther detail see Section IV.1: Controls: Determining positivity
by eliminating false positives). In theory, isotype and FMO
controls (termed in mass cytometry as Signal-minus-one or
Metal-minus-one controls, SMO and MMO, respectively) are
easily applicable to the mass cytometry. However, the sole fact
that, in mass cytometry, typical panels include approximately 40
antibodies renders the routine and consistent realization of these
controls quite complicated, and often unfeasible. Isotope controls
require the use of an antibody with a matching isotype and the
same amount of metal per antibody as the reagent that is to be
controlled, and are presently not commercially available.
As a result of these practical limitations, the SMO/MMO con-
trols are either performed exemplarily or combined, sometimes, in
a metal-minus-many (MMM) strategy, in which a few rather than
individual antibody conjugates are omitted during the staining
procedure, e.g. a group of markers specific to a certain project on
the backbone panel shared between different projects. However,
both strategies deliver only limited control information.
In addition, biological controls are frequently employed to ver-
ify metal conjugate-antibody specificity. Here, the expression of a
givenmarker is evaluated in the same sample on different cell pop-
ulations, or by comparing samples from untreated versus treated
conditions. For example, the expression of CD40L by T cells needs
to be induced in vitro in order to be able to evaluate the perfor-
mance of a CD40L mAb conjugate. Contrary to the impracticabil-
ity of the isotype and SMO/MMO controls, biological controls are
particularly adapted to mass cytometry, since they take advan-
tage of the high dimensional level of the data. Counterstaining
for multiple cell lineage markers in antibody conjugate evaluation
experiments enables the identification of reference cell popula-
tions serving as positive and negative controls for a given anti-
body conjugate in the multitude of populations identifiable by a
40 parameter panel.
Finally, mass cytometry data sets and their evaluation, espe-
cially by computational means, benefit from bundled, batch-wise
sample processing and data acquisition in addition to sample bar-
coding (as opposed to processing and acquiring samples of a given
study one-by-one, on different days over a long period of time) to
achieve the highest levels of data consistency. Therefore, sample
banking and assay automation are actively pursued research areas
in the mass cytometry field.
5.7 Conclusions
Mass cytometry is a new hybrid technology employing principles
of flow cytometry and mass spectrometry. The core technology is
rapidly developing along with bioinformatics and reagent chem-
istry, thereby creating a largely universal and extendable next-
generation platform for high-dimensional single-cell cytometry
applied in translational research, systems biology, and biomarker
discovery.
II. Cell sorting
Introduction to cell sorting
There is great diversity amongst biological cells. Studying the func-
tion of different cell types and subsets often requires the isolation
of many cells of a specific population with a high degree of purity
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Figure 10. Check-list: parameters for selecting a
sorting method. The parameters that affect cell sort-
ing and therefore must be prioritized when choosing
a sorting strategy are shown. Starting from the avail-
able material (amount, fragility), they range from
the mundane cost aspect to practical and method-
ological concerns such as the available time, to the
important experimental approaches regarding what
yield, purity, or versatility is needed for down-stream
applications. Optimization of one parameter may
downgrade another parameter, e.g. a high purity
may be at the expense of a high yield or speed, or
unchanged functionality of the cells may not allow
direct positive selection.
or the isolation of single cells for a better understanding of the
heterogeneity of cells within a subset.
In the following sections, “parallel” and “serial” cell sorting
techniques are discussed, together with both their advantages and
limitations.
Parallel cell sorting (also called bulk cell sorting) is useful when
either simple physical parameters, e.g. size or density, or a very
few cell surface markers can be used to differentiate cell sub-
sets. In particular, magnetic cell sorting techniques (see Section
II.1.2) use the specificity of antibody-staining. As detailed in Sec-
tions II.1.3–1.5, other parallel cell sorting technologies exploit the
characteristics of size, density or sensitivity to hypotonic shock to
isolate large numbers of cells from a biological sample in one step,
often with very simple techniques. With some methods more than
1011 cells can be processed in less than 1 h. This approach is also
useful for reducing the number of cells through pre-enrichment of
specific cells of interest for subsequent processing with serial cell
sorting technologies.
Serial cell sorting technologies use rapid measurements at the
single cell level. This allows the isolation of even very rare cells
from complicated mixtures. Serial cell sorting discerns cell subsets
by staining with combinations of (fluorescently) labeled antibod-
ies. The data are processed in real time, to classify and make
a decision on a cell-by-cell basis about which cell to collect. Cells
can be collected into a tube, a well in a microtiter plate, a chamber
in amicrofluidic device or droplet sorters, and additionally a single
cell in a sub-nanoliter size droplet can be deposited in a specific
spot. Analytical methods for rapid electrostatic serial cell sorting
have been refined to use multiple lasers and more than 18 optical
parameters derived from the reaction of cells with fluorescently
labelled affinity reagents providing diverse excitation and emission
signatures to define very specific subsets with many applications
in immunology (see Section II.2.1). Microfluidic technologies also
allow single-cell sorting based on immunofluorescence and mor-
phological microscopic image analysis. The combination of many
serial cell sorters in a microfluidic chip promises very high sorting
rates (see Section II.2.2). Present serial cell sorters process cells at
rates from a few cells per hour to 105 cells per second depending
on the diverse range of applications being done and the specific
cell sorter configuration being used.
1. Parallel cell sorting
1.1 Introduction and general considerations
Parallel or bulk cell sorting is generally used to isolate a large
number of cells in a batch mode, often as a pre-enrichment step
before a single-cell sort. Parallel sorting uses parameters like cell
size, density, magnetic, or electrical properties. Affinity binding
reagents (e.g. antibodies) for specific cell subsets can be used to
change specific properties e.g. magnetism or density to achieve an
antigen-specific bulk sort.
General considerations: Bulk cell sorting from a cell mix-
ture can be done by many methods, each one having different
advantages and challenges. The main variable parameters to be
considered are specificity, yield, purity, viability, functionality.
Moreover, speed, cost, and consumables for equipment must be
also taken into account (Fig. 10). The importance of the dif-
ferent functional parameters will depend on the specific exper-
imental goals, e.g. very high purity may be essential in many
cases, while yield may be less important, because sufficient mate-
rial is available. Instrumentation features depend on the spe-
cific needs and the experience of the user(s). Figure 10 illus-
trates the various parameters needed in deciding on a sorting
strategy or method. Not always can all parameters be set at
optimal levels simultaneously. For cell isolations, where multi-
parameter sorting is not needed, but where speed is of essence, e.g.
because high numbers of cells must be sorted, bulk cell sorting is
preferred.
Flow cytometry cell sorting, where cells are sorted one-by-
one, is the gold standard for multi-parameter cell sorting. This
procedure yields very high specificity according to one or sev-
eral surface markers, which are made visible by fluorescence-
labeled antibodies. The limitation is mainly the number of cells
which can be sorted during a work-day. Pre-enrichment for
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Figure 11. Improvement of population dis-
crimination after pre-enrichment. Cytome-
ter histograms of unwanted (gray lines) and
wanted (solid green) populations. (A) A large
excess of an unwanted population may create
substantial overlap with the target population,
making it impossible to achieve a good single-
cell sort. (B) After a pre-enrichment bulk sort,
which removes most of the unwanted popu-
lation a good discrimination between the two
populations can be achieved.
subsequent flow cytometry cell sorting is another important appli-
cation of bulk sorting and should always be considered, especially
when the wanted cells are comparatively rare. First, because it
reduces time of the cell sort, and second because it helps to
improve gating quality by eliminating potential fluorescence over-
lap between stained and unstained cells (Fig. 11). An overview
of cell sorting technologies and applications can be found in
[83].
Bulk cell sorting can either use any cell surface marker for
distinction, or use distinct physical properties of cells, such as
density differences (FicollTM isolation), size, plastic adherence,
phagocytic capacity (macrophage enrichment), or sensitivity to
hypotonicity (erythrocyte lysis). Keeping track of cell numbers,
viability, and analyzing the sorted cells before, during and after
any separation is good routine in order to determine cell yield and
cell purity, and to detect any unreasonable cell losses or damages.
Cell “yield” is the fraction of wanted cells in the original mixture
which could be recovered alive after the sorting procedure.
To quantitatively evaluate sorting performance, several calcu-
lations can be performed. The purity, i.e. fraction of positive cells
in the sorted fraction, can be expressed as the ratio of positive
cells and the sum of positive and negative cells. Then, using the
measured purity and yield, the yield for non-target particles, the
negYieldFraction (Fraction = Percentage/100), in the target sam-
ple after sorting can be calculated. This provides a helpful metric
when optimizing a sorting technology. Ideally this number will
be zero, when 100% purity is achieved in the separation. The
negYieldFraction, a measure for how many unwanted cells are
found in the sorted sample, can be calculated by re-arranging the
equation:
Purity Fraction = posFraction ∗ posYieldFraction
posFraction ∗ posYieldFraction + negFraction ∗ negYieldFraction
to obtain
negYieldFraction = posFraction ∗ posYieldFraction ∗ (1.0/PurityFraction − 1.0)
1.0 − posFraction .
Another approach for the evaluation of bulk sorting perfor-
mance is described in [84], where it only uses fractions of cells in
the original and positive fraction and does not need information
Table 1. Example of sort performance metrics. The values for purity,
yield, and the fraction of positive cells in the original sample are
measured and the negative logarithm of negYieldFraction, –log(Y–)
(the underlying equations are detailed in the text (Section II.1.1) and
the logarithm of Fe [84] are calculated
Purity (%) Yield (%) Orig (%) –log(Y–) log(Fe)
95 100 50 1.28 1.28
95 90 50 1.32 1.28
95 10 50 2.28 1.28
99 90 1 4.04 3.99
95.6 90 0.1 4.38 4.34
about the yield of the positive (wanted) population. The enrich-
ment factor Fe in [84] is the inverse of the negYieldFraction, if
the yield of positive cells is 100%. At lower yields there are small
differences between the two metrics. Table 1 provides an example
showing that final purity values alone are not a good measure for
sorting performance (rows 4 and 5 in Table 1), even though it
may be the important measure for biological activity.
1.2 Antibody based bulk cell sorting
Physical properties of cells can be changed by the reaction with
specially tagged affinity reagents like antibody conjugates with
magnetic particles. In this way specific subsets can be isolated
with bulk sorting methods.
1.2.1 Magnetic beads coupled to antibodies. This technique uses
the force of magnetism to sort out cells according to specific cell
surface markers. Several commercial systems are available, which
use either inorganic superparamagnetic or ferromagnetic materi-
als embedded in polystyrene beads or in a matrix such as dextran,
or coated with graphene [85]. Beads in sizes from tens of nanome-
ters up to several times the size of a typical mammalian cell are
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available for bulk cell sorting. The bead-size is not disclosed by
all companies. Cells are incubated with the beads and then drawn
to a magnet of appropriate strength either in a column, tube, or
96-well plate. Nanometer sized beads require high field strength
and field gradients, generally achieved in columns or microflu-
idic channels with optimized ferromagnetic structures. Unwanted
cells are poured off or eluted. In negative selection strategies, all
unwanted cells are labeled, leaving the wanted ones untouched for
downstream applications or a second round of selection by another
surface marker. Several bead or affinity reagent chemistries allow
the detachment from the cells if needed. The bulk sorting method
hinges on the quality of the antibodies used, and the density of
the surface markers on the cells. Cells with a low density surface
marker expression may be more difficult to sort. Rare cell sort-
ing is possible, albeit it may require several rounds of sorting and
intensive washing to remove non-magnetic cells. Bulk sorting with
beads, especially with large beads, cannot distinguish between
high and low expression of a given antigen on the cells. Selec-
tion of a good antibody is crucial for successful sorting, as is the
concentration of beads in the labeling step. Non-specific binding
associated with antibodies clustered on beads has to be addressed
with some reagents and cell types. Nowadays, many kits for sorting
a range of cell types in various species are commercially available.
Custom-made beads may be a choice as well, and are offered by
some companies. Conjugation of antibodies to magnetic beads in
your own laboratory or the use of avidin beads with second-step
labeling with biotinylated antibodies is another option.
Advantages: Fast, high cell numbers, specific, positive and neg-
ative selection possible.
Pitfalls: No distinction of antigen density in sorting with larger
beads (some nanometer-sized colloidal beads show some differ-
ences in magnetic retention in some systems [86]); activation
of cells by bead attachment is possible (must be excluded for
individual down-stream applications). Temperature and duration
for binding must be considered (in the context of phagocytosis,
decreasing possibility of non-specific binding, capping, or efficient
binding kinetics). Note: the sort quality must always be analyzed
to detect possible cell losses and impurities.
Manufacturers: miltenyibiotec.com, Sepmag.eu, stemcell.com,
thermofisher.com, turbobeads.com
1.2.2 Non-magnetic beads coupled to antibodies. Non-magnetic
beads coupled to antibodies (pluribeads R©) use strainers to fish out
cells, attached to large polystyrene beads. The method is based on
the size-enlargement of cells as the beads are larger than cells.
Specificity is achieved by the antibodies and, again, the quality
of the antibodies is important. As beads vary in size, several cell
subsets can be sorted out of a mixture by using different sized
beads for different antibodies. A potential advantage is that the
size of the beads may prevent phagocytic uptake. Beads can be
detached by a special buffer, and sequential sorting is possible.
Advantages: Fast, high cell numbers, specific, positive and neg-
ative selection possible.
Pitfalls: Generally no distinction of antigen density in sorting;
activation of cells by bead attachment/detachment procedure is
possible (must be excluded for individual down-stream applica-
tions); non-specific binding (the sort quality must be analyzed
to detect possible cell losses and impurities). Temperature and
duration for binding must be considered (in the context of phago-
cytosis, decreasing possibility of unspecific binding, capping, or
efficient binding kinetics).
Manufacturer: pluriselect.com
1.3 Methods based on density differences
Cells, organelles, parasites etc. have different densities, and their
density differences can be used for cell separation [87, 88].
1.3.1 Ficoll-PaqueTM, LymphoprepTM. Ficoll-Paque contains
FicollTM, a highly branched polysaccharide, and metrizoate.
LymphoPrepTM replaces the latter with sodium diatrizoate. Side-
by-side comparisons of the gradient media have been done [89].
They have low viscosity, are non-toxic, and can be prepared for
different densities. Ready-made solutions are also commercially
available. Ficoll-PaqueTM gradients are frequently used to separate
peripheral PBMCs versus granulocytes/erythrocytes from whole
blood. Efficient removal of dead cells from a mixture is possible
as well (note of caution: this procedure is stressful for the living
cells). When separating blood, the upper fraction contains both
lymphocytes and other mononuclear cells. Addition of iohexol,
a nonionic X-ray contrast agent, to the gradient medium can
remove monocytes as well [89]. NycoprepTM and OptiPrepTM
are gradient solutions without FicollTM, based on a tri-iodinated
derivative of benzoic acid with three aliphatic, highly hydrophilic
side chains or on iodixanol, respectively. They thus are not based
on a polysaccharide net [90]. From the granulocyte/erythrocyte
mix, neutrophil granulocytes can be isolated further by dextran
sedimentation [91, 92], and erythrocytes lysed by hypotonic
shock (see Section II.1.5).
Advantage: Easy to use, little equipment needed.
Pitfalls: Density for similar cells between species can differ,
(e.g. for mouse, horse, and human lymphocytes [93]); erythro-
cytes and granulocytes can become captured in the upper layer, if
the gradient is overloaded or the blood was frozen. Centrifugation
must be done at room temperature and without brakes. The step
of overlayering blood on the gradient is time-consuming and must
be done with care. Various commercially available systems such as
SepMateTM exist to aid in this, including prepared Ficoll-gradients
in containers to draw blood. Loss of cells and recontamination
when harvesting them from the gradient surface is possible. Cell
activation can be an issue, e.g. when isolating neutrophils [91].
Manufacturers: gelifesciences.com, http://www.stemcell.
com/en/Products/Popular-Product-Lines/SepMate.aspx
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1.3.2 Percoll. A second density separation medium is Per-
coll, made from colloidal nanosized silica particles coated with
polyvinylpyrrolidone [94]. Percoll is non-toxic and has a low vis-
cosity, so cells can be centrifuged at low centrifugal forces. Iso-
osmotic gradients of densities between 1.0 and 1.3 g/mL can be
formed by layering solutions of different percentages of Percoll
in a tube. Cells of differing densities collect at the different inter-
faces and can be taken off. Colored density marker beads made
of SephadexTM are helpful to visualize the density borders in the
gradients.
Advantage: Versatile, as several cell types separate in the dif-
ferent layers in one tube.
Pitfalls: See Ficoll-Paque; cell activation can be an issue and
must be considered.
1.4 Methods based on cell size
Size differences of cells of interest, e.g. erythrocytes, platelets,
leukocytes, or circulating tumor cells (CTCs) in blood, can also be
used for separation.
1.4.1 Filters. Membrane filters are applied in sample de-bulking
as they can separate particles or molecules based on size. The
pore size enables larger cells to be retained on the membrane
and smaller cells to pass through. For example, leukocytes (mean
diameter 8–10 μm) can be isolated from erythrocytes (6–8 μm but
disc shaped) by flowing whole blood through a membrane filter;
back flushing will recover the captured white blood cells. However
classical filter membranes do not have homogeneous and precisely
controlled pore sizes, so the resolving power of this separation is
limited and, due to the material of the filter, the recovery of white
blood cells may be inefficient.
Another separation method based on cell size that targets red
blood cells and platelets specifically uses microfibrated silicon
chips. These feature homogeneously etched slots of a certain size
designed to let erythrocytes pass through under a certain pressure
whilst retaining leukocytes on the surface of the chip. The leuko-
cytes can then be recovered by elution. Early evaluation of this
technology has demonstrated 98.6 ± 4.4% recovery of leukocytes
without bias to any leukocyte subpopulation and 99% removal
of erythrocytes. The enriched leukocytes have over 95% viabil-
ity [95].
Mesh-size based catching of cells from adipose tissue directly in
culture has been demonstrated using various filter materials [96].
Advantages: Easy to use and little equipment is needed.
Pitfalls: Throughput of the filters is limited by surface area and
overload may result in reduced purity and recovery of leukocytes.
So far the commercial devices can only handle up to 2 mL of whole
blood which is sufficient for some cell analysis assays but not
enough for blood transplantation and cell therapy applications.
The recovery of leukocytes is sensitive to the pressure applied—
pushing with higher pressure and higher flow rate may result in
decreased recovery.
Manufacturer: avivabio.com (for microchip devices)
1.4.2 Deterministic lateral displacement. A method of bulk sort-
ing currently under development is based on cell size. There are
several publications reporting a microfluidic device that separates
particles and cells with high resolution [97] and is able to not
only fractionate whole blood components by their sizes [98] but
to also isolate CTCsfrom whole blood [99]. Recent work describes
improvements for the routine use of the technology [100].
The micro-fabricated silicon device consists of a matrix of
obstacles, and the gap and the size of the obstacles are precisely
calculated. When the particle mixture is introduced to the device,
the laminar flow goes through the arrays of obstacles and the
smaller particles will follow the streamlines and the larger parti-
cles will be “bumped” by the obstacles and deflected into a dif-
ferent flow stream. Multiple sections of an obstacle matrix with
varying gap sizes can be built in one device so that multiple sized
particles can be isolated because each sized particle will follow its
own determined path flowing through the device. In theory, there
should be no throughput limitation of the technology as it is a
continuous flow system; however, some surface treatment of the
device may be needed to avoid cell adhesion. The device has little
tolerance to clogging, air bubbles or cell aggregates, as changes
in the fluid flow profile alter the particle travel path and deflect
the flow streams possibly resulting in decreased purity and/or
recovery.
Advantages: High resolution, continuous separation, and hav-
ing the potential to be high throughput, high resolution size-
discrimination with high purity of cell populations with non-
overlapping sizes.
Pitfalls: Clogging with samples with cell aggregates.
1.4.3 Acoustic particle sorting. Particles exposed to an acoustic
field are known to move in response to an applied acoustic radi-
ation force. Numerous researchers have investigated the effect of
acoustic waves on cells and particles in aqueous solution. The
force exerted on a particle by an acoustic field can be described by
the following equation:
Fx ∼ r3Kφ sin(2π x/λ)
where r is particle radius, K is a constant proportional to density
of medium and particle, φ is the acoustic contrast factor (propor-
tional to density and compressibility), and x is the distance from
the pressure node in the direction of the wave [101]. Thus, acous-
tic focusing can be used to separate and position particles based on
size, density, and deformability. The ultrasonic standing wave is
generated by a piezoelectric transducer and resonance vibration
of the microfluidic device made in silicon or glass. The channel
width is designed to match half a wave length resonance of 2
MHz in order to have larger cells “focused” in the middle of the
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channel. Dykes et al. [102] demonstrated the removal of platelets
from peripheral blood progenitor cell product on a microfluidic
device in which an acoustic standing wave is generated in the
fluidic channel. The acoustic pressure pushes leukocytes to the
pressure node located at the center of the channel and leaves
platelets at the side stream going to a waste outlet. Size is a domi-
nant parameter for acoustic cell sorting but not the only parameter
as shown in the equation above. For example, separation of leuko-
cytes from erythrocytes in whole blood is not easily done on an
acoustic device as erythrocytes, though having a smaller diame-
ter, move to the acoustic energy node along with leukocytes as the
erythrocytes have a higher density.
Advantages: Continuous flow—no throughput limitation, label
free.
Pitfalls: The cell moving trajectory in the flow channel is deter-
mined by both the acoustic pressure and the shear pressure so
the flow rate and channel configuration need to be well controlled
otherwise the separation efficiencywill suffer. Due to the heteroge-
neous nature of cells in biological sample and the multi-parameter
physics of acoustic separation, separations have to be optimized
for specific samples. No commercial product is available yet.
1.5 Erythrocyte lysis
Enucleated erythrocytes are more susceptible to hypotonic shock
than nucleated cells. Either a low isotonic Tris/NH4Cl buffer for
several minutes at room temperature or 37°C, or pure water
for several seconds will lyse erythrocytes in cell mixtures. The
latter method is particularly useful for blood, which contains
approximately 1 000 times more erythrocytes than leukocytes.
Several other cell lysis solutions are available commercially as
well [103, 104].
1.6 A historical note
The methods described in Sections II.1.2–1.5 have superseded
older methods to specifically isolate cells, such as panning on
antibody-coated plastic dishes [105], nylon–wool based isolation
of T cells, or sheep red blood cell rosetting followed by a Ficoll gra-
dient [106, 107]. The latter is still commercially available under
the name RosetteSepTM for specific uses, in particular for the
removal of unwanted cells from blood. These older methods are
not discussed here, but they are summarized in [108].
2. Serial cell sorting
2.1 Cell sorting by flow cytometry
Successful flow cytometry cell sorting often requires that more
attention be paid to sample preparation than is typically done
when preparing samples for analysis only. When sorting, the often
challenging objective is to not only separate some sample fraction
in a timely manner such that the sorted output is a pure viable
fraction, but also that the sorted cells be functionally capable, that
they expand well in culture or perhaps be competent to perform
in some other subsequent assay (e.g. produce cytokines or some
other vital cellular function). Another requisite for good cell sort-
ing is to have a proper single-cell suspension, ensuring the best
sample behavior in flow where good doublet discrimination can
be done and with minimal conflict aborts during the sort. How to
best achieve good sample behavior and maximize performance?
2.1.1 Choice of buffers. The most commonly used media/buffers
for processing mammalian cells were designed to work at 1 atmo-
sphere pressure either on a laboratory bench or within a CO2
incubator, yet inside the sample chamber of most cell sorters the
pressure can often exceed 2 to 4 atmospheres depending on the
conditions and nozzle size chosen for the sort. Sample buffers that
historically tend to perform well for sorting such as Dulbecco’s
Phosphate Buffered Saline or HBSS (minus Ca2+ and Mg2+), both
with 10 to 25 mM HEPES and protein (usually 1 to 2% heat inac-
tivated serum or BSA), and more recently BD FACSTM Pre-Sort
Buffer plus from 0.2 to 2% protein (application dependent) are
recommended. Bicarbonate media buffers such as Roswell Park
Memorial Institute (RPMI) or DMEM usually do not make the best
candidates for sample sort buffers or sort collection buffers since
they (i) are a different buffer type than the cytometer’s sheath
buffer (bicarbonate versus phosphate), and (ii) by design require
5% CO2 to maintain physiological pH, and (iii) usually contain
divalent cations (Ca2+ and Mg2+) plus phenol (very fluorescent).
If a bicarbonate media is used, one should be wary and use either
Ca2+ or Mg2+ minus formulas without phenol or mitigate the
undesirable divalent cation side effects for sorting (making the
cells “sticky”) by adding 1 mM EDTA in addition to 25 mM
HEPES and protein. HEPES buffered bicarbonate media has been
reported to be light sensitive [109], and it is generally a good idea
to protect any sample for flow cytometry cell sorting from light.
2.1.2 Considerations for adherent cells and cells isolated from solid
tissues. In preparing adherent cell lines for sorting a common
pitfall is often within the protocol to remove the cells from a
dish using trypsin or trypsin-EDTA and subsequently inactivate
the trypsin by adding back culture media containing a significant
amount of serum. This step is designed to stop the proteolytic
activity of the trypsin and make the cells “sticky” to easily adhere
to a plastic dish when passaging the cells. The opposite effect is
desired for flow cytometry cell sorting, the sample should not be
“sticky” with a tendency to adhere to plastic. As a result, good
flow cytometry cell sorting protocols for adherent cells will typ-
ically either inactivate the trypsin with soybean trypsin inhibitor
or use one of the many available non-enzymatic cell disassocia-
tion buffers (e.g. AccutaseTM); in either case, if the cells grow in
media with serum, the culture should be gently rinsed twice with
Dulbecco’s Phosphate Buffered Saline before disassociating and
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removing the cells from their substrate. Some cell types, when
disassociated with non-enzymatic disassociation buffers that rely
on chelating agents, may show decreased viability as compared
to trypsin disassociation [110]. If there is any doubt, a few sim-
ple pilot experiments designed to determine the best preparation
method for the specific cells in question is often a very good invest-
ment toward successful sorting.
Similarly, isolating cells from any primary tissue for flow
cytometry cell sorting can be very challenging, care should be
taken to ensure the chosen protocol is optimized and tested to not
only provide the intended cells (e.g. regarding isolated dendritic
cells from spleen different protocols can enrich for different phe-
notypes), but helps coerce the cells into a well behaved single-cell
suspension. The highest quality reagents should be used, especially
when using proteolytic enzymes such as collagenase, pronase, dis-
pase, or trypsin since small amounts of contaminants can have
serious undesirable effects resulting in poor sample performance.
Collagenase is dependent on calcium for activation, for example,
and other divalent cations may be activators (Zn2+) or inhibitors
(Mg2+) [111], and care should be taken to ensure any additive
endotoxin levels are as low as possible.
2.1.3 Stickiness to plastic: The menace of cell sorting. When per-
forming bulk sorts and collecting a sorted fraction into a plastic
tube, it is usually best to pre-coat the tube with serum leaving some
at the bottom, or if desired, additionally seed the tube with a small
volume of the sample buffer containing 2 to 10% serum. Adding
unbuffered bicarbonate media to the collection tube and sorting
on top of it runs the risk of high pH conditions causing undesir-
able salts to form while the phosphate and bicarbonate buffers
mix with the cells present, thereby reducing cell viability. When
performing single-cell sorts into a microtiter plate, any media pre-
added to the wells should be HEPES buffered and conditioned
beforehand if possible. Additionally, when sorting onto/into small
targets such as microtiter plate wells extra care should be taken
to ensure the accuracy of the deflected drops during the sort by
choosing an appropriate nozzle size to minimize the effects of cells
on drop breakoff [112] (choose a nozzle at least 5–6 times the cell
diameter as verified under a microscope).
2.1.4 Cell concentrations and sorting rates. Once prepared, the
sample should have a final cell concentration that allows the
desired event rate to be achieved with only a modest differential
pressure on the sample. Increasing the sample rate significantly by
simply forcing more through the system is not recommended. The
sample should be filtered just prior to being loaded onto the sorter
to help ensure no clumps are present and further disperse any
weakly adhered cells. After filtering the sample through a Nitex
nylon monofilament mesh with an appropriate pore size (30 to
50 μm depending on cell size), any samples that tend to dynami-
cally reaggregate during a sort are best dealt with by installing an
in-line nylon sample filter of the same pore size to help prevent
clogs. Generally, since the theoretical sorting efficiency of a single-
cell preparation is that of a homogenous Poisson process [10], the
operational efficiency of the sorter may be estimated by
Efficiency = e−
(
rate × (1.0−fraction)× drop packetfrequency
)
where rate is total events/second, fraction is percent being sorted,
drop packet is the number of drops including any additional
temporal purity mask, and frequency is the drop rate in drops
per second. Normalizing to sorter drop frequency, this means
when sorting a fraction that is 10% of the total at an event
rate of one cell to every 4 to 5 drops, it can be expected to
sort with an efficiency of 80 to 85% when using a single drop
sort.
2.1.5 Purity and doublets. If, after optimizing the sorter during
setup, suddenly the application sorting efficiency is low (higher
than expected conflict abort rate), it is indicative that the sample
is not a monodisperse cell suspension, that cells are likely “sticky,”
adhering to one another during entrainment and not arriving into
the sensing zone as a homogenous Poisson process. This is a very
common scenario withmany cell preparations, especially adherent
and primary cells, and often the sorter performance is blamed
for what is a behavior intrinsic to the sample. Much of the time
this can be significantly mitigated by reexamination of the sample
preparation protocol to discover what might be improved to help
coerce the cells into a well-behaved single-cell suspension. This
often involves the addition of EDTA or DNase etc. to the sample
sort buffer.
Whenever a sorted sample using a purity sort mode (where
system-defined spatial-temporal drop zones in the stream are
examined logically for potential contaminants for each sort event)
is not as highly sorted as desired, the most common reasons are
that either the classification scheme for single cells is not robust
enough and hidden passenger cells are occasionally sorted, or that
there are particles in the stream that are disturbing the droplet
breakoff stability and, as a result, the wrong drops will occasion-
ally appear in the collection tube, or a combination of the two.
Sorters certainly cannot read the operator’s mind and will attempt
to do exactly what they are set up to do so, if a positive selec-
tion from the sorter suffers from disappointing purity, one simple
performance check is enough to sort a completely negative cell
fraction for comparison. If that sorted negative fraction is 99%
pure or higher, yet the positive fraction is only 80 to 95% pure,
then the likely cause is undetected “doublets” due to an insuffi-
ciently constrained single-cell gating strategy. In many flow sys-
tems, doublets tend to align with the doublet figure’s major axis in
line with the partially developed laminar flow and the pulse width
becomes a very useful parameter to help distinguish singlets from
doublets. Other systems, such as the BD FACSAriaTM family that
use fully developed laminar flow in their fluidics design can have
those same doublet figures rotate off axis after entrainment in flow
such that Forward Scatter (FSC) pulse width alone will not detect
enough doublets, and in such cases using both FSC and Side Scat-
ter (SSC) looking at plots of Height versus Width (or Height versus
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Figure 12. PBMC Sort. A PBMC sort on a BD FACSAriaTM where by adding both FSC and SSC Height versus Width plots and carefully gating on
singlets an additional 9% of likely doublets are removed (reproduced with permission from [113]).
Area—but that usually leaves less screen real estate for drawing
gates) will help reveal many more doublets, boosting the purity to
a more acceptable level with careful gating. Figure 12 (reproduced
with permission from [113]) is an example of such a strategy
where pulse geometry gates on both FSC and SSC detect an addi-
tional 9% of doublets that would pass through a standard scatter
gate.
Matching nozzle size to particle size is key, and the general
rule of thumb is that the nozzle should be 4 to 5 times that of the
particles for bulk sorting and 5 to 6 times that of the particles for
plate deposition where accuracy is more critical. Ensure that the
actual cell size is what you expect it to be when choosing a nozzle,
and whenever there is doubt it is very useful to quickly compare to
known bead size standards by simply putting small drops of each
on a microscope slide and checking, not only the size(s) within
the sample but also the quality as the amount of debris should
be low, the number of single cells high, and clumps/aggregates
should be the rare exception rather than the rule. Electrostatic
cell sorters tend to perform very well with monodisperse samples
and struggle with poorly dispersed ones so, as with many other
applications, sample preparation can be the limiting or enabling
step.
The International Society for the Advancement of Cytome-
try (ISAC) Cell Sorter Biosafety Standards were published in
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Figure 13. Staining pattern and gating strategy for a CD34+ enrichment. The cells are stained with CD34-Pe and CD45-APC. For analysis purposes
only, PI was added for post analysis only.
2014 by the ISAC Biosafety Committee [114], and related infor-
mation is readily available and is a highly recommended read-
ing before embarking on any series of cell sorting experiments
including:
1. The ISAC web site (http://isac-net.org) Resources for
Cytometrists → Biosafety
2. CYTO University (ISAC’s on-line portal for cytometry edu-
cation) http://cytou.peachnewmedia.com → Course: Flow
Cytometry Biosafety
2.2 Microfluidic
Recently, microfluidic devices have entered the arena of flow
cytometry and, in particular, cell sorting devices [115–118]. As
these devices also utilize sequential sorting and similar fluores-
cence detection technologies to identify the cells of interest, best
practices for microfluidic devices have a lot in common with
those applicable to droplet sorters. This is especially true for
considerations regarding sample preparation, such as choosing
the right marker panel or appropriate buffer selection as discussed
in the previous section (Section II.2.1). While sequential sorting
Figure 14. Result of a sequential sorting process. 109 total cells have been processed sequentially in 5 hours to a final purity greater than 99%.
Overall 280 000 target cells have been harvested from 800000 target cells starting material, resulting in an overall yield of approximately 35%.
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technologies have a lot in common, there are also some major
differences and knowing and understanding these differences is
key to successful application.
One of the biggest differences is that droplet sorters are
typically operated in resonance [119], whereas many microfluidic
sorters are operated purely on demand [117, 120, 121]. To
explain further, operated in resonance means that the drop-
generating nozzle is running in resonant mode, stably generating
a constant stream of drops. This way, drop volume and spacing
is fixed and cells are randomly “positioned” inside the drops. This
contrasts with many microfluidic sorters, where the displaced
volume can be fine-tuned in size (volume) and time/space
(centering the target cells).
Even though the enabling principles vary, the sorting effect is
mainly generated by displacing a certain volume [120, 122]. Given
that the sort-timing is precise and correct, this volume defines
expected purities and yields of target cells. In an ideal system,
target cells and non-target cells are totally uncorrelated and thus
follow a Poisson distribution [123]. In the case of a “yield sort,”
where all target cell candidates are to be sorted independently of
the non-target-cells nearby, the expected yield is 100% by defini-
tion. The expected purity can be calculated as follows:
Let λT be the average number of target cells per displaced
volume, then the relative number of sort-actuations is defined by
NλT = e−λT . For each displaced volume, there is a chance to catch
a non-target cell, defined by λN , the average number of non-target
cells per displaced volume. With this, the expected purity P can
be calculated to be
P = 1
1 + λN e−λT .
On the other hand, in case of a “purity sort,” every time a second
cell is in close proximity to a target cell, the potential displacement
will be inhibited. Thus, the theoretical purity is 100%, whereas
the expected yield decreases. In this case, the yield calculation is
simply the likelihood of having a single cell within the displaced
volume:
Y = (λN + λT )
1
(λN + λT ) 1! e
(−λN−λT ) = e(−λN−λT ).
Besides the obvious close formal relationship between the two
formulas, it is worth noting that the expected yield in a purity
sort is solely determined by the total cell frequency (λN + λT ) and
not by the target/non-target ratio, whereas the expected purity in
yield sorts is strongly dependent on the target cell frequency.
In order to give a practical example, these two figures are here
calculated for a virtual sorting device assuming that the microflu-
idic sorter:
1. has a sample flow rate of 4 mL per hour and does not require
a sheath to be operated.
2. is able to redirect 100% of the sample stream into the target
cell reservoir for 50 μs and then instantly return the flow back
to the non-sorted fraction.
3. uses a sample with 106 total cells/mL with 0.1% target cells.
This translates to a flow of 1.1 μL per second and cell detection
frequency of 1.1 × 103 total cells per second. Since in this example
Table 2. Expected purities, yields, and processing times for different
starting cell concentrations
Total cells/mL 106 107 108
Purity in Yield Sort [%] 96 69 18
Yield in Purity Sort [%] 96 64 11
Time to process cells 309 31 3:05
0.1% of all cells are target cells, the target cell frequency is 1/s;
resulting in an average time of 1 000 000 μs between target cells
and 900 μs between any two cells. Given that the sorting volume
displacement is done in 50 μs, λT and λN can be calculated as:
λT = 50 μs1 000 000 μs = 0.00005
λN = 50 μs900 μs = 0.056.
Thus the expected purity in a yield sort would be
P = 100%
1 + 0.056 e−0.00005 = 96%.
Similarly the expected yield in a purity sort would be
Y = 100% · e(−0.05605) = 96%.
Using the same calculation for 1 × 107 total cells/mL and
1 × 108 total cells/mL, generates the data presented in Table 2.
The key observation here is that, even though the resulting purity
in the above yield sort example is limited, especially when process-
ing input material with a concentration of 1 × 108 total cells/mL
(Table 2), the enrichment from 0.1 to 18% purity is still 180-
fold. This opens up the opportunity to utilize a sequential sorting
strategy, where a fast yield sort is followed by a purity sort.
When starting the experiment with the higher frequency yield
sort from the above example, the first pass would have theoreti-
cally yielded an 18% pure target cell fraction being processed with
a rate of roughly 100 000 cells per second. If re-suspended again
in the original volume, the second pass is processed with a total
cell count very close to the one in the first example and would
have yielded the target cells in a greater than 99% pure fraction.
The above is demonstrated with a microfluidic sorter using a
MEMS sorting chip in a completely closed cartridge performing a
CD34+ cell enrichment from a non-mobilized donor. As seen in
Fig. 13, the staining pattern and gating strategy is straightforward.
The target cell frequency was determined to be 0.08% and the
total concentration was chosen so that the 109 total cells were
suspended in 10 mL solution. From there, a yield sort was carried
out, with a flow rate of 4 mL/h. The resulting cell processing
rate was 110 000 total cells per second. With a target frequency
of 0.08%, approximately 90 sorting actuations per second were
expected. The enriched cells were then re-suspended in 10 mL
solution and processed a second time for purity. The results are
shown in Fig. 14. As a result of this sequential sorting strategy,
with an overall sorting time investment of only 5 h, a result was
achieved equaling a typical 20 h single-pass sort.
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Figure 15. Spillover and compensation: (A) the emission spectra of PerCP-Cy5.5 and PE-Cy7. (B) Peripheral Blood Lymphocytes stained with
PerCP-Cy5.5 CD4 mAb. The Median Fluorescence Intensity (MdFI) is shown for the PerCP-Cy5.5 and PE-Cy7 detectors without (left) and with (right)
compensation.
Since microchip sorting devices are particularly powerful in
sorting cells gently due to the absence of high shear forces or elec-
trostatic charges, they are ideally suited to follow such a sequential
sorting approach. The rarer the target cell population or the higher
the total cell count, the more advantageous this method becomes.
III. Setup: Instrument setup and quality
control
1. Compensation
1.1 Introduction
In flow cytometry, fluorescence spillover (i.e. which can be over-
come by compensation) is probably the single greatest source of
frustration for the scientist and cause of bad data. Correctly com-
pensating for spillover is critical to accurately identify populations
in multicolor flow experiments. Errors in compensation for one
fluorochrome can be propagated into other detectors resulting
in erroneous “virtual” positive populations or errors in popula-
tion percentages due to incorrect gating. Mastering fluorescence
spillover is much like chess, the rules are simple, but becoming a
skilled practitioner can take some effort. Here the basic concepts
of fluorescence spillover are reviewed and some simple principles
to follow in order to maximize data quality are provided, while
debunking some of the myths that surround this field. For further
information on this subject readers are referred to the following
references [124–127]. In addition, a guide as to the Minimum
Information about a Flow Cytometry experiment has been devel-
oped and vetted by the International Society for the Advancement
of Cytometry (ISAC) [128]. This includes recommendations for
ways to document compensation of complex panels.
1.2 Principle of spillover and compensation
Fluorescence spillover is the amount of signal, measured inmedian
fluorescence intensity (MdFI), that a fluorochrome emits in a sec-
ondary detector specific for a different fluorochrome (Fig. 15A
shows the fluorochrome PerCP-Cy5.5 is spilling into the PE-Cy7
detector [dark red]). This is equivalent to a background in that
detector. We can calculate a spillover value (SOV) of PerCP-Cy5.5
into PE-Cy7 as Y/X × 100% (Fig. 15B, left). Compensation is the
mathematical process used in all flow cytometers and software in
which these SOVs are used to determine a compensation matrix
which effectively subtracts/corrects background due to spillover
in all detectors (Fig. 15B, right).
The accuracy of this correction is totally dependent upon the
accuracy of the SOVs determined from the appropriate single-color
compensation controls. In Fig. 15B, the spillover is correct when
the MdFI [PE-Cy7] of the PerCP-Cy5.5 positive (+) population
is equal to the MdFI [PE-Cy7] of the PerCP-Cy5.5 negative (–)
population. With a few exceptions, the mathematical calculation
of SOVs is the same for all cytometers and flow cytometry software
packages.
1.3 Measuring SOVs/compensation controls
On all cytometers, SOVs should be determined using single-color
compensation controls. Most errors in calculating SOVs are due
to the use of inappropriate compensation controls. A compensa-
tion control should consist of a positively stained population and a
negative or unstained population. The positive and negative pop-
ulations do not need to be run in the same tube. Cytometer and
software protocols will specify what combinations can be used. It
is never good practice to try to run two controls in the same tube,
for example using FITC CD4 mAb and PE CD19 mAb. This makes
the assumption that there is absolutely no antibody bound to the
“negative” cells which is typically not the case.
Many software packages from flow cytometer manufactures
and third party companies have an “auto-compensation” feature.
While these can be very powerful, they are based on automated
gating algorithms in which the software identifies the positive and
negative populations. These gates may not always be appropriate.
It is recommended that for new controls the user confirm that the
software is providing correct gates and results.
In general, correct SOVs can be obtained by following four
simple principles for single-color compensation controls:
1. The fluorescence spectrum of the compensation control
fluorochrome-conjugated reagent should be identical to the
reagent used in the experiment. More specifically, the
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Table 3. The consequences of using positive and negative
populations with differing autofluoresence: Lymphocytes were
stained with diluted FITC CD4 mAb. The MdFI of the CD4+ [Cells (+),
unstained [Cells (–)] cells and unstained beads [Beads (–)] were
measured in the FITC and PE detectors. SOVs were calculated using
positive and negative cells or positive cells and negative beads
Fluorescence (MdFI)
FITC PE SOV
Cells (+) 3 135 903 n/a
Cells (–) 95 78 27%
Beads (–) 107 228 22%
fluorochrome should be identical not similar. For example,
even though Alexa Fluor R© 488 and FITC are spectrally very
similar, an Alexa Fluor R© 488 compensation control cannot be
used for a FITC reagent or vice versa. Other examples are allo-
phycocyanin (APC)/ Alexa Fluor R© 647 and APC-Cy7/ APC-H7.
This principle is especially critical for tandem reagents (e.g. PE-
Cy7, APC-Cy7) where there can be significant spectral differences
from lot to lot, which can lead to differences in the SOV [129].
In such cases, it is recommended that users run individual single-
color, lot-specific compensation controls.
2. The autofluoresence of the positive and negative populations
must be equivalent. The spillover calculation assumes that
any difference in the MdFI of the spillover detector (e.g. Y
in Fig. 15A, left) is due to the presence of the fluorochrome
measured by the primary detector. If the autofluoresence dif-
fers, then part of the MdFI in the spillover detector will be due
to the difference in autofluoresence and not the fluorochrome
itself. An example is shown in Table 3. In measuring the SOV
of FITC into PE when similarly autofluorescent positive and
negative cells are used, the calculated SOV is 27%; however,
incorrectly using beads for the negative population results in
an SOV of 22%, a 5% error.
This also applies to cell types. Cell lines and lymphocytes
should not be used for the same control. If a stained cell line is
used as a positive control, the same unstained cell line should
Figure 16. Brightness of positive population.
be used as a negative control. It is similar with cell subsets,
for example if lymphocytes are analysed, lymphocytes, and
not monocytes, should be used as both the positive and nega-
tive control. Some software programs allow a universal nega-
tive population (e.g. unstained lymphocytes); however, this is
acceptable only as long as all analysed samples are exclusively
lymphocytes.
Myth: the SOV depends upon the type and autofluoresence
of the cells you are analyzing. FALSE. The SOV is only a func-
tion of the fluorochrome. When correctly measured, the SOV
is independent of the cell type(s) in the biological sample.
3. The positive population should be as bright as possible.
As noted earlier, the SOV is equal to the slope of the MdFI
of the two detectors (Fig. 16, dashed line). The actual SOV is
not a function of the brightness of the positive population but
is the same all across the dynamic range. A truly correct SOV
will provide correct compensation whether it is derived from a
bright or dim positive population (Fig. 16, Correct SOV). When
calculating a slope, the most accurate measurement (i.e. SOV)
is obtained when the two data points obtained are apart as far
as possible. This is especially important for low spillover values
such as PE-Cy7 into PE.
However, we rarely get “perfect” SOVs, and the impact of
any errors in the SOV are magnified as the MdFI of the primary
detector increases as shown in Fig. 16. In this example, if there
is a 1% under compensation error in the SOV (Fig. 16; red
line), it would have a minimal impact on a dim population.
In this example, in an MdFI of 103 in FL1, the error would
be 10 MdFI in FL2, not noticeable. However, if the FL1 MdFI
is 105, the MdFI error in FL2 would be 1 000 and this would
incorrectly look like a new positive population.
Myth: For spillover to be correct it is required that the com-
pensation control positive population needs to be as bright as
your sample. Partly FALSE.
To restate the message here, you want to get the most accu-
rate slope/SOV possible. Therefore as noted in the title, it is
good practice to have the positive control population as bright
as possible, preferably close to your sampleMdFI (static or acti-
vated). However, for spillover to be correct, it is NOT required
that the compensation control positive population needs to be
as bright as your sample. In some cases, the positive popu-
lation of compensation beads may not be as bright as your
sample. This does not mean it is not a valid compensation
control. In general, if the positive population is approximately
equivalent to CD4, you will get good results. There is one major
caveat to this statement. For all measurements, it is critical that
the positive population is in the linear range of the detector.
Outside of this range, the corrected data will be inaccurate.
Most cytometer manufacturers provide linearity information
for their instruments.
4. Collect enough events to obtain meaningful accurate SOVs.
As a rule of thumb, collect at least 5 000 events for both your
negative and positive population. Again this is to ensure the
accuracy of the measurements, especially for low SOVs.
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1.4 Compensation controls
Compensation controls typically fall into two categories: i)
stained cells; ii) beads, these are seen as either (a) directly
fluorochrome-coated or (b) anti-immunoglobulin capture beads
and are available from a number of sources. Each of these
controls has advantages and disadvantages. In a given multi-color
experiment, compensation controls can be mixed and matched
including all three types. That is beads (positive and negative) can
be used to compensate Fluorochrome A, and cells (positive and
negative) to compensate Fluorochrome B. The key is to follow the
second principle and not mix and match different control types
within the same single color fluorescent control.
Stained cells
The advantage of using stained cells is that these controls most
closely replicate what is happening in the assay tube. The disad-
vantage is that you may have to use precious biological material.
In particular, if you need a tandem, lot-specific control for a spe-
cific CD marker, splitting the sample to generate such a control
decreases the number of cells available for analysis. This may
therefore require the use of even more of the biological sample at
the outset.
Beads
The advantage of beads is that no biological material is required
and they are easy to prepare and use. Following the manufac-
turer’s protocols, for many fluorochromes, beads provide suffi-
ciently accurate SOVs. The disadvantage is that these beads are a
surrogate for cells and may not in all cases provide a perfect match
to cells. This can result in discernible and reproducible differences
in the SOVs obtained from the exact same reagent measured on
beads versus cells. Where different SOVs are obtained, the cells
must be considered the biologically relevant gold standard.
Compensation controls using fluorochrome-coated and anti-
immunoglobulin capture beads are available from a variety of
sources. Some are used as stand-alone controls, some are inte-
grated into software packages. However, when used for 10–18
color instruments, differences in SOVs can be seen in all of these
beads when comparing the SOVs obtained with the beads to the
SOVs obtained with the gold standard of cells. These differences
can vary from manufacturer to manufacturer. For example, the
beads from Manufacturer A may be more accurate than the beads
from Manufacturer B when calculating the SOV of Fluorochrome
X into Y, while the beads from Manufacturer B may be better for
calculating the SOV of Fluorochrome Y into Z. SOV differences
between beads and cells can be as large as 5–10%.
Compensation beads are a powerful tool for making the pro-
cess of determining SOVs fast and easy and should be used where
appropriate. However, it is important to use them with reasonable
caution. The best laboratory practice to ensure accurate compen-
sation when using beads is to pre-test any new reagent on both
beads and cells to ensure that they are providing you with SOVs
equivalent to your stained assay samples. For example, if you are
using a new fluorochrome or a new lot of a tandem, run a quick
test staining both cells and beads; calculate the SOVs from both.
If the SOVs are effectively equivalent then you can be comfortable
using the beads as controls for all future assays. However, if there
are significant differences, you may need to use cells as your con-
trols or try a different bead. Finally, in such a test you may want
to treat the cells and beads as you would in your assay, e.g. if your
assay includes a fix/perm step you can include this in your control
staining. Fix/Perm buffers can sometimes, but not always alter the
SOV of your fluorochromes.
1.5 What are “good” SOVs?
This is really a question that cannot be definitively answered.
There is great deal of misunderstanding regarding what SOVs
actually mean in terms of a multicolor flow cytometer and the
experiments run on them. First and foremost, SOVs are empirically
determined mathematical values which are used by flow cytom-
etry software to correct for the background due to fluorescence.
While these values are related to fluorescence spillover, they ARE
NOT direct absolute measurements of the fluorescence spillover
of one fluorochrome into another detector. SOVs are based upon
median fluorescence measurements which are gain (i.e. PMT volt-
age) dependent. That means that when you change the PMT volt-
age on a detector, the SOVs associated with that detector will
change. However, the actual spillover of fluorescence from one
detector into another is unchanged. So you cannot ask “Why is
the SOV on my instrument different than the lab next door?” with-
out knowing the PMT voltages. The single most important fact to
remember is “Changing the PMT voltage on an instrument will
change the SOVs but it has absolutely no impact on the actual flo-
rescence spillover and its associated spread and DOES NOT affect
the quality of the data.
1.6 What is “good enough” accuracy for SOVs?
Using the right compensation controls under the right conditions
will maximize the accuracy of your spillover values. Still, nomatter
which controls are used it is likely that there will be some error in
some of the SOV measurements you make. This brings up the final
question of what SOV accuracy is good enough to provide you
quality data. The honest answer is that “it depends.” It depends
upon the design of your assay, the fluorochromes used and the
density of the antigens being analyzed. Any error in the final data
is directly proportional to both the error in the SOV measurement
and the brightness (MdFI) of the population being analyzed. This is
demonstrated in Fig. 17. In the assay represented in the top panels,
the Brilliant VioletTM (BV) 510 positive population is somewhat
duller (MdFI 6000). In this situation, small (±2%) errors in the
BV510 into BV605 detector do not significantly affect the error in
the MdFI in the BV605 detector (±100).
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Figure 17. Accuracy for SOV: The figure shows
twodifferent assays inwhich lysedwhole blood
was stained with the same fluorochromes: BD
HorizonTM Brilliant Violet 510 (BV510) and BD
HorizonTM Brilliant Violet 605 (BV605). Both
assays used the same BV605 reagent. In the
top panels the BV510 positive population was
dim will in the bottom panels the BV510
positive population is very bright. For each
assay the SOVs were determined and the
correct spillover was applied (Middle pan-
els). For the left panels the BV510→BV605
SOV was increased by 1% (over-compensated)
and compensation applied. For the right pan-
els the BV510→BV605 SOV was decreased by
2% (under-compensated) and compensation
applied.
The situation in the assay shown in the bottom panels is quite
different. The BV510 positive population is quite bright (MdFI
68000). Identical errors (i.e. ±2%) in the BV510 → BV605
SOV results in truly BV605 negative populations appearing to be
positive (BV605 MdFI errors of ±1300). The MdFI error in the
spillover detector (here BV605) = the MdFI of the population in
the primary detector (BV510)× the% error in the SOV. Therefore,
an “acceptable” error in the SOV for one assay (e.g. the top panels)
may be quite unacceptable for another (the bottom panels). This is
again why it is important to pre-test your compensation controls
to better understand and manage any potential errors that can
impact the quality of the final assay.
In conclusion, with an understanding of the concepts of com-
pensation/fluorescence spillover and following a simple set of
principles when using compensation controls, it should be rela-
tively easy to obtain and present high quality multi-color flow
cytometry data.
2 Maintenance
2.1 Introduction
Maintaining flow cytometric instruments is an important step in
ensuring a constant quality level of measurement. The signals
generated by flow cytometric instruments are dependent on many
factors (i.e. optical layout (laser and laser power, optical filter)
sheath fluid, room climate etc.). A prerequisite is thereby a deeper
knowledge of the performance of the respective system, making it
necessary to define the original status once and track it over time.
This can be done at different levels and is dependent on the
type of instrument (analyzer, cell sorter), the instrumental lay-
out (number of lasers, high throughput system) and the type of
measurement one wants to conduct on such an instrument (e.g.
screening, diagnostic, qualitative versus quantitative or volumetric
tests). Due to the high diversity of available flow cytometers on the
market, there is no common routine of conducting maintenance
and also the time frames andmaintenance intervals may vary from
instrument to instrument. While most of the manufacturers offer
service contracts for their systems, the user can do several things
to prevent potential damage and maintain or restore the instru-
ment’s original level of performance. Be aware that for some steps
during maintenance (e.g. laser alignment), additional precautions
(e.g. wearing laser safety goggles) are necessary to accommodate
for an altered hazardous potential (optical (high energy laser),
biological or electrical (high voltage)) as compared with normal
instrument operation.
Why is tracking of instrument performance so important? One
reason is that the data generated by flow cytometers have no
absolute unit numbers but are relative. They are strictly dependent
on the context of and the conditions during data acquisition. Only
if one “knows” the capabilites of the system at a certain time
point and has the appropriate controls or standards is one able
to interpret flow data accordingly. Maintaining a flow cytometer
means being able to retrieve information about the actual status
of an instrument and compare it to the original (ideal) situation.
If the performance check fails one needs to know how to bring
it back to the original level (if possible). The following section
describes several options for how to check the performance of a
flow cytometric instrument and what can be done as a preventive
procedure (summarized in Table 4).
2.2 Cleaning of instruments
2.2.1 Optical devices. Maintenance starts with cleaning the
instrument. For example, it is necessary to remove dust from
the ventilation systems to allow effective air-cooling of lasers and
power supplies as well as from optical filters (Band-, Short-, and
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Figure 18. Examples for performance tracking with and without a CS&T module [130]. (A) A Levey-Jennings chart of a weekly measured perfor-
mance for one parameter (out of 10) is shown. The cross in red indicates a failure in the performance check (a higher PMT-Voltage is needed to
reach the target values of the beads, which corresponds to a loss of sensitivity). After checking and changing the band-pass filter in front of the
corresponding PMT, the performance is measured again and is compared to the previous situation (blue dots). With the correct band-pass filter
installed, the performance of the PMT is back to the previous level. The graph is taken from a CS&T-Cytometer Performance Report of a BD FAC-
SCanto II equipped with 3 lasers. (B) The histogram of channel A of the violet 405 nm laser shows the corresponding measurement to the situation
described above in (a) and is taken from a self-defined, instrument-specific calibration worksheet. The blue population represents the “standard”
setup (with a 510/50 band-pass filter in front of the PMT of channel A, where the beads are reaching the respective target values (brackets). The
red curve shows a measurement with a 610/20 nm band-pass filter instead. The beads are clearly outside the target values and the positive and
negative populations are barely separated from each other. This is an example, how one can easily track basic instrument performance without
having a separate software module available.
Long-pass), (dichroic) mirrors, and prisms of the optical path. Dust
will impair the laser-alignment and sensitivity of fluorescence sig-
nals by generating additional background and loss of fluorescence
signals. These parts can be cleaned with unsoiled pressurized air
(e.g. as used for electronic parts or computers) and more resis-
tant dust can be carefully removed with cotton swaps or dust free
paper wipes (moistened with a drop of pure methanol (e.g. as
for microscopy, methanol will evaporate without leaving residues
on the optics). How often these types of preventive maintenance
have to be performed strictly depends on the environmental con-
ditions and are sometimes included in maintenance contracts of
the vendors. Many flow cytometers’ lasers are directed via glass
fibers to the detection site and, therefore, are stable over time
in their alignment. Other machines are equipped with fixed opti-
cal benches, making repetitive laser- and filter-alignment nearly
obsolete. But in any case, it is important to check (or “know”) the
instrument status prior to the measurement.
The Cytometer Setup and Tracking (CS&T) module from Bec-
ton Dickinson is an example of how instrument performance can
be monitored over time [130]. The combination of software and
the use of standardized beads make it possible to retrieve critical
parameters in one run. After installation through a service engi-
neer or exchange of components (e.g. lasers, filters, or PMTs), the
status of the instrument is documented in a so-called “baseline.” A
lot of information (not all are listed here) about the linear range
of each PMT (important for proper measurement and compensa-
tion (see Section III.1: Compensation)), electronic noise and back-
ground (Br, SDEN), detector efficiency, (Qr) as well as sensitivity
(Peak ratio between negative and positive population) and quality
of laser alignment (%rCV) is stored in this file. All the introduced
values are summarized in Table 5 with a very brief explanation
and cannot be discussed further here but are described in much
greater detail elsewhere [131–139].
Table 5. Summary of critical parameters defining the optical
performance of a flow cytometer
Parameter A measure for Recommended
value
SDEN Electronical noise As low as possible
%rCV Laser alignment As low as possible
Qr Detector
efficiency
As high as
possible
Br The channel
background
As low as possible
Signal-to-noise
ratio
Sensitivity of
Detector
As high as
possible
In a second step, the instrument performance can be tracked
and compared to the baseline values by running the same lot
of standard-beads at different time points. The software module
reports every observed change compared to the baseline (and has
some more features, which are not described here). In Fig. 18A,
a Levey-Jennings chart of a CS&T performance check is shown. A
wrong bp filter in front of the PMT-detector resulted in a lower
signal. As a consequence, the system needed a higher PMT-Voltage
(V) to reach the defined target value for this particular channel.
The change in V was larger than the accepted range (normally
between 20 and 50 V [130] and instrument performance failed
with notice to the user (red cross).Note that in the linear range
of many PMTs, a change of about 40 V results in a doubling of
the MFI of a population. On flow cytometers without a CS&T-
option, a similar result can be achieved by using nearly any kind
of standardized particles (e.g. Rainbow Beads, 6- or 8-Peak Beads,
Calibrite
R©
or other fluorescent labeled beads, CS&T Beads [130],
etc.). Instead of a “baseline,” one has to generate a system-
specific calibration containing all the fluorescent channels and
parameters. At the already suggested time intervals, the beads are
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Figure 19. How one can detect suboptimal alignment of lasers? Both histograms display a negative and positive bead population in the 450/50
channel of the UV-Laser of a BD FACSAria SORP cell sorter. Although the positive peak in (A) still falls into the defined target area (brackets =
P2), the shape and %CV of the peak suggest a suboptimal alignment of the UV-Laser. After realignment the shape of the positive peak become
narrower with only the half of the %CV. (B) Laser-alignment is optimal, when the lowest %CV values are reached.
measured with defined instrument settings and the results saved
as a (instrument specific) “standard.” Future measurements with
the same kind of beads and the same instrument settings will
allow a comparison to the first “standard” measurement and thus
monitors changes in instrument performance. In Fig. 18B, a result
for the same situation as described for the CS&T-option is shown.
With the correct bp-filter (510/50), the beads are falling inside
the target values (positive peak of the blue curve is inside the
brackets), whereas with a wrong bp-filter (610/20), the instru-
ment performance fails (red curve). This kind of information for
all parameters at various time-points (every day or week) will give
a good overview of the stability of the system.
Besides the target channels, the shape and width of the peaks
are also of importance and can indicate for instance a laser mis-
alignment. As shown in Fig. 19A, the peak of the positive beads is
still inside the defined target area, but the width (%CV) is twice
as big as the corresponding measurement during the standard
performance (Fig. 19B). After realigning the laser the shape of the
peak and the %CV value are again in the expected range.
The selected examples illustrate that tracking an instrument
performance is possible in different ways (8-Peak Beads, CS&T
or fluorescent labeled beads, etc.) as long as one knows where
to look at and to what instrument specific “standard” an actual
result has to be compared to. As noted earlier, there are several
additional parameters, which can be tracked (e.g. laser delay and
area scaling factors), but with a correct standard setup, most of
them can be accessed via appropriate bead measurements.
2.2.2 Fluidic system. The fluidic system of most flow cytometers
is assembled with parts that need to be maintained on a regular
basis. One has to ensure that the fluidic lines and filters are free of
air bubbles. Entrapped air compresses differently than sheath fluid
and can cause unstable (“dancing”) fluorescence signals due to
incorrect time calculation of the incoming signals. The more lasers
a machine has, the less tolerant the system is against air bubbles or
unstable compressed air supply. Sheath or saline filters therefore
have to be vented on a daily basis and replaced every 6 months
(the most commonly suggested time interval by manufacturers).
In machines without an extra sheath supply (e.g. Guava EasyCyte,
Partec/Sysmex etc.), air in the system will cause false values for
volumetric cell counting or will lead to empty fcs-files without any
measured event.
Sheath tanks, especially when they are pressurized, have to be
refilled and checked for leakiness on a frequent basis. Ball seals
have to be replaced before they lose integrity. The consequences
are similar to those described above for entrapped air bubbles.
An additional consequence in cell sorters is an unstable droplet
breakoff point, which is critically dependent on a constant and
stable pressure (especially for nozzle sizes above 85 μm).
To ensure sterile cell sorting, one has to clean/autoclave the
sheath tanks from time to time. This goes in line with cleaning
the sample injection port (SIP) and the sample tubing (see Table
4). Some machines offer semi-automated start-up and shutdown
protocols, as well as cleaning routines one can run after a defined
period of time or on demand as detailed in reference manuals
e.g. [140–144]. In general, there are at least 4 major protocols
to maintain a fluidic system, depending on the intention of the
cleaning:
 sterilization/ decontamination
 avoid crystallization for long-term storage (e.g. overnight)
 unclogging
 bleaching (get rid of cross-contaminating dyes)
For long-term storage, such as an overnight shutdown or prior
to maintenance through a service engineer, most labs run a
decontamination protocol followed by a wash cycle before they
switch off the instrument (or hand it over to a service techni-
cian). The most commonly used solutions to decontaminate a
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flow cytometer are 1% sodium hypochlorite or 70–80% ethanol
but freshly prepared 1% hydrogen peroxide can also be used.
Distilled or deionized water is ideal for washing out the clean-
ing solution. To keep a machine in a “dormant” / unused state
for a longer period of time (weeks/month), one could dry the
tanks and system tubing completely after the cleaning process
or leave them filled with distilled or deionized water. This is to
ensure that even if the SIP or tubing were to dry out, no salt crys-
tal formation, which could subsequently cause clogging, would
occur. To minimize the danger of bacterial or fungal outgrowth
adding of 1 mM EDTA or 1% bleach is recommended.
Sticky or clumpy cells, which are either not properly filtered
or used at too high a cell concentration, could block the orifice of
an instrument. In some (mostly pump driven) instruments (e.g.
BD Accuri, Merck/ Millipore Guava EasyCyte) one can revert the
direction of the fluidic to push the blockade backwards out of
the tubing. In other cases (e.g. FACSCanto II, BC Galios), run-
ning a (pre-warmed) detergent through the system for several
minutes, followed by filtered deionized water or PBS, can help to
release the blockade. In machines where one can easily access and
remove the SIP, sonication (in clean water) of the tubing is also
an option (e.g. Guava EasyCyte). As a last resort, the usage of thin
wires to clean the SIP, working like a sweeper is cleaning a chim-
ney, can be recommended. If an optional High Throughput Sytem
or Carousel Module is available, the washing steps become even
more important and fluidic parts and tubing should be changed as
recommended by the vendor. The usage of fluorescent dyes such
as PI, DAPI, or Acridine Orange (AO), which are used to stain
nucleic acids (e.g. live/dead, cell cycle or RNA-DNA-Ratio) makes
an additional cleaning step necessary and, because the use of AO
can cause a lot of trouble, there are different alternatives (e.g.
lysotracker, Syto
R©
dyes, Pyronin Y) available for many applica-
tions when AO is used(see Section VII.7.1 DNA synthesis and cell
cycle analysis and Section VII.8.5 Caspase activation). These dyes
are often stained in excess to ensure a good staining profile. Due
to their planar structure, they are sticky and can also adhere to the
tubing. Therefore a high likelihood of cross-contaminating sam-
ples between different users exists. Running a bleaching solution
(e.g. 1% sodium hypochlorite) for 5–10 min followed by a run of
distilled water will prevent this.
In all situations, one has to be careful with the use of aggres-
sive/corrosive solutions and make sure that they are washed
out/replaced by the respective sheath fluid or distilled water and
are not left inside the flow cell for an extended period of time
(e.g. overnight) [145]. This will damage the tubing and sealing
and ends up in leakiness of the system.
Some flow cytometers (e.g. Accuri C6, Guava easyCyte, Attune
Nxt, MACSQuant, CyFlow) allow volumetric measurement, which
enables counting and direct calculating of the cell number and
concentration of a sample. A prerequisite for accurate cell counting
is again an air bubble and particle free (filtered) sheath fluid and
intact sample tubings. Mechanical stress makes it necessary to
replace the tubing at constant intervals (e.g. a bi-monthly change
of the peristaltic pump tubing is recommended for the BD Accuri
C6 system [146]).
2.3 Computer and software
Beside the above-described maintenance steps to ensure proper
function of a flow cytometer, the computer and software need
some attention. Defragmentation of the computer’s hard drive and
backups of the FCS-files should be scheduled in a frequent way
(weekly/monthly, depending on the usage). If the FCS-files are
organized in databases, one should take care that the size of the
database does not exceed recommended size limits (e.g. 45% of
available disk space [147]) . This will impair and slow down the
performance of the entire system at a certain time point.
Although most flow cytometers on the market are very robust
and reliable, there are still many things that need to be con-
trolled. Table 4 summarizes many common steps to consider dur-
ing instrument maintenance. As already mentioned, it depends on
the instrument and environmental setup, as to which steps have
to be done in which frequency, and the focus might vary from lab
to lab. Therefore, this is an overview and a suggestion of proce-
dures, which should help to get the best results out of your flow
data. In any case of doubt, the reference guidelines should be
consulted and/or service engineers of your vendor contacted to
prevent damage to your system and to keep it in a good condition.
IV. Before you start: Reagent and sample
preparation, experimental design
1 Controls: Determining positivity by eliminating
false positives
1.1 Introduction
For antibodies the desired way of binding is the specific binding of
the antibody, i.e. via its antigen-binding site, to its antigen. How-
ever, antibodies can bind in another manner to cells, also deemed
as “specific,” by interaction with that cell’s endogenous Fc recep-
tors. A third possible interaction between antibodies and antigens
is “nonspecific,” and occurs through ionic and hydrophobic inter-
actions between the two molecules (“stickiness”). It is of critical
importance to exclude the latter two to be able to reliably quan-
tify antigen expression by immunofluorescence. Therefore proper
controls are essential in flow cytometry to determine background
fluorescence and/or background staining, to distinguish false pos-
itivity from true staining and to quantitate “true” positivity as
such. Antibodies, the most widely used staining reagents in flow
cytometry, can bind a cell in many different manners.
1.2 Fluorescence spreading into the channel of interest: FMO
controls
The first step in establishing what a positive signal should look
like is to obtain a reference for the natural or background lev-
els, autofluorescence, in that particular detection channel. For
this purpose, a sample without the staining of interest should
C© 2017 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.eji-journal.eu
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be acquired. In the case of multiparameter staining, this should be
the fluorescence minus one (FMO) control. In the FMO control, all
antibody conjugates in the experiment are included except the one
which is controlled for. The FMO control provides a measure of
the spread of fluorescence from the other staining parameters into
the channel of interest, and is required to accurately determine
the threshold for positive staining [148]. It does not, however,
provide any measure of non-specific binding.
1.3 Specificity of reagent for staining target: Biological
controls
There are several methods to control for the specificity of antibody-
mediated immunofluorescent staining, each of which confers
varying degree of confidence. The most reliable, but often also
the most difficult to obtain, control is a negative control consisting
of cells which do not express the marker of interest. The negative
control should be as similar as possible to the experimental sample
to exclude differences due to autofluorescence, size, “stickiness,”
etc. Such a negative control could be represented by using cell lines
that do not usually express the marker of interest, and comparing
these against cell lines engineered for ectopic overexpression of
the marker, or by comparison to cells genetically deficient for the
marker of interest, both of which provide excellent controls for
establishing staining protocols and for testing staining specificity.
Depending on the nature of the marker of interest, the comparison
to activated versus non-activated cells may be suitable if markers
dependent on activation are analyzed, although one has to con-
sider that activation may also change properties of the cell, such
as its size and shape, which may also increase the inherent aut-
ofluorescence or unspecific staining. The use of internal controls,
by staining additional markers to identify cells not expressing the
marker of interest within the same sample, e.g. using CD8+ T cells
as a negative control for CD4+ T-cell-specific markers, or CD19+
B cells when examining CD3+ T cell-specific markers, should also
be considered.
1.4 Specificity of reagent for staining target: Blocking and
isotype controls
In cases where biological negative controls are not available or dif-
ficult to come by, blocking controls can also provide an excellent
measure of unspecific binding. Specific binding is blockable, i.e.
loss of staining by the fluorescently labeled antibody after the addi-
tion of either excess soluble antigen or unlabeled antibody, both of
which block the specific interaction of the staining antibody with
its cognate antigen. Unlabeled blocking antibody must recognize
the same antigenic epitope with comparable affinity of the labeled
antibody whose specificity has to be verified. Ideally the same
antibody clone should be used. Any positive signals still detected
despite the use of blocking controls indicate that unspecific bind-
ing due to ionic and hydrophobic interactions of the antibody or
the fluorochrome has occured. When using these controls, how-
ever, one has to be aware that blocking controls do not exclude
cross-reactivity of the staining antibody to other antigens. Normal
human serum (10% in PBS with an optional addition of 0.5%
BSA) can be used to block the binding of labelled antibodies to
FcγR when human cells (particularly B cells or myeloid cells i.e.
monocytes, dendritic cells, macrophages) are analyzed.
Probably the most widely used staining control, the isotype
control, is of limited use in determining the threshold of positiv-
ity/level of background fluorescence due to unspecific binding.
The rationale behind using isotype controls is the assumption that
unspecific staining is due to the isotype of the antibody. As a
matter of fact, positive staining with isotype controls may be an
indication that antibodies bind via Fc receptors to the cell. In that
case, Fc receptor blocking reagents should be used to prevent such
an interaction [149]. However, isotype controls are by nature dif-
ferent reagents than the staining antibody, with a different amino
acid composition in the variable region, different numbers of flu-
orochromes bound to the antibody and different concentrations,
and, thus, have different “unspecific” binding properties. There-
fore, a negative staining with the isotype control does not infer
that the staining one observes with the experimental antibody is
specific.
2 Titration: Determining optimal reagent
concentration
Before any experiment it is good practice to validate and optimize
the reagents used. In flow cytometry, these reagents are generally
specific antibodies used to detect and quantify proteins on sin-
gle cells. Using too much or too little of the staining reagent will
result in increased unspecific staining, decreased SNR, decreased
sensitivity, lack of linearity between level of expression and stain-
ing intensity, and increased experimental costs. Thus, it cannot
be stressed enough that determining the optimal concentration
of antibodies for your experiment is of utmost importance. The
optimal concentration or “titer” of an antibody or any other stain-
ing reagent has to be determined empirically for target and your
staining condition (i.e. staining time and temperature), and for
every new batch of staining reagent for that matter. Live cells
may have a different staining optimum than fixed cells, proteins
stained on the cell surface different than the same protein stained
intracellularly. As it is very improbable that commercial reagents
have been tested on your particular experimental conditions, they
should also always be titrated rather than being used at the man-
ufacturer’s recommended titer or concentration.
To determine the optimal titer for the staining antibody it is
recommended to make a serial dilution of the antibody. If it is not
known from which concentration to start from, a generic starting
point is 10 μg/mL of antibody, which is then serially diluted 1:2
for 6–8 dilution steps. The number of cells used for the titration
should be orientated toward the number of cells being stained
in the actual experiment. However, while the number of cells
affects the staining quality, staining tends to be quite robust within
quite a large density range, e.g. 105–5 × 106 cells. Once titrated,
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Figure 20. Titration of a CD4 mAb (clone GK1.5) conjugated to FITC and titrated on murine splenocytes. The antibody was titrated in 1:2 dilution
steps starting from a 1:100 dilution (5.4 μg/mL) up to 1:12 800 (0.04 μg/mL). (A) Histograms of the stained samples are shown. (B) MFI of the positive
and negative populations (left axis) and signal-to-noise ratio between the positive and negative populations (right axis) are plotted. Best separating
titer for this particular antibody was determined to be 0.7 μg/mL (1:800 dilution).
an antibody concentration generally gives comparable staining
quality within a 10- to 50-fold range of cell concentrations. If
cell concentrations are increased by more than that, it is usually
sufficient to increase antibody concentrations by 2- to 3-fold, or to
make a quick 2–3 step titration.
Once a titration series has been made, there are several ways
to evaluate the data to determine the optimal titer. The simplest
method is to calculate the ratio of the MFI of the positive pop-
ulation (stained by the CD4 mAb) to the MFI of the negative
population, i.e. the SNR (Fig. 20A and B). It should be taken into
consideration that the applied gates for the negative and positive
population will have to be adjusted for each sample in the titration
series. The titer for the best separation will be the one with the
highest SNR (Fig. 20B), i.e. in this case 0.68 μg/mL or a 1:800
dilution of the original antibody stock.
One can also consider the lowest antibody concentration which
gives near maximum signal. This will be the concentration at
which staining is saturating andmost robust toward changes in cell
number, staining time, and temperature. Other methods to assess
optimal staining by determining the staining index are described
here [150]:
Additional aspects to consider are
1. When using antibodies, it is the concentration of the antibody
which is the critical parameter, i.e. when upscaling an exper-
iment to stain in a bigger volume, increase the amount of
antibody correspondingly to keep the concentration the same.
2. When titrating an antibody, make sure you have a population
which does not express the antigen of interest; this helps to
correctly assess background staining. If there are no “negative”
cells in the population, consider spiking in cells.
3. Once an optimal titer has been determined, indicate the con-
centration of the staining antibody for optimal staining, and not
the dilution factor, when it comes to publishing your results.
4. If possible, use counterstains to identify subsets of cells which
coexpress or do not coexpress the marker you are titrating for.
This will help determine/confirm the specificity of the titrated
antibody.
3 Preparation of single-cell suspensions
3.1 Introduction
The fluidic nature of counting in flow cytometry requires single-
cell suspensions. If cells from either solid tissue or an adherent
cell culture have to be analyzed, a disintegration of the tissue or
the cell layer into single cells is an absolute prerequisite for any
flow analysis.
Techniques for the disaggregation of tissue into single cells are
very old withmost of the basic protocols being from the 1980s
or 1990s. Since flow cytometry was first developed, it has always
been of great importance to measure cells not only from a sus-
pension culture but also from adherent cell cultures or from solid
tissue. In particular, in tumor research, disaggregation of the tis-
sue has to be done carefully for the application of flow cytometry.
Nonetheless, despite all the protocols and even some automatic
disaggregation systems, disaggregation is still a process which
has to be optimized specifically for each tissue in order to get
the best possible results. A high degree of standardization can
be maintained in the cytometric laboratory using automatic pro-
cessing machines from industrial companies. For non-automated
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protocols, companies provide a large variety of special enzymes
and protocols for enzymatic digestion.
The protocol for cell preparation depends strongly on the cellu-
lar properties which are under study. These staining targets could
either be markers on the cell surface, in the cell plasma, or in
the nucleus. Alternatively, it could be DNA or RNA extracted from
each cell after cell sorting.
With similar techniques, subcellular components such as
nuclei, chromosomes, and mitochondria can be extracted either
directly from the tissue or after disintegration.
The twomain principles for dissociation of a tissue or an adher-
ent cell culture into single cells are mechanical or enzymatic dis-
sociation; however, the effect of the enzymes on each protein of
interest needs to be determined, e.g. some cell surface proteins are
cleaved by collagenase. Also note, just as a reminder, if unknown
clinical material is to be analyzed, biological safety regulations
have to be maintained.
3.2 Mechanical disintegration
From a tissue (e.g. solid tumors), a sufficient number of cells have
to be extracted by applying mechanical forces. The tissue is gen-
erally placed into a Petri dish containing some growth medium
and held by forceps. Using a scalpel, the tissue is then scraped and
minced, as long as it takes until cells are released. The solution
is then filtered to remove large tissue pieces and very gently cen-
trifuged. The resulting pellet is resuspended in growth medium
afterward.
3.3 Enzymatic digestion
For enzymatic digestion, very often trypsin and collagenase Type
II are used. In addition, other commonly used enzymes include
papain, elastase, pronase, hyaluronidase, and Dispase R©. If the
degree of ploidy has to be determined, as in the case of tissue
from solid tumors, DNase I should be added to the cocktail to
remove DNA from non-intact cells. The tissue is incubated in the
enzyme solution, usually at 37°C for some time. This is followed
by removing the enzymatic cocktail by centrifugation and resus-
pending the cells in medium.
It is advised after dissociation by either mechanical or enzy-
matic methods to determine the number of cells and their viability.
An easy way of determining viability is to use a dye exclusion test
with the classical Trypan blue test in a hemocytometer by visual
microscopic inspection being the “gold standard.” Use of either this
test, or other dye exclusion tests with fluorescing dyes that can be
assessed by flow cytometry are helpful to perform. Further infor-
mation on establishing/controlling for viability is covered later
in this article (Section IV.5: Frozen samples and cell viability).
After viability has been established, the cell suspension can be
used directly for flow cytometric analysis or stored after fixation
or freezing for later measurement.
In many published protocols, both mechanical and enzymatic
methods of generating single-cell suspensions from original mate-
rial are commonly combined and modified appropriately to give
the best results in term of cell yield, cell viability, and integrity
of aneuploid populations. A good representation of all kinds of
cells in the sample after tissue dissociation is always aimed for;
however, it can never be taken for granted that it is 100% and that
the proportion of different cell types in the final sample resembles
exactly their proportions in the tissue. Furthermore, the physiolog-
ical state of the generated cell suspension may be different from
that in the starting material.
3.4 Special disaggregation techniques
Two special disaggregation techniques deserve a mention and
these are nuclei from paraffin-embedded tissue and nuclei and
chromosome isolation.
3.4.1 Nuclei from paraffin-embedded tissue. The preparation of
samples from paraffin-embedded sections for flow cytometry
requires a different protocol from those described above. In clini-
cal research, the flow cytometric analysis of cells from a paraffin-
embedded section can be required, especially if backward screen-
ing of patients needs to be performed. Preparations of cell nuclei
from paraffin sections are possible. In principle, a section cut from
the paraffin block has to be dewaxed using a solvent such as
xylene, followed by treatment with ethanol and water for rehydra-
tion. However, this can be a very lengthy procedure. Thereafter,
DNA staining of the isolated nuclei with intercalating dyes can
give reasonably good DNA histograms.
3.4.2 Nuclei and chromosome isolation. Pure cell nuclei and/or
micronuclei can be isolated directly from most tissues and the
protocols used for nuclei preparation for cells in suspension can be
adopted. Excellent results from adherent cell cultures are possible
even without using trypsination. The tissue is first treated with
salt solutions containing a detergent and RNase. This is followed
by treatment with an acidic sucrose solution. In this way, the
cytoplasm is destroyed and nuclei are released [151]. In a very
similar way, whole chromosomes can be isolated from metaphase
cells and their DNA content can be measured with high precision.
Even single chromosomes can be sorted based on their difference
in DNA content.
3.5 Ensuring a single-cell suspension/removing oversized
aggregates after extraction
For all disaggregation methods described, it is essential to ensure
a single-cell suspension and to remove oversized aggregates after
extraction. To do so, the suspensions should be filtered through a
simple mesh (30 to 50 μm) or a cell strainer to remove larger
aggregates, which otherwise can clog the flow cytometer’s nozzle
or channel.
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3.6 General comments
Once a protocol for a certain cell type and experiment has been
developed, it is strongly recommended to always proceed in a
highly standardized way. Automatic systems with high repro-
ducibility provide mechanical as well as enzymatic tissue disag-
gregation in a more or less automatic process and may be advan-
tageous in the routine cytometric laboratory. For a typical solid
tissue, the cell yield is about 107 cells per mg material and it
should be possible to achieve >50% viability in the isolated cells.
What should not be underestimated, however, is the probability
of perturbing cell surface structures and epitopes or disrupting
the cell, which could occur in solid tissue disaggregation. In some
cases, cell clumping, dramatically reducing the cellular yield, can
be a big obstacle for a productive flow analysis.
Many protocols for tissue dissociation and cell isolation use
a combination of the above procedures as one technique on its
own may not deliver a high cell yield and cell viability. Alternative
methods such as aspiration may also be used [152]. A successful
protocol depends in general on the personal experience in the
laboratory. It is also highly dependent on the amount of available
tissue(s), the nature of the tissue, and the planned use of the
material.
4 Pre-enrichment of low abundant cell populations
prior to acquisition/cell sorting
4.1 Introduction
One of the major advantages of flow cytometry is the capability to
measure multiple parameters per cell with a speed of several thou-
sand cells per second. This allows the measurement and detection
of rare cell populations with frequencies below one in one million
cells (1/1 × 106). But even with this relatively high number of
cells analyzed per second, a lot of time is required to acquire a
significant number of rare cells for statistical analysis. Assuming a
frequency of 1 cell of interest per 1 × 106 cells in a given sample,
one would need to acquire a minimum of 1 × 109 cells to have
at least 103 cells of interest at the end of acquisition. The average
acquisition speed of many flow cytometeric analyzers, at which
they will detect and acquire all incoming signals without signifi-
cant loss due to coincident or electronic aborts, is around 104 cells
per second. It would therefore take more than 24 h to acquire
enough of the described sample in order to reach the 1 000 cells
of interest.
While this time calculation is basically true for many available
flow cytometric analyzers, for cell sorting, the time calculation is
different. Here additional parameters come into focus. In common
flow cytometers which hydrodynamically focus the cells in front
of the laser intersection point (point of fluorescence detection),
see section I.1.2 Hydrodynamic focusing, the speed of the carrier
stream is given by the system and only the volume of sample run-
ning through per time can be adjusted by the user (generally in
three steps between approx. 10μL/min until approx.120μL/min).
The fluidic of most cell sorters is more variable and allows adjust-
ments of speed and flow-through volumes at various steps (both
on the sample and instrument side). In most cell sorting experi-
ments, there is a demand/ necessity to maximize both the yield
and purity of the sorted cells and minimize the time you need to
run your cells through a machine. Yield and purity influence each
other and are both dependent on the speed (cells running through
a sorter per second) and the frequency of cells of interest (see
Section V.3 Rare cells: General rules). Unfortunately they cannot
be maximized both at the same time. The less abundant a cell
population is, the lower the speed of acquisition/sorting has to be,
in order to ensure a high yield/outcome with an acceptable purity
(>95%). If you speed up, (increase the number of cells running
through the machine per time) your yield will drop significantly
(up to 50% in some cases) or alternatively, the purity is sacrificed
for a higher yield obtained in a shorter period of time. Therefore,
sorting 1 000 rare cells with high purity could last twice as long
as the acquisition only (the relation between speed, frequency of
cells, yield and purity are discussed in more detail in Section V.3
Rare cells: General rules). This crude calculation only accounts for
the time needed for acquisition and cell sorting; not counted is the
time already invested in preparing and staining the cells (see e.g.
Section IV.3: Preparation of single-cell suspensions).
Given that flow cytometry as a method allows the identifica-
tion and quantification of single/individual cells within a given
population and given that in flow cytometry cell sorting this deci-
sion takes even more time, thereby slowing down the process, it is
obvious that enumeration/evaluation of every single event espe-
cially of samples with large cell numbers prior to sorting is not a
practicable way to go about analysis of rare cell populations. How
then can we achieve acceptable work times and make it possible
to analyze those rare cell populations?
We need to reduce the workload—in this case, meaning the
amount of cells that need to be counted/measured in the flow
cytometer. One way to overcome this situation is to get rid of
as many “unwanted” cells as possible prior to acquisition, in
the form of pre-enrichment. Cells can be separated from each
other in many different ways and some methods of pre-enriching
rare cells before flow cytometric analysis are discussed in this
article.
4.2 Pre-enrichment by physical properties
Physical properties of cells may be exploited to enrich them. For
instance, monocytes, macrophages, and dendritic cells within a
mixed cellular population adhere to plastic and are in general
adherent within the first 2 h of being incubated on a Petri dish.
Cells other than macrophages and dendritic cells can be removed
and washed off with the supernatant. After longer incubation peri-
ods (approx. 20 h), dendritic cells start detaching from the plastic
again. With this method, an enrichment of up to 70% could be
reached for dendritic cells. This method is used in the process
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Figure 21. Schemata of density gradi-
ent centrifugation with Ficoll
R©
as pre-
enrichment. The distribution of different
cell types such as mononuclear cells, gran-
ulocytes and erythrocytes after the separa-
tion through the Ficoll
R©
density gradient is
shown.
of generating and isolating dendritic cells out of monocytes and
macrophages derived from blood or bone marrow [153, 154].
Another simple method to eliminate unwanted cytometry
events is the lysis of red blood cells (see also Section II.1.5:
Erythrocyte lysis), which are a common “contaminating element”
in tissue preparations. In contrast to nucleated cells, erythrocytes
burst upon brief exposure (60 s) to a hypotonic medium (ery-
throcyte lysis buffer: 155 mM NH4Cl; 10 mM KHCO3; 100 mM
EDTA) . Remember that human and mouse erythrocytes differ in
size and ability to resist hypotonic shock over time. Various buffers
and protocols are available, which differ in temperature and expo-
sure time, affecting lysis outcome. It is therefore necessary to adapt
the lysing protocol to the experimental conditions [155].
Peripheral PBMCs can be enriched by density gradient centrifu-
gation using Ficoll
R©
. This biological inert polysaccharide allows
the separation of PBMCs from plasma, granulocytes, and erythro-
cytes based on their cellular density (Fig. 21) (see also Section
II.1: Parallel cell sorting: 1.3.1 Ficoll-PaqueTM, LymphoprepTM”).
While many users report a lower recovery (up to 10–15%) in
the absolute numbers of target cells after density gradient centrifu-
gation, they profit from faster operational times in downstream
assays and lowered costs, because fewer (staining) reagents in less
buffer are needed for the significantly reduced total cell numbers.
In functional assays, e.g. antigen presentation or proliferation
assays and transplantation (e.g. hematopoietic stem cell transplan-
tation to reconstitute bone marrow and blood formation in irra-
diated mice), a higher cell viability and reconstitution frequency
is reported when Ficoll-enriched cells were used, as compared to
preparations without pre-enrichment via density gradients.
Elutriation [156–158] is another method of separating cells
based on their size, which uses centrifugal forces. The technique
is also called counter flow centrifugation and makes use of a mod-
ified elutriator rotor containing a separation chamber with which
one can gently separate a large variety of cells from different
tissues and specimens. The cells are separated in this chamber
mainly based on their different sizes by the opposing action of
the centrifugal field generated by the rotation of the rotor and
the liquid flow inside the chamber (Fig. 22; centripetal, means in
direction to the rotor axis (counter flow)). Because the separation
is not dependent on a specific density gradient, this method is
compatible with a wide set of media. Another big advantage is
high viability and low activation of the cells of interest [159].
4.3 Pre-enrichment by immunological properties
Although pre-enrichment methods based on physical properties
(such as size, density etc.) are straightforward, they do not allow
for functional or biological discrimination of sub-populations, e.g.
discrimination between T and B lymphocytes. To do so, immuno-
logical separation methods, which make use of antibodies to reach
the specificity and cell population of interest, could be used.
One of the first methods established (in the early 1970s) is
antibody-mediated complement lysis of unwanted cells. The cells
(e.g. erythrocytes or T cells in a mixed lymphocyte pool) that you
want to eliminate are detected and opsonized with specific anti-
bodies (at the beginning serum from immunized animals were
used, nowadays one can also use monoclonal antibodies against
Figure 22. Cells from different sources and with different sizes can be concentrated in a centrifuge containing an elutriation chamber. Without
centrifugal force, the cells would just pass through (A). If you apply a centrifugal force cells of a particular size and density will start concentrating
in the chamber. The equilibrium formed inside the chamber depends on the speed of the cellular flow, the amount of applied centrifugal force
and the viscosity of the medium used (B). This is the reason why elutriation is compatible with a wide range of cell types and carrier media.
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Figure 23. Unlabelled cells will pass the mesh without any (enrich-
ment) effect (A). If you add beads which are coated with specific anti-
bodies against your target cells (black) to the cell suspension, the target
cells will form aggregates with the beads. These aggregates are held
back on the top of the mesh while the rest of the cell suspension is
passes through (B). With this method one can either deplete or enrich
for a specific cell population. Combining different mesh and bead sizes
allows for a serial enrichment of target cells.
the antigen of interest). Soluble parts from the complement C sys-
tem are added to the cell suspension, bind to the antibody-tagged
cells and lyse them [160, 161]. This method is mentioned only to
complete the overview of pre-enrichment possibilities because, in
the meantime, a variety of easier and more efficient techniques
have become available. These techniques combine the advantages
of beads and antibodies.
To enrich or deplete subpopulations out of a heterogeneous
cell population, one can use beads coupled with monoclonal anti-
bodies against antigens expressed on the cells of interest that
bind to the antigens forming larger aggregates. These cell-bead-
aggregates can now be easily separated from the unbound cells
in the solution by passing the bead/cell-mixture over a mesh
(Fig. 23). Cells that are bound to beads would not pass through
the mesh, and are thus enriched on the mesh surface, whereas all
other cells are smaller than the mesh-size and flow through. After
filtration through the mesh, the antibody-coupled beads can be
detached from the cells to allow the cells to be further analyzed.
Using varying sizes of mesh and beads make sequential separa-
tions possible. For example, the pluriBead
R©
technology allows cell
enrichment as well as depletion of specific subpopulations [162].
The most commonly used methods for pre-enrichment of sub-
populations are based on beads passing a magnetic field. A variety
of companies offer different solutions for enrichment or depletion
of cell populations. One system of immunological pre-enrichment
employing magnetic fields is the MACS
R©
Bead-Technology [163].
As described above for mesh-filtration based enrichment, the con-
cept is based on the attachment of small, inert, supra-magnetic
particles to monoclonal antibodies specific for antigens on the
target cell population. Cells labelled to these antibody-bead con-
jugates are then separated via a column containing a ferromag-
netic matrix. By applying a magnetic field to the matrix, the beads
stick to the matrix inside the column and the bead-carrying cells
are held back from passing through. Unlabelled cells can pass
through the matrix and are collected in the flow-through. To
elute the trapped cells from the column, the magnetic field is sim-
ply removed. The MACS
R©
technology therefore enables different
strategies for positive enrichment or depletion of cells. MACS
R©
beads are very small and offer the advantage of not interfering
with downstream assays such as fluorescence staining and cell
sorting (see also section VIII.8 Bone marrow stromal cells). In
contrast to cell sorting, up-scaling the cell numbers doesn’t signif-
icantly increase processing times. For some cell types (e.g. CD4+
T cells or B cells), a high enough purity can be achieved such that
further enrichment is not necessary (of course this is dependent
on the quality needed for the downstream assay e.g. RNA/ DNA
purification) (Figs. 24 and 25).
Solutions using magnetic beads other than MACS
R©
beads are
also available for cell separation (e.g. Dynal
R©
-Beads [164] or BD
iMagTM [165]). The beads in these kits are generally larger than
the MACS
R©
beads and do not require a separate matrix to retain
the cells in the magnetic field. The disadvantage of using these sys-
tems is that, for many downstream assays, it is necessary to detach
the beads from the cells to avoid interference with the system.
To pre-enrich your cells you can choose a protocol from a vari-
ety of different techniques, which separate your cells based on
their physical and/ or immunological properties. Pre-enrichment
could be useful to cut down the processing time of your experi-
ment, increase the quality of downstream assays or to reduce the
amount of reagents needed.
5 Frozen samples and cell viability
5.1 Freezing cell samples
The freezing of cell samples offers the advantage of being able to
perform studies over large periods of time, or manage epidemio-
logical studies with many patients and/or healthy donors. Freez-
ing cells allow them to be stored with suspended metabolism. In
this way, the cells are protected from self-destruction by chemical
reactivity. Cells are further protected against genetic drift of cell
lines, and transformation and differentiation.
Freezing cellular samples also facilitates the logistics of mea-
surement, such as when only a few samples per day are to be
analyzed. The collective samples can be stored and measured at
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Figure 24. Examples for MACS R© -enriched cell popu-
lations. Pooled mouse lymphocytes from the spleen
and lymph nodes were positively enriched with CD25
MACS
R©
microbeads to isolate regulatory T cells (Tregs:
CD4+CD25+FoxP3+). After theMACS R© -enrichment cells
were stained for flow cytometry cell sorting and anal-
ysed on a flow cytometer. Compared to the non-
enriched sample (upper panel), the target population
of regulatory T cells is significantly increased in the
MACS
R©
pre-enriched sample (lower panel) and cannow
be sorted on a flow cytometric cell sorter with higher
sort efficiency (higher yield) in a shorter period of time.
The gating strategy is shown in Fig. 25 (A). Human
peripheral blood lymphocytes were enriched for B cells
with CD19 MACS
R©
microbeads. After the enrichment,
the lymphocytes were stained with antibodies against
CD45 and CD19 and analysed in a flow cytometer. In
the MACS
R©
-enriched sample, the B cell population is
already highly enriched (purity> 95%). Formany down-
stream applications (e.g. functional assays), this purity
might already be high enough (B). (Data kindly provided
by Dr. Michael Delacher, DKFZ).
a single time point, and at an instrument setting which does not
need to be reproduced for several experimental measurements.
This keeps the operating time and costs down, enabling long-term
and large studies.
However, even if precautions are taken, it has to be considered
that frozen samples never have exactly the same status (immuno-
logical, viability, culturability or other) as fresh cells or tissue.
This is one of the main obstacles which should be accounted for if
frozen samples are used, in particular if data from these samples
are to be compared against those of fresh cells.
To keep the cells alive as much as possible, cryoprotective solu-
tions should be added to the cells before freezing. DMSO is a
commonly-used solution. A concentration of around 5–10% in an
appropriate medium gives in many cases a high degree of viability
after storage.
One technical point to consider is that the best recovery
is achieved with a gradual freezing process, i.e. lowering the
temperature of the cells by 1°C to 2°C per minute. This proce-
dure is intentionally slow in order to prevent cells from being
ruptured by the formation of ice crystals. A solution with a
high concentration of DMSO (up to 10%) allows faster freezing.
A 10% DMSO freezing solution has been tested to give more
than 85% post-thaw viability, with some variability between
different types of leukemia. Automatic freezing techniques using
temperature-controlled setups have been developed for the rou-
tine cytometry laboratory. In these systems, the cell samples are
slowly moved down a tank of liquid nitrogen by a motor-driven
spindle. Commercially available cell freezers are the most suitable
appliances for this process. However, manual methods have been
widely reported to give sufficient results.
The thawing process is as important as the freezing one, and it
has to be done very rapidly. Active thawing is preferential to pas-
sive one. Cell samples from different sources can behave variably
after thawing. To give an example, Alsayed et al. [166] reported
that cells from a myeloid leukemia sample had better recovery
than cells from a lymphoid leukemia sample. In the clinical labo-
ratory, immunophenotyping is an important and frequently used
method in risk assessment and post therapy follow-up. In gen-
eral, to ensure reliable results, a high degree of standardization is
required. Post-thaw viability tests should be performed to deter-
mine the fraction of cells that are alive.
5.2 Testing for cell viability
The “gold standard” of viability determination is the Trypan blue
staining technique, which is carried out with a hemocytometer
under a conventional microscope by visual inspection. Using flow
cytometry, however, to determine the viability of a cellular sample,
either for fresh cells or cells that have been thawed from frozen
storage, allows the analysis of a variety of viability parameters at
the same time. In flow cytometry, different parameters related to
cell viability can be evaluated, such as cell morphology and cellu-
lar fluorescence due to dye exclusion or retention. The influx of
fluorescent dyes, which should be non-permeable to the vital cell,
is a good indicator and comparable to the Trypan blue technique.
The Trypan blue test can also be performed by flow cytometry, if
absorption can be measured as a parameter. As an approximation
for this, forward light scatter determination can be used.
If the dye influx into cells is used as an indicator for cell death,
intercalating DNA dyes are used, which bind to the DNA in the
nucleus; any non-viable cell is then measured with high fluores-
cence, in contrast to the non-fluorescing, viable cells. Dyes such as
ethidium bromide, propidium iodide or 7-aminoactinomycin D (7-
AAD) are typical examples of intercalating dyes commonly used in
flow cytometry. An extensive overview of life/dead cell discrimina-
tion based on dye exclusion can be found in Johnson et al. [167].
Alternatively, dyes with very different absorption and/or fluo-
rescence wavelengths are available, which allow for the combined
evaluation of the live/dead cell distinction and the determination
of other parameters at the same time. Broadly known is the use of
such dyes in combination with Annexin V apoptosis measurement
in order to find out the percentage of late apoptosis and necrosis
in the cell population.
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Figure 25. Lymphocytes from spleen and lymph nodes were pooled and stained for regulatory T-cell identification (CD3, CD4, CD8, CD25 and
FoxP3). One part of the sample was measured before (left column), the second part of the sample was analysed after a positive MACS
R©
enrichment
for CD25 (right column). The first gate was set on FSC/SSC to include the lymphocyte population (A). Based on the lymphocyte gate doublet
exclusion on FSC-H vs FSC-A was done (B). From the single cells the dead cells were excluded (C). T cells were divided by gating on CD4 or CD8 (D).
Out of the CD4+-subpopulation the regulatory T cells (CD25+FoxP3+) were sorted (Fig. 24A).
Dye retention can also be used to measure viability, such as by
the use of supravital dyes, which are nonfluorescent molecules in
an extracellular state, but once permeated through the membrane,
are transformed to a fluorescent state by esterases inside the cell.
An example of such a supravital dye is fluorescein-diacetate, which
is enzymatically processed inside the living cell to the fluoresc-
ing compound fluorescein. All viable cells subsequently fluoresce
green and can be measured by flow cytometry.
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Amino-reactive dyes can be used for identifying dead cells in
samples which will be fixed later. These dyes stain cells irreversibly
by fixation [168]. This allows the identification even after fixation.
All the different protocols for viability testing can be tested
against each other and, in general, they give comparable results.
Many of the protocols are very old and have been used for 30
or more years. Here the work of Combrier et al. [169] has to be
mentioned, which compares the many different procedures and
different cell types. The authors prove that there are no significant
differences between the various staining and treatment protocols
in the accuracy by which viability is measured.
As an alternative, if no staining protocol for cellular viability is
appropriate for the experimental design, the combination of for-
ward and sideward scatter provides a tool, which although not as
precise as the fluorescence methods or Trypan blue, still gives
valuable results in many assays. If cells die or the membrane
undergoes permeabilization, a change in their light scatter char-
acteristics is observed. It results in a reduction of FSC signals as
well as in an increase in SSC signals. However, the exact shape
of the scatter populations may differ from cytometer to cytome-
ter depending on the optical design of each instrument. Apoptotic
or dying cells can therefore be identified without any staining by
FSC and SSC parameters only. Reardon et al. [170] describe exten-
sively the application of light scatter versus fluorescence methods
after cell freezing.
The application of a viability test to cells may itself cause a loss
in cell viability, if perhaps the dye used in the experiment is toxic. It
may in certain situations even cause apoptosis or severe damage.It
is important to mention that cell viability as determined in any
protocol is not a guarantee that the cell will survive further culture.
One can think of many conditions in which a cell is detected
as being viable but cannot be cultured and does not grow. In
particular, in microbiological work, the fraction of viable but non-
culturable bacteria can be extremely large. The combination of
different assays can help to define the true vitality of the sample.
6 Cell fixation and permeabilization for flow
cytometric analyses
6.1 Introduction
The analysis of intracellular targets using flow cytometry (intra-
cellular cytometry) presents a number of technical challenges that
are not generally encountered in the measurement of cell sur-
face epitopes, or in the measurement of dye uptake/processing
(e.g. Calcein AM) in viable cells. In general, cells (in suspension)
must be first “fixed” to preserve and maintain both the structure
and location of target epitopes, then “permeabilized” to allow
probe (e.g. antibodies) access—ideally to all cellular compart-
ments (cytoplasm, mitochondria, ribosomes, nucleus, etc.).
In general, cell fixation is accomplished by the use of either
crosslinking fixatives (e.g. formaldehyde, glutaraldehyde), or low
molecular weight alcohols (methanol, ethanol), which generally
act to “coagulate” proteins. Formaldehyde has the advantage
of generally maintaining the overall conformation of the native
protein. However, since formaldehyde generates multiple reactive
sites on peptides, polysaccharides, and lipids, crosslinking can hide
or sequester epitopes such that they are not freely accessible to
antibody probes after fixation. An additional benefit of formalde-
hyde fixation in the study of post-translational protein modifica-
tions (e.g. phosphorylation, methylation, acetylation, ubiquitina-
tion, etc.) is that formaldehyde appears to both “fix” the modifica-
tion of target amino acids (serine, threonine, tyrosine), and also
inhibits the degradation of these targets in living cells (e.g. phos-
phatase removal of phosphorylations, demethylase removal of
methylations, etc.). In contrast, alcohol fixation generally results in
poor detection of some (phospho-, and potentially other protein)
modifications.
6.2 Fixation of whole blood specimens
Studies in the field of immunology frequently utilize peripheral
blood, lymph node, or bone marrow cells, often with a prelim-
inary purification step (Ficoll–Hypaque, hypotonic lysis, ammo-
nium chloride) to remove red blood cells. In addition, preliminary
purification techniques can remove potential target cell popula-
tions (e.g. loss of blasts using Ficoll–Hypaque). In this section,
we will first cover fixation and permeabilization techniques for
samples containing red blood cells, and subsequently cover fixa-
tion and permeabilization techniques for isolated cell populations
(tissue culture cells, isolated lymphocytes, monocytes, etc.)
Following fixation, cell permeabilization is performed in order
to gain access to the cell interior. This can be accomplished using
either detergents (e.g. Triton X-100, NP-40) or saponifiers (e.g.
Saponin), or with low molecular weight alcohols (methanol or
ethanol). A complete discussion of the advantages and disadvan-
tages of different approaches/reagents is beyond the scope of this
guideline, but also see Section VII.15: Transcription factors. Here,
we focus on a fixation and permeabilization technique developed
for use with clinical samples (whole blood, bone marrow) [171].
We set out to develop a technique that would allow the direct
addition of fixative to clinical samples (to immediately “fix”
phospho-epitopes and prevent dissociation of signaling inhibitors
out of cells, which can result in rapid reversal of their inhibi-
tion). However, the addition of fixative directly to whole blood
presented the problem of how to remove RBCs after fixation. We
discovered that the addition of Triton X-100 at the appropriate
concentration and time directly to the sample (still containing
formaldehyde) achieved RBC lysis and WBC fixation without any
significant loss of WBC populations. As a cautionary note, it is
important that the incubation times are strictly followed.
As shown in Fig. 26, whole blood from a healthy human was
fixed using the formaldehyde/Triton X-100 technique shows three
major populations using FSC versus SSC (lower panel). Here, the
location of the monocyte population (blue) is determined using
CD14. The separation of lymphocytes from monocytes by light
scatter alone is sufficient to identify both populations; and as
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Figure 26. Human whole blood fixed with formaldehyde and perme-
abilizedwith TX-100.White blood cell populationswere identified using
CD14-PE-Cy7 and CD45-Krome Orange. Debris (red) is identified using
CD45 vs SS (top panel - region C). Identification of peripheral blood
monocytes (shown in blue in both panels) was accomplished using CD-
14-PE-Cy7 (not shown).
shown in the figure, the use of CD14 provides a good resolution of
these cell types. The resolution of lymphocytes from cellular debris
using light scatter alone, however, is problematic. The lysis of
RBCs generates a significant amount of debris which overlaps with
lymphocytes in light scatter measurement. However, as shown in
Fig. 26 (top panel), staining the sample with CD45 allows clear
resolution of CD45-positive/negative lymphocytes from CD45-
positive/negative debris. The data shown here were generated
after a single wash following the RBC lysis step. Use of additional
washes at this point reduces debris significantly for most samples.
6.3 Materials
6.3.1 Staining whole human blood.
1. Fresh human whole blood (5–10 mL) collected in anticoagu-
lant (K2EDTA or sodium heparin).
2. Formaldehyde, 10% (methanol-free). Store at room tempera-
ture in the dark. Use within 6 months.
3. Triton X-100 detergent (e.g. Surfact-AmpsTM X-100, Thermo
Fisher). Prepare working solution by diluting 116 μL 10%
aqueous Triton X-100 solution with 10 mL 1X PBS. Store stock
and working solutions at room temperature. Working solution
is stable for 1 month.
4. PBS, calcium- and magnesium-free, pH 7.4.
5. Wash buffer — PBS/5% Bovine Serum Albumin (preferably
protease-free BSA if also using for antibody dilutions).
6. Methanol — 100% reagent grade, dilute to 50 or 80% with
NaCl (final concentration 0.9%), store at –20°C; use at 4°C).
6.3.2 Procedure: Whole blood fixation and permeabilization.
1. Place anticoagulated whole blood sample into 37°C and allow
temperature to equilibrate.
2. For 100 μL whole blood sample, add 65 μL 10% formalde-
hyde, and immediately vortex. Incubate at room temperature
(24°C) for exactly 10 min.
3. After exactly 10 min of incubation in formaldehyde at room
temperature, add 1 mL of room temperature Triton working
solution, vortex, and place in 37oC bath and set timer for 15
min.
4. Add 1 mL of cold (4°C) wash buffer and vortex. Centrifuge at
500 × g for 4 min.
5. Inspect tube for complete RBC lysis (rust red pellet, clear red
supernatant — not turbid). If RBC lysis is incomplete, resus-
pend pellet in 1 mL Triton working solution at 37°C for an
additional 15 min.
6. Remove supernatant, and wash pellet 3X using cold wash
buffer (centrifuge at 500 × g).
7. For methanol treatment, slowly add 1 mL 4°C methanol solu-
tion (50 or 80% depending on target epitope) while vortexing
pellet. Incubate in ice for 10 min.
8. Centrifuge (500 × g) and wash pellet 2X using 2 mL cold wash
buffer.
9. After final centrifugation, carefully remove as much super-
natant fluid as possible. Resuspend pellet by vortexing. Add
antibody cocktail, incubate and wash 2X with cold wash buffer.
10. Resuspend cell pellet in 0.5 mL wash buffer and analyze
immediately on flow cytometer. For intracellular epitopes that
degrade, or for samples that need to be analyzed more than
6 h after resuspension, resuspend in 0.1% paraformaldehyde
in PBS. Store at 4°C in the dark until analysis.
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Figure 27. Impact of methanol concentration on P-STAT5 immunore-
activity in peripheral bloodmonocytes activated in vitro using GM-CSF.
Whole blood from a normal donor was treated with GM-CSF for up to 20
min in vitro at 37°C. One part of the fixed and permeabilized samples
was treated with 50% methanol (A) and the other with 80% methanol
(B) at 4°C. After washing, all samples were stained with (__) P-STAT5,
(__) P-ERK, and (__) P-S6.
6.4 Effect of methanol on epitope staining
Some intracellular or intranuclear epitopes remain poorly acces-
sible to antibody probes after fixation and permeabilization using
the formaldehyde–Triton technique described above. This is likely
a limitation of all similar aldehyde–detergent (only) fixation and
permeabilization techniques. In our experience, phospho-STAT
proteins are largely undetected after this type of processing.
However, treatment of the fixed and permeabilized cells with cold
(4°C) methanol for 5–10 min “unmasks” these epitopes [171],
although care must be taken to validate the effects of methanol
treatment particularly when used post-staining and when using
tandem dyes as described below. As shown in Fig. 27, treatment
of fixed and permeabilized whole blood (activated using GM-CSF)
with up to 50% cold methanol has minimal impact on the quality
of P-STAT5 staining (same signal intensity for 50% methanol
or untreated sample indicating almost no P-STAT5 staining, not
shown). However, treatment with 80% cold methanol produces
a significantly stronger P-STAT5 signal. The impact of treatment
with methanol at both 50% (top) and 80% (bottom) concentra-
tions on P-ERK and P-S6 staining (ribosomal S6 protein) is also
shown in Fig. 27. Here, methanol treatment has minimal effect
on the P-ERK signal intensity and reduces the P-S6 signal by
about 20%. It is therefore important, when first developing and
optimizing fixation and permeabilization for new cytoplasmic
epitopes, to determine the impact of methanol treatment on all
target epitopes that will be measured in the assay.
While methanol “unmasking” is important for the evaluation
of some phospho-epitopes, it also has the effect of decreasing
(or eliminating) the immunoreactivity of other important epitopes
used to detect specific cell populations. In our experience, this is of
particular importance in the analysis of some myeloid–monocyte
markers in human blood or bone marrow (CD14, CD33, CD64),
and of less importance for stem-cell or progenitor cell markers
(CD34, CD117). See [172, 173] for details regarding cell surface
CDmarkers which we have tested, which are effected by methanol
treatment.
In the example illustrated in Fig. 28, we have compared the sig-
nal strength obtained when staining whole blood CD14-positive
monocytes using either 50 or 80% cold methanol. In addition,
in this study cell surface CD14 was stained with a tandem dye
(PE-Cy7) either before fixation and permeabilization (and prior to
cold methanol treatment), or after fixation, permeabilization, and
cold methanol treatment. Looking at the impact of 50% methanol
treatment (upper panels), comparing the CD14 fluorescence inten-
sity for monocytes labelled before or after fix-perm and methanol,
the MFIs are very similar for cells labelled before or after fixa-
tion and subsequent treatment. In contrast, when considering the
impact of pre- or post-fixation staining as shown in the lower pan-
els, cells labelled with CD14 after fix-perm and 80% methanol
(lower right panel) show a significant reduction in CD14 stain-
ing intensity (compared with that of cells stained after 50% cold
methanol, top right). While cells stained with CD14 mAb before
fix-perm and 80% cold methanol treatment (bottom left) show a
4-fold higher MFI than cells stained after, they still show a 50–
60% loss in CD14 staining intensity (relative to unfixed whole
blood). Together, these data support the concept that the CD14
epitope detected by the antibody used here (BCI clone RMO52) is
not affected significantly by treatment with 50% cold methanol,
but is affected following 80% cold methanol. In addition, these
data show that the antibody-conjugate is also impacted by 80%
cold methanol (MFI is lower for cells stained following fix-perm
and 80% methanol treatment). These data should reinforce the
concept that all of the details of fixation–permeabilization and
methanol treatment need to be validated for the complete set
of antibody conjugates used for a new experiment. For more
information regarding the use of pre- or post-staining peripheral
blood in relation to intracellular and CD epitopes, see [174]. This
technique [174] has been utilized to stain both cell surface and
intracellular epitopes for the analysis of MAP Kinase, STAT, and
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Figure 28. Effect of methanol treatment on CD14 staining of human peripheral blood monocytes. Whole blood samples from one individual were
stained with CD-14-PE-Cy7 before (left panels) or after (right panels) fixation and permeabilization. Samples were treated with either 50% (top
panels) or 80% (lower panels) methanol. See text for details.
ribosomal S6 signal transduction pathways in human bone mar-
row samples [172, 173].
6.5 Fixation and permeabilization for non-adherent tissue
culture cell preparations
Routine fixation and permeabilization of tissue culture cells
(anchorage-independent cell lines) is accomplished using
formaldehyde fixation followed by permeabilization of cytoplas-
mic and nuclear membranes using absolute methanol. Although
we routinely stain both cell surface and cytoplasmic or nuclear
epitopes simultaneously, it is also possible to stain cell surface
epitopes with some antibody conjugates prior to fixation and per-
meabilization [174]. This approach is particularly useful for cell
surface markers which are altered (e.g. CD19) or destroyed (e.g.
CD14, CD15, CD64) by fixation using alcohol treatment alone.
6.5.1 Determining optimal formaldehyde fixative concentration.
Optimal detection of phospho-epitopes appears to be influenced
by the formaldehyde concentration used to fix different types of
cells. As shown in Fig. 29, P-STAT5 in K562 cells is optimally
detected following treatment with 0.05 to 0.4% formaldehyde
(37°C for 10 min). Since the degree of potential epitope cross-
linking/fixation is proportional to the formaldehyde concentra-
tion, incubation time, and temperature, all three of these vari-
ables should be controlled and performed identically each time. As
shown in Fig. 29, at higher final formaldehyde concentrations, the
P-STAT5 signal decreases, likely from over-fixation, and limitation
of phospho-epitope accessibility by antibody conjugates [175]. As
also shown in this figure, treatment with absolute methanol alone
(no formaldehyde: first data point) results in a background level
of signal.
6.5.2 Routine fixation, permeabilization, and antibody staining for
non-adherent cultured cell preparations. For fixation and perme-
abilization of non-adherent tissue culture cells, we add the optimal
formaldehyde concentration (Section IV.6.5.1: Determining opti-
mal formaldehyde fixative concentration) directly to sub-confluent
cells (ideally re-fed 12–24 h prior to harvest) in tissue culture
media (routinely containing 15–20% FBS), and return cells to
the 37°C tissue culture incubator for 10 minutes. Cells are then
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Figure 29. Effect of formaldehyde concentration on P-STAT5
immunoreactivity in K562 cells (from [165], usedwith permission). Cells
were fixed at 37°C for 10 minutes using increasing final concentrations
of formaldehyde, permeabilized and stained with anti-P-STAT5-PE as
described.
centrifuged (400 × g for 10 min), and resuspended using a vortex
mixer (note: cells are clumped at this point and require vigorous
treatment with vortex to achieve resuspension of all cells). While
vortexing, absolute methanol (stored at minus 20°C) is added with
 1 mL absolute methanol per 107 cells being added. At this point,
the cells can be stored in a well-sealed container at minus 20°C
for several weeks with no significant decrease in the detection of
phospho-epitopes (epitopes tested thus far).
For staining of intracellular epitopes, place 3–5 × 106 cells
into each tube (we routinely perform staining of tissue culture
cells in 1.2 mL microfuge tubes). Centrifuge tubes (for refriger-
ated microfuge, use 10 000 RPM for 12 s), carefully aspirate off
supernatant, and resuspend the cell pellet in 1 mL cold (4°C) wash
buffer (Dulbecco’s PBS/5% FCS or Dulbecco’s PBS/5% protease-
free BSA) while vortexing. Place tube on ice for 5 min to allow
buffer to equilibrate and remove residual alcohol. Centrifuge as
above. Repeat, wash twice with cold wash buffer.
Carefully remove supernatant following the last centrifugation
step, and resuspend cells in 100 μL of antibody conjugate (or
antibody conjugate mixture). It is important that each antibody
used is titrated to ensure optimal SNR. Incubate cells with antibody
(or antibodies) on ice (4°C) in the dark (if using photosensitive
conjugates) for 30 min.
Resuspend cells in 0.5 mL cold wash buffer for flow cytometry
analysis (if cells are to be analyzed within 1–2 h). If cells will not
be analyzed within 1–2 h, centrifuge the washed cells, and resus-
pend the cell pellet in cold PBS/0.1% paraformaldehyde. Cells
post-fixed in 0.1% paraformaldehyde and stored at 4°C (dark)
are stable (light scatter and phospho-epitope detection) for at
least 24 h. It should be noted that the signal intensity of some
phospho-epitopes start to decrease significantly within minutes of
the final resuspension in cold wash buffer (e.g. P-S6). For these
epitopes, it is strongly recommended to immediately place the cells
in PBS/0.1% formaldehyde, which significantly decreases the rate
of signal loss.
7 Barcoding in cytometric assays
Sample barcoding denotes a procedure in which distinct cell sam-
ples are stained with unique labels, pooled, and then further pro-
cessed and acquired as a mixture of samples, often referred to
as “sample convolute.” After acquisition of the convolute, data of
the original samples are recovered by resolving the label signature
used for sample tagging (Fig. 30).
Barcoding allows for multiplexed analyses in flow and mass
cytometry. Importantly, this contributes to harmonization of assay
conditions, a reduction in the amount of wet work, technical errors
resulting from pipetting and staining variability in different assay
tubes, and reduced reagent consumption, as compared with pro-
cesses involved in preparing and acquiring multiple single sam-
ples. For example, fewer pipetting steps mean a smaller likelihood
of erroneous pipetting, and since all samples are stained, washed,
and optionally fixed and permeabilized in the very same sample,
no sample-specific artefacts can arise from these procedures. This
results in increased data consistency and robustness. After sam-
ples have been pooled, the assay is performed in a single vial,
which reduces the complexity of sample preparation work and
allows for sample acquisition with only a minimal need for manual
interference.
Compared to running multiple single samples, no instrument
cleaning cycles are necessary when acquiring one barcoded con-
volute, thereby reducing instrument run-time. Similarly, this prac-
tically excludes sample-to-sample carryover, which can occur dur-
ing one-by-one sample acquisition by the cytometer.
Barcoding of samples is particularly useful when high data
consistency is required, e.g. when shifts in median signal are used
as the assay readout, such as in the case of cell signaling studies.
The reduction of unwanted noise in cytometric data by sample
barcoding/pooling benefits the quality of results achieved with
algorithmic data analyses, which require a high degree of technical
data consistency [53].
Cytometric sample barcoding was first developed as intracellu-
lar barcoding for phospho-flow applications [176]. Barcoding was
later similarly applied to mass cytometry [70], with two barcode
staining intensity levels (on/off) for each channel. More recent
efforts moved barcoding to earlier steps in the sample preparation
protocol to extend the number of protocol steps that benefit from
sample barcoding. Behbehani et al. [177] introduced intracellu-
lar barcoding with only minimal permeabilization using 0.02%
saponin buffer. Mei and colleagues and Lai et al. [61, 71, 178]
used differently labeled CD45 Abs to achieve cell surface barcod-
ing of PBMCs in mass cytometry [61, 71, 178], a concept that has
been recently transferred to flow cytometry [179] using antibodies
against murine CD4 and B220.
While barcoding of samples has many benefits, it represents an
additional step in the protocol, needs to be optimized on its own,
and usually occupies cytometric channels which would be other-
wise available to the measurement of target analytes. Preparation
of larger barcoding reagent mixtures can be time-consuming
and require a high degree of precision. For larger studies, and
to avoid errors and variability in barcoding from experiment to
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Figure 30. Workflow of cell sample barcoding for
flow and mass cytometry. (A) Schematic overview; (B)
example of flow cytometric barcoding for a Phospho-
Flow experiment. PBMC were stimulated in vitro with
eight different stimuli or controls, fixed and perme-
abilized, and cells from each condition were barcoded
using Alexa Fluor R© 750 and/or PacificOrange succin-
imidyl esters. Following the barcoding reaction, single
samples were washed and pooled and further stained
for major lymphocyte lineage antigens such as for the
detection of B cells, and for pSTAT1 expression, as a
pooled sample. After selecting B cells by gating (not
shown), the barcode is deconvoluted by gating in the
two dimensions used for barcode labeling. The left plot
depicts the barcode labeling of all cells in that pool.
Eight major populations corresponding to different
stimulation conditions can be discriminated (indicated
by gating). Cells of a given single sample group together
as a “population” with homogeneous Alexa Fluor R© 750
and PacificOrange labeling, respectively. Annotations
indicate stimulation conditions applied prior to bar-
coding, aswell as the frequencies of gated populations.
The similarity of these frequency values confirms that
the pool contains similar amounts of cells from each
barcoded condition. On the right side, the histogram
overlay representation depicts pSTAT1 expression in
the different stimulation conditions. pSTAT1 signal
was induced in B cells treated with IFN-α and IFN-
γ, but not or only minimally in the other conditions,
which are visually indifferent in pSTAT1 signal from
the “unstimulated” control. Data were generated by
Patty Lovelace, HIMC, Stanford.
experiment, one should consider automating the generation of
barcode reagent mixtures, and/or to prepare them in batches that
can be stored frozen or lyophilized. A drawback of using sample
barcoding is that any error associated with only one or a few sam-
ples in the convolute will not be discovered until deconvolution,
such as the lack of cells in a sample, unexpectedly low cell number,
high frequency of dead cells, excess presence of debris or con-
tamination events such as erythrocytes in PBMCs. Additionally,
any errors in barcoding will result in issues during deconvolution,
which can lead to the loss of some or all data of the barcoded sam-
ple convolute. When using unrestricted combinatorial barcoding
schemes (Fig. 31), mishaps during barcode preparation result in
miscoding of the sample(s), while with restricted schemes, only
the miscoded sample will be lost in most of the cases.
Principally, any number of samples greater than one can be
processed as a convolute of barcoded samples. The sample accom-
modation capacity of a barcoding scheme is determined by the
number of cytometric channels reserved for barcode markers and
the number of different signal intensity levels per channel.
Example barcoding schemes are summarized in Fig. 31. The
simplest approach is to label each sample by one unique marker
(Fig. 31A). Here, pooling of n samples requires n different mark-
ers/cytometric channels. By leveraging the capacity of some bar-
coding reagents to stain at different signal intensities when used
at different dilutions in the assay [176], more samples can be bar-
coded using the same number of channels, multiplying the capac-
ity by the number of intensity levels used (Fig. 31B). This strategy
is frequently used in flow cytometry but not routinely applied in
mass cytometry. In combinatorial barcoding, samples are labelled
by unique combinations ofmultiplemarkers rather than by a single
marker (Fig. 31C). In a scheme with two intensities per channel
(i.e. “positive” and “negative”), the capacity of such a scheme is
2n. However, using the full combinatorial capacity entails certain
limitations. Different barcode labels often compete for identical
binding sites, leading to different barcode marker signal intensi-
ties. For example, a sample marked by one label usually exhibits
higher signal than another sample where that label is one of four
different labels. In addition, non-homogeneous barcode labelling
of a sample may limit or even entirely preclude the retrieval of
the original sample cells from the barcoded convolute. Doublet
events, containing differently barcoded cells (inter-sample dou-
blets), can mimic cells of a third sample that carries the marker
combination of the other two cells combined. This is especially
relevant in mass cytometry, which lacks the light scatter param-
eters available in flow cytometry which are applicable for cell
doublet removal. When occupying the full capacity of a combi-
natorial barcoding scheme, such issues can neither be reliably
detected nor corrected. Mislabelled cells will be lost for analysis,
and will contaminate another barcode/sample of the convolute. As
a consequence, a restricted combinatorial scheme has been devel-
oped, in which only unique combinations, with equal numbers
of barcode labels per sample are used. This strategy allows for
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Figure 31. Barcoding schemes. (A–C) Schematic
two-dimensional dot plot representations of (A)
two samples, each barcoded by a unique sin-
gle marker, (B) 12 samples barcoded by gradu-
ally increasing label signals (6 levels each) in 2
channels, or (C) 8 samples using a combinato-
rial barcoding scheme based on 3 intensity levels
per channel. Colored circles/ellipses indicate dif-
ferent barcode-labelled samples, different colors
indicate distinct cytometric signaling, color sat-
uration depicts staining intensity. The open cir-
cle represents unstained cells, which can formally
be assumed as a “label” itself, but tends strongly
to accumulate insufficiently labelled cells of other
samples anddebris, and is therefore recommended
not be to used for barcoding. (D) Pascal’s triangle
can be used as a tool for the construction of bar-
coding schemes. The line numbering indicates the
number of barcode channels, and the ordering of
numbers in each line reflects the number of labels
per sample, not counting the “1.” Different scenar-
ios are indicated by the numbers highlighted. Four
samples labelled by one marker each consumes
four barcoding channels (red), dual barcodemarker
labelling in 6 channels (blue) can be used to bar-
code and pool 15 unique samples, and, in theory,
210 samples could be barcoded by quadruple com-
binations in 10 cytometric channels (green). Blue
numbers denote sums of each line that equal the
capacity of unrestricted combinatorial barcoding
schemes consuming the indicated number of bar-
coding channels.
the detection of samples erroneously labelled by more or fewer
of the fixed number of labels, thereby permitting exclusion of
wrongly labelled cells, as well as virtually all inter-sample dou-
blets [71, 72]. With identical numbers of barcoding channels, the
capacity of restricted schemes is significantly lower, but this is
justified by the removal of doublets, especially in mass cytome-
try. Technically, intra-sample doublets are not removed by bar-
coding. However, with increasing numbers of samples barcoded
and pooled, the likelihood of cell doublets being inter-sample
(removed in restricted barcoding schemes) increases relative to
intra-sample doublets, and leads to indirect but significant reduc-
tion of intra-sample doublets [71]. The sample accommodation
capacity of restricted barcoding schemes equals n!/(k!(n – k)!),
with n being the number of barcode channels and k being the
number of labels per sample [72]. Pascal’s triangle provides quick
visual access to the sample capacity of restricted and exhaustive
combinatorial barcoding schemes (Fig. 31D).
The effort required to establish sample barcoding for flow or
mass cytometry depends on the complexity of the desired scheme,
and includes its development and validation. Development steps
include the selection of the barcode scheme fitting the study’s
needs, the barcoding reagent type (depending on sample type,
aspired protocol coverage, and the available mass/flow cytometer
in combination with available dyes or mass-tags), the titration of
barcoding reagents and the optimization of labelling conditions,
which is especially key when more than two signal intensity
levels per cytometric channel are desired. Optimal reagent
concentrations and labeling conditions need to be experimentally
determined, using the type and number of target cells the bar-
coding is finally intended for. This is specifically important when
using intracellular, protein-reactive barcoding reagents, as these
bind to proteins in a stoichiometric fashion, under commonly
non-saturating conditions, so that fluctuations in cell numbers (or
protein content and composition), buffer composition, incubation
time, and temperature can lead to differing barcode label staining
intensities, which can complicate deconvolution of data. It is
important to use protein-free media for covalent barcode labeling
to avoid reaction of barcode reagents with buffer proteins instead
of cellular proteins.
CD45 antibody-based barcoding operates at ideally saturating
conditions, which make the barcode staining more robust to small
assay fluctuations, but leads to competition between CD45 conju-
gates for CD45 target epitopes in the case of combinatorial bar-
coding, causing a decrease in barcode staining intensity depending
on how many different antibody conjugates are combined on the
same cell sample. It is therefore essential to incubate cells with
premixed cocktails of barcoding antibodies rather then adding
barcoding reagents one by one to the cell suspension. Finally, cell
washing conditions following the barcode labeling reaction prior
to sample pooling have to be established. Careful washing of cells
is required to minimize the carryover of barcode reagents into
the sample pool. Remaining reagents can cause unwanted low-
level labeling of all cells in the pool, which negatively impacts
on cytometric resolution of barcode signals, thereby complicating
deconvolution. More washing steps usually mean a better sepa-
ration of barcode/labeled cells from unlabeled background but
also cause greater cell loss due to removal of supernatant. In our
hands, 3–5 washing cycles are usually sufficient to achieve a clean
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barcode staining pattern. As for covalent barcoding reagents,
washing buffer should contain protein such as BSA or FCS which
serves to catch unbound barcode reagents. The barcoding reaction
typically lasts 10–15 min.
Experiments such as the checkerboard test or the retrieval
of sample-specific traits should be conducted, which address the
reproducibility of results achieved by measuring the samples sep-
arately (without barcoding) [61, 70–72, 180] to establish and
validate sample barcoding protocols. Analyses of unique sample
characteristics, such as the known lack of a certain cell population
within PBMCs in individual samples which are either run barcoded
or separately must provide matching results. The checkerboard
test is an extension of the above strategy which takes into account
that many experiments involving sample barcoding are prepared
in microtiter plates. When plotting data (e.g. cell frequencies or
signal intensities) of samples with and without a known character-
istic which have been plated in different orders, heatmap represen-
tations generate a characteristic checkerboard or similar pattern.
It should also be confirmed that barcoding does not introduce sys-
tematic error, e.g. by interfering with the binding of specific probes
post-barcoding, or due to spill-over between barcode marker and
analyte-specific signals. Barcoded sample convolutes typically con-
tain unusually large amounts of cells which mandates titration of
the post-barcoding antibody staining cocktail on the same amount
of cells.
Original sample data can be extracted from barcoded, pooled
samples by deconvolution through consecutive manual gating in
standard flow cytometry software, by Boolean gating for combi-
natorically barcoded samples [71], or using scripts developed for
that purpose. Debarcoding software can be developed in-house
or retrieved from https://github.com/nolanlab/single-cell-
debarcoder (accessed August 15, 2016) [72]. The better the cyto-
metric separation of the barcoded samples from each other, the
better the recovery of original sample cells in the deconvolution.
When different cell types in a given sample show heterogeneous
barcoding marker staining intensity, resulting in suboptimal cyto-
metric separation in the barcode channels, one should consider
separating those first (e.g. by gating for lineage markers), and
then deconvoluting the data of different cell types separately.
Different barcoding reagents have been explored. Usually, sam-
ple barcoding is achieved by covalently labelling cellular proteins
with dyes or mass tags via reactive thiols or primary amines
[70, 72, 176, 177, 181], or by antibodies [61, 71, 178, 182].
In mass cytometry, lipid-reactive RuO4 and OsO4 have also been
demonstrated as applicable for barcoding [180].
Covalent labelling is usually used for barcoding of fixed
and permeabilized cells, giving the reagent access to the cell
interior with many more binding sites than present on the
cell surface. In principle, “fixable Live/Dead markers” should
work well as intracellular sample barcoding labels. In flow
cytometry, succinimidyl derivatives of fluorescent dyes such as
PacificBlueTM, PacificOrangeTM, or Alexa Fluor R© dyes are fre-
quently applied [176, 183–190]. In mass cytometry, thiol-reactive
mDOTA loaded with lanthanide isotopes [70, 181], thiol-reactive
BABE, or amine-reactive isothiocyanobenzyl-EDTA loaded with
palladium isotopes [72, 177, 191] have been used for intracellular
barcoding. DNA intercalators (containing rhodium or iridium) are
also candidates for intracellular barcode labels, as are cisplatins
which are available in different formats holding isotopically-
enriched platinums [192]. For intracellular barcoding, cells
require fixation and at least “partial” permeabilization [177] prior
to barcode labelling, which limits the benefits of barcoding to
subsequent steps in the protocol.
Sample barcoding by antibodies [61, 71, 178, 182] is imple-
mented earlier in sample preparation protocols. Because of this,
more protocol steps—including surface staining of live cells—are
performed on the barcoded sample convolute, facilitating the
staining of fixation-sensitive markers in barcoded samples [71].
When using antibody-based sample barcoding, choosing the right
target is key. The selected antibody target should be stably and
abundantly expressed by the cells of interest and should not be
modified by the clinical or experimental conditions applied in the
assay prior to sample barcoding. Since CD45 is expressed by all
“normal” leukocytes, and particularly by lymphocytes and PBMCs
at high levels, combinations of CD45-antibody conjugates have
been used to barcode PBMCs in immune phenotyping experiments
[71]. For other cell types, different antibody targets might be
more suitable. It should be kept in mind that antibody labelling of
live cells can induce biologically functional responses to antibody-
based sample barcoding. Barcode labelling can be applied to fixed
cells, if target epitopes are fixation-insensitive, which is the case
for e.g. CD45 (Mei et al., unpublished observation).
The decision regarding using cell-surface versus intracellular
barcoding is usually determined by the overall study outline and
protocol. For complex immune phenotyping of live cells, cell-
surface barcoding prior to fixation will be more suitable. Intra-
cellular barcoding is often used in signalling studies in which cell
activation is stopped by fixation, and therefore all cytometric stain-
ings are performed post-fixation.
Sample barcoding has been frequently applied not only to
human and mouse primary leukocytes, PBMCs, and cell lines, but
also to platelets [188] and erythrocytes [190]. The technique is
often used in cell signaling analysis using flow and mass cytom-
etry. Since the induction of phosphorylated states of intracellular
signaling mediators is usually characterized by shifts in staining
intensity/signal, which can be small and can therefore be affected
by technical tube-to-tube variations, barcoding of sample aliquots
that underwent different stimulation conditions and their pool-
ing for joint acquisition and analysis is often employed to protect
against such error and resulting misinterpretation. Fluorescent
and/or mass-tag barcoding has been employed in B cell signaling
studies [193] and various other cell signaling studies [185, 186],
in the characterization of the effects of pharmacological inhibitors
on primary mouse and human immune cell subsets [70, 184],
in the mapping of myeloid cells in mice [191], in stem cell
research [43, 194] and also in clinical immune monitoring that
revealed a cellular signature of better recovery after hip replace-
ment surgery [44].
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Figure 32. Spreading error and loss of detection sensitivity. (A) APC (here conjugated to an anti-human CD8 antibody) spread into the Alexa 700
channel (left empty). Red lines indicate the threshold of positivity in the Alexa 700 channel according to APC fluorescence. (B) A given marker
detected in the Alexa 700 channel is bright enough to allow 100% detection even if co-expressed with APC (dark grey). (C) A given marker detected
in the Alexa 700 channel is not bright enough to be separated from the APC spread (green lines indicate the portion of cells that are “covered”). In
this case, only 50% of the cells are detected as positive (dark grey). In both cases, Alexa700+APC− cells (light grey) are not affected. Figure modified
from Lugli et al., Methods Mol Biol. 2017;1514:31–47 with permission.
8 Key concepts for the design and testing of
multicolor panels
Flow cytometers can now measure as many as 30 fluores-
cent parameters simultaneously, thanks to advances in hardware
(which allow for more multiplexing, with less electronic noise)
and reagents (including new dyes that rival or exceed the bright-
ness of phycoerthrin and allophycocyanin) [195]. Still, the power
of this single cell technology for revealing biological mechanisms
will depend on the ability to build high quality, highly multiplexed
antibody panels.
It is a common misconception that successful panel design
requires limiting spectral overlap; this is not true. In fact, high
quality multi-color panels will usually include dyes that overlap.
The process of compensation subtracts this reliably—even for dyes
that overlap a great deal such as Cy5.5-PE and Cy5-PE [196].
There is little reason, therefore, to be concerned with avoid-
ing compensation in panel design; one must simply ensure that
compensation controls are made correctly (as described in Sec-
tion III.1: Compensation). The success of panel design, instead,
depends heavily on a phenomenon known as “spreading error
(SE)” [196]. SE cannot be avoided; it is an intrinsic characteristic
of flow cytometry measurements, which arises from the count-
ing error associated with low photon numbers. Spreading can be
summarized by the following key points:
1. As the wavelength of the photon emitted increases, the flow
cytometer’s ability to see it decreases.
2. The photons in the far red end of the spectrum (600–800 nm)
have low energy and are not efficiently detected by the PMT
i.e. many photons can hit the detector, but very few are turned
into photo-electrons by the PMT, meaning that more photons
have to be counted to obtain a detectable signal.
3. The spread associated error ofmeasure increases as the number
of photons to be counted for a detectable signal increases.
SE is not caused by compensation; it is instead revealed in
compensated data as the effects of counting error are more easily
observed at the low end of a log scale fluorescence plot. When
SE is very high in a particular channel, a dim marker cannot be
resolved from background; it is masked by the spreading of the
negative population (Fig. 32). Successful panel design involves
managing this key consequence of SE. As described below, SE is
a unique product of the instrument and dyes used in an experi-
ment; therefore, web-based panel building tools—which only con-
sider spectral overlap and cannot account for SE on one’s own
instrument—are of limited value.
To manage SE, it is important to consider how it relates to
photon detection. This, in turn, is influenced by laser choice and
power, dye brightness, and quality of PMTs. For example, PE and
its tandems are more strongly excited by 532 and 561 nm lasers
than a 488 nm laser, resulting in greater photon emission, and
lower SE into neighboring channels; higher power lasers often
have the same effect [197]. In contrast, when photon release is
relatively poor (as with the far-red dye Cy7-APC), there is greater
counting error in neighboring channels, and SE may be high. The
brightness of a dye is influenced bymany factors, including charac-
teristics inherent to the fluorochrome (quantum yield) and those
associated with individual instruments (e.g. lasers (as described
above) or choice of optics). Similarly, the performance of PMTs
strongly influences SE. Therefore, once laser choice and dye bright-
ness are considered, panel design requires assessing performance
of all PMTs by measuring sensitivity (the capability to detect dim
signals above background noise, known as the B value), and res-
olution (the photoelectron detection efficiency, known as the Q
value), as described elsewhere [136]. It is important to recognize
that measurements of Q and B, and ultimately the success of panel
design, is heavily dependent on proper setup and calibration of the
instrument, in particular the appropriate choice of PMT gains.
A simpler approach is available in FlowJo software. For an
existing (and working) multi-color panel, a spillover-spreading
matrix (SSM) can be calculated from the Compensation Wiz-
ard window. The SSM indicates the SE created by each dye
(in rows) into each detector (in columns). Where no working
multi-color panels are available, antibody-capture beads can be
singly stained with all the dyes/reagents of interest, and acquired
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on the cytometer. These samples can be used for compensa-
tion in FlowJo and generation of the SSM (SSM can also be
calculated manually, by reconstructing the formulas described
in [127]). Notably, SSMs are normalized for marker expres-
sion; therefore, the SSM/SE information from one panel will be
applicable to all possible panels on that instrument. However,
since PMT performance can differ dramatically within, and
between instruments, an SSM from one instrument is unlikely
to be relevant for another, particularly if PMT performance has
not been characterized on both instruments.
The information described above—laser choice/power, dye
brightness, quality of PMTs, and SSM—can then be integrated
with information on protein expression; this allows careful, data-
driven, panel building. First, consider markers that are diffi-
cult to measure because they are dim (for example, chemokine
receptors (CCR2, CCR5), inhibitory molecules (LAG-3, TIM-3 or
CTLA-4), or transcription factors (Eomesodermin)), or markers
that are expressed by rare populations, (like antigen-specific T-cell
receptors or proliferation markers (Ki-67) in ex vivo T cells). These
markers should go on channels with the highest performance:
where dyes are optimally excited by their lasers, where fluores-
cence quantum yield is high, and/or where PMTs have high sensi-
tivity/low background and high resolution. A useful shortcut is to
place dim markers on detectors with low total SE values (summed
over all rows) in the SSM. Bright markers can be placed on chan-
nels with lower performance—where dyes fluoresce weakly, or
where B values are high/Q is low. Here, again, the SSM table
provides a useful shortcut to complete characterization of dye and
instrument performance: bright (on/off) markers can be placed
on dyes that affect other channels minimally (as indicated by the
sum of all columns for a particular row entry). Markers that are
never co-expressed by the same cell (e.g. CD3 and CD20) can be
placed on detector/dye combinations in the SSM where SE values
are particularly high. Finally, in general, an SE value over 3–4 is
dangerous for resolution of dim populations.
As panels are designed, it is important to include a channel
dedicated to the exclusion of dead cells; these can be identified
with a variety of dyes. For intracellular applications, live/dead
fixable (amine-binding) dyes are particularly useful, and avail-
able with a variety of different excitation and emission profiles.
Dead cell exclusion is particularly critical in rare event analysis,
where the non-specific binding of antibodies to dead cells can
dramatically elevate the proportion of cells positive for a given
marker [198, 199]. Similarly, many fluorescent probes routinely
used to measure the metabolic activity of the cell (such as those
detecting ROS generation, mitochondrial membrane potential and
others) require active metabolism, which is generally not func-
tional in dead cells [200].
Titration is also central to panel design. In this procedure,
the cells of interest are stained with two-fold serial dilutions of a
reagent, under the same conditions (e.g. time and temperature) as
the studywill employ. This approach identifies the optimal concen-
tration for experiments, namely where the best SNR is achieved.
Typically, this occurs at the point of saturation—where increas-
ing concentration of antibody no longer improves signal. When
using concentrations above this “saturating titer,” one runs the
risk of high levels of non-specific antibody binding. Concentra-
tions below the saturating titer may be used with care, provided
population identification or quantitation is not affected. These sub-
saturating concentrations are particularly valuable for improving
panel design, as the lower intensity signal induces less SE in other
channels. This strategy is most useful when the primary channel
(stained at sub-saturating concentration) is bright and exhibits
on/off expression patterns (like CD3), and when the secondary
channel (receiving the spillover) must be used for detection of a
dim antigen.
Once the dye–marker combinations are chosen, dead cell mark-
ers are slotted in, and titration experiments have been performed,
the panel can be tested. Panel tests can be performed with an add-
in approach, in which subsets of markers are stained together,
analyzed and approved, and then additional markers are added
in iteratively [201]. Alternatively, researchers may wish to try the
entire panel at once. When using this approach, it may be valu-
able to include FMO controls for any dim markers or channels
with high SE. This allows accurate gating and panel evaluation.
It is worth noting, however, that FMO controls are of limited
value when increased background fluorescence of the negative is
observed as a consequence of improper titration or because of the
intrinsic property of the reagent, even when used at optimal con-
centration [202]. Panels should also be evaluated in the context
of N-by-N plots, in which every parameter is plotted against every
other parameter [201]. For combinations where compensation is
incorrect (mostly due to improper controls; see Section III.1: Com-
pensation), under- or over-compensation of those channels may
be occurring. It is worth examining the staining characteristics of
the compensation tube to check that it is at least as bright as the
test stain and that it is combined with the proper matched nega-
tive control with the same autofluorescence [203]. Should these
properties not be met, compensation tubes should be modified,
run again, and compensation matrix recalculated. For combina-
tions of markers that do not make biological sense, e.g. that are
co-expressed in the test stain but are known to be mutually exclu-
sive (as an example, CD4 and CD8), an alternate sample should
be tested. If problems are not solved with these re-tests, the panels
should be rearranged by assigning new dye-marker combinations.
9 Variable lymphocyte receptor antibodies
9.1 Introduction
The recently identified variable lymphocyte receptor (VLR) anti-
gen receptors of jawless vertebrates have contributed greatly to
our understanding of the evolution of the adaptive immune sys-
tem [204]. Three VLR genes (VLRA, VLRB, and VLRC) have been
described which are assembled by a gene conversion-like mech-
anism, and are expressed by cells reminiscent of αβ T cells, B
cells, and γδ T cells respectively, with VLRB being secreted in
the form of disulfide-linked decameric complexes. Conventional
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Figure 33. Structural characteristics of immunoglobulins. Ribbon diagram of a mouse monoclonal IgG antibody consisting of two identical heavy
and light chain proteins, respectively. Antibody heavy chain residues are indicated in blue and light chain residues in green. Amino acid residues
encoding the CDR1, 2 and 3 regions are shown in red. (Image was generated using the Swiss PDB viewer and PDB accession number 1IGT).
antibodies utilize the immunoglobulin domain as the basic struc-
tural unit and are generated by recombination of the variable
(V), diversity (D), and joining (J) gene segments for the antibody
heavy chain and the V and J gene segments of the antibody light
chain. As illustrated in Fig. 33, the resulting antibody consists of
an F(ab)/F(ab’)2 domain which engages the antigen primarily via
interactions mediated by residues located in the complementarity
determining regions (CDR) 1, 2, and 3 whereas the Fc domain
allows for the communication with various cells of the immune
system to elicit biological responses. The ability of antibodies to
recognize their antigens with a very high degree of specificity and
to label these reagents with fluorescent dyes makes antibodies the
key component of most flow cytometric applications.
Unlike conventional antibodies, VLR antibodies utilize the
leucine-rich repeat (LRR) as a basic structural unit [205]; the
resulting gene product assumes a solenoid shape (Fig. 34A),
wherein the corresponding antigen interacts with residues located
at the inner concave surface, and with a variable loop structure
protruding from the capping C-terminal LRR unit [206, 207]. VLR
antibodies have become a novel class of highly specific biomedical
research tools, by virtue of the vast VLR antibody repertoire. An
established protocol harnesses the expansive repertoire to gener-
ate antigen-specific monoclonal VLR antibodies with ready appli-
cability in standard laboratory techniques such as flow cytometry
and enzyme-linked immune sorbent assays [208].
Several research groups have used monoclonal VLR antibod-
ies, either unmodified or engineered as Fc fusion proteins for
purification using protein A/G columns and detection with a vari-
ety of commercially available reagents recognizing the IgG Fc
domain. Alternatively, purification is also readily performed using
Ni-columns targeting an engineered 6 × His followed by detec-
tion of the VLR antibody targeting the incorporated HA-epitope
tag (Fig. 34B). Here we describe a protocol for use of VLR anti-
bodies in multicolor flow cytometry analyses of human PBMCs
in combination with conventional, directly labeled monoclonal
antibodies. Depending on the type of VLR antibody used and the
expression levels of the targeted antigen, a two-layer or three-
layer staining approach can be used (see below for protocol).
The use of monoclonal VLR antibodies with engineered epitope
tags or VLR-Fc fusion proteins permit a more two-layer staining
approach. The use of unmodified monoclonal VLR antibodies or
experiments targeting antigens expressed at low levels require
a three-layer staining approach since the established anti-VLRB
monoclonal antibody 4C4 cannot be readily modified with com-
mon labeling systems that target primary amines. Several positive
and negative control reagents for VLR-based experiments have
been described [208–210].
9.2 Reagents
 Fluorescently labeled anti-epitope tag or Fc-specific reagents
are available from several commercial sources.
 Monoclonal mouse anti-VLRB clone 4C4 [211]. Note that this
antibody is reactive with an epitope in the stalk region of all
VLRB molecules, and it displays impaired antigen-binding char-
acteristics following modification with amine-reactive dyes.
 Negative control monoclonal VLR4 antibody (specific for the
BclA antigen of the exosporium of B. anthracis [208]).
 Positive control VLR32 antibody (specific for human CD5)
[212] or VLRB MM3 antibody (specific for human CD38 on
plasma cells). Suitable cell lines for testing of positive controls
are the Jurkat T-cell leukemia and the Daudi Burkitt’s lym-
phoma, respectively [209].
9.3 Two-layer staining approach
 Incubate PBMC with monoclonal VLR antibody in PBS/0.5%
BSA for 25 min on ice (v = 40 μL).
 Wash with PBS/0.5% BSA.
 Resuspend cells in antibody cocktail containing fluorescently
labeled lineage-specific conventional monoclonal antibodies
and fluorescently labeled anti-epitope tag antibodies (or anti-Fc
antibodies if VLR-Fc fusion proteins are used), incubate for 15
min on ice.
 Wash 2× with PBS/0.5% BSA.
Resuspend in PBS/0.5% BSA/1 μg/mL propidium iodide and
analyze by flow cytometry.
9.4 Three-layer staining approach
 Incubate PBMC with monoclonal VLR antibody in PBS/0.5%
BSA or 25 min on ice (v = 40 μL).
 Wash with PBS/0.5% BSA.
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Figure 34. Structural characteristics of VLR antibodies. (A) Ribbon diagram of the antigen-binding units of a monoclonal VLR antibody. Parallel
β-sheets lining the concave antigen-binding surface are shown in blue and a variable loop structure involved in antigen binding is depicted in
red. The invariant stalk region necessary for multimerization of the secreted VLR antibody was omitted (Model was generated using the Protein
Model Portal Algorithm [210]). (B) Structural characteristics of VLR antibodies. Individual VLRB units consist of a signal peptide (SP), N-terminal
LRR (LRR-NT), LRR-1, up to nine variable LRRv units, a connecting peptide, C-terminal capping LRR (LRR-CT) and the invariable stalk region and
can be modified by inclusion of engineered 6 × His and HA-epitope tags or Fc-fusion sequences.
 Resuspend cells in PBS/0.5% BSA, add anti-VLRB clone 4C4 at
a concentration of 1 μg/mL and incubate for 15 min on ice (v
= 40 μL).
 Wash with PBS/0.5% BSA.
 Resuspend cells in PBS/0.5% BSA, add fluorescently labeled
goat anti-mouse reagent (typically at a 1:300 dilution), incu-
bate for 15 min on ice (v = 40 μL).
 Wash with PBS/0.5% BSA.
Important Blocking Step: This blocking is important to prevent
binding of directly labeled antibodies from the next incubation step to
potentially unoccupied binding sites of the goat anti-mouse reagent
from the previous step.
 Resuspend cells in PBS/0.5% BSA/5% normal mouse serum,
incubate for 10 min on ice.
 Add antibody cocktail containing fluorescently labeled lineage-
specific conventional monoclonal antibodies, continue incuba-
tion for 15 min on ice.
 Wash 2× with PBS/0.5% BSA.
Resuspend in PBS/0.5% BSA/1 mg/mL propidium iodide and
analyze by flow cytometry.
 As is the case with all conventional antibodies, monoclonal VLR
reagents must be titrated prior to use and 2 μg/mL serves well
as a starting point. While background signals with the nega-
tive control VLR4 are not typically observed, negative control
stains lacking any VLR antibody, in addition to negative con-
trols for the various conventional antibodies, should be rou-
tinely included.
V. Data acquisition and cell sorting
1 Suspended sample
In order to run a successful cell sorting experiment, a cell sorter
needs to be optimized in terms of optics, electronics, and fluidics.
In addition, cell size, quality of cell suspension (see Section IV.3:
Preparation of single cell suspensions), and cell density are also
important parameters, which ultimately have a high impact on
sort parameters such as recovery, purity, and yield.
1.1 Nozzle diameter, clogging, and cell filtration
The cell diameter should not exceed one-fourth of the cell sorter
nozzle diameter in order to prevent destabilizing effects of the cells
on the break-off point [112]. This ensures stable sort conditions
and minimizes nozzle clogging. Even if these criteria are met, it is
still possible that a nozzle clog occurs during cell sorting due to
the presence of adherent cells in the sample.
To avoid generation of cell aggregates/clumps it is recom-
mended to filter the samples as the final preparation step before
sorting, by passing them through a cell filter. As a general rule, the
filter pore size should be smaller than the orifice of the nozzle, e.g.
for sorting of lymphocytes with a diameter of 10 μm, a filter with a
30 μm pore size should be used for cell filtration. Note that in this
example a nozzle with a diameter of 70 μm should be used. Differ-
ent filter types and sizes from different companies are available:
 Sysmex, CellTrics R©
 Miltenyi, Pre-Separation Filter
 Becton Dickinson, Falcon R© 5mL Round Bottom Polystyrene Test
Tube, with Cell Strainer Snap Cap
Cell count and viability should be checked before and after
filtration to measure inadvertent cell loss. Besides pre-filtering
before sorting, it is also possible to use a sample line filter inside
the cell sorter. These filters are installed at the end of the sample
line. Such filters are available as a commercial product (Sample
Inline Filter, Becton Dickinson) but can easily be made by melting
a cropped pipette tip and attaching a piece of filter mesh to the
cropped end. These line filters are useful to prevent nozzle clogs
due to cell aggregations in the sample tube, but they cannot be
used as a replacement for pre-filtering since the filter surface is
very small and usually clog rapidly. Furthermore, such filters need
to be replaced between different sample tubes in order to avoid
cross-contamination. If cells tend to aggregate repeatedly during
the sort process one should dilute the cell suspension or add some
EDTA (up to 5 mM) and 1–5% protein (BSA or heat-inactivated
fetal calf serum).
1.2 How to keep cells in suspension
The sedimentation rate of cells in a fluid depends on their physical
properties such as density, cell size, cell shape, viscosity of the
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Figure 35. The threshold value defines a signal intensity, in one or more parameters, above which the cytometer starts to recognize an event.
All other events will be invisible to the instrument’s electronics. A particle passing the laser beam emits a certain amount of light over time. The
threshold is set on the height of the signal that is emitted by each particle. On the left-hand side a dotplot with the forward scatter as the trigger
parameter is shown. Only particles with a signal higher than this threshold value are recognized by the software as an event and shown in the
dotplot (black and orange dots). The dots in on the left side of the threshold value (grey and blue dots) are not included in the data file.
surrounding medium, and gravity [213]. In addition, the effective
density of a cell is also affected by its water content, and thus the
sedimentation rate is not a constant property for an individual cell
type [213, 214].
1.2.1 Physical treatment of cell suspension. Another possibility to
avoid cell sedimentation is the physical treatment of the cell sus-
pension before or during the cell sort. This is achieved by shaking
or rotating the sample tube, or stirring with the sample line inside
the cell sorter [215]. Rotating unidirectionally is not very effective
since the sedimentation is delayed but not prevented. For exam-
ple, the threshold rate of human leukocytes decreases to 80%
after 30 min of cell sorting and then to 50% after an additional
15 min. Moreover, the constant rotation of the tube, especially if
cells stick between the lower end of the sample line and the tube
bottom, acts like a “cell crasher.” A more effective and gentle
treatment is achieved by shaking or pipetting the cell suspension.
Another possibility is to employ surface acoustic waves (SAW)
to keep the cells in a homogeneous suspension. SAWs are gen-
erated on the surface of a piezoelectric crystal by applying a
high-frequency electrical signal to specially formed pairs of elec-
trodes deposited on the crystal [216]. By use of a coupling fluid
(e.g. water) between the crystal and the sample tube, the SAWs
are conducted to the sample via the tube bottom. This allows a
mechanical and gentle resuspending of the sample by acoustic
streaming. This approach is specific in that it uses low ampli-
tudes and high frequencies and is therefore not detrimental for
living cells and can be implemented in a cell sorter (e.g. BD
FACSAriaTM) [217]. Using this approach, it could be shown that
the amount of dead cells (human leukocytes) after 45 min cell
sorting was not increased in comparison to unmixed cells, while
the yield was 30% higher [217].
1.2.2 Density of cell suspension. The sedimentation of cells can
be controlled by using isopycnic (i.e. equal or constant density)
media [214]. The rationale behind this is to resuspend cells after
the last wash in media of equal density. This can be achieved by
using various reagents e.g. Percoll R©, Ficoll R©, HBSS, Nychodenz R©,
Xanthan Gum [213, 218, 219]. For example, a 60% Percoll solu-
tion results in a media density of 1.07 g/cm³, which is equal to the
density of human lymphocytes but different from that of human
erythrocytes (1.10 g/cm³). However, in practice the sedimentation
rate of both cell types is decreased or stopped and therefore sedi-
mentation is drastically minimized. In any case the toxicity of the
final buffer should be tested by leaving cells in the buffer overnight
at 4°C and the resultant cell viability should not be below 80%.
The use of an isopycnic medium is an option but only necessary if
sedimentation is an issue. Furthermore, the resulting density and
viscosity of the cell suspension needs to be optimized to enable
a stable cell suspension uptake within the cell sorter. Finally, the
reagents should not change the optical properties of the resulting
media to avoid scatter noise.
2 Trigger, thresholds, and live gating
2.1 Trigger and threshold
To facilitate the discrimination of particles of interest from back-
ground events it is useful to define a minimal signal value, the
threshold value, which a particle passing the optics of a flow
cytometer must reach to be actually recognized as an event.
The threshold value defines the signal intensity above which
the cytometer starts to recognize an event and therefore limits the
number of events coming from background signal (Fig. 35). Every
event showing a lower signal than the threshold defined will not
be detected by the cytometer and will not be represented in the
data file.
Background noise coming from the instrument itself (electronic
noise), microparticles in the buffer as well as cellular debris can
overlap with the signal from the relevant events especially if the
analysis is focused on small particles likemicroparticles, exosomes,
or platelets. Therefore it is advisable to look for a leading parame-
ter (i.e. a parameter with a clear discriminator for the population
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of interest) as the trigger parameter, and predefine a threshold
value.
2.2 Trigger parameters
The default setting of the trigger parameter, i.e. the parameter
used to exclude signals below a certain intensity, on most instru-
ments is set to forward light scatter.
Depending on the cells or particles of interest it is also
possible—and sometimes even necessary—to set a threshold on
a fluorescence parameter. The resolution of small particles, e.g.
platelets, erythrocytes, or extracellular vesicles, is much easier
when the threshold can be set on a fluorescent signal (e.g. a com-
mon surface marker that clearly defines the target population) as
background discrimination in FSC and SSC is often difficult.
Sometimes even a combination of two triggers is used to opti-
mize the analysis. In this case the event must meet the value of
both thresholds to be recognized by the flow cytometer. Such a
threshold combination is often used when the expected signal of
a particle is low and therefore quite close to the background noise
of the trigger channel.
It should be noted that many cytometers allow the user to col-
lect pulse area (A) to measure the total amount of fluorescence by
considering both, pulse height (H, fluorescence brightness) and
pulse width (W, pulse duration) [23] and this is what is then
by default depicted in dotplots and histograms. Threshold lev-
els however are applied to pulse height and it is advisable to set
threshold values while viewing pulse hight, especially if the trig-
ger parameter might be a fluorescence parameter where signal
levels are low and the main contributor to area is pulse width
(W). For many cytometers, pulse height and width are not col-
lected by default and have to be chosen in the instrument setting
beforehand.
2.3 Live gating
Setting a threshold is often used to reduce the data file size and
to facilitate data analysis with analysis software (see Section VI.1:
Data analysis: An overview). The same effect can be achieved with
the setting of a “live gate” on the population(s) of interest during
sample acquisition. This electronic preselection will exclude all
events not falling into the gate from being recorded into the data
file and can be set according to multiple parameters (hierarchical
gating) to enrich for a rare cell population. However, with com-
puter and analysis software becoming more and more powerful,
the risk of losing relevant information by setting a “live” gate often
outweights the necessity of reducing the data file size. Live gating
should be carefully thought through before excluding data that
might be of interest later on [218].
2.4 Threshold and cell sorting
Events with signals lower than the threshold value will not be
recognized by the flow cytometer and will be ignored completely
by the electronics of the instrument. This fact is important to
consider when it comes to cell sorting. Because the instrument
does not detect these events, they are not being included in the
process of the sort decision nor are they shown in the actual events
per second going through the instrument. Consequently, sorted
fractions can get contaminated due to the fact that these “invisible”
particles, although ignored by the electronics, are in fact still part
of the sample. When the droplets are formed these particles can
end up inside or in the neighboring drop of a target cell. Normally,
this would lead to a sort abort, depending on the sort mask, but
if the threshold is set in a way that the particle is invisible to the
software, there can be no decision on the particle, resulting in a
contamination of the sorted fractions.
It is therefore recommendable to use the minimal threshold
value possible for identifying the required population.
3 Rare cells: General rules
3.1 Introduction
Rare cell populations are of growing importance in several fields,
from basic research to translational medicine and diagnostics. In
several clinical settings, rare cell counts provide valuable infor-
mation on the status and stage of the patient’s disease. Some
examples are rare CTCs in the peripheral blood, tumor stem cells,
circulating endothelial cells, hematopoietic progenitor cells and
their subpopulations, and fetal cells in maternal circulation. Inter-
esting applications of rare cell analysis include the detection of
metastatic breast cancer cells [220] or neuroblastoma cells infil-
trating the bone marrow [221], monitoring of minimal residual
disease [222, 223], detection of stem cells and rare HIV-infected
cells in peripheral blood [224], antigen specific T cells, invariant
natural killer T (iNKT) cells, and analysis of mutation frequencies
in genetic toxicology [225]. Moreover, polyfunctional assays, such
as the Ag-induced production of different cytokines by T lympho-
cytes, are often performed, and these raise the problem of finding
rare cells within these T-cell populations aswell. In this section, the
main issues of this topic will be discussed, including the amount of
biological material required, the use of pre-enriched populations,
the number of markers to use and cells to acquire, the importance
of excluding doublets and the use of a DUMP channel.
3.2 Optimization
Studying rare cells requires attention, optimal methodologies in
all phases, including collection of biological samples, well defined
controls and adequate use of software and hardware [226]. The
term “rare” generally refers to events with a frequency of 0.01% or
less, although the record claimed in the literature has long stood
at 1 cell in 10 million for tumor cells spiked in the peripheral
blood [227, 228]. For this, the acquisition of a large number of
events (see Section V.3.2.3: Number of acquired events) and a
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high SNR (see Section V.3.2.5: Thresholds, gating, and DUMP
channel) are the most relevant aspects.
3.2.1 The quantity of the biological material. On the basis of the
estimated frequency of the rare cells under investigation, it is cru-
cial to calculate how much biological material is required. For
example, if the endpoint of the experiment is to enumerate rare
cell populations present in the cerebrospinal fluid (CSF), consid-
ering that only a few mL can be obtained from a patient, it is
logical that all the CSF has to be used. If blood is the biologi-
cal matrix of interest, the rare cell population of interest and the
pathology of the patient should be considered in depth. Should
the endpoint of the study be the evaluation of cytokine production
after in vitro stimulation by cells such as iNKT cells in patients
with HIV infection, some pre-analytical considerations should be
taken into account. For example, iNKT cells are extremely rare
among peripheral PBMCs (0.01–1%), and in order to define this
population several markers must be used, including those for rec-
ognizing CD3, CD4, CD8, invariant TCR, as well as those for cell
viability and several cytokines such as TNF-α, IFN-γ, IL-4 and,
IL-17 could be of interest, meaning that nine markers are required.
HIV+ patients who do not take antiretroviral therapy are obviously
severely immunocompromised, and have a low number of CD3+ T
lymphocytes. Thus, the amount of blood required to detect a rea-
sonable number of rare cells (according to Poisson statistics) can
be as much as 50 mL of blood, since either resting or stimulated
cells have to be analyzed [229].
3.2.2 Enrichment and choice of markers. On the basis of the
experimental endpoint(s) (e.g. phenotyping, functional assays),
the rare population may be enriched or not, and the number of
markers that are needed to unambiguously identify a rare cell pop-
ulation needs to be defined. For example, the accurate quantifica-
tion of circulating endothelial cells and their progenitors, shown in
Fig. 36, is a matter of debate. Several studies have been published,
but no consensus has thus far been reached on either the markers
that should be used to identify these cells, or on the necessity of a
pre-analytical enrichment (by density gradient, buffy coat and/or
magnetic enrichment). The enrichment, however, can have nega-
tive effects if rare cells are lost, or these effects may be positive,
if unwanted cells are removed [230–234]. Unfortunately, quite
often, the lack of well standardized methods influences the deci-
sion regarding the number of markers, which are necessary for
the identification of the population of interest. Depending on the
technical characteristics of the flow cytometers, which have a vary-
ing number of fluorescence channels and the speed of acquisition,
the most important marker allowing the identification and char-
acterization of such populations should be decided. For example,
in the case of iNKT cells, the Vα24Jα18 invariant TCR allows the
unique identification of these cells. Having done that, the marker
panel has to be built following a general rule that the brightest
fluorochrome has to be used for the weakest expressed marker.
Finally, attention should be paid to compensation, and acquisition
of FMO controls, which is covered in more detail in Section III.1:
Compensation and Section IV.1: Controls: Determining positivity
by eliminating false positives).
3.2.3 Number of acquired events. Concerning the number of
events which need to be acquired it is recommended to use Pois-
son statistics, which defines the probability that a given number of
events will occur in a fixed interval of time/space, assuming these
events would occur with a known average rate and independently
of the time elapsed from the previous event [235]. Therefore, Pois-
son statistics are applied to count randomly distributed cells in a
certain volume. Let us consider a general case of enumerating a
total of N events, of which R meet a certain criterion (i.e. they are
positive, P). In this case a proportion of P events is defined as P =
R/N. The probability of any single event to be positive is obviously
0  P 1, and this is related to the random manner in which
cells are selected for analysis. As with all statistical distributions,
the variance, Var, is a fundamental parameter, and is defined as:
Var(R)= NP(1 – P). The SD is the square root of the variance,
and the CV is the SD equal to 1/square root of Var [236]. These
equations can be used to examine some practical situations. Let
us consider a phenotype analysis of human PBMCs stained with a
mAb for detection of B cells (e.g. CD19 mAb). In healthy individu-
als, 10% of the cells can be positive, so that: P = 0.1 and P(1 – P)=
0.09. Good experimental practice suggests to keep CV below 5%;
thus, acquiring even 5 000 events could be sufficient, because the
CV is 0.047 (i.e. in percentage, 4.71%). Using a number of cells
such as 10 000, the CV becomes 3.33%. However, should posi-
tive events be less frequent, a higher number of events must be
acquired. Table 6 reports an example for events whose frequency
is 0.01%, as often occurs studying antigen-specific T cells.
This is clearly the ideal methodology. However, real life is dif-
ferent from theory, and very often the final number of events can-
not be high enough to satisfy this golden rule. For example, we can
consider the case in which 1 million peripheral T cells are stimu-
lated with an antigen that activates less than 0.1% of them, namely
100 cells in one million. Nowadays, by polychromatic flow cytom-
etry, T-cell activation can be analyzed by evaluating the polyfunc-
tionality of these cells, and protocols have been developed that
can identify in a relatively easy manner 4 or even 5 functions per
cell. Thus, among responding cells, up to 32 populations can exist,
likely with a different frequency, and each subpopulation contains
a few cells that are completely absent in the control, unstimulated
sample. Can we consider such cells positive, even if their number
is much lower than that indicated by a strict statistical approach?
A pivotal paper by Mario Roederer, an opinion leader in this field,
gives us very useful and clear suggestions [237]. Indeed, if alter-
native explanations for the presence of such positive events can be
excluded (i.e. if there is no noise due to dead cells or fragments,
and if cell activation is really due to the antigen used in vitro and
not to a pre-activation in vivo of T cells), the events can be con-
sidered positive, irrespective of their number. Thus, there is no
reason to fix a threshold for the number of events below which
any frequency must be considered “negative” [237]. In this case,
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Figure 36. An example of a gating stategy for rare
cells. Gating stategy used to identify circulating
endothelial cells (CECs) and their precursors (EPCs)
among peripheral blood leukocytes. (A) Debris and
aggregates were eliminated using FSC-Area versus
FSC-Height, (B) possible clogs were removed using
the parameter Time versus SSC. (C) a DUMP chan-
nel was used to remove CD45+ cells and dead cells
from the analysis. (D) nucleated cells were identi-
fied based on Syto16 positivity. (E) Stem cells were
identified according to CD34 positivity, (F) EPCs
(CD133+,CD31+) and CECs (CD133–, CD31+) were
identified. The expression of CD276, also named B7-
H3 (G, I)., and CD309 (H,J), also named VEGFR-2 or
KDR, was evaluated in each subpopulation. In this
example, more than tenmillion events were initially
acquired in order to enumerate a population that,
according to the literature, is always represented
less than 0.1%.
“positivity” can be determined after comparison of the measure-
ment against a set of control samples, among which the adequate
negative controls, using standard statistical tools to compare the
frequencies. For example, assuming that from the technical point
of view the experiment is well performed, if T cells from “n” unvac-
cinated controls show no activation after the stimulation with the
adequate peptides, while T cells from “n” vaccinated individuals
do, even extremely low frequencies can be taken as positive. The
same logics can be applied in thousands of other cases, assuming
that the relative controls are well chosen.
3.2.4 Sample concentration and flow rate. Because it is crucial
to acquire a high(er) numbers of events for detection of rare
cell population, sample concentration and flow rate are critical
Table 6. Example to calculate the number of acquired events for a rare cell population representing 0.01%.
Acquired events(N) 10,000 500,000 1,000,000 4,010,000 10,000,000 20,000,000
Positive (R) 1 50 100 401 1000 2000
Proportion (P) 0.0001 0.0001 0.0001 0.0001 0.0001 0.0001
Variance (Var) 0.9 49.99 100.0 400.1 999.9 1999.80
Standard deviation (SD) 0.9 7.07 10.00 20.02 31.62 44.72
Coefficient of Variation (CV) 100.00 14.14 10.00 4.99 3.16 2.24
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parameters, which can typically shorten acquisition time. How-
ever, care must be taken that increasing the flow rate results in
an increase of coincidence, and thus higher CV, if flow cytometers
use hydrodynamic focusing (which is the system used at present
in most commercially available flow cytometers).
3.2.5 Thresholds, gating, and DUMP channel. A threshold should
be fixed in order to distinguish the signal (using fluorescence or
scatter) required to define the population of interest from the
noise/background (see Section V.2: Trigger, thresholds, and live
gating). Hence, maximizing the SNR of the cells of interest is
mandatory. Gates should be drawn to exclude dead cells, iden-
tified by viability marker, doublets/aggregates/debris and all the
unwanted cell populations from the analysis, and a “DUMP” chan-
nel containing antibodies that identify cells of no interest is highly
recommended. Moreover, using a dot plot with the parameter
“time” versus that of interest allows to remove the event bursts
caused by clogs or other transient problems during the acquisi-
tion. The instrument should be kept clean, and it is essential to
wash the instrument between acquisitions of different samples in
order to minimize sample contamination, which could cause the
detection of false positive events.
3.3 Data analysis
Finally, data analysis requires adequate software and powerful
hardware (more than 8GB RAM or higher), because acquired data
file tend to be huge, depending on how many events and parame-
ters have been acquired (e.g. 10 colors and 2 scatters in 10 million
events are indeed a good test for your computer). To minimize
the file size, parameters that are not really needed can be unse-
lected, and a fluorescence/scatter threshold trigger can be used.
Data analysis will be covered in greater detail in Sections VI.1–3:
Data analysis: An overview, Data analysis—automated analysis:
Automated flow cytometry cell population identification and visu-
alization and Statistics for flow cytometry. In conclusion, flow
cytometry is at present the most potent technology to address
rare cell analysis, and the so called “next generation” instruments
with very high speed and sensitivity are already allowing an easy
detection and analysis of such cells.
4 Collecting cells
4.1 Introduction
Even if a cell sorter is well adjusted i.e. the instrument is able to
deflect the right drop with the cell of interest at the right moment,
it is still possible that the drop does not hit the collection vessel,
due to issues regarding the relationship between cell size, nozzle
size, sheath fluid temperature, pressure stability. This results in
a low sort yield and sometimes low purity. Optimal collection
efficiency therefore depends on the setup of the cell sorter as well
as the position and properties of the sample collection tubes.
4.2 Cell sorter-specific parameters
For a cell sort with high purity and yield an optimal gating strat-
egy and detector setup is mandatory. Often, the discrimination
between stained and unstained cell populations is problematic
if they have a high overlap. In “dim” populations (i.e. low signal
intensity e.g. due to lowmarker expression or weak fluorochrome)
the distribution of the cell events is dominated by the photon
counting statistic of the PMTs and the background light and elec-
tronic noise of the detection channel. In other words, when the
light intensity emitted from a single cell is measured by a PMT,
the specific signal has an additive part of a constant amount of
non-specific signal (coming from the background light, electronic
noise etc.). Thus, when a specific cell signal decreases, the non-
specific part remains stable and more and more dominates the
entire signal and hence the distribution of the population. Con-
sequently, the relative position of a cell inside a dim population
is dominated by the background signal. This can lead to low cell
recovery if gates are not well adjusted. Proper staining controls
such as FMO (fluorescence minus one) [196] controls instead of
unstained/ single stained cells are very helpful to find the real
boundaries of cell populations (see Section IV.1: Controls: Deter-
mining positivity be eliminating false negatives). Furthermore, an
optimal SNR by choosing the required PMT gain is essential for
good population discrimination and optimal cell recovery [238].
Modern cell sorters can sort up to six cell populations simul-
taneously in collection devices equipped with tubes (e.g. Falcon R©
5–50 mL round buttom tubes, 1–2 mL microcentrifuge tubes).
Depositions of single cells in multi well culture plates or onto
slides, are also possible. Droplet sorters allow drops to be charged
on different charge levels either positively or negatively, which
allows drops to be deflected either to the left, far left or to right,
far right. Deflection streams containing populations with the high-
est number of events to be sorted should be placed close to the
center stream (i.e. left or right), since the focusing of the deflection
streams is often better if their deflection is low. This minimizes the
risk of cross contamination between the collection tubes.
Furthermore, the position of the deflection stream should be
monitored during the sort process. This can be achieved by using
the AccuDropTM technology [215] which consists of a red diode
laser for side stream illumination, a filter block, and a camera
mounted in the back of the sort chamber. The camera provides an
image of the deflection streams with the intercept points of the
laser beam. This allows the user the monitoring of the deflection
stream quality in terms of position, focusing, and stability. Some
sorters allow the monitoring of the break-off point using a camera
and control the amplitude of the drop drive frequency depending
on the camera image. This keeps the break-off point in a stable
position by increasing or decreasing the amount of drop drive
energy to the stream. This is a useful approach as long as the
viscosity, density, and pressure of the sheath fluid is stable. If
not, the cell recovery decreases even if the position of the break-
off point is stable. Rapid temperature fluctuations of the sheath
fluid of 1–2 K inside or next to the nozzle can become critical for
cell recovery as well as for the side stream focusing. Therefore,
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good air conditioning or a sheath cooling [17] device is highly
recommended.
The side stream position for cells sorting in multi well plates
is essential and needs to be verified by test sorting of the target
cells because the final drop positioning is often slightly different
for beads or other cells. For single-cell sorting of 384-well plates,
a plate cooling device is recommended to avoid evaporation of the
cell media.
4.3 Sample collection tubes
The collection tubes can differ in terms of material as well as
size. Polypropylene tubes are preferable over polystyrene tubes
because the cells adhere less to the tube wall. Polystyrene tubes
may build up the charge of the deflected drops on their surface.
This can generate cross-contamination between collection tubes
due to “jumping drops” caused by repulsion of incoming drops
but can be prevented by using a grounded wire connected to a
bent injection needle hung over the side of tube, such that the
needle is in the fluid [218]. Different tubes sizes can be combined
in a specific tube holder depending on the flexibility of the cell
sorter. Moreover, a custom made tube holder became available
recently as 3D print file [239].
The size of the collection vessel should fit to the expected vol-
ume of the sorted cell suspension and is correlated to the drop size
and therefore to size of the nozzle. For example, 4 × 106 cells fill
approximately a 5 ml Falcon R© tube (12 × 75 mm), when using
a 70 μm nozzle. The same amount of cells would require five 5
mL tubes when a 100 μm nozzle is used. Especially for long term
sorts these correlations should be concerned, in order to prepare
enough collection tubes beforehand. On the other hand, there is a
high risk that cells may not be recovered in the collection tube if
the tube size is much higher than the expected sample volume.
Collection tubes should be coated with proteins to avoid that
the sorted cells stick to the tube wall as this results in reduced
recovery and viability. This can be done by filling the tubes with
10% FCS (fetal calf serum) 30 minutes before sorting or incu-
bated overnight at 4°C with 10% BSA (bovine serum albumin).
As a general rule, the collection tubes should be prefilled with
a small volume of media optimized for the cells of interest. This
prevents the dehydration of the sorted cells and keeps the cells
under optimal conditions to ensure their viability [240].
VI. Evaluation and data handling
1 Data analysis: An overview
1.1 Introduction
Flow cytometry data analysis presents a complex problem
because of recent rapid increases in the number of parameters
measured, and because of some peculiarities of flow data. Current
datasets include 20 or more parameters even for conventional
fluorescence cytometry, and other methods yield 35 or more
channels. Traditional bivariate gating, which involves manually
drawing boundaries on sequential two-parameter plots, can still
be performed on high-dimensional datasets, but this becomes
progressively more time-consuming and less thorough as the
parameter number increases. There has been rapid development
of automated gating and clustering algorithms, which are likely
to be the methods of choice in the future [241–249], and these
strategies are described in more detail in Section VI.2 Data
analysis—automated analysis: Automated flow cytometry cell
population identification and visualization. However, manual
analysis is still critically important in flow analysis for providing
“reality checks” for the results returned by different algorithmic
strategies, for investigators who do not yet have ready access to
automated methods, and for investigators who prefer to continue
manual gating for consistency with previous results. This section
will describe common issues in analysis, in three stages—pre-
processing, gating and post-processing. This section should be
read in conjunction with Section VI.2: Data analysis—automated
analysis: Automated flow cytometry cell population identification
and visualization on automated data analysis.
1.2 Pre-processing flow data in preparation for
sub-population identification
1.2.1 Batch effects. Flow cytometry data are difficult to standard-
ize between batches that have been analyzed days or months apart
because cytometer settings can change with time, or reagents may
fade. Imperfect protocol adherence may also lead to changes in
staining intensity or machine settings. Such variations need to be-
identified, and where possible, corrected. In addition to batch vari-
ation, individual outlier samples can occur, e.g. due to temporary
fluidics blockage during sample acquisition. Identification of these
changes can be performed by detailed manual examination of all
samples. However, this involves evaluating the MdFI between
samples after gating down to meaningful sub-populations. For
high-dimensional data this is difficult to perform exhaustively
by manual analysis, and is more easily achieved by automated
methods. As an example, samples from a study performed in
two batches, on two cytometers, were analyzed by the clustering
algorithm SWIFT [246, 250], and the resulting cluster sizes
were compared by correlation coefficients between all pairs
of samples in the study (Fig. 37). The most consistent results
(yellow squares) were seen within samples from one subject,
analyzed on one day and one cytometer. Samples analyzed on
the same day and cytometer, but from different subjects, showed
the next smallest diversity (compare subjects 1 vs 2, and 4 vs
5). Weaker correlations (blue shades) occurred between samples
analyzed on different days, or different cytometers. Similar batch
effects are seen in datasets from many labs. These effects should
be addressed at two levels—first, at the experimental level,
day-to-day variation can be minimized by stringent adherence
to good protocols for sample handling, staining and cytometer
settings (see Sections III: Setup: Instrument setup and quality
control. 1 and 2: Compensation and Maintenance). For multi-site
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Figure 37. Quality control analysis to detect batch effects. Eight
sequential blood samples each from six subjects were analyzed by flow
cytometry, clustered using the SWIFT algorithm, and Pearson corre-
lation coefficients in the number of cells per cluster were calculated
between all pairs of subjects. Samples were analyzed on two days, and
on two identically configured LSR-II cytometers.
studies, cross-center proficiency training can help to improve
compliance with standard protocols. If shipping samples is
possible, a central laboratory can reduce variability in the staining
and flow cytometer settings. Clearly, performing a study in a
single batch is ideal, but in many cases this is not possible.
1.2.2 Ameliorating batch effects during analysis. At the analysis
level, some batch effects can be reduced during further analysis. In
experiments in which batch effects occur due to variability in stain-
ing or cytometer settings, algorithms for reducing this variation
by channel-specific normalization have been developed (below).
Batch effects due to other causes may be more difficult to cor-
rect. For example, increased cell death is another potential batch
problem that is not completely solved by just gating out dead cells,
becausemarker levels on other sub-populations can also be altered
before the cells die.
1.2.3 Curation of datasets. In some datasets, curating names
and metadata may be necessary. The manual entry error
rate can be greatly reduced by using an automated Lab-
oratory Information Management System (e.g. FlowLIMS,
http://sourceforge.net/projects/flowlims) and automated sample
data entry. As manual keyboard input is a major source of error,
a LIMS system can achieve a lower error rate by minimizing
operator input through automated data input (e.g. by scanning
two dimensional barcodes) or pre-assigned label choices on pull-
down menus. Although compensation is conveniently performed
by automated “wizards” in popular flow cytometry analysis pro-
grams, this does not always provide the best values, and should be
checked by e.g. N×N displays showing all possible two-parameter
plots. Further information on compensation can be found in [148].
CyTOF mass spectrometry data needs much less compensation,
but some cross-channel adjustment may be necessary in case of
isotope impurities, or the possibility of M+16 peaks due to metal
oxidation [68].
In some datasets, further data curation is necessary. Defects
at specific times during data collection, e.g. bubbles or changes
in flowrate, can be detected and the suspect events removed by
programs such as flowClean [251]. Furthermore, compensation
cannot be performed correctly on boundary events (i.e. events
with at least one uncompensated channel value outside the upper
or lower limits of its detector) because at least one channel value
is unknown. The upper and lower detection limits can be deter-
mined experimentally by manual inspection or by programs such
as SWIFT [246]. The investigator then must decide whether to
exclude such events from further analysis, or to keep the satu-
rated events but note how this may affect downstream analysis.
1.2.4 Transformation of raw flow data. Fluorescence intensity
and scatter data tend to be log-normally distributed, often exhibit-
ing highly skewed distributions. Flow data also typically contain
some negative values, mainly due to compensation spreading
but also partly because of subtractions in the initial collection
of data. Data transformations (e.g. inverse hyperbolic sine, or
logicle) should be used to facilitate visualization and interpre-
tation by reducing fluorescence intensity variability of individual
events within similar sub-populations across samples [252]. Sev-
eral transformation methods are available in the package flow-
Trans [253], and should be evaluated experimentally to determine
their effects on the data with regard to the automated methods
used and further downstream analysis.
1.2.5 Registration/normalization of fluorescence intensity values.
Normalization between data sets with regard to fluorescence
intensities can be accomplished either by adjusting gates (i.e. man-
ually specified filters or probabilistic models designed to enumer-
ate events within defined regions of the data) between samples,
or by moving sample data closer to the gates via fluorescence
intensity registration. Auto-positioning “magnetic” gates can rec-
oncile slight differences between samples in programs like FlowJo
(FlowJo, LLC) and WinList (Verity Software House), but large
shifts in sub-population locations are difficult to accommodate.
Several semi-automated methods of fluorescence intensity regis-
tration are available (e.g. fdaNorm and gaussNorm [254, 255]).
These methods attempt to move the actual data-points across sam-
ples to similar regions, thus allowing gates to be applied to all
samples without adjustment. Both fdaNorm and gaussNorm reg-
ister one channel at a time, and do not address multidimensional
linkages between biological sub-populations. The methods further
require pre-gating to expose sub-population “landmarks” (peaks
C© 2017 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.eji-journal.eu
Eur. J. Immunol. 2017. 47: 1584–1797 Evaluation and data handling 1653
Figure 38. Model data illustrating
the very different interpretations of
two samples with similar propor-
tions of cells in a positive gate.
Left: A double-negative (A−B−) pop-
ulation with a random normal distri-
bution is modeled. Middle: Two small
sub-populations with random nor-
mal distributions are added to the
A−B− sub-population. The red and
green sub-populations contain few
cells, but are well separated from the
A−B− population. Right: The “nega-
tive” sub-population has been shifted
slightly, but no distinct smaller sub-
populations are present.
or valleys in one-dimensional histograms) to register effectively.
However, this “global” approach does not adequately capture the
semantics of biologically interesting rare sub-populations that
are often obscured by high-density data regions. A recent exten-
sion [255] of the fdaNorm method attempts to address this short-
coming by tightly integrating “local” (sub-population specific) reg-
istration with the manual gating process, thus preserving the mul-
tidimensional linkages of rare sub-populations, but still requiring
a hierarchy of manual gates derived from a reference sample.
Fully automated fluorescence intensity registration methods are
in development.
1.3 Identification of sub-population sizes and properties by
gating
1.3.1 Sequential bivariate gating. Sequential gating in two-
dimensional plots is the standard method for manual analysis.
Rectangular gates are convenient for well-separated sub-
populations, but more subtle gates are often required, e.g.
elliptical gates to define sub-populations in close proximity, or
“spider” gates (available in FlowJo) to allow for fluorescence
spreading due to compensation. The sequence of gates can be
important because the desired sub-population may be visualized
more effectively by particular marker combinations.
1.3.2 Back-gating. A critically important step for gating high-
dimensional data is to optimize the gates using back-gating, which
involves examining the cell sub-populations that satisfy all but one
of the final gates. This procedure is performed for each gate in turn,
and is critically important because small cell sub-populations may
be defined by boundaries that are different from the boundaries of
bulk sub-populations, e.g. stimulated, cytokine-producing T cells
display less CD3 than unstimulated T cells, so setting the CD3+
gate on the bulk T-cell sub-population will give an incorrect gate
for the stimulated T cells. Back-gating partly compensates for the
inability of manual gating to use all dimensions simultaneously,
as can be achieved in algorithmic clustering.
1.3.3 Validation of gated or clustered sub-populations. Another
critical issue is to examine the final gated sub-populations care-
fully, using prior knowledge and expectations from the biology.
Figure 38 shows three samples—a negative control that has no
positive cells in either dimension (left); a positive sample that has
small sub-populations of A+B− and A−B+ cells (middle); and a
sample that has no obvious positive sub-populations, but has a
slightly increased fluorescence intensity resulting in cells appear-
ing in the A+B− and A−B+ gates (right). If the results of gating
are accepted blindly, then the middle and right samples will be
evaluated as having similar A+B− and A−B+ responses, whereas
examination of the plots suggests a very different interpretation.
Biological insight is also very useful—if a large sub-population
appears to be positive for a marker that is usually expressed only
on a minor sub-population, it should be suspected that there is
an unusually high background for that marker on some cells and
further experiments should be done to confirm the specificity of
binding.
A limitation of manual gating in sequential two-dimensional
plots is that two sub-populations may not be fully resolved in any
combination of two dimensions, even though the sub-populations
are fully resolved if all dimensions are considered simultaneously
(which is only possible by algorithmic analysis). Thus in manual
gating it is sometimes necessary to make choices based either on
recovering the largest number of the target cells (wider gates, at
the expense of increased contamination), or identifying cells with
the most certainty (narrower gates, at the expense of some loss of
positive cells).
An important extension of this careful examination of the
results is to validate the results obtained by automated methods.
As for manual gating, the results of automated analysis should not
be accepted blindly, but should be checked in the familiar bivari-
ate scatter plots, or in recent dimensional reduction tools such
as VISNE [256]. Tools for examining the output of automated
methods are built in to programs such as FLOCK and SWIFT, and
available as plugins in FlowJo, Cytobank, and FCS Express.
1.3.4 Description of final sub-populations. The final sub-
populations identified by analysis are identifiedmainly by their flu-
orescence intensities for each marker. For some markers, e.g. CD4
on T cells, the positive cells comprise a log-symmetrical, clearly
separated peak, and the center of this peak can be described by
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the geometric mean, the mode, or the median with very similar
results. However, if a positive peak is incompletely separated from
negative cells, the fluorescence values obtained by these methods
can vary substantially, and are also highly dependent on the exact
positioning of a manual gate. If a sub-population is present as a
shoulder of a larger, negative peak, there may not be a mode, and
the geomean and median may have substantially different values.
1.4 Post-processing of sub-population data: Comparison of
experimental groups and identification of significantly
altered sub-populations
Regardless of the primary analysis method, the output of most
flow cytometry analyses consists of the sizes (cell numbers) and
median fluorescence intensities of many cell sub-populations. Dif-
ferences between samples (e.g. in different groups of a clinical
study) can be performed by standard statistical analysis, using
methods appropriate for each particular study. It is very important
to address the problem of multiple outcomes, and this is evenmore
critical in high-dimensional datasets because the potential number
of sub-populations is very large, and so there is a large potential
multiple outcome error. By automated analysis, hundreds or even
thousands of sub-populations can be identified [246, 250], and
manual analysis also addresses similar complexity even if each sub-
population is not explicitly identified. As in the analysis of microar-
ray and deep sequencing data, it is important to consider the false
discovery rate, using a strong multiple outcomes correction such
as the Benjamini-Hochberg strategy [257] or alternative strate-
gies [258]. Applying corrections to data from automated analysis
is relatively easy because the total number N of sub-populations
is known [259], but it is very difficult to identify N for manual
bi-variate gating, because a skilled operator exploring a dataset
will consider many sub-populations before intuitively focusing on
a smaller number of “populations of interest.” To avoid errors in
evaluating significance due to multiple outcomes in manual gat-
ing, strategies include: performing the exploratory gating analysis
on half of the data, and calculating the statistics on the other half;
or performing a confirmatory study with one or a few predictions;
or specifying the target sub-population before starting to analyze
the study.
2 Data analysis—automated analysis: Automated
flow cytometry cell population identification and
visualization
2.1 Introduction
The current generation of flow cytometers are capable of simul-
taneously measuring 50 characteristics per single cell, thereby
identifying up to 350 possible cell populations within hundreds
of thousands of cells per sample [260]. Given the vast amount of
data that can be generated, manual analysis techniques lack the
capacity and rigor to bring out the full potential of signals within
Figure 39. Typical automated analysis workflows in flow cytometry.
Analysis usually starts with several pre-processing steps, including
quality assessment data normalization and data transformation (blue
boxes). Pre-processing is followed by identifying cell populations of
interest (orange boxes) and visualization (green box).
such large datasets [261]. Furthermore, human subjectivity has
been identified as a primary source of variation within analyzed
results [249, 262]. Automated analysis methods have reached a
state where they can now provide a solution to the challenge of
analyzing big sets of flow cytometry data (Fig. 39). If chosen and
used with care, many of these automated tools show as good, or
even better, as well as more consistent analytic results compared
with those performed by “human” users [242, 247, 263, 264].
Prior to analysis, it is essential to make sure that each
file is properly compensated, quality controlled, normalized (if
required), and transformed (see pink and blue boxes in Fig. 39).
Additionally, potential outlier data at the event and sample level
should be identified and removed as needed. An overview of the
automation of these steps is outlined in Sections VI.1 and VI.2.
Once these data pre-processing steps are complete, users can iden-
tify cell populations using one or more of more than 50 automated
gating algorithms currently available [241] (see orange boxes in
Fig. 39).
Automated gating algorithms can be categorized as either
supervised or unsupervised. Supervised approaches to cell popula-
tion identification incorporate user knowledge into the algorithm
at various points. As such, supervised approaches are especially
beneficial when users have project-specific expectations (e.g. tar-
get cell populations of interest, based on an existing gating strat-
egy the user is trying to replicate). OpenCyto [265] and flow-
Density [266] are two such approaches which mimic the manual
gating process. Users can specify everything from gating param-
eters to the dimensions on which the algorithm should gate.
These gates can then be extracted, plotted, and adjusted until
they are satisfactory. Since the plots produced can be specified to
match a gating strategy, they can easily be used to communicate
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with those who are not familiar with the computational aspects
of analysis. Moreover, comprehensive analysis of state-of-the-art
supervised algorithms through the FlowCAP effort has shown that
these approaches produce unbiased results and can reduce anal-
ysis variability by up to 94% compared with that occurring with
manual analysis [247].
While supervised algorithms gate two dimensions at a time,
unsupervised “cluster analysis” algorithms “cluster” or group cells
with similar fluorescent intensities for similar groups of markers
directly in high-dimensional space. These algorithms often do not
require user input but do allow users to change a limited num-
ber of global parameters, such as the number of cell populations
expected, to allow tweaking of the results. The main aspect differ-
entiating unsupervised clustering methodologies from each other
is how they perform clustering. Tools assume different distance
measures, data distributions, or graph structures to define how
the cells are positioned in multi-dimensional space. Though there
is no best tool for all situations, design decisions dictate the types
of algorithms that will be suitable for specific samples or analy-
sis goals. For example, one of the targets that can be optimized
for is the identification of rare cell populations. Such populations
are often not robustly identified and are grouped together with
larger clusters, or with cell populations that are highly overlap-
ping in all dimensions. Several unsupervised algorithms have been
developed to aid users who aim to discover, or target, those cell
populations (e.g. SWIFT [267]).
2.2 Visualizing big flow cytometry data
Comprehensible visualizations are essential for the communica-
tion, validation, exploration, and discovery of possibly significant
cell populations. In conjunction with cell population identifica-
tion algorithms, visualization is an often overlooked but essen-
tial part of the discovery and diagnosis process (see green box
in Fig. 39). Visualization can be a challenge for unsupervised
clustering algorithms, as it is difficult for users to comprehend
the cell populations identified in high-dimensional space. There-
fore, dimension reduction is increasingly being applied to map
multi-dimensional (i.e. samples using more than two markers)
results onto a two-dimensional plane for viewing. For instance,
the SPADE algorithm colors and connects significant, structurally
similar immunophenotypes together in the form of a minimum
spanning tree, or a tree like form [249]. Dimensionality reduc-
tion techniques such as those based on t-distributed stochastic
neighbor embedding (t-SNE) arrange cell populations in a way
that conserves the spatial structure of the cell populations in
high-dimensional space. This way, users get a more represen-
tative view of cluster distributions [268]. However, these and
some other dimensionality reduction methods do not explicitly
identify and partition cells into subpopulations. Conversely, the
PhenoGraph algorithm robustly partitions high-parameter single-
cell data into phenotypically distinct subpopulations and has been
shown to perform well in comparative evaluation [264]. Algo-
rithms such as RchyOptimyx [269, 270], gEM/GANN [271] and
FloReMi [272] use already-labelled samples (e.g. participant has
or does not have a certain disease) to extract and display only
the cell populations that most significantly discriminate between
the differently labelled samples. These cell populations can then
be used as indicators, and thus one can target these cell popula-
tions, when determining the label of future samples [263]. Such
visualizations aim to focus in on only the most important data
structures present to facilitate human interpretation of the data.
Another visualization tool is the SPICE data mining and visualiza-
tion software (https://niaid.github.io/spice/) developed by Mario
Roederer and Joshua Nozzi at the NIH. This is a powerful freeware
program for representing complex cytometry datasets. A compre-
hensive review of the available visualization algorithms is covered
in [55].
2.3 Next steps
Manual analysis may be a quick and sufficient way to identify
target cell populations if few (5) markers are used, the target
cell populations are large and well known, and the user is an
experienced flow cytometrist. However, as the number of dimen-
sions and samples scale up, automated analysis quickly becomes
the best (and perhaps the only) option. Nevertheless, automated
gating algorithms are simply one more tool to aid in the gen-
eration and validation of a proposed hypothesis. Yet knowing
how to do lab work does not necessarily prepare the scientist
for bioinformatics. One option is for users can collaborate with
and exploit the expertise and experience of bioinformaticians as
they, in turn, collaborate with other domain experts. Learning how
to use the algorithms is another option. The most comprehensive
library of flow cytometry analysis tools built to date can be found
on R/Bioconductor [241]. Although not the most user-friendly
choice, R uses a command-line interface to provide a powerful
foundation for many data mining and statistical computational
tools. A subset of Bioconductor tools are available with more user-
friendly GUIs (graphical user interfaces) such as FlowJo, FCSEx-
press and GenePattern [273].
With the growing amount of data becoming available, auto-
mated analysis is becoming an essential part of the analysis pro-
cedure [274]. Only by taking advantage of cutting edge computa-
tional abilities will we be able to realize the full potential of data
sets now being generated.
3 Statistics for flow cytometry
3.1 Background
One of the attributes of cytometric systems is that a large number
of cells can be analyzed. However, the data sets produced are
just a series of numbers that need to be converted to information.
Measuring large numbers of cells enables meaningful statistical
analysis, which “transforms” a list of numbers to information.
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At the most basic level, the objective of cytometric measure-
ments is to determine if there is more than one population in a
sample. In the case that two or more populations are completely
separated, e.g. the subsets studied can be gated by virtue of phe-
notypic markers or easily separated by cluster analysis (for more
detail please see Section VI.2: Automated data analysis: Auto-
mated flow cytometry cell population identification and visual-
ization), then the proportions of cells within each subset and
additional measurement parameters for each subset can easily
be calculated, and the analysis would be problem-free. However,
problems arise when there is overlap between subsets, based on
the parameters of the specific measurement e.g. fluorescence or
light scatter intensity.
Those performing DNA histogram cell-cycle cytometric analysis
are accustomed to resolving the problem of overlap as this occurs
at the G1:S and the S:G2+M interfaces of the histogram. G0, G1,
S, and G2+M are phases during cell division and obviously have
different DNA contents, which can be measured with DNA reactive
fluorescent dyes by flow or image cytometry. A considerable body
of analytical work has addressed this problem [275–278]. In con-
trast, relatively little such work has been carried out in immunocy-
tochemical studies, where the time-honored method of resolving
histogram data has been to place a delimiter at the upper end of
the control and then score any cells above this point as (positively)
labelled. This approach can lead to large errors and is best over-
come by improvements in reagent quality to increase the separa-
tion between labelled and un-labelled populations in a cytometric
data set, or by the addition of extra independent measurements
like additional fluorescence parameters [242]. But, this may not
always be possible and any subset overlap needs to be resolved.
See Section VI.1.2 that discusses data analysis and display. The
tools available to resolve any subset overlap in mixed populations
require an understanding of (i) probability, (ii) the type of distribu-
tion, (iii) the parameters of that distribution, and (iv) significance
testing. An overlapping immunofluorescence example is shown
below in subsection 3.6-Immunofluorescence example Table 13.
Additionally the use of statistical methods for drawing conclu-
sions at the level of data, derived from cytometric measurements,
is essential, but not covered here specifically.
3.2 Probability
Qualitative statements on probability are not very useful for quan-
titative analysis of cytometric data, which are affected by variabil-
ity of sample collection, sample preparation, sampling, measure-
ment imprecision, and variability in manual or automated data
analysis. Statistics allows us to derive quantitative probabilities
from cytometric data, especially as many data points are generally
measured in flow cytometry. Probability designated with a p-value
has a measurement range of zero, or absolutely impossible, to
unity, or absolute certainty. Very few events, if any, occur with a
p-value at these extremes. “The sun will rise tomorrow,” is a state-
ment with a p-value very close to unity. In contrast, “Man, one
day, will run the 100 meters in 1 second,” has a p-value of zero.
3.3 Types of distributions
There are many distributions but those most commonly encoun-
tered in the biological sciences are the Gaussian, binomial and
Poisson distributions.
3.3.1 The Gaussian distribution. The Gaussian distribution
(error function, “normal” distribution) is a bell-shaped curve sym-
metrical about a mean value with the following formula
Y = 1
σ
√
2π
e−(X−X )
2
/2σ2 (1)
where σ is the SD and X¯ is themean of the distribution. Algorithms,
based on the Gaussian distribution, have been used extensively for
cell cycle analysis by flow cytometry [278].
3.3.2 The binomial distribution. The binomial distribution is con-
cerned with occurrences of mutually exclusive events and is given
by the formula
(p + q)n = 1 (2)
where p is the chance of something happening and q is the chance
of that same something not happening. If we throw two regular
six-faced dice, n in the binomial equation is 2 and this expands the
equation to p2 + 2pq + q2 = 1. The chance of getting 2 threes on a
single paired throw is p2 = (1/6)2, the chance of getting one three
and any other number is 2 pq = 2 × 1/6 × 5/6 and the chance that
neither die will be a three is (5/6)2. Hence, the total probability
is given by ((1/6) × (1/6)) + (2 × 1/6 × 5/6) + ((5/6) × 5/6))
which sums to unity. Rosenblatt JI et al. describe the use of a
binomial distribution based algorithm to optimize flow cytometric
cell sorting [279].
3.3.3 The Poisson distribution. The Poisson distribution is used
to describe the distribution of isolated events occurring in a con-
tinuum, originally formulated by Poisson [280]. A good example
is the number of cells passing the analysis point in the cytometer
per second. Clearly you cannot ask the question of how many cells
did not pass the analysis point per second, so neither the Gaussian
nor the binomial distributions can handle this type of problem. In
order to use the Poisson distribution all we need is z, the average
number of times the event occurs within the continuum, where
the probability of observing the event n times, p(n), is given by
p(n) = zne−z/n! (3)
where n! is factorial n. The notation for the whole distribution that
sums to unity is
P =
n=∞∑
n=0
zne−z/n! (4)
C© 2017 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.eji-journal.eu
Eur. J. Immunol. 2017. 47: 1584–1797 Evaluation and data handling 1657
The Poisson distribution is important in cytometric cell sort-
ing purity for investigating coincidence in which there could be a
possibility of two or more cells being in the analysis point simulta-
neously. Poisson statistics also applies to the measurement of low
intensity signals, where just a few photons contribute to the mea-
surement, and to the counting of rare subpopulations, discussed
in some more detail below.
3.4 Distribution parameters
These include measurement of (i) central tendency namely, the
mean, percentiles, median and mode and (ii) dispersion parame-
ters namely, the mean deviation, variance, SD and coefficient of
variation, wherein the last of these, the CV of limited statistical
significance, is the SD divided by the mean.
3.4.1 Central tendency. The goal of many cytometry measure-
ments is the determination of the expression level of a given
marker in a cell and its distribution in a cell population. The
mean of a distribution is the sum of all the data points divided
by the number of the values in the distribution. The median is the
point in the distribution where half the data lie on either side;
it is also known as the 50th percentile, the point, where 50% of
the data has been accumulated. 25th percentiles and 75th per-
centiles are also determined for distributions. The mode is the
maximum frequency. But, this is an unreliable measurement of
central tendency in cytometry for two reasons. First, the mode is
meaningless if this is located in the first or last channel of the his-
togram. In some cases cytometry histograms have many off-scale
events, which makes the fist or last channel in the histogram the
highest point. Second, even though a large number of cells will
have been sampled, the distribution is not continuous, due to the
analog-to-digital conversion (ADC) step i.e. intensity values are
used as indices for incrementing histogram channels (e.g. 0 to
1023), and counting statistics as the SD of a count in a discrete
“channel” is equal to the square root of the count (more below in
Section VI.3.7: Rare cell analysis). Therefore, typical unsmoothed
cytometry histograms are often very noisy. Any “noise” around
the mode will give an erroneous result. The relationship between
these parameters is shown in Fig. 40.
3.4.2 Dispersion parameters. Just as central tendency gives a
measure of the overall “average” difference between Gaussian
distributions, the dispersion parameters give a measure of the
different spreads within and between those distributions.
The mean deviation is given by
∑
(X − X¯ ).
The variance, mean squared deviation, is given by
∑
(X − X¯ )2.
The SD is given by
√ [∑
(X − X¯ )2
]
.
3.5 Significance testing
The central axiom in statistical theory is that the variance of the
sum or difference of two independent and non-correlated random
Figure 40. Measurements of central tendencies for cytometric inten-
sity histograms. The curve is an ideal distribution, showing key mea-
surements. Cytometric intensity histograms span a finite intensity
range with a noisy curve and frequently with off-scale events at the
lower and/or upper end(s) of the scale. Generally the median is the
most robust measure, because the mean is heavily influenced by off-
scale events and the mode by noise.
variables is equal to the sum of their variances. These tests are
designed to give a measure of how different two or more dis-
tributed populations might be.
The most commonly asked questions in cytometry are (i) is
there more than one subset? and (ii) if there is more than one,
how many cells are in each? This is far too naive a perspective,
and with the statistical tools available we should be asking the
following:
1. Is there more than one subset?
2. If there is more than one, how far “separated” are they?
3. What is the significance of that separation?
4. If the subsets are significantly separated, then what are the
estimates of the relative proportions of cells in each ?
5. What significance can be assigned to the estimated propor-
tions?
The statistical tests can be divided into two groups. (i) Paramet-
ric tests include the SE of difference, Student’s t-test and variance
analysis. (ii) Non-parametric tests include the Mann-Whitney U
test, Kolmogorov-Smirnov test and rank correlation.
3.5.1 Parametric tests. These may best be described as functions
that have an analytic and mathematical basis where the distribu-
tion is known.
3.5.1.1 Standard error of difference. Every cytometric anal-
ysis is a sampling procedure as the total population cannot be
analyzed. And, the SD of a sample, s, is inversely proportional to
the square root of the sample size, N, hence the SEM, SEm =
s/N. Squaring this gives the variance, Vm, where
Vm = s2/N (5)
We can now extend this notation to two distributions with X¯1,
s1, N1 and X¯2, s2, N2 representing, respectively the mean, SD and
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number of items in the two samples. The combined variance of
the two distributions, Vc, can now be obtained as
Vc =
(
s21/N1
)+ (s22/N2) (6)
Taking the square root of equation (6), we get the SE of differ-
ence between means of the two samples. The difference between
means is (X 1 − X 2) and dividing this byVc (the SE of difference)
gives the number of “standardized” SE difference units between
the means; this standardized SE is associated with a probability
derived from the cumulative frequency of the normal distribution.
3.5.1.2 Student’s t (test). The approach outlined in the pre-
vious section is perfectly satisfactory if the number of items in the
two samples is “large,” as the variances of the two samples will
approximate closely to the true population variance from which
the samples were drawn. However, this is not entirely satisfac-
tory if the sample numbers are “small.” This is overcome with the
t-test, invented by W.S. Gosset, a research chemist who very mod-
estly published under the pseudonym “Student” [281]. Student’s
t was later consolidated by Fisher [282]. It is similar to the SE of
difference but, it takes into account the dependence of variance
on numbers in the samples and includes Bessel’s correction for
small sample size. Student’s t is defined formally as the absolute
difference between means divided by the SE of difference:
Student′s t =
∣∣X 1 − X 2∣∣√N
σ
(7)
When using Student’s t, we assume the null hypothesis, mean-
ing we believe there is no difference between the two populations
and as a consequence, the two samples can be combined to calcu-
late a pooled variance. The derivation of Student’s t is discussed
in greater detail in [283].
3.5.1.3 Variance analysis. A tacit assumption in using the null
hypothesis for Student’s t is that there is no difference between
the means. But, when calculating the pooled variance, it is also
assumed that no difference in the variances exists, and this should
be shown to be true when using Student’s t. This can first be
addressed with the standard-error-of-difference method similar to
Section 5.1.1 Standard Error of Difference where Vars, the sample
variance after Bessel’s correction, is given by
Vars =
{
(n1 × s21) + (n2 × s22)
n1 + n2 − 2
}
×
{
1
2n1
+ 1
2n2
}
(8)
The SE of the SD, SEs, is obtained as the square root of this
best estimate of the sample variance (equation (8)). This is now
divided into the difference between the two sample deviations.
The secondmethod of addressing the variance analysis is to use
the variance ratio [284], designated the F-test by Snedcore [285].
F is calculated as the ratio of the greater variance estimate of
sample variance to the lesser estimate of sample variance. After
Table 7. Comparison of two data sets X and Y in a rank analysisa)
Y-group y1 y2 y3 y4
X-group x1 x2 x3 x4 x5
Values 3 7 9 15 23 31 36 44 51
Rank 1 2 3 4 5 6 7 8 9
a)The values have been ordered according to magnitude in the third
row with their rank position in the last row. The populations from
which the data were drawn are shown in rows 1 and 2, the Y-group
and X-group, respectively. It is clear that the Y-group is tending to
be more to the right (greater magnitude) than the X-group, and the
question is whether this arrangement could have occurred purely on
a random basis. Reproduced with permission from [283].
Bessel’s correction we get the best estimate of the variances, σ2,
as,
σ2 = Vars ×
{
N
N − 1
}
(9)
3.5.2 Non-parametric tests. These rely on rankingmethods when
there is no known, or suspected, distribution that can be assigned
to samples being analyzed.
3.5.2.1 Mann–Whitney U. This problem was originally
addressed by Wilcoxon [286] and was later refined by Mann and
Whitney [287]. Consider two sets of data, the X-group and Y-
group, containing 5 and 4 values respectively; these are illustrated
in Table 7. These values have been ordered according to magni-
tude in the third row with their rank position in the last row. The
populations from which the data were drawn are shown in rows 1
and 2, the Y-group and X-group respectively. It is clear that the Y-
group is tending to be more to the right (greater magnitude) than
the X-group, and the question is whether this arrangement could
have occurred purely on a random basis. To do this, we determine
how many x-values lie to the right of every y-value and sum the
result to get Uy for the Y-group. There are three x-values (x3, x4
and x5) to the right of y1 and one x-value to the right of y2, thus Uy
sums to four. The same process is now carried out for the x-group
to give Ux equal to 16. For small sample numbers this procedure
is satisfactory but it can be prohibitively time-consuming for large
samples for which the following expressions are used.
Uy = NxNy + Ny(Ny − 1)2 − Ty
Ux = NxNy + Nx(Nx − 1)2 − TX
(10)
Nx and Ny are the number of values in the X- and Y-groups
respectively and Ty and Tx are the sums of the rank positions for
the Y- and X-groups, respectively.
If the X- and Y-values are randomly distributed in the rank, the
sum of the rank position T has a mean value of T and a variance
of σ2T given by the following expressions:
T x = Nx(Nx + Ny + 1)2 and T y =
Ny(Nx + Ny + 1)
2
(11)
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Table 8. Part of the Mann–Whitney probability table example for the
X-group size of Table 7 (N2 = 5)a)
U N1 = 1 N1 = 2 N1 = 3 N1 = 4 N1 = 5
0 .167 .047 .018 .008 .004
1 .323 .095 .036 .016 .008
2 .500 .190 .071 .032 .016
3 .667 .286 .125 .056 .023
4 .429 .196 .095 .048
5 .571 .286 .143 .075
6 .393 .206 .111
7 .500 .278 .155
8 .607 .365 .210
9 .452 .271
a)Reproduced with permission from [283].
These values of T x and T y will be identical if Nx and Ny are
equal, but the variance, σ2T, will be the same irrespective of the
numbers in each group and is given as
σT2 = NxNy(Nx + Ny + 1)12 (12)
If both samples are large, >20, we take the values of T and T¯
associated with the smaller of the pair of U-values, in this example
the Y-group, to calculate the Z-statistic as follows:
Z =
∣∣Ty − T y∣∣√
((NxNy(Nx + Ny + 1))/12) (13)
The numerator in equation (13) represents the difference
between the values of T for the Y-group and the mean, T¯ , that
would be expected if the numbers were randomly distributed
within the rank structure and the denominator is the square root
of the variance. Hence, Z represents the observed deviation from
the mean in SD units and the associated probability can be read
off from the cumulative frequency of the normal curve because,
for large samples, the Z-distribution approximates very closely to
the Gaussian distribution.
With small sample sizes, e.g. with less than 30 values, the Z-
distribution does not approximate to a Gaussian curve, andMann–
Whitney computed the probabilities associated with U-values for
different-sized samples. These data are arranged in tables for N2
= 3, 4, 5, 6 etc. and within each table there are sample sizes for N1
= 1, 2, 3, 4, 5 etc. versus the U-values and associated probabilities
for the N2 and N1 sample sizes. The example for N2 = 5 is shown
in Table 8. The sample size of the X-group (N2 in Table 8) is 5,
and the associated U-value is 4. The number of data points in the
Y-group is also 4, and hence, the probability that this distribution
of data points in Table 7 is different can be read off as 0.095 in
Table 8 and does not reach “significance” at the 1:20 level (0.05).
3.5.2.2 Kolmogorov–Smirnov (K–S) statistic. In the
Kolmogorov-Smirnov (K-S) statistic, D is a measure of the
maximum vertical displacement between two cumulative
frequency distributions. The one-tailed test compares an exper-
imentally derived distribution with a theoretical cumulative
frequency distribution and, the two-tailed test compares two
experimentally derived distributions (for more detail, see Chapter
6 in [288]). In any biological system, a test sample should always
be compared with a control, i.e. the two-tailed test, and this was
first used in flow cytometry by Young [289].
The cumulative frequency distributions containing n1 and n2
cells in the control and test samples respectively can be calculated
as follows for i = 1  256,
Fn1(i) =
j=i∑
j=1
f n1( j) and Fn2(i) =
j=i∑
j=1
f n2( j) (14)
These cumulative frequencies are now normalized to unity and
the null hypothesis is assumed (ie. both distributions are samples
derived from the same population) where the probability functions
P1(j) and P2(j) that underlie the respective frequency density func-
tions (the histograms) ƒ n1(j) andƒ n2(j) are samples assumed to
be drawn from the same populations so that
P1( j) = P2( j), −∞ ≤ j ≤ +∞ (15)
The D-statistic is computed as the maximum absolute differ-
ence between the two normalized cumulative frequency distribu-
tions over the whole of the two distributions, where
D = max
j
| f n1( j) − f n2( j)| (16)
As with the Mann–Whitney U, there is a variance, Var, associ-
ated with the assumed common population from which the two
samples, containing n1 and n2 items, respectively, are drawn. This
is given by
Var = (n1 + n2)
n1 × n2 (17)
The SD s can now be found by taking the square root of this
relationship, then dividing D by s gives Dcrit, where
Dcrit = max |Fn1 − Fn2|√
((n1 + n2)/(n1 × n2))
(18)
This type of relationship, in which we divide a difference by
a measure of dispersion, has been seen in all the other statistical
tests described previously. Two-tailed critical Dc for large samples,
along with their probabilities, are shown in Table 9.
3.5.2.3 Rank correlation. Correlation between two or more
sets of measurements can be determined with Spearman’s rank
correlation coefficient [290]. This enables an objective assessment
to be made regarding the consistency between paired laboratory
results as in the purely hypothetical data shown in Table 10.
When we look through these data, we find that both labora-
tories score sample 8 with the lowest results and in both cases
these are ranked 1. Sample 9 from lab A has the next lowest value
(0.07) and is ranked 2 but, it is sample 10 (0.12) that is ranked 2
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Table 9. Kolmogorov–Smirnov (K-S) statistic critical values, Dc, with their associated p-values (probabilities)a)
Dc 1.0727 1.2238 1.3581 1.5174 1.6276 1.7317 1.8585 1.9525
p 0.200 0.100 0.050 0.020 0.010 0.005 0.002 0.001
a)Reproduced with permission from [283].
Table 10. Hypothetical results of the same determinations from two
different laboratoriesa)
Sample 1 2 3 4 5 6 7 8 9 10
Lab A .61 .23 .31 .11 .41 .19 .10 .03 .07 .17
Lab B .54 .38 .42 .20 .36 .27 .21 .11 .14 .12
a)Reproduced with permission from [283].
Table 11. Ranking of the data from Table 10 with rank differences (d,
and d2)a)
Sample 1 2 3 4 5 6 7 8 9 10
Lab A 10 7 8 4 9 6 3 1 2 5
Lab B 10 8 9 4 7 6 5 1 3 2
Rank difference, d 0 –1 –1 0 2 0 –2 0 –1 3
d2 0 1 1 0 4 0 4 0 1 9
a)Reproduced with permission from [283].
in the lab B series, and these ranking positions are shown in Table
11.
In terms of ranking alone, the two laboratories agree exactly
for only 4 of the 10 samples, namely 1, 4, 6 and 8. Spearman’s
rank correlation coefficient R is given by the expression:
R = 1 −
{
6
∑
d2
n3 − n
}
(19)
d2 is the sum of the squared rank differences and n is the
number of samples; in our particular example, these values are 20
and 10, which gives R = 0.8787. This coefficient was designed to
have a value of +1 if there is perfect ranking agreement and –1
where there is total ranking disagreement.
This value of 0.8787 for R would suggest that there is fairly
close agreement between laboratories and where there are 10 or
more samples being compared we can use Student’s t to assess the
significance of comparison:
Student′s t = R ×
√
((n− 2)/(1 − R2)) (20)
which gives t = 5.2 with 8 degrees of freedom associated with
p < 0.01, which is highly significant and suggests there is close
agreement between laboratories. However, this does not tell us
anything about the quality of the “inter sample” agreement from
the two laboratories. This can be addressed by analysis of the
differences in results from the laboratories as shown in Table 12.
The mean difference X¯ is calculated by summing the data in
the difference row and dividing by n, the number of samples which
gives –0.052. If there are no differences between laboratories, this
mean value should not differ significantly from zero since any
random differences should cancel out.
The variance, s2, is calculated from the convenient relationship
as
s2 =
(∑
X 2/n
)
− X 2 (21)
where X2 is equivalent to d2 = 0.0824 yielding s2 = 0.0055.
After Bessel’s correction and using equation (6), we get Student’s
t = 2.1. This value of t, with 9 degrees of freedom, does not quite
reach the 5% probability level and we can conclude that the inter-
laboratory differences are not significant. However, in a quality
control exercise such as this, we would be justified in setting more
stringent statistical criteria. If we now take a probability level
of 0.1 for magnitude discrepancies between laboratories, which
would be reasonable as we know they should be getting the same
results, we must conclude there is something suspicious occur-
ring in the generation of the results, which would require further
investigation.
3.6 An example of immunofluorescent staining in cytometry
Figure 41 shows a histogram representation of weak staining of
a small population. Statistical analysis of this datum must ask a
number of questions.
First, is there any difference between these two datasets? This is
addressedwith a Kolmogorov-Smirnov analysis, which reveals that
there is a maximum normalized vertical displacement of 0.0655
at channel 37 with 8976, N1, and 8570, N2, cells in the control
and test sample respectively (Fig. 42). K-S statistic gave p < 0.05,
suggesting there is a statistical difference between the two datasets
at the 1:20 probability level. The remaining data shown in this
figure will become apparent later.
Second, can we establish the “meaning” of the discernible
shoulder in the lower histogram of Fig. 41? This is addressed ana-
lytically using a concept derived from mechanics; namely, taking
moments about a point. Imagine a weightless beam with two dif-
ferent weights hanging from the beam that will balance according
to equation (22)
W1(B − X 1) = W2(X 2 − B) (22)
where W1 and W2 are the “weights” hung from the beam, B is the
balance point, and X¯1 and X¯2 are the distances of the respective
weights from the balance point, B. On rearranging equation (22),
we get
B = ((W1X 1) + (W2X 2))/(W1 + W2) (23)
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Table 12. Differences between values from Table 10 by subtracting Lab B results from those of Lab Aa)
Sample 1 2 3 4 5 6 7 8 9 10
Lab A .61 .23 .31 .11 .41 .19 .10 .03 .07 .17
Lab B .54 .38 .42 .20 .36 .27 .21 .11 .14 .12
Sample difference, d .07 –.15 –.11 -.09 .05 –.08 .–11 –.08 –.07 .05
d2 .0049 .0225 .0121 .0081 .0025 .0064 .0121 .0064 .0029 .0025
a)Reproduced with permission from [283].
Figure 41. The histogram representation of fluorescence from a weak
staining of a small (rare) population. The upper histogram shows an
unstained control. A small shoulder from the staining of the rare pop-
ulation is visible in the lower histogram. Reproduced with permission
from [291].
Figure 42. Cumulative frequencies from the two histograms in Fig. 41
and difference. Details on the calculation of X ̅1 ̅, X ̅2 ̅, and Dm are
described in the text. Reproduced with permission from [291].
Let us suppose that the distances X¯1, X¯2 and B are known for a
normalized total mass of unity, where W1 + W2 = 1. We can now
calculate the relative proportion of W2 by replacing W1 with (1.0
– W2) in equation (23) and simplifying to give
W2 = (B − X 1)/(X 2 − X 1) (24)
The “weight” in equation (24) that will now be referred to as
“labeled cells,” is defined by three distances namely, X¯1, X¯2 and
B. X¯1 is the mean of the control unlabeled fraction, B is the mean
of the test sample containing labeled and unlabeled cells, and
both of these can be obtained directly from the experimental data.
We now need to obtain X¯2, the mean of the labelled fraction, as
follows:
It has been shown in [291] that the mean of the distribution
obtained by subtracting the N2 cumulative frequency from the
cumulative frequency of N1, is independent of the number of cells
in N1 and, the mean of the subtracted distribution Dm, depicted in
Fig. 42, is exactly half way between the means of N1 and N2. How-
ever, this applies to a continuous distribution and all cytometric
distributions are not continuous due to the ADC conversion and a
C© 2017 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.eji-journal.eu
1662 Andrea Cossarizza et al. Eur. J. Immunol. 2017. 47: 1584–1797
Figure 43. Result of the histogram analysis. The two original his-
tograms and the calculated stained population are shown with pop-
ulation means. Reproduced with permission from [291].
half channel correction must be applied to give the mean of the
N2 distribution as
X 2 = (2.0 × (Dm + 0.5)) − X 1 (25)
All the data have now been derived to calculate the propor-
tion of cells in the N2 distribution as W2 from equation (24) by
substituting the X¯2 of equation (25) and simplifying to give
W2 = (B − X 1)/(2.0 × (Dm + 0.5 − X 1)) (26)
The data depicted in Fig. 41 were analyzed according to this
ratio analysis of means to give X1 = 29.1, Dm = 37.4 and X¯2 =
46.7 as shown on the figure and the predicted proportion in N2
was 0.08. These data are shown in Fig. 43 where the control,
test sample and the predicted labeled fraction are labelled on the
figure. The test sample results are shown Table 13. We now have
to ask if this result is reasonable and what significance can be
placed on the result.
3.6.1 Kolmogorov–Smirnov analysis. The cumulative frequency
distributions of the control and test sample were re-analyzed over
a range of ±3 SD about the mean of the predicted labeled dis-
tribution, X2. With the number of cells involved, the K-S analysis
showed that the two cumulative frequency distributions over this
±3 SD range had a probability of being different at the 99% con-
fidence interval, p < 0.01.
3.6.2 Student’s t. The results from the analysis of the test sample
shown in Table 13 were also submitted to Student’s t analysis
(Chapter 7 in [283]). This gave t = 65.58 with 8 568 degrees of
freedom, p < 0.001.
Hence, we can present the results in probabilistic terms by
saying the analysis was compatible with two subsets with means
separated by 17.6 channels containing 92% and 8% of the popu-
lation at the 99% confidence interval.
This analysis should only be used for symmetrical data sets with
constant, or near constant, variance, and these data were chosen
for illustration as they conformed to this condition. However, there
are a number of other factors that should be considered, including
positive skew that tends to be minimized with log-amplification as
discussed elsewhere [291]. Nevertheless, this analysis goes some
way to producing a more statistically convincing method of pre-
senting results of immunofluorescence data.
3.7 Rare cell analysis
Flow cytometric analysis of cell samples is often applied to char-
acterize subsets of very low frequency, ranging from 1% to less
than 1 ppm. In those cases, it is very important to understand the
inherent variation when randomly sampling a small number of
events. As mentioned above, the SD of a count is the square root
of the number, e.g. when sampling from a cell/particle suspension
several times a volume, which should contain 4 cells/particles the
SD will be 2, the CV 50%.
If enough cells in the full sample are available, cytometric
data acquisition should be continued until a number of cells is
reached in the rare subset which assures the desired measurement
precision—a feature available in most commercial data acquisition
software. If not enough cells are available, care must be taken to
not come to conclusions, which are not supported by the limited
precision associated with limited acquisition.
Table 14 shows an example, where four consecutive determi-
nations indicated a progressive change of a property; but all of the
data are from the same distribution, and there is no change from
series 1 to series 4 (the data is from a simulation with a Gaussian
random number generator with a mean of 9.0 and a SD of 3.0).
This issue is discussed in more detail in a paper by Roederer [237].
In certain cases the limitation of the imprecision of count-
ing small numbers of cells can be overcome. For example one
can evaluate a bulk cell separation technology by dispensing a
known number of cells into a sample, subjecting the sample to a
separation process, and analyzing the total volumes of the result-
ing fractions.
Table 13. Results of the immunofluorescence analysis example, data from Watson [291]
Test sample Number of cells proportion Mean Standard deviation
Unlabeled 7889, N1 0.92 29.1,′X1 6.69, s1
Labeled 681, N2 0.08 46.7,′X2 7.13, s2
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Table 14. Illustration of potential interpretation problems, when
counting extremely rare cellsa)
Run 1 2 3 4
11 11 9 9
15 13 9 10
15 13 11 7
10 7 9 8
5 8 9 7
Mean 11.2 10.4 9.4 8.2
St.Dev 4.1 2.8 0.9 1.3
Overall mean: 9.8
Overall St.Dev: 2.7
a)The table shows integers from four different runs with five measure-
ments each from a random number generator. This could reflect a
study with four conditions with five replicates each. The table indi-
cates a trend from run 1 to 4; however, all of the data is from the
same distribution, and there is no change from run 1 to 4 (generated
with ROUND(NORMINV(RAND(),9,3),0) with a mean of 9.0 and a SD
of 3.0 in MS Excel. The cumulative mean and SD from the 20 values
approximate the real population numbers well.)
4 Analysis presentation and publication (MIFlowCyt)
4.1 Introduction
The complexity of cytometric data requires careful consideration
of how to display results in scientific presentations and publica-
tions in order to make them understandable “at a glance.” To eas-
ily reproduce published cytometric experiments the used methods
and results need to be described and presented comprehensively.
By flow cytometry, thousands of cells are acquired within sec-
onds by obtaining information about their scatter properties and
expression of multiple markers. Manual analysis of these multi-
dimensional and complex data requires special software skills,
gating knowledge, time and can be quite laborious. Manual gat-
ing is still considered by most cytometrists to be the “standard,”
although semi-automated algorithms exist. Some basic rules for
data visualization allow presenting these data in a directly com-
prehensible format.
4.2 Minimal display requirements
First of all, the full gating strategy should be displayed so that
data analysis strategy used is obvious to the reader. This display
should also include the position of positive and negative controls
and essential statistical information, such as the percentage of
cells in the region or gate or event count. Axis legends should
include the marker (e.g. antigen) and the dye used, and show
the scaling (log/lin). This information should also be provided in
the source list-mode data and non-informative legends such as
FL-1A, FL-1H etc. should be avoided. Simple experiments with
one or two colors can be presented in one dimensional histograms
(Fig. 44A); this allows easy comparison of the expression level of
the marker of interest for different samples in overlay histograms.
Within these histograms, positive and negative populations can be
easily distinguished from one another. For better comparison, the
histograms should be normalized, i.e. the maximum values set to
100%.
Amore common display is the one using two-dimensional pseu-
docolour density plots (Fig. 44B). Plotting the expression of two
markers against each other allows a more precise distinction of
double negative, single positive and double positive, as well as
weakly or strongly labelled subsets. The 2D-plot presentation also
helps to identify errors of automated compensation for manual
correction, as needed. Usually, axes scaling is logarithmic for
immunofluorescence and gene expression analysis. Linear axes
are mostly used to display light scatter signals and DNA content in
cell cycle analysis. In order to better visualize the quality of com-
pensation especially of dim and negative markers the logarithmic
scale should be transformed into a biexponential scale. Correctly
compensated negative cells should then be evenly distributed as
one population between the negative and the positive log-scale.
Multi-color experiments are normally analyzed by a sequential
gating strategy. A full gating strategy is performed in a step by step
procedure (an example can be found in [292, 293]). To analyze
discrete populations such as T-cell subsets within blood samples in
a first step CD45 negative red blood cells (CD45 expression versus
scatter) are excluded. Furthermore, only lymphocytes are gated
based on their scattering signals (FSClow, SSClow). By exclusion
of CD3 negative B cells (CD16/56−) and NK cells (CD16/56+)
only CD3 positive cells will be analyzed in the next step. By the
expression of CD16/56 positive NKT cells (CD3 versus CD16/56)
can be excluded from T cells. In a final step CD4+ T-helper cells
and CD8+ cytotoxic T cells (CD4 versus CD8) can be analyzed
(see Fig. 44B). This process is strongly driven by a priori expec-
tation and knowledge of the cytometrist analyzing the data. That
means the cytometrists will expect e.g. to analyze within the T
cells at least four subsets: CD4+CD8− T-helper cells, CD8+CD4−
cytotoxic T cells, CD4+CD8+ immature T cells and CD4−CD8−
mature T cells. But within these subsets additional T-cell subsets
might be neglected that would be taken into account by auto-
mated approaches. Keep in mind, by using small (conservative)
gates instead of overlapping gates, disease-specific cells might be
excluded already in the first step of the analysis, or novel subsets
might not be recognized.
Analyzing data by the conventional step by step method in
sequential 2D-plots has several drawbacks: e.g. loss of information
by the loss of rare cell subsets by pre-gating, and somemarker com-
binations that might help to further subdivide a subset might not
be analyzed. With the constant increase of the complexity of cyto-
metric measurements and data, there is also a need to develop new
algorithms to analyze and visualize these complex data. One exam-
ple for a user-friendly visualization of multi-dimensional data at
one glance is the radar plot (e.g. provided as a visualization tool in
the Kaluza R© software by Beckman-Coulter), which plots pre-gated
subpopulations in a multi-parameter way (Fig. 44C); this allows
analysis of the heterogeneity of the pre-gated populations and
to identify new subpopulations. We demonstrate this using data
of a healthy subject and a cancer patient from the German LIFE
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Figure 44. Uni-, bi- and multi-parameter
presentation of flow data. Comparison of
two gender- and age-matched patients: a
healthy one (67 years) and a patient with B-
CLL (64 years) from [294]. (A) 1D-histogram
presentation of CD3 expression on lympho-
cytes (red: B-CLL, grey: healthy), (B) 2D-dot-
plot presentation of CD3 expression on x-
axis vs. CD16/56 expression on y-axis, (C)
multivariate presentation of expression of
12 different antibodies on 9 colors (OMIP-
023, exclusion of low CD25 expression) for 9
different leukocyte subsets in a radar-plot.
Abbreviations used: B-CLL (B-cell chronic
lymphocytic leukemia), Th (CD4+ T-helper
cell), Tc (CD8+ cytotoxic T cell), NK (natural
killer cell).
study [294]. Comparing the lymphocyte population of the patient
with chronic lymphocytic leukemia (CLL: lymphocyte count>90%
of all leukocytes) with an age- and gender-matched healthy sub-
ject (lymphocyte count<20% of all leukocytes) in a CD3:CD16/56
dot-plot shows a massive increase in the B-cell compartment in
the leukemia patient versus the healthy control (Fig. 44B). By
just one glance the different distributions of all leukocyte sub-
sets can be seen in the radar-plot presentation (Fig. 44C), result-
ing in two completely different patterns for healthy and dis-
eased subjects. Radar-plots also allow the visualization of higher-
dimensional features which fail to be identified by lower dimen-
sional visualization, such as by conventional 2D projections. Exam-
ples are given in Fig. 44C. At least 3 T-helper T-cell subsets can
be clearly distinguished in the sample of the healthy individual
(marked by *) and two different cytotoxic T-cell subsets (marked
by #).
Besides manual analysis and their cell subset visualization,
several methods exist to perform software-assisted, unsupervised
or supervised analysis [242]. For example, using several open
source R packages and R source codes often requires manual
pre-gating, so that they finally work just as a semi-automated
computational method. For identification of cell populations e.g.
FLAME (suitable for rare cell detection based on clustering tech-
niques), flowKoh (self-organizing map networks are produced)
or NMFcurvHDR (density based clustering algorithm) are avail-
able [242]. Histograms (2DhistSVM, DREAM–A, fivebyfive), multi-
dimensional cluster maps (flowBin) and spanning trees (SPADE)
are suitable visualization tools for sample classification [242]. To
find and identify new cellular subsets of the immune system in the
context of inflammation or other diseases analysis in an unsuper-
vised manner, approaches such as SPADE (spanning-tree progres-
sion analysis of density-normalized data [249]) can be a better
approach.
Out of a plethora of today existing dimensionality-reduction
based visualization tools we will show examples with the SPADE
tree. SPADE is a density normalization, agglomerative clustering,
and minimum-spanning tree algorithm that reduces multidimen-
sional single cell data down to a number of user-defined clusters
of abundant but also of rare populations in a color-coded tree plot
(Fig. 45). The tree plot structure was generated from healthy and
CLL samples representing 15-dimensions, the clustered expression
of 13markers and scatter characteristics [293]. Each node summa-
rizes cells of identical phenotype concerning the 15 parameters. In
near vicinity nodes with cells of similar phenotype are arranged.
Therefore, related nodes can be summarized in immunological
populations determined by their expression pattern. For instance,
red blood cells were annotated on the right branch of the tree
plot based on the absence of CD45 and their scatter characteris-
tics (Fig. 45). SPADE trees are in general interpreted as a map of
phenotypic relationships between different cell populations and
not as a developmental hierarchical map. But finally SPADE tree
maps help to (i) reduce multi-parameter cytometry data in a sim-
ple graphical format with cell types of different surface expres-
sion, to (ii) overcome the bias of subjective, manual gating, to
(iii) resolve unexpected, new cell populations and to (iv) identify
disease-specific changes. Other ways for comprehensive analysis
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Figure 45. Semi-automated analysis of flow cytometric data by SPADE.
Spanning-tree progression analysis of density-normalized data (SPADE)
is a technique described in [249]. (A) Identification of nodes based on
scatter characteristics and CD45 expression. (B) Comparison of expres-
sion of HLA-DR and CD4 on blood cells for two male patients: (1,3) a
healthy one (67 years) and (2,4) a patient with B-CLL (64 years). Color
codes correlate with expression level from low (blue) to high (red)
and size of the nodes correlate with cell frequencies. For SPADE tree
construction by pre-gating doublets were discriminated and removed,
500 000 events were downsampled to 20 000, target node number was
100 and cluster markers (12) were scatter channels (FSC, SSC) and fluo-
rescence channels (FL1-10).
and display of complex data can by unsupervised approaches can
be found in [54] and include Heatmap Clustering, viSNE and
Phenograph.
4.3 Presentation checklist for publication (MIFlowCyt)
Next to the appropriate illustration of flow cytometry data it is
crucial that the essential details of flow experiments are displayed
in order to allow others to accurately reproduce the experiments.
Lack of reproducibility is of great concern in biomedical research
and rough estimates say that up to 50% of the results published
are not reproducible, meaning billions or trillions US$ of funding
money lost [295, 296]. To reduce this problem the MIBBI (Min-
imum Information for Biological and Biomedical Investigations)
project was launched in 2008 [297]. Its goal is to provide com-
prehensive checklists for different types of experiments so that all
essential information for repeating the experiment is provided.
Relevant for flow cytometry is MIFlowCyt (Minimum Informa-
tion about a Flow Cytometry Experiment) [128]. These standards
were defined by an international group of cytometry experts from
bioinformatics, computational statistics, software development,
and instrument manufacturers, from clinical and basic research.
With this information, cross-experiment comparisons are possi-
ble. Several scientific journals, the first being Cytometry Part A,
have adopted these regulations, as have journals from the Nature
Publishing Group and the European Journal of Immunology but
so far journals have only rarely implemented them. MIFlowCyt-
compliant manuscripts should have a checklist table contain-
ing information on reagents, instrumentation, and experimental
setup, including information on controls, gating strategies, among
others (for details see [128], Table 15). Importantly, it is required
that original primary list-mode data are made publicly available in
an open access data base such as the FlowRepository. This allows
others to analyze published data by alternative methods and better
understand the published material.
Although several MIFlowCyt-compliant manuscripts for flow
data have been published in Cytometry Part A, comparable guide-
lines for image cytometry (e.g. MIImaCyt) have not been adapted
so far [298]. In order to improve the quality of polychromatic flow
cytometry, a special publication type for multicolor flow cytom-
etry protocols, Optimized Multicolor Immunofluorescence Panels
(OMIP), was developed in Cytometry Part A [299]. The central
issue in multicolor flow cytometry is to demonstrate that the
developed multiplexed panel has been optimized by testing dif-
ferent reagents and reagent combinations. Until now, 34 different
OMIPs have been published with the aims of (i) reducing the time
to develop similar panels and (ii) providing a starting point for
the development of new panels, or for optimizing existing ones.
OMIPs present unique reagent combinations, document the devel-
oping progress, explain the final choice and should be useful to a
wide range of readers.
To avoid biases by manual analysis of high complex flow data
software tools are available that work partly operator indepen-
dent. This stresses also the importance of the reproducibility
in complex, (semi)-automated data analysis [300]. O‘Neill and
Brinkman have recently suggested that certain data besides com-
pensation, gating details and mathematical algorithms, should be
shared for reproducible FCM bioinformatics [301]. One major aim
is to make FCM data easily accessible to the users by open-access
databases for flow data (e.g. FlowRepository), as well as the source
codes. A series of data sets have already been provided by the Flow-
CAP (Critical Assessment of Population Identification Methods)
project, comparing different mathematical models and automated
methods for analysis. The cytometry community has already
made great steps toward reproducible research by standardizing
instrumentation, measurement and data analysis, but still looks
forward to optimize the reproducibility in different cytometry
fields.
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Table 15. Important provided data for cytometric publications (a)part of MiFlowCyte)
Data set Details
Sample/Specimen Typea), sourcea), source treatmenta), taxonomy, agea), gendera), phenotypea),
genotypea), locationa)
Sample Treatment Analytesa), Ab clonea), names/numbersa), manufacturera), catalogue numbersa)
Reagents Concentration, purity
Controls Quality Control Measuresa), FMOsa), Positive/negative controla)
Instrument Manufacturera), modela), configurationa), settingsa), detector voltagesa), optical
filtersa)
Data Analysis List-mode data filea), compensationa), gatinga)
5 Data repositories: Sharing your data
Scientific research is more data intensive and collaborative than
ever before. Transparency and public availability of well anno-
tated data is crucial for independent validation, verification and
extending research from prior results [302]. The availability of
primary data is therefore increasingly required by national poli-
cies, international regulatory bodies, scientific journals as well as
research funding agencies [303–307].
In both, fluorescence-based and mass-based flow cytometry,
primary data is generally represented by FCS files that contain a
matrix (table) of expression values of all measured “channels”
(characteristics) of all particles (cells) analyzed by the instru-
ment. These files should be properly annotated as per applicable
domain-specific guidelines. In flow cytometry, such guidelines are
represented by the Minimum Information about a Flow Cytometry
Experiment [128]. In additional, the biosharing.org portal (MIBBI
project [297]) should be checked for extra requirements that may
be applicable.
Depositing data in a public repository is generally the rec-
ommended, and increasingly the required way of sharing flow
cytometry data. Below, we introduce four public repositories suit-
able for flow cytometry data: Cytobank [308, 309] (http://www.
cytobank.org/), FlowRepository [298, 310] (https://flow
repository.org/), ImmPort [311, 312] (https://immport.
niaid.nih.gov), and ImmuneSpace [313] (https://www.immune
space.org/). An overview with technical notes and highlighted
features is provided in Table 16.
Cytobank is an online data analysis and management platform
developed and hosted by Cytobank Incorporated. A community
version of Cytobank provides free functionality including web
access, data storage, experiment sharing and basic online anal-
ysis. The Community version of Cytobank contains close to 400
public experiments (datasets) from about 60 different authors.
In addition, Cytobank offers paid Premium and Enterprise ver-
sions with advanced data analysis options (including SPADE [249]
and viSNE [314, 315]), better customer support and dedicated
computing resources. If your lab is using Cytobank already, then
choosing its Community version presents a straightforward option
of sharing your data publicly. In addition, all versions of Cyto-
bank give you the option of sharing data privately with your
collaborators.
FlowRepository is a public repository allowing researchers to
deposit, annotate, analyze, share and publish flow cytometry data,
mainly those associated with peer-reviewed manuscripts. The
repository is provided free of charge by the International Soci-
ety for Advancement of Cytometry. While FlowRepository was
developed by extending Cytobank’s code base, the two platforms
drifted apart by adding different functionality over the past 5
years. However, there are still many common aspects allowing
users of one system to adapt to the other easily. While Cytobank’s
platform offers more advanced data analysis options, FlowRepos-
itory focuses on data sharing and annotations, including a full
support of MIFlowCyt. In addition, FlowRepository works closely
with several scientific journals and allows for linking data with
related publications. Collaboration with Thomson Reuters and
FlowRepository’s Data Citation Index interface help researchers
get proper credit for deposited data. Unlike with most other repos-
itories, users do not need to register in order to download pub-
lic data from FlowRepository. They can do so anonymously by
using a web-based interface, or from within the R statistical lan-
guage using the FlowRepositoryR BioConductor library, or from
within FlowJo using the FlowRepositoryServer plugin. At this
point, FlowRepository contains over 1,000 data sets from 1,200
scientists and links to papers in 30 different journals. Half of the
data sets are currently public and most of the remaining data are
related to ongoing studies where underlying data will be released
along with publication of the study results. Depositing data to
FlowRepository is recommended by Nature, Cytometry Part A and
PLOS journals.
The Immunology Database and Analysis Portal (ImmPort) sys-
tem provides an archive of immunology research data generated
by investigators mainly funded through the National Institutes of
Health (NIH), National Institute of Allergy and Infectious Diseases
(NIAID), Division of Allergy, Immunology, and Transplantation
(DAIT). It is an extensive data warehouse containing an integra-
tion of experimental and clinical trial data generated by dozens of
assay types, including 63 flow cytometry and 5 CyTOF data sets.
In addition, the ImmPort system also provides data analysis tools
and it contains implicit knowledge and ‘‘best practices’’ for clinical
and genomic studies in the form of nearly 50 templates for data
deposition, management, and dissemination. ImmPort has been
developed under the Bioinformatics Integration Support Contract
(BISC) by the Northrop Grumman Information Technology Health
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Table 16. Overview of repositories for flow cytometry data
Name URLs and references Technical notes and highlighted features
Cytobank http://www.cytobank.org/
PMID: 24590675
PMID: 20578106
Free community version, requires registration
Web access
Advanced online data analysis options in paid versions
Extended CyTOF data support
FlowRepository
https://flowrepository.org/
PMID: 22887982
PMID: 22752950
Free and open source, no registration required to download
data
Web access, R library, FlowJo plugin
Full MIFlowCyt support
Basic online data analysis options
Integrated FCS de-identification (optional)
Included in Thomson Reuters Data Citation Index
Recommended by Nature, Cytometry Part A and PLOS
journals
ImmPort https://immport.niaid.nih.gov/
PMID: 24791905
Free, requires registration and approval
Web access
Data from dozens of assay types including cytometry
Online data analysis tools
Templates for data deposition, management and
dissemination
Used mainly for NIAID/DAIT funded studies
ImmuneSpace https://www.immunespace.org/
PMID: 24441472
Free, requires registration
Web access, R library
Database and analysis engine that leverages ImmPort
infrastructure
Exploring, integration and analyses of data across assays
Ontology support through standards-aware data templates
Used mainly for HIPC data
Solutions team for the NIH NIAID/DAIT. If your research funding
comes from this source and you are generating immunology data,
you should deposit it in ImmPort. Immport’s support for different
data types can be another reason to choose it if you are generating
flow cytometry data as well as data from different types of assays.
A (free) registration and approval by DAIT is required in order to
deposit and access data from ImmPort.
ImmuneSpace is a database and analysis engine built by cus-
tomizing the LabKey server for the Human Immunology Project
Consortium (HIPC). ImmuneSpace can be used to find and explore
studies, integrate and analyze data across assays, and perform cus-
tom analysis directly from within R. ImmmuneSpace takes advan-
tage of the infrastructure already developed for ImmPort, and
in many cases, ImmuneSpace provides a new interface and new
complimentary tools to data that are also available in ImmPort.
Currently, ImmuneSpace can be used to access 12 large (741 par-
ticipants) HIPC studies with flow cytometry data, and 4 HIPC
studies with CYTOF data. The typical data submission work flow
consists of data submission to ImmPort using a set of standard-
ized data templates. If you are a HIPC participant, then your data
should be deposited to ImmuneSpace; otherwise, you can still use
ImmuneSpace as a valuable resource of HIPC data and analysis
tools.
If you are in a clinical setting, there is one important thing
to consider before you start sharing your flow cytometry data
by depositing it in any of the repositories. Besides the expression
matrix, FCS data files contain a segmentwith keyword/value pairs.
Most of the keyword values keep basic information essential for
the interpretation of the raw data matrix and acquisition settings
related values. These include the number of acquired parame-
ters, their names, acquisition voltage settings, the total number
of events (particles), and many other keywords as specified in
the FCS data file standard. In clinical settings, some of the key-
words may include information that could be used to identify
the subject that was the source to generate the data in the file.
Such information has to be removed prior to sharing the data
file in order to comply with patient privacy requirements as spec-
ified by the Health Insurance Portability and Accountability Act
(HIPAA) [316] in the United States and similar rules enforced
by regulatory agencies in most other countries. Patient data must
be properly protected and cannot be publicly shared; however,
those rules generally do not apply as long as the data is prop-
erly de-identified. De-identification is the process of removing
identifiers that could be used to identify an individual. Identi-
fiers include items such as patient name, social security num-
ber, other public ID numbers, date of birth, etc. as specified
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by HIPAA and other applicable regulations. There are several
standalone tools available for the de-identification of FCS files
as listed, for example, in the FlowRepository Quick Start Guide
(http://flowrepository.org/quick_start_guide).
VII. Cytometric parameters
1 Organisms, cells, organelles, and chromosomes
Flow cytometry allows information about the structural and chem-
ical characteristics of particles to be measured. Although the most
common applications of flow cytometry use single mammalian
cells, it is also applicable to studies of bacteria, yeast and viruses
as well as whole organisms such as nematodes and Drosophila.
Conversely, parts of cells such as isolated nuclei, chromosomes
or organelles may also be examined. This section serves as an
overview of the diverse cell types and particles that may be exam-
ined using flow cytometric techniques. The use of high-resolution
flow cytometry can also be used to analyse the composition of the
microbiota at the single cell level by determining bacterial shape
(forward scatter) and DNA content (DAPI staining) [317].
1.1 Organisms
Model systems are used to study molecular biology, developmen-
tal biology and neurology and an example of this is the use of
Caenorhabditis elegans. These organisms are around 1 mm in
length, can be cultivated in large numbers, and have a short
life cycle which makes them ideal for studying many areas of
developmental biology. Particles of this size are not able to pass
through the injection port and flow cell of most cytometers so
specifically designed analysers and sorters are available to identify
and separate these organisms as well as, for example, Drosophila
melanogaster and Zebrafish embryos [318]. These large particle
sorters can also be used for analysing and sorting groups of cells
such as imaginal discs, pancreatic islets or embryoid bodies which
can be up to 200μm [319–321]. Unlike traditional droplet sorters,
these sorters use a puff of air to divert particles of interest into a
collection receptacle.
1.2 Cells
Flow cytometry is perfectly suited for cells that are naturally in sus-
pension e.g. blood, but any multicellular system (cell lines, tissue
samples, whole organisms) may be made into single-cell suspen-
sions using a variety of mechanical and enzymatic techniques. In
all cases there is a balance between creating a good single-cell sus-
pension and keeping cell viability high as well as ensuring that any
disaggregation technique does not have a detrimental affect on the
antigen under study (see Section IV.3: Preparation of single-cell
suspensions). It is always important to make sure that measure-
ment excludes dead cells as these will show increased autoflu-
orescence and may bind antibodies and probes non-specifically.
Exclusion of dead cells may be achieved by adding a viability
dye—either a DNA binding dye such as DAPI or Propidium Iodide
or an amine-reactive dye which will bind to proteins [322, 323].
Although individual cells will not be as large as whole organisms
there is still a range and it is important to know the size of the cells
under study. This is particularly important in cell sorting when the
nozzle used should be appropriate to the cell type. The nozzle size
should be approximately 3–4 times the size of the cell. So for small
cells such as lymphocytes which will be 8–12 μm, a 70 μm nozzle
is appropriate, whereas many cultured cells such as HeLa cells are
larger, around 20 μm, so a 100 μm nozzle would be used. Some
cells sorters can use nozzles up to 200 μm for use with very large
cells such as cardiomyocytes. With flow analysers, the flow cell
is usually larger so it is possible to use a greater range of cells
sizes although greater care should be taken with the preparation
of larger cells to prevent clogs of the sample injection probe.
Any part of a cell may be labeled with a fluorescent probe but
it is important to remember that flow cytometry gives whole cell
information, there is no localization of the fluorescence in or on
that cell nor any idea about its distribution within the cell. To
determine the location of fluorescence an imaging technique is
needed e.g. fluorescence or confocal microscopy or imaging flow
cytometry [324].
1.3 Nuclei
Sometimes only the DNA or a nuclear protein is of interest and
in these cases, cell nuclei can be produced which often will have
less non-specific binding and therefore a cleaner background. Pro-
duction of nuclei from cells can be achieved in unfixed samples
by treating cells with a detergent e.g. 0.1% Triton-X100 which
will lyse cells and release nuclei [325]. Or in fixed samples, cells
may be treated with an enzyme such as pepsin which will digest
the cytoplasm and again release nuclei [326]. Isolated nuclei will
often give a lower CV than whole cells making it easier to discern
certain parameters, e.g. cell cycle phases.
Isolated nuclei may also be used in the technique of FlowFISH,
where fluorescently labeled probes can be hybridized to DNA to
assess, for example telomere length [327].
1.4 Cell organelles
Although flow cytometry looks in general at whole cell information
it is also possible to stain specific organelles within whole mam-
malian cells by staining them with fluorescent dyes. This would be
useful, for example, when looking at calcium mobilization within
cells where there is often a component from several parts of the
cell. This may also be combined with imaging flow cytometry to
provide specific information about ion transport and mobilization
[328]. The dyes used to identify organelles may be fluorochrome-
labeled antibodies or fluorescent probes. Autophagosomes may
be identified by staining with LC3 antibody [329], whereas mito-
chondria can be stained with MitoTracker dyes [330]; lysosomes,
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endoplasmic reticulum, and Golgi can also be identified by using
fluorescent probes directed against specific components [331].
Lysosomes may be tagged with fluorescent LysoTracker dyes
[332], Golgi with fluorescent ceramide [333] and endoplasmic
reticulum with ER Tracker dyes [334]. Care must be taken with
many dyes that are organelle-specific as the staining time and con-
centration are strongly cell-type dependent or influenced by cell
treatments and these factors may need to be determined empir-
ically. For example, Salvioli et al. [335] showed that the dyes
JC-1, DiOC6(3) and rhodamine 123, all of which can be used
to label mitochondria showed differences in fluorescence when
cells were treated with drugs such as valinomycin. Also important
when analyzing organelles are controls; not just a negative con-
trol to assess background fluorescence but also a positive control
to ensure that staining is successful as the majority of these assays
involve unfixed samples. Furthermore, adding a kinetic element to
experiments may be important i.e. looking at time points following
treatment or stimulation.
Cell signaling events are often studied in immune cells and a
commonway to do this is to monitor changes in calcium levels that
result from the binding of antibodies to surface receptors. There
are several fluorescent dyes available that can monitor calcium
levels such as Indo-1, Fluo-4 and Fura Red [336]. Indo-1 is a
UV-excited dye which precludes its use in many common flow
cytometers but it does have the advantage that it uses a ratio of
the bound to unbound calcium signal and is therefore independent
of cell size and variability in dye loading.
If cell organelles are to be analyzed, in some cases it is better
to digest the organelle from the cell. It is possible to isolate mito-
chondria, endocytic vesicles, and endoplasmic reticulum by sev-
eral methods generally using tissue homogenization [337]. Such
treatment will inevitably lead to some cell loss and a sample that
will have a considerable amount of debris. However, the selection
of dyes combined with light scatter characteristics can allow spe-
cific organelles to be identified. Although isolated organelles can
often result in cleaner staining, the smaller the particle the more
problems there will be with co-incident events i.e. whenmore than
one event is being measured in the flow cell of the cytometer. Both
in analysis and sorting, the use of light scatter and fluorescence
is needed to delineate true particles from background. See also
Section VII.8.6: Cytofluorimetric analysis of mitochondria.
1.5 Chromosomes
Although interphase chromosomes cannot be delineated by stan-
dard flow cytometry, chromosomes at metaphase may be iden-
tified and isolated which is important in genomic analysis in
many animal and plant species [338]. Mitotic cell division may
be blocked in metaphase using a drug such as colcemid, and con-
densed chromosomes can be isolated following rupture of the
cells in a detergent solution. Isolated chromosomes are stained
with two DNA binding dyes that have different base-pair speci-
ficities [339]. In this way chromosomes may be separated on size
and base-pair ratio. Chromomycin A3 (G-C binding) and Hoechst
33258 (A-T binding) is the preferred pair of DNA dyes. This is an
extremely powerful technique but is not widely used as the dyes
used require non-standard excitation wavelengths (355 nm and
457 nm) and high-powered lasers which are not widely available.
Sample preparation, staining buffer and cytometer set-up are all
critical in chromosome analysis. Chromosome sorting is impor-
tant in clinical cytogenetics where individual chromosomes may
be sorted and used to generate “chromosome paints.” These are
probes that can be fluorescently labeled and used to hybridize to
metaphase spreads which will allow translocations and chromo-
somal breakpoints to be detected [340].
2 Surface parameters
Surface molecules comprise membrane proteins, lipids or polysac-
charides but also external ligands, either specifically loaded
onto their specific receptors e.g. cytokines or antibodies or non-
specifically attached to the cell surface (reviewed in [341]). These
molecules are easily accessible by flow cytometry and do not typ-
ically require special preparation of cells, such as fixation or per-
meabilization. Most surface markers, in particular those known as
lineage markers, are also expressed at reasonable density allowing
clear-cut discrimination between positively and negatively stained
cells.
In principle, surface molecules can be detected with different
types of labels in a range of affinities, such as antibodies, receptor
ligands, complex multivalent reagents, e.g. for increased binding
avidity, e.g. MHC/peptide-tetramers (see Section VII.6: Antigen-
specific T-cell cytometry), which in general are chemically conju-
gated to fluorescent reporter molecules.
2.1 Minimize artefacts by minimal cell manipulation
If possible, surface molecules should be stained on live cells to
avoid any kind of antigen denaturation possibly introduced by
pre-treatment, e.g. to clearly differentiate between intra- and
extracellular localization. For combined intracellular and surface
staining, surface markers should be stained first, followed by fix-
ation and permeabilization before staining for intracellular anti-
gens. Defined reagents such as recombinant antibodies [342] with
reduced “non-specific” interactions should be used whenever pos-
sible (see also Section IV.1: Controls: Determining positivity by
eliminating false positives), especially when cells do express high
or low affinity immunoglobulin Fc receptors, such as CD64 or
CD32. Unspecific, Fc receptor-mediated binding of immunoglob-
ulins can be suppressed by incubating cells in the presence of
blocking reagents, such as purified immunoglobulins.
In contrast to blood cells or cells from liquid exudates, primary
cells located in tissues often require an enzymatic pre-treatment
for tissue dissociation to finally obtain cells in suspension. But
during this procedure antigenicity of surface proteins can be also
affected. Therefore, depending on the tissue type and cells of inter-
est, conditions for enzymatic digestions have to be carefully estab-
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lished. In general, there are a variety of enzymes available, such
as elastase, hyaluronidase, dispase and different types of collage-
nases. They differ in their digestive characteristics and, therefore,
incubation time, temperature and concentration of enzymes have
to be optimized with respect to cell viability, cell yield and preser-
vation of antigens that will be investigated by flow cytometry. In
the case of very sensitive antigens, which can be not preserved
during tissue digestion, isolated cells may be cultured over night
to allow re-expression of affected cell surface proteins.
A very detailed protocol to isolate thymic epithelial cells is
given by Jain and Gray [343] and for human skin mast cells by
Gru¨tzkau et al. [344]. Moreover, The tissue dissociation guide from
Worthington summarizes all aspects of tissue dissociation in a very
comprehensive way [345].
Even when flow cytometry analyses should be best run with
fresh samples there are several opportunities to stabilize cells or
blood samples before preparation for flow cytometry. Short-term
preservation of blood up to 24 hours by Ficoll 70 kDa is mainly
aiming at inhibiting blood settling-induced stress that is caused
by red blood cell aggregation [346]. For long-term storage cryop-
reservation of PBMCs is another option. But it should to be kept
in mind that some surface molecules, like CD62L or chemokine
receptors in general, can be negatively affected by this procedure.
In addition, there are several commercial reagents available
that can be used for long-term storage of blood samples, such
as TransFix (CYTOMARK, Caltag Medsystems,Buckingham, UK),
Cyto-Chex BCT (Streck, Omaha, USA) and Smart Tube (Smart
Tube, San Carlos, USA) [347]. The latter one even allows ana-
lyzing frozen blood samples after appropriate treatment without
losing granulocytes.
But for all these stabilizing protocols it is strongly recom-
mended that they have thoroughly been validated for the surface
markers of interest.
Live cells may be sensitive to prolonged in vitro handling proce-
dures or may actively internalize surface molecules or shed them
from the surface, e.g. after labeling with antibodies. This can be
avoided by gentle treatment, e.g. careful pipetting, short handling
time, low temperature (on ice) or addition of sodium azide to
the staining buffers, which blocks active shedding/internalization.
After staining cells should be immediately analyzed or strictly be
kept on ice and in the dark to avoid photobleaching.
2.2 Exclude dead cells
The cell type and the isolation procedure from dissociated tissues
or liquid samples will effect cellular integrity and viability. In prin-
ciple, dead cells will increase background signals either caused by
a general increase in autofluorescence or by an increased behavior
to bind antibodies in a low-affinity and unspecific manner. There-
fore, dead cells should be labeled by high affinity DNA stains such
as propidium iodide, DAPI (4′,6-diamidine-2-phenylindole) or 7-
ADD (7-amino-actinomycin D), so that they can be excluded by
appropriate gating from further analysis (see live/dead discrimina-
tion see Section IV.5 and Section V.2). In general, fluorochromes
for discrimination of living and dead cells can be differentiated
between those that passively integrate in the DNA of plasma
membrane-permeable dead cells or those that were actively trans-
ported into living cells only. But these probes are not applicable
for intracellular analyses, since all cells have to be fixed and per-
meabilized before staining. For these purposes fixable dead cell
stains are available that bind to amines of proteins. These probes
are available in a wide range of different fluorescence colours,
and samples are to be stained first before applying the fixation
and permeabilization protocol.
2.3 Magnetic pre-enrichment for high-resolution detection
and analysis of rare cell populations
For the detection and analysis of cell subsets that are detectable
only in very low frequencies (<0.1%) appropriate pre-enrichment
strategies, as detailed in Section IV.4, may help improve gating
resolution for the cell population of interest. Typical applications
are the detection of hematopoietic stem cells [348], CTCs [349],
dendritic cells [350] or T-cell subsets, such as antigen-specific
cells [351]. As one of the most commonly used pre-enrichment
technologies immunomagnetic positive and negative selection
strategies have been established. This has been exemplified in
the context of detecting antigen-specific T cells (Section VII.6.2,
Fig. 58: Cytometric parameters - Antigen-specific T-cell cytometry
- Functional read-outs).
Surface markers are easily accessible for antibodies conjugated
to magnetic beads. Magnetic pre-enrichment is a unique tool to
improve resolution of cell populations, e.g. via isolation of weakly
labeled cells to achieve separation of “overlapping” populations,
depletion of irrelevant cells or enrichment of rare cells.
2.4 Transient surface markers
Some markers are only transiently expressed on the cell surface
and thus may escape detection. This can be caused by different
mechanisms, such as ectodomain shedding [352] or rapid internal-
ization and subsequent endocytic recycling [353]. Cytokine recep-
tors especially behave in a very sensitive manner during sample
preparation and thus different results may be obtained by analyz-
ing whole blood after hypoosmotic lysis of erythrocytes or enrich-
ment of PBMCs after Ficoll density gradient centrifugation [354].
Moreover, incubation temperature and time for antibody staining
have to be carefully adjusted for each particular antibody. For
instance, chemokine receptors are often stained rather at room
temperature than at 4°C to ensure highest sensitivity of receptor
detection [353]. Another example is the identification of antigen-
specific T cells by the detection of CD154 (CD40-ligand), which is
transported to the cell surface only upon T-cell activation and is
then rapidly internalized after binding to its receptor (see Section
VII.6: Antigen-specific T-cell cytometry). A final example is the
rapid down-regulation of the CD3/TCR complex upon TCR/CD3-
ligation [355]. In principle, depending on the marker investigated
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internalization can be prevented by pharmacological or antibody
blockade as shown for the chemokine receptor CCR5 by Mu¨ller
et al. [356] or alternatively the antigen has to be continuously
stained during culture or by intra-cytoplasmic staining.
2.5 Genuine membrane molecules versus membrane
adsorption
Not all molecules detected on the cell surface are genuine surface
molecules but may have been passively adsorbed to the cell surface
or exchanged by an intercellular transfer of membrane patches.
This might lead to significant artefacts and is particularly relevant
for cells from cell cultures and for cells getting in close contact with
each other, e.g. within cell pellets following centrifugation. On the
other hand it can be caused by alternative peptide/protein transfer
mechanisms, such as trogocytosis, exosome uptake or tunneling
nanotubes, which may allow an intercellular transfer of preformed
MHC class I and class II molecules in the immunological synapse
[357].
Principally, unspecific adsorption may be reduced by short pro-
cessing time and low temperature, addition of Ca2+ chelators
(EDTA) or neutral “blocking” proteins such as BSA to all staining
buffers and by repetitive washing steps, or even short treatment
with high salt or low pH. Passive adsorption can also be tested for
by incubation with the relevant molecule, block of transport to the
cell surface (e.g. brefeldin A for activation-induced molecules) or
by the use of purified cell populations to prevent cross-feeding.
However, if the results remain insensitive to these treatments they
have to be confirmed by alternative analysis methods, e.g. fluo-
rescence microscopy (to determine spatial distribution on the cell
surface), RNA-analysis, transgenic expression of the molecule of
interest in cell lines, etc.
Adsorption of molecules to the cell surface can also actively be
exploited for staining of surface receptors with the specific ligands,
such as chemokines [358], cytokines, soluble ligands/Fc-fusion
proteins, if suitable antibodies are not available.
2.6 Quantitative considerations
Quantification of surface marker expression on particular cell
types can be principally done in two ways: (i) calculation of rela-
tive frequencies of cells expressing a particular antigen or a com-
bination of several ones according to a threshold determined by
an isotope or fluorescence minus one (FMO) control; (ii) consid-
ering the mean, geometric mean or median value of fluorescence
intensity that can be used to calculate absolute numbers of a par-
ticular surface protein (see Section IV.1: Controls – determining
positivity by eliminating false positives).
For quantitative comparison of surface marker expression, it
should be kept in mind that the surface increases with the square
of the cell diameter, i.e. the same marker density results in much
brighter signals. Thus changes in cell size, e.g. upon cellular acti-
vation, have to be considered for selection of the proper controls.
3 Intracellular parameters
Flow cytometry is a powerful tool to measure expression levels of
proteins that can be found inside cells such as transcription fac-
tors, cytoskeletal components, and apoptosis regulators, or those
that are usually secreted like cytokines and chemokines. How-
ever, whereas proteins from the former category are normally
expressed constitutively, cytokine expression usually requires res-
timulation of the cell, as is the case for T cells, which express
cytokines approximately 2 to 24 h after T-cell receptor engage-
ment [359, 360]. However, some cell types, such as innate lym-
phoid cells, also express cytokines constitutively [361, 362]. To
enable the intracellular detection of otherwise secreted proteins,
secretion can be blocked by Brefeldin A or Monensin A which
block transport of vesicles from the endoplasmatic reticulum to
the Golgi or within the Golgi apparatus, respectively.
To activate cytokine expression, T cells can be stimulated in
two ways: While cytokine expression in some memory T-cell sub-
sets can be induced by cytokine signaling, such as IFN-γ which
can be induced by IL-12 and IL-18 [363, 364], most T cells have
to receive a T-cell receptor signal and a costimulatory stimulus.
This can be achieved in a polyclonal way by agonistic antibod-
ies against CD3ε and CD28, coated to the surface of a culture
vessel or in an antigen-dependent manner by the incubation with
peptide-pulsed antigen-presenting cells. Alternatively, cells can be
exposed to the chemicals phorbol 12-myristate 13-acetate (PMA)
and ionomycin (iono) which mimic TCR signaling by activating
protein kinase C/NFκB and calcineurin/NFAT pathways, respec-
tively. The restimulation conditions have a strong impact on the
cytokine expression results and should thus be chosen carefully:
1. PMA/iono is usually a stronger inducer of cytokine expression
compared to CD3/CD28 stimulation. While it might be argued
that this trigger is not physiological, it is very well suited to
reveal the maximal cytokine expression potential of the T cells
rather than their actual cytokine expression e.g. in vivo at the
time point of analysis.
2. For PMA/iono, the Ca2+ concentration of the medium can be
critical: Maximal cytokine expression requires 1.5 mM of Ca2+
as present for example in Iscove’s modified Dulbecco’s medium,
but not in the routinely used medium RPMI 1640 (Fig. 46A)
[365].
3. The cell concentration should not be too high as this will
reduce cytokine expression. For PMA/iono stimulation we have
noticed decreased cytokine expression when using 1–5 × 107
cells/mL compared to 2 × 106 cells/mL (Fig. 46B).
4. Expression kinetics can be important. Using PMA/iono, maxi-
mal cytokine expression is achieved as early as 4 h following
stimulation (Fig. 46C) [366].
For the detection of intracellular antigens, cells have to be
fixed and permeabilized. Numerous protocols and reagent kits
are available for fixation and permebilization, each optimized for
the detection of certain antigens, such as cytokines, transcrip-
tion factors, etc. For cytokine detection, cells can be fixed after
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Figure 46. An example of intracellular cytokine detection. Shown are viable, single, CD3+CD4+ C57BL/6 WT Th cells from the inflamed colon
of T-cell transfer-induced colitis. (A) Cells were restimulated for 4 h with PMA/iono (and Brefeldin A added after 1 h) in RPMI, IMDM, or CaCl2-
supplemented RPMI and stained for intracellular cytokine expression. (B) Frequency of IL-17+ cells among colonic Th cells restimulated with
PMA/iono at the indicated densities for n = 7 mice. (C) Frequency of IL-17+ cells among colonic Th cells restimulated with PMA/iono for the
indicated amount of time for n = 4 mice per group. *p < 0.05, **p < 0.01, and ***p < 0.001 by one-way ANOVA for repeatedmeasurements and Tukey’s
post hoc test. Data reproduced from [365] with permission. Reproduced with permission from [365].
surface antibody staining with 1–4% formaldehyde [367],
although in our experience the use of commercially available fixa-
tion kits can be beneficial for the integrity of the surface staining.
Cells are then permeabilized with a mild detergent, e.g. saponin
which builds complexes with cholesterol and hence forms holes in
the cholesterol-rich plasma membrane but not in the cholesterol-
poor nuclear membrane [368, 369]. It should be noted that res-
timulation of Th cells leads to internalization of CD3/TCR and
CD4 proteins from the surface of the cell [370, 371]. It can thus
be beneficial to stain these antigens following fixation and perme-
abilization to also detect the internalized molecules. To control for
true positive cytokine staining, unstimulated cells, cells that have
not been permeabilized, or endogenous negative control cells can
be used.
Transcription factors can usually be stained directly, i.e. with-
out prior acute restimulation, as they are normally expressed con-
stitutively. Nevertheless, the expression levels of certain transcrip-
tion factors might also change depending on the activation status
of the cell (Fig. 47A). Following surface staining, cells are com-
monly fixed and permeabilized with commercially available kits
for transcription factor staining, as saponin-mediated permeabi-
lization is too weak to enable nuclear penetration of antibodies.
The optimal fixation time and condition may vary for each differ-
ent transcription factor and among different cell types and should
thus be established for the specific setting of interest (Fig. 47B).
Using T cells from the inflamed gut of T-cell transfer colitis, we
have observed that overnight fixation impaired staining of the
transcription factor eomesodermin, which was clearly detectable
when fixing for only 1 h. In contrast, ROR-γt staining in these cells
was comparable between the two fixation regimens. In contrast,
for splenic T cells from the samemodel, overnight fixation resulted
in an even better ROR-γt staining compared with fixation for 1 h.
The topic of transcription factor staining is covered in more detail
in Section VII.15 of this guideline.
As for any flow cytometry application, optimal titration of anti-
bodies is instrumental for obtaining high quality results. Intracellu-
lar stainings tend have a higher background due to the abundance
of biologically active molecules inside of the cell. As transcription
factors are rather rare proteins, they should be stained with bright
fluorochromes when designing a panel. Most cytokines accumu-
late to high density within a cell during reactivation in the presence
of secretion blockers and can hence be detected with less-bright
fluorochromes. There are, however, also cytokines expressed at
low levels and, thus, the panel design should be adjusted accord-
ing to the expected results. Any intracellular staining panel should
include a fixable viability dye to discriminate dead cells. This is
especially important when analyzing cytokine expression, as the
restimulation can induce apoptosis in a significant fraction of the
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Figure 47. An example of intranuclear transcription factor detection. (A–D) Shown are viable, single, CD3+CD4+ C57BL/6 WT Th cells from the
inflamed colon or the spleen of T cell transfer-induced colitis. (A) Transcription factor expression can depend on activation state of the cell:
Interferon regulatory factor 4 (Irf4) and T-box expressed in T cells (T-bet) were stained directly ex vivo (grey shaded) or after 4h restimulation
with PMA/iono (black line). (B) Fixation time can positively or negatively influence staining quality of transcription factors: Eomesodermin (Eomes)
and Retinoic acid receptor-related orphan receptor gamma t (ROR-γt) were stained after 1 h or after overnight (o/n) fixation with the eBioscience
Foxp3/transcription factor staining buffer set. (C–F) Transcription factor staining can be combined with cytokine staining or fluorescent reporter
genes. (C and D) ROR-γt, T-bet, Interferon gamma (IFN-γ), and Interleukin 17 (IL-17) were stained simultaneously with the eBioscience Foxp3
staining buffer set. (D) Black indicates the full staining and grey the fluorescence minus one (FMO) control for the T-bet antibody (ab). (E and
F) Depicted are viable, single, CD45+B220−CD11b−F4/80−Gr-1−CD90+, TCRβ+, TCRγδ− cells from the small intestine of C57BL/6 RorcGFP/+ reporter
mice. (E) IL-22 was stained after 4 h of restimulation with PMA/iono and 5 μg/mL IL-23 with the Miltenyi Biotec inside stain kit. (F) ROR-γt stained
directly ex vivo with the Miltenyi inside stain kit is depicted for ROR-γt−GFP− (grey shaded) and ROR-γt−GFP+ cells (black line).
cells while maintaining their FSC/SSC profile, thus making their
distinction based on scatter parameters impossible. Fixable viabil-
ity dyes are now broadly available and are commonly based on
the unspecific binding of fluorochromes with an active chemical
group, e.g. succinimidyl esters, to amino groups of cellular pro-
teins. Thus, viable cells are poorly labeled through their surface
proteins while dead cells with a permeable plasma membrane are
labeled brightly through the binding to intracellular proteins.
For certain questions, a co-staining of transcription factors and
cytokines can be required. While transcription factors are poorly
detected following saponin-mediated permeabilization, several
cytokines can be detected with the same protocol as transcription
factors, i.e. with commercially available transcription factor stain-
ing kits. We were able to stain IFN-γ, IL-17A, T-bet, and ROR-γt
with a commercial transcription factor staining kit (Fig. 47C, D).
However, other cytokines, such as IL-22, can hardly be detected
using a transcription factor staining kit. In this case, iterative stain-
ing and fixation steps of first surface antigens, then cytokines, and
ultimately transcription factors might provide a solution.
Many researchers want to stain intracellular antigens while
maintaining the fluorescence of endogenous fluorescent proteins
such as GFP. Using commercially available staining kits, GFP fluo-
rescence is often lost, most likely due to the passive leakage of the
protein outside of the cell. This can be prevented by a pre-fixation
step with 0.5–2% formaldehyde prior to fixation/permeabilization
with commercial kits [372, 373]. We have obtained good results
for GFP/cytokine staining and for GFP/transcription factor stain-
ing using a commercial intracellular staining kit (Fig. 47E, F).
4 Combinatorial cytometry
Combinatorial cytometry is the subfield of cytometry, or single-cell
analysis, whereby researchers describe, study, and model com-
plex relationships between multiple combined cytometry samples
exposed to varying stimuli, environment, treatment, etc.
Examples include various techniques of multiplexing, such as
fluorescence barcoding [176], high-throughput cytometry, and
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Figure 48. This is an example of how a traditional flow
cytometry assay might be designed using test tubes or
even a 96-well plate assay. Because of the limitation in
the number of tubes or samples that can be run by tradi-
tional instruments, it is not possible to create very large
arrays. Using high throughput cytometry, typical assays
might be 384-well plates that can be processed in 10–20
minutes and produce a huge amount of data which can be
processed using advanced statistical operations.
cytometry-based compound screening [374], as well as multiple
computational techniques which combinemultiple data files either
during the data collection [375] or post hoc in order to create mul-
tifactorial and multidimensional datasets to allow for analytical
comparisons across properties not readily available or accessible
via a single experiment [242].
Combinatorial cytometry approaches have been implemented
successfully with innovativemass cytometry (CyTOF) systems (For
more information on the equipment and concept, see Section I.5:
Mass cytometry) [376], multispectral cytometry [30], multi-angle
elastic light scatter cytometry [377], high-throughput screening
flow cytometry [374], and computational clinical and research
cytometry of the immune system [378–380].
There is often a significant difference in the design of a tra-
ditional flow cytometry and a high-throughput or high-content
assay. This can be visualized in Fig. 48 where both traditional
tube (or even plate based) flow cytometry assays are performed,
and high throughput assays exclusively using 96 or 384 or larger
plates. Using such large arrays of data creates a fundamental dif-
ference in how the data are both collected and analyzed. What is
clear is that a high degree of organization and structure, complete
with significant metadata is required to establish high throughput
or high content flow cytometry assay systems.
One of the key advantages of the combinatorial cytometry
approach is the opportunity to employ advanced statistical and
machine-learning methods, such as various techniques of cluster-
ing, supervised learning/classification, Bayesian techniques, and
other state-of-the-art methodologies. On the other hand, combi-
natorial methodologies introduce complexity to the experimental
planning and design. As a result, they may increase the cost of the
experiential setup and heighten the risk of failure. Ultimately, the
benefits of complex, information-rich “all-in-one” assays, must be
balanced against the cost of assay development which is likely to
be greater than that of performing assays using regular techniques.
Compound screening is a prime example of a combinato-
rial cytometry approach. Multiple multicolor flow-cytometry cell-
stress assays can be rapidly executed in a sequential manner
using an automated robotic sampler. The cellular populations are
exposed to different concentrations of the compounds tested, but
they can also be measured in different environments (different
media) and/or at different times after exposure to the stress. The
assay can scan a dense grid of possible combinations incorporating
all the stress factors in various permutations. Consequently, a huge
number of individual cytometry measurements may be required to
complete the screen. It is self-evident that the key requirement for
successful execution of such an assay is a well-defined, repeatable,
and reproducible assay layout (sample organization), which must
be consistent throughout the entire cycle of experiments.
The assay sample organization defines the resultant data
structure and organization as well, as schematically indicated in
Fig. 49. A typical automated phenotypic assay executed using a
cytometry screen would employ a 96- or even a 384-well layout
which provides space for up to 32 drugs at 10 doses each, as well
as negative and positive controls. Preparing such a layout in an
automated, repeatable fashion allows glitch-free assay execution
and subsequent feature extraction. Figure 50 shows a window
of one example of a custom-built screening software package,
PlateAnalyzer, which automatically outputs response curves and
fits log-logistic models on the basis of the templates and gates pre-
defined by an operator [381]. Since such a system performs the
operations involving up to 384 FCS files per plate, it is crucial that
all the steps in the analytical procedure be fully automated and
be executed without the need for any interactive operator input.
A screening system such as the one described above also relies
on automated sample preparation and robotic liquid handling, as
the probability of pipetting errors and inaccuracies is too high to
allow for a manual assay setup. Automation of sample preparation
not only ensures a high level of reproducibility, but also shortens
the preparation time and guarantees that the minimal required
amount of sample and reagents can be accommodated to make
the assay more cost effective.
Opportunities for automated or semi-automated analysis of
FC screens can be achieved using many available toolsets for flow
cytometry data processing. R-language for statistical computing is
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Figure 49. Combinatorial cytometry integrates the ideas of screening biological responses. Biological responses can be screened across multiple
conditions (e.g. concentration, medium type, stress, temperature, time, etc.) with flow cytometry. The technique is enabled by fast autosamplers,
and informatics pathways aware of the multifactorial nature of the collected data.
a commonly used environment for cytometrists who are interested
in developing their own analysis tools and unique data processing
pipelines. Combinatorial flow cytometry incorporating dimensions
of time, concentration, media, and other factors certainly expands
the horizons for this field. Conversely, the availability of rapid
development tools for custom design of data processing pipelines
is a condition sine qua non for successful implementation of the
described combinatorial and multifactorial approaches, see also
Section VI.1: Data analysis an overview. When it is desirable to
measure biological responses across multiple conditions (e.g. con-
centration, medium type, stress, temperature, time, etc.) with flow
cytometry it is advantageous to approach the assay in an organized
fashion. The technique is enabled by fast autosamplers, and infor-
matics pathways aware of themultifactorial nature of the collected
data as demonstrated in Fig. 49 where the differences in analysis
of traditional flow data are compared with combinatorial analysis
routines. These routines can be highly complex, but depend upon
the ability to automatically extract features for all samples in the
array.
Other examples of combinatorial cytometry are the well-known
bead-based assays. Among those, cytokine assays are probably the
most widely used and broadly accepted [382]. In this technology,
2 to 10 types of cytometry-compatible beads of various sizes (rec-
ognized by flow cytometry by forward light scatter) can be dyed
with increasing amounts of a tracer dye to encode their ability
for capturing/measuring different analytes. For example, Fig. 50
shows 13 cytokines simultaneously recognizable by a commer-
cially available flow cytometry assay (any commercial plate could
be entered into the system). In this system there are two bead
sizes, and each bead type carries a different amount of target
marker, in this case APC (see Table 17). Although the discussed
technique employs only a 13-plex method, frequently up to 20 or
30 different cytokine tags can easily be simultaneously quantified
in a minimal volume of plasma. If the organization of samples
on multiwell plates is consistent, one can execute an automated
data-processing task immediately after assay completion. Gating,
recognition of different bead types, computation of calibration
curves, and other necessary tasks can be executed automatically
without operator intervention or a manual setup.
As mentioned before, multiplexing offers a huge advantage
in terms of assay execution time and reagent/sample cost sav-
ing. As a result, the multiplexed bead assays allow researchers
to identify concentration of analytes of interest in many samples
essentially simultaneously. A dedicated software package (such as
the PlateAnalyzer Cytokine edition in Fig. 51) provides the means
to show all the calibration and to visualize the concentration of
analytes across the entire plate. Such visualization techniques are
commonly used for other combinatorial approaches in biomedical
research and are equally valuable for flow cytometry data.
A third example of a combinatorial cytometry technique is
multispectral single-cell analysis. In contrast to traditional mul-
ticolor cytometry, which uses a dedicated detection channel for
each fluorescent label in the hope of separating signals from mul-
tiple labels, the spectral system essentially acts as a superfast
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Figure 50. Automated processing of bead-based cytokine assay. Results obtained in a cytometric bead assay in graphical representation of the
cytokine concentration in every well of the multi-well plate. Samples were run on an Attune NxT flow cytometer (ThermoFisher) using the
instrument plate reader. On the left side of the figure is a list of the analytes used in the assay. In the center part of the figure is a 96-well plate
layout showing a representation of each cytokine in a 13-piece pie chart. The colors represent the values in picograms/mL. The top right figure
shows the bead populations used to define each cytokine. On the bottom left, the heat map describes the fluorescence intensity measurements
for each well and each cytokine. The figure on the bottom right shows the standard curve derived from the standards run for this assay.
spectroscope connected to a flow cytometer. An approximation of
the entire spectrum using about 30–40 bands for every cell is mea-
sured, and the data can be further processed via spectral unmixing
techniques or directly used for spectral classification. There are a
number of advantages to the spectral approach, mainly related to
the less complex hardware as traditional optical filters are not uti-
lized and neither are individual detectors. This approach creates
a new opportunity for combining fluorescent probes which may
not be feasible in conventional flow cytometry [383]. For exam-
ple, dyes such as GFP and FITC can be used together because
chemometric techniques to process spectral cytometry data can
be utilized to classify and/or unmix the resultant signals. There
are several excellent recent examples of this approach in flow
cytometry [31, 32] in which combinations of fluorescent proteins,
together with a variety of fluorochromes, allowed a total of 11
markers to be used simultaneously and then separated by spectral
unmixing.
A final example of combinatorial cytometry and one that
demonstrates the extraordinary power of multiparameter datasets
can be seen in data collected by the CyTOF technology and demon-
strated in Fig. 52 (for an overview of the equipment, see Section
I.5: Mass cytometry). This approach uses lanthanide-conjugated
antibodies, as opposed to the fluorescently labeled probes of a con-
ventional FC system, and time-of-flight mass spectroscopy for ana-
lyzing single cells to produce information-rich population statis-
tics [37]. The final complexity of such data can be very high
indeed, requiring innovative techniques for data processing and
visualization. An ad hoc “what-if” analysis is possible using visual
development environments allowing for interactive construction
and modifications of data processing pipelines. A demonstration
of such a pipeline, capable of tackling an input of 30–40 different
biological parameters encoded by lanthanides, is represented in
Fig. 52. The data processed in this example (courtesy of B. Boden-
miller, University of Zurich, Institute of Molecular Life Sciences)
were produced by analyzing a bulk sample with seven lanthanide
tags used to encode the position of individual subsamples in a 96-
well plate. This experimental approachwas applied to characterize
human peripheral-bloodmononuclear-cell signaling dynamics and
cell-to-cell communication, signaling variability between PBMCs
from human donors, and the effects of various inhibitors on this
biological system. For each inhibitor, 14 phosphorylation sites in
14 PBMC phenotypes were measured [70].
The demonstrated data pipeline (or “logic map,” in PlateAn-
alyzer terminology) can extract individual dose-response curves
C© 2017 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.eji-journal.eu
Eur. J. Immunol. 2017. 47: 1584–1797 Cytometric parameters 1677
Figure 51. Response curves automatically produced
from data extracted from multiple FCS files. Data
across FCS files are collected using a robotic sampler
connected to a flow cytometer. The PlateAnalyzer soft-
ware recognizes the plate layout and creates response
curves on the basis of pre-defined gates. Each curve
results in an automatically calculated IC50 value as
shown on the right side of the figure.
for the 14 phosphorylation states from each of the 14 cell phe-
notypes. This is a striking example of combinatorial FC analysis,
which first creates relationships between different vectors of
FC measurements and subsequently explores and quantifies
these relationships. Where traditional cytometry is focusing
on mapping individual cells in a multidimensional space of
phenotypic descriptors, combinatorial cytometry looks at vectors
of multidimensional measurements and explores the differences
and similarities between those under various conditions.
Conclusion
The key requirements for combinatorial cytometry are (i) well-
defined reproducible assay layout, (ii) highly controlled, prefer-
ably automated, assay setup and preparation, (iii) data-collection
Figure 52. The pipeline design canvas of the PlateAnalyzer. This particular example of an analysis package (http://vault.cyto.purdue.edu) allows
rapid development of data-processing maps for complex combinatorial cytometry experiments. In contrast to traditional FC software packages,
all the operations are by definition applied to vectors or matrices of FCS files, rather than to individual datasets. On the left of the figure are
shown histograms of each of the phosphorylated proteins in the assay, the central group identifies the phenotype of cells being evaluated, and
the two boxes on the far right show the stimulating molecules (12 rows) each of which contains 8 concentrations. Yellow lines show the active
analysis connection pathway—i.e. the resulting dose response curves would be based on the phenotypic result of each component linked within
this pathway. As an example in the figure, the phosphorylation state is ZAP70- and the phenotype is NK cells (CD3–, CD7+).
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Table 17. Cytokine assay reagents. This table shows the multiplex
cytokine assay with bead location and target molecule. Using beads of
different sizes, with increasing amount of bead fluorescence, many
assays can be performed on very small samples of plasma (<15 μL).
This example demonstrates how one particular kit (which uses beads
identities as A4, A5 . . . .B2, B3, etc.) where each bead is associated with
one particular analyte. Each of these beads are in a small size (A) or
larger size (B) group. These are shown graphically in the upper right
panel of Fig. 50
Target Bead ID
IL-10 A4
IFN-g A5
IL-5 A6
IL-2 A7
TNF-a A8
CM-CSF A10
IL-4 B2
IL-17F B3
IL-9 B4
IL-17A B5
IL-13 B6
IL-22 B7
IL-6 B9
method recognizing the relationships between the collected FCS
files and organizing the measurements in higher-order data struc-
tures, and (iv) automated data analysis and reporting software.
When this combination of tools is available, complexmultiparame-
ter and multifactorial experiment designs can be executed and the
resultant data can be rapidly processed to produce useful insight
leading to mechanistic models of the studied biological systems.
5 Measuring antigen specific T-cell responses
5.1 Introduction
T cells recognize antigen in the context of major histocompatibil-
ity complex (MHC) molecules. Over 20 years ago, Davis and col-
leagues developed the technique to mimic the interaction between
the T-cell receptor and the peptide (p)MHC complex in the labora-
tory [384]. Using fluorescently labeled pMHC multimers, antigen-
specific T cells could be visualized and this has become a crucial
tool in the analysis of antigen-specific T-cell immunity in mouse
and human. For a more detailed description on antigen-specific
T-cell cytometry, see Section VII.6.
The classical approach with pMHC multimer detection is hav-
ing the pMHC complex coupled to a single fluorescent dye. The
major drawback of this approach is the limited number of epitopes
to which T-cell reactivity can be detected in parallel. This limita-
tion is given by the limited number of fluorochromes and detectors
available as well as limitations in patient material. Multiplexing
strategies have been developed that increase the number of T-cell
reactivities that can be detected in a single sample [385, 386].
The multiplexing strategy developed by us is based on the gen-
eration of pMHC complexes with dual fluorochrome codes. How-
ever, additional approaches have been published including work
from Newell et al. [385]. Using the dual fluorochrome labeling
approach the number of unique codes that can be generated can
be calculated using factorial operations.
As an example 8 distinct fluorochromes yield 28 possible
unique dual codes: (8 × 7) / (1 × 2) = 28.
5.2 UV light-mediated peptide exchange method
Peptide MHC complexes can be generated by a process called
refolding, here the heavy- and β2m chain of the MHC allele are
placed together with the peptide of interest in an optimized buffer
which allows correct formation of the pMHC complex. Having a
biotin group on the heavy chain allows the biotinylation of the
complex after refolding. As refolding the pMHC complexes is a
time consuming and laborious process this approach is not optimal
for generation of large numbers of different pMHC complexes.
To overcome this limitation we developed an UV light-
mediated peptide exchange method [387]. With this technology
the MHC complex is refolded using a peptide ligand which holds
an UV light sensitive amino acid. Exposure to UV light results in
degradation of the p*MHC complex. However, when this process
takes place in the presence of a rescue peptide, this peptide can
bind and stabilize the MHC complex, thereby giving rise to pMHC
complexes with the peptides of choice [387]. This UV-mediated
exchange can be performed in a multi-well format, allowing the
generation of thousands of unique pMHC complexes in parallel.
Multiple factors can influence the ligand exchange reaction.
Crucial is to keep the p*MHC complexes in the dark as much as
possible as they are light sensitive and as cool as possible as the
p*MHC complexes can be unstable at temperatures above 4°C.
Furthermore, it is important that these protein-containing reac-
tions are performed using polypropylene material. This is to avoid
loss of protein through sticking to the plates/tubes. As the solu-
bility of the peptide influences the ligand exchange it is possible
to add ligands that have a poor solubility in water from stocks
in DMSO. It has been shown that the ligand exchange reactions
proceed normally in conditions up to 10% DMSO [387].
After the exchange of peptides the pMHC complexes can be
multimerized by conjugation to fluorochromes for the gener-
ation of dual color-coded multimers (Fig. 53). As the pMHC
complexes contain biotin groups, streptavidin-conjugated fluo-
rochromes allow easy and strong binding to the pMHC complexes.
Titrations of the pMHC complex:streptavidin-fluorochrome are
crucial to ensure optimal SNR. After multimer formation addition
of D-biotin ensures the blockage of any remaining free binding
sites on the SA-conjugated fluorochromes, thereby preventing the
binding of unconjugated pMHC complexes to other fluorochromes
when collecting the pMHC multimer collections prior to staining.
5.3 Staining and flow cytometry
Besides the major benefit of increasing the number of specificities
that can be screened for in a single sample the other advantage of
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Figure 53. An example of a combinatorial
staircase giving 28 unique dual color codes
to 28 different peptides.
using multiplexing is the fact that the background signal is signif-
icantly reduced when using dual fluorochrome codes. This is due
to the fact that the vast majority of background signal is detected
in either one or more than two channels detecting fluorescent sig-
nal. As the false positive signal decreases, the sensitivity of the
assay increases. This increase in sensitivity is accomplished using
Boolean gating strategies, only including signal that is dual color
positive. Due to this gating strategy we are now working with
a cutoff of 0.005% of total CD8+ T cells and a minimum of 10
recorded events. When staining the same TCR with two different
fluorochromes a two-fold reduction in MFI should be expected.
However, as data are viewed on log scale a two-fold decrease is a
minor issue. We have successfully detected e.g. MART-1 specific
T-cell responses, andMART-1 TCRs are known to be of low affinity
in general. Nevertheless, if the T-cell response of interest is of low
affinity/avidity it can happen that the dual color coding makes
is more challenging to pull out the positive population from the
background.
Using multiple multimers in a single staining can lead to the
formation of aggregates, causing background issues in the stain-
ing. Therefore, it is important to spin down the pMHC multimer
panels to eliminate aggregates. In case of increased risk for aggre-
gates (e.g. using rescue peptides that may not be able to bind
sufficiently to stabilize the MHC complex), the addition of an
1% skim milk solution (in PBS) to the multimers directly after
adding the streptavidin-fluorochrome can help to reduce the level
of aggregates.
To ensure that the T-cell reactivities detected are indeed
real, a confirmation is required in an independent experiment.
For this purpose it is recommended to make new reagents for
the potential hits, changing the fluorochrome code and stain,
with the newly prepared reagents, the other half of the sam-
ple tested. We have previously demonstrated that the repro-
ducibility between these independent experiments is high (R2 =
0.9638)5.
When selecting what fluorochromes are better suited to include
in the making of the multimers the main determinant is the con-
figuration of the flow cytometer that will be used. Next is a consid-
eration of brightness. In case the goal of using the technology to
detect viral responses the brightness is of less concern compared
to detecting T-cell responses against self-antigens. Nevertheless,
it is advisable to select bright fluorochromes, and when using less
bright fluorochromes to only combine them in the dual-codes with
the fluorochromes that give a brighter signal. As an example we
only use quantum dot 585 together with the brightest dyes in our
setting, e.g. PE, quantum dot 655 and brilliant violet 421.
On the basis of the high sensitivity and robustness this is a
highly suitable tool for the analysis of T-cell responses in patient
material. We have previously demonstrated the value of the tech-
nology to map T-cell responses against shared antigens in large
patient cohorts [388, 389] as well as T-cell responses against
mutated antigens on a patient specific basis [390, 391].
5.4 Example: Detection of neo-antigen specific T-cell
responses in a melanoma patient
Resected tumor material was used to identify tumor specific muta-
tions using exome sequencing. Based on the sequencing 1657
somatic mutations were identified, of which 1075 were non-
synonymous mutations. Based on RNA sequencing, the expres-
sion of each mutation was assessed. Mutations that were found
to be expressed based on RNA sequencing data were included
and HLA restricted epitopes were predicted using a previously
published bioinformatics pipeline [392]. In total a set of 1036
peptides was predicted and used to generate peptide-MHC com-
plexes with the UV-induced ligand exchange method. Complexes
were formed using HLA-A*03:01, A*32:01, B*13:02 and B*27:02
monomers. Using 8 different fluorochromes for multimer forma-
tion 26 dual color combinations were used in parallel. With this
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Figure 54. Dot plots showing an antigen specific T-cell population
detected in T cells isolated from a tumor lesion. The antigen specific T
cells are positioned in the diagonal of the upper right corner of the plot
(green circle) as they are dual positive for two fluorochromes.
setup screening the TILs from this patient for all peptides was
possible in 55 tubes with approximately 0.75 × 106 TILs per tube
(90% CD8+ T cells).
The analysis of the TILs revealed two neo antigen specific T-cell
responses. One of low frequency (0.003%, HLA-A*32:01) against a
mutated epitope of the ZNF462 gene and a response of significant
magnitude, 3.3% of CD8+ T cells within the tumor were specific
for a mutated epitope from ATR serine/threonine protein kinase
that functions to signal DNA damage.
In the initial screen the epitope related to the mutation in the
ATR kinase was found using a multimer in the combination of PE
and Qdot705 (Fig. 54).
For the confirmation of the detected responses a new UV
exchange with the ATR kinase mutated peptide was executed and
multimerization was accomplished using streptavidin-Qdot655
and streptavidin-PE-Cy7.
6 Antigen-specific T-cell cytometry
Antigen-specific T cells play a pivotal role in immune protection
toward infection or some cancers, and are currently used more
frequently for adoptive immunotherapy (i.e. as donor lympho-
cyte infusion or engineered autologous lymphocytes). Antigen-
specific T cells are also crucially involved in the pathophysiology
of autoimmune diseases, like type I diabetes or multiple sclerosis.
Therefore, the direct visualization, quantification and character-
ization of these cells have important diagnostic and therapeu-
tic implications. Peptide-major histocompatibility complex (MHC)
molecules present antigenic peptides (epitopes) to T cells, which
are recognized by specific binding of a suitable T-cell receptor
(TCR), which is expressed in multiple identical copies (usually >1
× 105 molecules) on the T cell surface. CD8+ T cells recognize
peptides presented by MHC class I, while CD4+ T cells recog-
nize antigen via MHC class II molecules. Two main experimental
approaches have been developed for the detection of antigen-
specific T cells: function-independent methods such as staining
with soluble MHC multimers, and function-based assays (such as
intra-cellular cytokine staining, ELISPOT or cytokine capture tech-
nology). Their advantages and limitations are described below.
6.1 MHC multimers
Function-independent antigen-specific T cell identification has the
advantage that it can be applied directly to a sample ex vivo, and
does not rely on in vitro T-cell activation, in contrast to many
function-based assays.
Compared to the broadly applied detection of antigens by mon-
oclonal antibodies (mAbs), the detection of TCR-ligand (=MHC)-
binding antigen-specific T cells has turned out to be challenging.
This is mainly due to the relatively low binding affinity of TCR-
MHC interactions, which do not allow using soluble (monomeric)
MHC for stable T-cell staining. Altman and Davis addressed this
problem by the development of so-called MHC Tetramers [384].
The principle behind this approach is the multimerization of the
natural TCR ligand, e.g. to tetrameric complexes, thereby increas-
ing the binding avidity to surface-expressed TCRs (Fig. 55A).
Dimerization of MHC via immune globulin fusion proteins can be
sufficient to detect antigen-specific T cells [393], but such MHC
dimers often fail to identify all antigen-reactive T cells present
in a polyclonal population [394]. However, MHC tetramers also
might not label all epitope reactive T cells, which could be due to
very low affinity TCRs [395] or TCR/co-receptor downregulation
or variable surface distribution [396, 397].
Reagents with different degrees of multimerization have been
developed, asmultimerization seemed to be relevant for stable and
antigen-specific binding. Surprisingly, a direct comparison of MHC
tetramers, pentamers, dextramers, octamers and higher polymer-
ization reagents has failed to show significantly improving bind-
ing properties with increasing degrees of multimerization [398].
It seems that an avidity gain with MHC trimers represents the cru-
cial threshold to result in stable MHC multimer staining for most
TCRs. This interpretation was based on the finding that also in con-
ventional PE-conjugated MHC “tetramers,” three out of the four
MHC molecules simultaneously take part in binding to surface-
expressed TRCs, although they stain polyclonal T-cell populations
effectively with high staining intensity [399].
MHC tetramers are based on multimerization with biotinylated
ligands and avidin/streptavidin. Conjugation with fluorochromes
allows usage in flow cytometry cell sorting-based applications and
conjugation with paramagnetic particles promotes combination
with magnetic purification technologies [400, 401] (Fig. 55A).
However, binding of TCR ligands can lead to T-cell stimula-
tion/activation and labeling-reagent internalization, as well as
apoptosis and cell death [402–404]. Therefore, the reversible
MHC Streptamer technology was developed, allowing removal
of staining reagents from the cell surface after their application
(Fig. 55B, 55C) [405, 406]. This is achieved by targeted dis-
ruption of multimer complexes, leaving only MHC monomers
which rapidly dissociate from the cell surface. With directly
fluorochrome-labeled MHCmolecules, the dissociation can be pre-
cisely measured and serves as an important parameter for TCR
avidity [407]. Reversible staining has recently been further trans-
ferred to low affinity antibody-derived Fab fragments (Fab Strep-
tamer), extending the applicability of this labeling technology to
virtually any surface antigen [406].
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Figure 55. Principle of MHC multimer staining by increasing the binding avidity of MHC-TCR interactions. (A) Conventional MHC tetramers (B)
MHC modification for generation of reversible MHC Streptamers; (C) principle of reversibility of MHC Streptamers.
A large spectrum of MHC multimers is commercially avail-
able for the analysis of antigen-specific CD8+ T cells. In order
to enable versatile epitope selection for MHC multimer analy-
ses, a technology based on UV light-cleavable surrogate peptides
has been developed [387]. Multiplexed staining of samples with
different fluorescence-conjugated MHC multimers is possible and
promotes simultaneous analysis or sorting for multiple epitope
specificities [385, 386]. Combinatorial MHC multimer staining
can now be used not only to combine and distinguish large num-
bers of different MHC molecules within the same sample, but
also to increase staining sensitivity for the detection of rare cell
populations. Cell incubation with two MHC multimers, which are
specific for the same antigen but are conjugated to different fluo-
rophores, results in double-staining of antigen-specific T-cell pop-
ulations. This approach significantly reduces background staining
(Fig. 56) [408], which is fundamentally important to identify rare
cell populations.
Co-receptor (CD8 or CD4) interaction is often required for sta-
ble binding of MHCmultimers. Therefore, parallel surface staining
for CD8 or CD4 has to be controlled carefully to avoid artifacts by
blocking (or sometimes even enhancement) of co-receptor bind-
ing. In order to control this problem, most staining protocols are
based on an incubation period with MHC multimers alone before
antibody reagents for co-receptors are added. An initial incuba-
tion with MHC multimer reagent alone for 25 minutes, followed
by the addition of co-staining mAbs for further 20 minutes, has
proven to be applicable to most MHC multimers in practice. In
particular, when using phycoerythrin (PE)-conjugated MHC mul-
timers, background staining—especially coming from B cells and
dead cells—can complicate the analysis. Therefore, implementa-
tion of a CD19 dump channel and live/dead discrimination has
become standard for most MHC multimer staining protocols. By
using covalently-linkable DNA staining probes (such as ethidium
monoazide bromide), it is also possible to combine live/dead dis-
crimination with cell fixation [409].
Optimal MHC multimer concentrations have to be determined
for each batch by using positive and negative controls, as done for
all other cellular labels used in flow cytometry. Besides reagent
concentration, the duration of incubation-time as well staining
temperature are crucial parameters for MHC multimer labeling.
Since this technology relies on binding of the natural TCR lig-
and to the cell surface, at higher temperatures (above 10–15°C)
signaling events and potential cell changes (e.g. cell surface mark-
ers, activation-induced cell death) can occur. Therefore, whenever
possible, MHC class I multimer staining should be performed at
low temperatures, i.e. 4°C. For reversible MHC multimer staining,
cell labeling/sorting at low temperatures is particularly essential,
as reagent internalization would negatively interfere with its sub-
sequent removal. In contrast, for most of the currently available
MHC class II multimers, successful antigen-specific cell labeling is
only possible at higher temperatures (usually at 37°C for approxi-
mately 1 h), since signal accumulation by reagent internalization
seems to be required in this case [410, 411].
In addition to conventional experimental controls (single color-,
compensation- and FMO-controls), biological controls for MHC
multimer staining are recommended to determine the degree of
background staining (e.g. by MHC mismatch controls). General
considerations regarding minimal numbers of positive events that
have to be acquired and optimal gating strategy (FSC/SSC, sin-
glets, live/dead discrimination, co receptor/multimer, etc.) are
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Figure 56. MHC multimer staining of
human PBMCs for CMV peptide pp65 with
BV421 and APC. Pregating CD8+ and CD3+
improved separation. Additional staining
with pp65 APC MHC multimer separates a
distinct population of antigen specific cyto-
toxic T cells.
essential to achieve meaningful and highly reproducible results.
A detailed protocol for MHC multimer staining including some
examples for staining artefacts is described in [412].
For more information, including instructions for the devel-
opment of MHC class I reagents, please visit the website
http://www.mikrobio.med.tum.de/node/51.
6.2 Functional read-outs
As antigen-specific T cells are rare, a major goal in antigen-specific
cytometry is to analyze as many parameters as possible from each
single antigen-specific T cell. Recent advances in multi-color flow-
cytometry have increased the number of markers that can be
analyzed, but have also complicated the design and optimization
of multi-color antibody panels, as well as the multi-dimensional
analysis of such experiments. These important topics have been
reviewed elsewhere [201, 241, 413–415] and are also discussed in
Section IV.8: Key concepts for the design and testing of multicolor
panels and Section VI: Evaluation/data handling. In this section,
we will focus on use of flow cytometric methods for the detection
of antigen-specific T cells following stimulation with an antigen.
Direct labeling of specific T cells can be achieved by
peptide/MHC(MHC)-multimers (see Section VII.6.1: Antigen-
specific T-cell cytometry – MHC multimers). However, MHC-
multimers can only be generated for a limited number of pre-
defined MHC combinations, in particular for MHC class I pep-
tides and CD8+ T-cell analysis. In contrast, MHC class II multi-
mers for identification of antigen-specific CD4+ T cells are still
less well established. In addition, tetramer use is limited for com-
plex antigens or antigens not fully characterized, e.g. microbes,
tumors or autoantigens, and for the heterogeneous MHC back-
ground in humans. As an alternative, functional tests provide
more flexibility, since they rely on T-cell stimulation by autolo-
gous antigen-presenting cells, which can process and present all
types of antigens, peptides, proteins, or crude cellular extracts in
the context of the physiological MHC background. Following in
vitro antigen-stimulation, the antigen-induced T-cell response is
analyzed as an indirect read-out indicating specific T cells, i.e.
proliferation, activation-induced surface or secreted molecules or
cytotoxicity [416] (Fig. 57).
6.2.1 Selection of the right parameter: Minimal manipulation.
Functional assays require stimulation, which may affect T-
cell frequency, function and phenotype [416]. Cellular prolifer-
ation as a result and readout of stimulation requires several days
(typically 3–5 days) of stimulation (see also Section VII.7: DNA
synthesis, cell cycle and proliferation) and introduces an unpre-
dictable bias due to significant in vitro selection and “bystander”
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Figure 57. Principle of antigen-specific stimulation
assays. Peripheral blood mononuclear cells (PBMC)
or single-cell suspensions from tissues are incubated
with the antigen of interest or without antigen as neg-
ative control to determine background levels of the
assay. If whole proteins are used for stimulation, the
antigen has to be taken up by the autologous antigen-
presenting cells of the cell source, processed and pre-
sented on MHCmolecules. Peptides of a certain length
can bind externally to MHC molecules. The antigen-
specific T cells will start to secrete cytokines and/ or
cytotoxic molecules (5–12 hours), express activation
markers (5–16 hours) and at later time points start
to proliferate (3–5 days). For all these different func-
tions of T cells, such as cytokine release, cytotoxic-
ity, expression of activation markers and proliferation
single-cell flow-cytometric assays are available and for
most technologies also selection markers on the cell
surface are available allowing additional isolation of
the specific cells.
proliferation. Therefore, it is difficult to extrapolate from fre-
quency and phenotype of cells after proliferation to the origi-
nal sample, and proliferation-based assays should be used with
caution for quantitative or qualitative T-cell analyses. Therefore,
short stimulation times may be preferred; for instance cytokines
and rapid activation markers (e.g. CD154, CD69) typically require
only 5–8 hours of stimulation before their levels are measurable
intracellularly, on cell surfaces or in culture supernatants, ensur-
ing minimal manipulation [416].
For antigen-specific stimulation experiments, it should also be
considered that the source of material (whole blood; PBMCs;
different tissues sources), as well as the treatment of the cell
source (fresh or frozen material; resting periods before stimu-
lation; culture medium), might have a profound influence on T-
cell marker expression and the detection of antigen-specific T-
cell responses [365, 417–420]. In our hands, overnight resting
(<16 h) of freshly isolated PBMCs has been proven to reduce
background expression of activation markers and cytokines, while
retaining responsiveness of antigen-specific CD4+ Tcon and Treg,
leading to an increased SNR for antigen-specific T-cell analyses
(unpublished). However, in multi-center trials, cryopreservation
of PBMCs is often unavoidable. Therefore, standardized proce-
dures are needed to compare antigen-specific T-cell data from
different laboratories [421, 422]. When analyzing and comparing
antigen-specific T-cell responses from blood and tissue, also the
presence of functional antigen-presenting cells with comparable
processing and presenting capacity should be considered.
6.2.2 Selection of the right parameter: Integrate all T-cell subsets.
T cells are heterogeneous and cover a wide range of different phe-
notypical and functional subsets. Information about the frequency,
differentiation stage (e.g. naive, memory), phenotype and func-
tional properties of antigen-specific T cells is essential to gain a
comprehensive picture about the immune response against a cer-
tain antigen and the immune status of an individual. As CD4+ and
CD8+ T cells provide different functions, also different read-outs
apply for the detection of antigen-specific CD4+ and CD8+ T cells
(see Table 18).
In particular CD4+ T cells can acquire a highly diverse set of
functional properties. Therefore, antigen-induced cytokine secre-
tion is widely used as functional read-out for CD4+ T cells.
Cytokines can be detected on the cell surface by retention of the
secreted cytokine on the surface of the secreting cells via a cap-
ture matrix [423, 424] or intracellular when cytokine secretion
is inhibited by addition of secretion inhibitors like Brefeldin A or
Monensin [425] (see also Section VII.3: Intracellular parameters).
Differences may apply regarding the usage of different secretion
inhibitors [421], for example, Monensin has been shown to only
insufficiently inhibit TNF-α secretion [426]. Due to the hetero-
geneity of CD4+ T cells, ideally, the functional read-out should
encompass all relevant T-cell types to obtain a complete picture of
the immune status, i.e. all conventional T (Tcon) cells, i.e. na¨ıve,
all memory subsets as well as FOXP3+ regulatory T (Treg) cells,
which typically comprise 5–10% of all CD4+ T cells and are essen-
tial for tolerance. An alternative to individual cytokines, such as
IFN-γ which are often only expressed by a minor fraction of all
antigen-specific CD4+ T cells [427–429], and thus may ignore a
significant fraction of specific T cells, are so called activation mark-
ers that are up-regulated on the T-cell surface upon specific T-cell
receptor triggering. We recently showed that the combination of
the activation markers CD154 (CD40L; which is expressed on all
Tcon subsets) and CD137 (4-1BB; which is expressed on Tregs)
following short-term (6 h) stimulation allows in parallel detection
of naive and memory Tcon and Tregs reacting against the same
antigen [427, 429–432]. In addition the combination of CD134
(OX-40) and CD25 with and without CD39 expression has been
suggested to detect antigen-specific Tregs and Tcon [433, 434],
after prolonged stimulation time (40-48h).
For CD8+ T cells, cytokines like TNF-α, IFN-γ are widely used,
since these are expressed by the majority of the antigen-activated
CD8+ population. The activation marker CD137 is also expressed
by CD8+ T cells following stimulation for >12 hours [435–437],
but may also be induced due to bystander activation. Furthermore,
for CD8+ T-cells detection of cytotoxic activity by staining for cyto-
toxic effector molecules (e.g. granzyme or perforin) can be used.
In contrast to most other mediators, these molecules are found
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pre-formed in the cells and can be immediately released follow-
ing antigen stimulation. An alternative approach for measuring
cytotoxicity is the detection of CD107a, which is only present on
the cell surface transiently following degranulation [441, 442]
(see also Section VII.11: Cytotoxicity).
6.2.3 Combination with magnetic enrichment of rare cells.
Antigen-specific T cells typically comprise <1% and often <0.1%
of the total T-cell population [416]. Therefore, magnetic pre-
selection of rare antigen-specific T cells from large cell sam-
ples is frequently used to decrease background and improve
optical resolution. Pre-selection increases the sensitivity for the
detection of antigen-specific T cells (frequencies of 10–5–10–6,
detection of specific T cells within the na¨ıve repertoire is pos-
sible) [423, 427, 443–446]. Enrichment allows the collection
of sufficient target cells for subsequent multi-parameter anal-
ysis and resolution of small cell subsets. Magnetic enrichment
may employ surface markers, e.g. tetramers, CD154, CD137, or
secreted cytokines [423] (Fig. 58) (see also Section VII.3: Intra-
cellular parameters).
6.2.4 Type of antigen. As for the functional read-out, there are
differences between the antigens used for stimulation of CD4+ and
CD8+ T cells. CD4+ T cells recognize antigens that are presented
via the exogenous pathway of antigen presentation on class II MHC
molecules [447]. Accordingly, for CD4+ T cells, peptides, proteins
and even cellular extracts can be used for stimulation. Presenta-
tion of peptides from whole proteins depends on the processing
activity of the available antigen-presenting cells, which may vary
between cell sources (blood, (lymphoid-) organs) and donors.
Antigen preparations containing potential innate immune sig-
nals (pathogen-associated molecular patterns, PAMPs) may cause
bystander activation and specificity of the antigen-reactive T cells
has to be confirmed for each antigen (see also Section VII.6.2.5:
Controls and statistical analyses).
In contrast, stimulation of CD8+ T cells with whole proteins is
not reliable, since MHC class I epitopes are not easily generated
from endocytosed proteins which depends on cross-presenting
capacity of the antigen-presenting cells. Therefore, short synthetic
peptides are preferable. The use of peptides as antigen stimulants
is advantageous as peptides are instantly presented by all antigen-
presenting cells expressing MHC molecules, including B cells or
other non-classical antigen-presenting cells. However, differences
of effective peptide presentation and subsequently T cell stimu-
lation may occur due to the heterogenous MHC background in
humans. Peptides can be used individually or in pools, such pools
being able to cover complete protein amino acid sequences (pro-
tein spanning peptide pools). The use of peptides of 15 amino acids
length and 11 overlaps has proven very successful for both CD4+
and CD8+ T cells [448, 449]. The use of 15mers is in conflict with
the concept that the binding groove of class I MHC molecules can
only accommodate a peptides of 8–9 amino acids in length. Since
15mer peptides are successfully used for CD8+ T-cell stimulation
inmany experimental systems, it is assumed thatmechanisms exist
that shorten these peptides in the extra cellular space (clipping,
trimming, peptide degradation) [450, 451]. However, since these
mechanisms have so far not been characterized, 15mers have to
be used with caution since individual MHC class I binding peptides
might not be generated efficiently.
6.2.5 Controls and statistical analyses. Standard controls for
flow-cytometric multicolor analyses which apply here (single
color, compensation, FMO-controls, exclusion of doublets and
dead cells, as well as a dump channel), are described in Section
IV.1: Controls – determining positivity by eliminating false posi-
tives. However, special emphasis has to be given to elimination of
background due to the low frequencies of antigen-specific T cells,
as noted above. A non-stimulated sample processed under iden-
tical conditions is absolutely required to determine background.
Specificity should be verified for each MHC-multimer and antigen,
especially for preparations containing PAMPs, as well as for differ-
ent cell sources (blood, tissue). Specificity can be determined, for
example, by MHC blocking antibodies, the use of fixed antigen-
presenting cells (for processing dependent antigens) or expansion
of cell lines and single-cell clones for confirmation of specificity by
antigen re-stimulation [427].
Also, a positive control for the assay should be included, to
determine functionality of the T cells and antigen-presenting cells.
Polyclonal stimulation can be achieved by e.g. agonistic antibodies
against CD3 and CD28 or by stimulation with the chemicals phor-
bol 12-myristate 13-acetate (PMA) and ionomycin (iono). How-
ever, these controls only apply for the T cells and are independent
of the presence of functional antigen-presenting cells. Alterna-
tively, super-antigens like Staphylococcus enterotoxin B (SEB) can
be used, which crosslinks MHC molecules and specific Vβ regions
of T-cell receptors. Thus, usage of SEB might be limited in samples
with restricted Vβ repertoires. An antigen-specific control might
represent a more physiological control, e.g. an antigen derived
from an ubiquitous pathogen like Candida albicans, or a standard
vaccine like tetanus, to which typically all donors react [427]).
When frequencies of antigen-specific T cell are calculated, back-
ground values have to be subtracted from that of the antigen
sample. Regarding statistical significance of rare event analyses,
considerations have to be applied to determine the minimal num-
ber of events that have to be acquired for statistically relevant
analyses. To describe the precision of flow-cytometry data, the CV
can be calculated from the variance and the SD [452]. For exam-
ple, for a CV of 5% at least 400 antigen-specific T cells have to be
acquired (see Fig. 58). If the antigen-specific cells occur with a fre-
quency of 0.1%, at least 400.000 total events should be acquired.
If the frequency of specific cells is just 0.01%, at least 4.000.000
total events have to be acquired and so on. This illustrates that
for many antigens, magnetic pre-selection of the rare antigen-
specific T cells from large cell samples is necessary to increase the
sensitivity of the assay and obtain sufficient target cells for statis-
tically relevant analyses (see also Section VI.3: Statistics for flow
cytometry).
For methods employing enrichment, the absolute count of tar-
get cells obtained from a certain input cell number has to be
determined to calculate frequencies in the original sample. The
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Figure 58. Enrichment of antigen-specific T cells increases sensitivity for the detection of rare cells. (A) CD154 and TNF-α expression was analyzed
on CD4+ T cells without addition of an antigen and following stimulation wit the neo-antigen keyhole limpet hemocyanin (KLH). Cells are gated
on CD4+ T cells and percentage and absolute numbers of CD154+ cells after acquiring 5 × 105 PBMCs (upper plots) or obtained from 1 × 108 PBMCs
after enrichment of CD154+ cells (lower plots). (B) Phenotypic characterization of the enriched CD154+CD4+ T cells to discriminated between
CD45RO+ memory cells and CD45RO-CCR7+ naive T cells, following stimulation with a peptide pool of C. albicans MP65 as recall antigen or KLH
as neoantigen. (C) Parallel detection of antigen-specific Tcons (CD154+) and Tregs (CD137+) following stimulation with birch pollen lysate and
magnetic enrichment for CD154+ and CD137+ cells from 2 × 107 stimulated PBMC. Upper plots: cells are gated on CD4+ T cells and absolute cell
counts of CD154+ and CD137+ cells with and without stimulation are indicated. Lower plots: Overlayed flow-cytometric analysis of birch-specific
CD154+ and CD137+ cells. Numbers indicate percentages among CD137+CD154-CD4+ T cells and absolute numbers of CD137+CD25+FOXP3+ Tregs.
(D) To describe the precision of flow cytometry data, the coefficient of variance (CV) can be calculated from the variance and the SD. For rare cell
analysis, the approximations SD = r and CV [%] = 100/r can be used, where r is the number of positive events [452]. From CV [%] = 100/r
follows r = [100/CV]2. Using this approximation the number of total required events is illustrated depending on the frequency of target cells for
different CVs.
frequency of positive cells after enrichment is not relevant for
quantification. A minimal SNR and minimal number of events per
input cell number has to be determined for each test system inde-
pendently (see also Section V.3: Rare cells (general rules)).
6.2.6 Interpretation of results. Originally, specific T-cell anal-
ysis relied on the idea that antigen-specific T cells can only
be detected in antigen-experienced individuals. However, recent
advances, in particular in the enrichment of rare cells, has allowed
detection of rare specific T cells even within the na¨ıve reper-
toire [427, 445, 446, 453–456] (Fig. 58B). These analyses also
showed that the memory compartment contains a significant frac-
tion of specific T cells against bona fide “neo-antigens,” i.e. anti-
gens not previously encountered by the immune system. This may
result from specific (structurally related epitopes) or from statisti-
cal cross-reactivity, i.e. recognition of a neo-epitope by TCRs from
a polyclonal repertoire [454, 456]. Thus, the presence of memory-
type T cells does not per se imply that this results from a genuine
antigen-specific immune response. Therefore, additional biolog-
ical parameters have to be considered to determine the actual
immune status: overall ratio between specific memory to naive
and Treg cells, ratio of memory T cells in the antigen-specific pop-
ulation versus the total T-cell population (expected to be >1 in
genuine memory responses), clonal composition of TCRs (deep
sequencing), and affinity or functional avidity which can be esti-
mated be restimulation of expanded antigen-specific clones or
cell lines with decreasing antigen concentrations or via reversible
MHC-multimers [457] if available.
Taken together, antigen-specific cytometry allows combination
with multiparametric single-cell analysis tools for full resolution
of the antigen-specific immune response.
7 DNA synthesis, cell cycle, and proliferation
Cell cycle analysis was one of the very first applications for which
flow cytometry was used, and has since been used in a large range
C© 2017 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.eji-journal.eu
Eur. J. Immunol. 2017. 47: 1584–1797 Cytometric parameters 1687
of different settings such as interrogating the biology of cancer,
drug development and toxicology studies [458]. Inmammals, non-
dividing cells in the G0 Phase enter the G1 Phase when they are
preparing for division. G1 Phase does not result in an increase in
DNA, but does involve the synthesis of proteins that are required
for subsequent progression. DNA synthesis occurs when cells enter
the synthetic (S) Phase of the cell cycle, in which they will remain
until the DNA content has doubled, at which time they will enter
the G2 Phase and undergo mitosis. Cells in G0 and G1 therefore
contain the same amount of DNA and will exhibit the same flu-
orescent properties when stained with a DNA-binding dye. The
fluorescent intensity of cells will progressively increase as cells
increase their DNA content as they move through S Phase until
they have twice the amount of DNA than cells in G0 when they
reach the G2 and M Phases.
7.1 DNA synthesis and cell cycle analysis
The determination of DNA synthesis and cell cycle analysis
involves the use of fluorescent dyes that bind to DNA, of which
there are many (e.g. propidium iodide—PI, Hoechst stains,
TO-PRO-3, SYTOX, acridine orange, pyronin Y, 7 aminoactino-
mycin D—7-AAD, Diamino-2-phenylindole—DAPI, DRAQ5ۛ and
DRAQ7ۛ). The selection of the dye to be used will be dependent
on the instrument which is available and the spectral parameters
which it can detect. One should also be aware of the binding
characteristics of the dyes and their preference for particular base
pairs. The compatibility of an instrument for a particular dye will
be dictated by the wavelength of the lasers that are available, and
the optical characteristics of the filters with which each laser is
associated. This highlights the issue of understanding your instru-
ment and its capabilities, as without this understanding, it will
not be possible to design and deliver valid experimental data. The
investigator should consult the manufacturer’s instruction manual
for specific information regarding the operation and capabilities
of their flow cytometry platform. Online flow cytometry resources
such as Chromocyte (www.chromocyte.com) provide a repository
of key information and tools for informing and facilitating
good experimental design, and for improving flow cytometry
practice.
Another consideration relates to whether there is a need to
analyze viable or fixed cells, and whether to only fix or fix and per-
meabilize samples. Given that permeabilization can remove intra-
cellular components, this approach can givemore definite peaks on
the fluorescent histograms. Crosslinking agents such as formalde-
hyde lower dye binding as a consequence of chromatin crosslink-
ing. Dehydrating fixatives such as methanol and ethanol can also
be used, but at high concentrations these can cause cell clumping
due to the coagulation of proteins. Dehydrating fixatives can also
negatively impact on fluorescent dyes if DNA is being stained in
association with surface marker staining for the expression of anti-
genic determinants, as many protein-based fluorescent molecules
are sensitive to the dehydrating effects of the alcohols. One should
also be aware that signals from Green Fluorescent Protein (GFP),
Figure 59. Representative DNA fluorescence histogram of PI-stained
cells. Isolated cells are fixed and stained as described above, and their
fluorescence determined on a linear fluorescence scale. The presence of
a sub-G1 peak can be used to indicate the presence of cells undergoing
apoptosis (programmed cell death), see also Section VII.8.4.
mCherry, and Cerulean can be destroyed by alcohol treatment. The
addition of permeabilizing detergents to disrupt the plasma mem-
brane such as Triton, NP-40 and saponin can improve access of
the DNA dye. Another issue to consider is that the concentration of
the DNA dye must be sufficient so that it binds in proportion to the
amount of the DNA in the cell. It is therefore essential to determine
the DNA profiles that are generated at different concentrations
and incubation times for a defined cell number, and identify the
approach which generates the lowest CV, but in the absence of any
cytotoxic effect (i.e. check the viability of cell populations, and the
influence of the dye thereupon). One should also remember that
some dyes (PI, for example) will bind to both DNA and RNA. In
such instances, it is necessary to include a ribonuclease (RNase) in
the staining buffer, otherwise the fluorescence histograms that are
generated will be sub-optimal as they will include a signal from
the RNA. A typical experimental protocol using PI for staining
and generating a typical staining profile (Fig. 59) will involve the
following:
1. Fix cells that have been harvested and washed in phosphate-
buffered saline (PBS) in 70% v/v ethanol. Adding the ethanol
dropwise to the cell pellet while vortexing will ensure that all
cells are fixed and will minimize clumping.
2. Fix cells for 30 min at 4°C, after which wash cells twice in PBS
(850 ×g). Be careful to avoid cell loss when discarding the
supernatants.
3. Treat cells with RNase (50 μl, 100 μg/mL) in order to ensure
that only DNA is stained
4. Add PI (200 μl PI, 50 μg/mL stock solution) immediately
before analyzing.
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Figure 60. Identification of single-cell populations for
analysis using flow cytometry. Cultured tumor cells
were harvested, washed and stained as described in
[458]. (A) Tumor cells are identified on a forward scat-
ter (FSc) versus side scatter (SSc) plot and gated to
exclude debris which is found in the lower left corner.
(B) Single cells can be separated from cell aggregates
by analyzing cell height and area (upper right)—single
cells will show as a correlated line, with any clumped
cells below. (C) Viable cell populations can be identified
using viability stains such as the LIVE/DEAD
R©
fixable
range of products from Life Technologies, the eFluorۚ
fixable dyes from eBioscience, BioLegend’s Zombie
range of fixable dyes, Tonbo biosciences’ Ghost DyesTM
and the Fixation andDeadCell DiscriminationKit from
Miltenyi Biotec, as described in Section VII.8.2. Repro-
duced with permission from [458].
The “quality” of the DNA histogram which is generated is typ-
ically indicated by the appearance and CV (data spread) of the
G0/G1 peak, which must be as low as possible (Fig. 59). Factors
which can influence this element of the data acquisition include
the flow rate (which must be low) and laser alignment and hydro-
dynamic focusing (both of which should always be optimized as
part of the routine maintenance and quality control procedures
that are stipulated by the instrument and calibration bead manu-
facturers). It is essential to maximize the electronic signal intensity
and minimize variability of the measurement of the beads in order
to achieve accurate DNA measurements. The precise definition of
“low,” “medium” and “high” flow rate will depend on the instru-
ment and its configuration. It is better to run a more concentrated
sample at a slower flow rate, than a diluted sample at a higher
flow rate.
Although it would appear obvious, it is crucial that the pres-
ence of cell aggregates or doublets is minimized, and that these
are excluded from the analysis. Doublets or cells going through
the cytometer together can mimic cells in the G2/M phase. Such
problems can be avoided by employing good experimental tech-
niques for the preparation of samples and filtering samples before
the analysis [458] (see Section IV.3: Preparation of single-cell
suspensions). The analysis gate can be set to acquire data on
singlet cells by acquiring data using a “Pulse/Cell Width” versus
“Pulse/Cell Area” plot or “Pulse/Cell Height” versus “Pulse/Cell
Area” which can be set using the instrument software (Fig. 60).
This approach allows doublets and aggregates to be easily iden-
tified and excluded from the analysis. As with all experiments,
controls should be included. Chicken and trout erythrocytes have
been proposed as internal standards for analysis of DNA content by
cytometry in order to control andmaintain consistency in the stain-
ing and measurement approaches. However, it should be noted
that the ploidy of DNA in fish can also vary, and so it is important
to be aware of ploidy when using cells as a standard [459].
It is also crucial to exclude non-viable cells from any analy-
sis, as the presence of these can introduce heterogeneity into the
datasets that are generated. Although DNA analysis, by its nature,
requires that cells are fixed and therefore non-viable, it is possible
to stain cells using non-fixable dyes (protein-binding dyes) prior
to their fixation for DNA staining. Details on these approaches are
provided in the relevant section (see Section VII.8.1: DNA-binding
dyes).
A typical instrument set-up and sample acquisition could use
the following sequential series of plots, and 10 000 to 20 000 rel-
evant (NOT total) events should be collected:
 FSC versus SSC plot to identify relevant cell population(s)
 “Pulse Width” versus “Pulse Area” plot or “Pulse Height” versus
“Pulse Area” plots (to exclude doublets)
 Live/Dead versus FSc (to exclude dead cells)
 DNA stain (e.g. PI) versus FSC (to monitor instrument perfor-
mance)
 DNA histogram (using a linear scale)
A typical analysis could use the following sequential series of
plots:
 “Pulse Width” versus “Pulse Area” plot, or “Pulse Height” versus
“Pulse Area” plots (to exclude doublets)
 Live/Dead versus PI (to exclude dead cells)
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 FSc versus SSc plot (to exclude unusual-looking populations)
 DNA histogram (using a linear scale)
The placement of markers on the G1, S and G2 peaks for the
analysis of cell cycle profiles can be subjective, as a consequence
of which the analysis and interpretation of cell cycle analysis
data now involves a number of mathematical models, all of
which attempt to deconvolute the peaks and provide a more
objective approach. Specialized programs such as ModFit LTۛ from
Verity Software House (http://www.vsh.com/products/mflt/
mfFeatures.asp) and Multicycle AV ۛ from Phoenix Flow Sys-
tems (http://www.phnxflow.com/MultiCycle.stand.alone.
html) have been designed for this purpose.
Although cell cycle analysis is a powerful tool, it requires a
great deal of optimization for the data to be robust, interpretable
and meaningful. Cell cycle analysis provides information on the
proliferation of cells, but other approaches must be used if you
are quantifying how many times cells have replicated (see Section
VII.7.2: Proliferation).
7.2 Proliferation
The analysis of cell proliferation is at the core of many biolog-
ical studies, and is typically used for cell growth and differen-
tiation studies, and for the evaluation of toxicity and therapeutic
responses to stimulators and inhibitors in a variety of settings. Cell
proliferation can be determined on the basis of direct cell counting,
on the basis of DNA synthesis (using an approach which typically
involves measuring the uptake of 3H-thymidine), or by measuring
metabolic activity such as mitochondrial dehydrogenase activity
using colorimetric assays such as the MTT (3-(4,5-dimethythiazol-
2-yl)-2,5-diphenyl tetrazolium bromide) assay. For the latter, cells
are incubated with MTT, and the yellow MTT is converted into
an insoluble purple formazan product by mitochondrial succinate
dehydrogenase. The product is solubilized and level of prolifera-
tion determined by measuring the absorbance of the medium with
a spectrophotometer. An alternative colorimetric approach uses
the [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-
(4-sulfophenyl)-2H-tetrazolium] (MTS) tetrazolium salt which
results in a soluble, rather than an insoluble, formazan product.
Although all of these approaches are effective, their common dis-
advantage is that they provide a measure of proliferation in the
bulk population, and do not provide insight into the proliferative
responses of cell subpopulations. The multi-parameter capabil-
ities of flow cytometry offer a number of options for studying
cellular proliferation in complex settings, and the majority of the
approaches involve the measurement of nucleotide incorporation
or dye dilution. The approach which needs to be used will very
much depend on the experimental setting (Table 19).
7.2.1 DNA synthesis: Nucleotide incorporation. Analogous to the
measurement of proliferation on the basis of 3H-thymidine incor-
poration, cell division can be monitored by flow cytometry using
Table 19. Approaches for determining cell proliferation
Nucleotide incorporation/dye
dilution
Determination of
cell divisions
5-Bromo-2′-deoxyuridine (BrdU) 1–2
BrdU / Hoechst / PI (quenching)
technique
3–4
Dye dilution >4
Figure 61. Schematic representation of fluorescent dot plot for the flow
cytometric analysis of cell proliferation on the basis of BrDU incorpo-
ration. Human peripheral blood mononuclear cells have been labelled
with BrdU and a phenotypic marker, with unlabeled cells acting as the
control. The total viable cell population was used for the analysis.
5-bromo-2′-deoxyuridine (BrdU), a synthetic nucleoside analogue
of thymidine. For this, BrdU is incorporated into the newly syn-
thesized DNA of replicating cells (during the S phase of the cell
cycle), and its incorporation detected using conjugated antibodies
specific for BrdU, which are widely available from a number of
commercial sources. Binding of the antibody requires denatura-
tion of the DNA, usually by exposing the cells to acid or heat. The
measurement of BrdU is typically undertaken in conjunction with
viability dyes and/or DNA stains for cell cycle analysis.
Although appearing to be a straightforward assay, sample
preparation and DNA denaturation for BrdU-based measurements
of cell division must be performed carefully, as too little treatment
will result in a low signal and too much treatment will influence
the DNA and the signal which is generated. Samples need to be
washed well (at least 3 times), as any residual acid will denature
the detecting antibody. Furthermore, BrdU is labile even at 4°C
and so must be used fresh. A typical experimental protocol pro-
ducing a typical staining profile (Fig. 61) involves the following:
1. Incubate cells with BrdU (10 μM) for 30–60 minutes.
2. Fix harvested and pelleted cells by suspending in ice-cold 70%
v/v ethanol at 4oC for at least 30 minutes (samples can be left
for up to 7 days).
3. Pellet cells, wash in phosphate-buffered saline (PBS) and incu-
bate for 30minutes at room temperature (RT) (with occasional
mixing) in freshly prepared 2M HCl.
4. Wash cells twice in PBS, and then in PBS-Tween (PBS contain-
ing 0.1% w/v BSA and 0.2% v/v Tween 20, pH 7.4).
5. Add an appropriate amount of anti-BrdU monoclonal antibody
(mAb, conjugated / unconjugated), as determined by titration
experiments, to the cell pellet and incubate samples at RT for
20 minutes in the dark (BrdU is photo-unstable).
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Figure 62. Schematic fluorescence histogram depicting a progressive
decline in the fluorescent intensity of proliferating cells stained with
CFSE. For the assays, 106 isolated cells (e.g. human peripheral blood
mononuclear cells) are incubated with CFSE (5 mM final concentra-
tion) at room temperature for 8 min, at which time the reaction is
blocked by the addition of fetal bovine serum (FBS, 2% v/v final con-
centration). Cells are washed in phosphate buffered saline contain-
ing 2% v/v FBS, after which they are stimulated. The fluorescence of
the stimulated cells is then measured at appropriate time-points using
flow cytometry. (A) The bright/strong, undiluted fluorescent signal of
non-proliferating / arrested cells. (B) The (serially) diluted fluorescence
intensity of cell populations from successive generations of proliferated
cells.
6. Wash samples twice in PBS-Tween and, if an unconjugated
monoclonal antibody has been used, incubate samples with an
appropriate secondary antibody at RT for 20–30 minutes.
7. After washing in PBS, incubate cell pellets with RNase (50 μL,
100 mg/mL) for 15 minutes at RT or 37°C.
8. Add an appropriate volume of the required viability stain (e.g.
PI, 200 μL, 50 mg/mL).
9. Analyze the viable cell populations(s) by flow cytometry, col-
lecting a minimum of 10 000 relevant events per sample.
An alternative to BrdU is the modified nucleoside, EdU (5-
ethynyl-2′-deoxyuridine). Assays such as the Molecular ProbesTM
Click-iTTM EdU cell proliferation assay are based on the labelling of
proliferating cells with a bright, photostable Alexa Fluor R© dye in a
fast, highly specific click reaction. Unlike BrdU assays, EdU assays
are not antibody-based and therefore do not require DNA denatu-
ration for the detection of the incorporated nucleoside. Click-iTTM
EdU can also easily be multiplexed with fluorescent proteins like
R-PE, R-PE tandems, and Green Fluorescent Protein (GFP). Only
a mild fixation and detergent permeabilization is sufficient for the
small molecule-based Click-iTTM EdU detection reagent to gain
access to the DNA. A typical experimental protocol producing a
typical staining profile and improved DNA histograms has previ-
ously been reported [460, 461].
7.2.2 Dye dilution. The essence of dye dilution approaches is
that cells are labelled with fluorescent dyes that intercalate into
the cells such that the dye is approximately equally distributed
between the two daughter cells following division. As the cell
divides, the dye is diluted out and, by counting the peaks (or
modelling the pattern), the number of original dividing cells can
be calculated (Fig. 62).
As originally described in 1994 by Lyons and Parish [462],
cells were stained with the protein-binding, amino-reactive dye
carboxyfluorescein succinimidyl ester (CFSE). One limitation of
CFSE is that there is a proliferation-independent loss of fluores-
cence in the first 24–36 hours, and therefore, this must be taken
into account during the analysis and interpretation of the data.
Although alternatives for which there is no loss of signaling after
labelling include membrane-labelling lipophilic dyes such as PKH2
(green), PKH67 (green), PKH26 (orange) and CellVue ۛ claret (far
red) dyes from Sigma-Aldrich, these are more suitable for cell
tracking experiments. More suitable for dye dilution studies are
protein-binding dyes such as the CellTraceۛ range from Molecular
Probesۚ, the eFluor
R©
Cell Proliferation dyes from eBioscience, the
BD Horizonۛ dyes from BD Biosciences and the Tag-it VioletTM Pro-
liferation and Cell Tracking Dye from BioLegend. If cells require
fixing, then it is important to avoid organic solvents when using
membrane dyes. It is also important to use the correct dilution of
dyes, as they can have adverse effects on cell viability and func-
tion. Use the highest concentration which does not induce such
negative effects for a given cell number. Protocols for the staining
and analysis approaches can be accessed from the many suppliers
of the reagents that are being used.
As with all experiments, it is essential to include the relevant
negative and positive controls. Moreover, once the instrument set-
tings have been optimized, it is important to place unstimulated
cells at the highest decade on the fluorescence plot. Non-viable
cells should be excluded, as they lose the dye as they enter apop-
tosis. Doublets should be excluded as a doublet of two cells in
the G0/G1 phase would exhibit the same fluorescence intensity on
a DNA stain as a single cell in the G2/M phase. G0/G1 doublets
would therefore create false positive results for G2/M cells [463].
Furthermore, a doublet formed between a positive and negative
cell would be seen as being positive during a cell sort, as a con-
sequence of which the sort would be contaminated with negative
cells. The presence of doublets would also cause problems for
DNA content/ploidy analyses, and could lead to misinterpretation
of double positives during immunophenotyping studies, in that
a double positive cell could in fact be a mixed doublet of two
individually positive cells.
7.3 Useful resources
 Chromocyte Limited—Resource for flow cytometry and cell-
based assays (www.chromocyte.com)
 Expert Cytometry—Flow cytometry training (www.exp
ertcytometry.com)
 Purdue University Cytometry Laboratories (www.cyto.
purdue.edu)
 International Society for Analytical Cytology (ISAC, http://isac-
net.org)
 European Society for Clinical Cell Analysis (ESCCA,
www.escca.eu)
 BitesizeBio Flow Cytometry Channel (http://bitesizebio.
com/category/technical-channels/flow-cytometry)
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8 Cell death
The analysis of cell death in flow cytometry experiments can be
required for a number of reasons. In some instances, the aim of the
experiment is to determine the influence of different treatments on
cell viability or apoptosis (programmed cell death). These experi-
ments could determine direct, and possibly selective, toxic effects
of agents on the cell population of interest. They could also be
undertaken in the context of cytotoxicity assays such as antibody
dependent cellular cytotoxicity (ADCC), cytotoxic T-cell activity
or natural killer (NK) cell cytotoxicity [464] against relevant tar-
get cells. In addition to such applications, the determination of
cell viability and the detection and exclusion of dead cells is also
an essential component of any flow cytometric analysis for the
following important reasons:
 Non-viable cells and debris can non-specifically take up and
bind probes and antibodies, and so must be excluded from the
analysis
 Non-viable cells are likely to exhibit a higher level of autofluo-
rescence
 Non-viable cells release DNA which can promote cell clumping
and aggregation, both of which are problematic for fluorescent
single-cell analysis and cell sorting platforms.
The increase in background fluorescence that accompanies the
non-specific binding/uptake of fluorescent probes by non-viable
cells and/or the enhanced autofluorescence of non-viable cells
will reduce the sensitivity of analyses and their capacity to detect
weakly positive signals. Cellular autofluorescence is commonly
associated with myeloid cells, as their intracellular flavins are eas-
ily excited by the 488-nm laser line. As the peak emission of flavins
occurs at approximately 525 nm, any signal generated by autofluo-
rescent cells will be registered and processed by the same PMT that
processes FITC and equivalent fluorescence. It is therefore essen-
tial that cell viability is routinely assessed in all experiments. The
approach for assessing cell viability will be dependent on whether
the aim of the experiment is to determine the levels of cell death
in response to a treatment, cytotoxicity or exclude non-viable cells
from the analysis.
Before considering the approaches that can be used to detect
non-viable cells and cell death, it will be helpful to highlight
approaches which can be used to minimize cell death in those
experiments which do not involve cell death as being an endpoint
for the assay. Although the viability of cells that have been directly
isolated from animal lymphoid tissues is typically high (>95%),
the viability of cells that have been mechanically isolated from
other tissues, and that of cultured cells can be highly variable.
The loss of viability and integrity of cells during isolation, har-
vesting and processing can be minimized by performing all cell
preparations and staining procedures (including wash steps) at
an appropriate temperature and in the presence of bovine serum
albumin (BSA), heat-inactivated fetal bovine serum (FBS) or other
proteins. In the majority of instances, samples should be processed
at 4°C or on ice, as this slows down metabolic activity and other
cellular events which could influence the data that are generated.
For all experiments, cells should be stained promptly and, if not
fixed, analyzed as soon as possible.
Cell aggregation during staining can be inhibited by including
a small amount of DNase (200 μg/mL) in the staining solution.
Cell clumping can also be inhibited by including an Mg2+ ion
chelating agent such as EDTA (1–5 mM), which inhibits cell
adhesion events in the suspension buffer. If a DNase needs to be
included, then it is better to use EGTA which has a lower affinity
for Mg2+ ions, which the DNase requires.
The information provided herein is focused on the analysis of
cells by flow cytometry. A number of additional considerations
need to be taken into account to preserve cell viability in cell
sorting experiments: the medium in which cells are suspended,
the physical attributes of the instrument, especially the nozzle size,
the speed of sorting and the approach which is used for collecting
sorted populations.
Although it is possible to eliminate dead cells from appropri-
ate experiments prior to staining using techniques such as density
gradient centrifugation, this is not recommended as it could lead
to an unpredictable and inadvertent loss of viable, and poten-
tially important, cell populations from the sample and, as a con-
sequence, generate erroneous results. Under some circumstances,
the sample could be “cleaned” by isolating the cell populations(s)
of interest using magnetic bead approaches (see Section V.3: Rare
cells (general rules)). It is typically better to eliminate cells from
the analysis, rather than the tube in the majority of cases. How-
ever, even when using this approach, one should be very cautious
when interpreting data from samples that are exhibiting high pro-
portions of non-viable cells, as the presence of these cells and the
intracellular components that they release could influence the biol-
ogy of the viable populations that are being analysed. It is therefore
essential that the viability of the population under examination is
known, irrespective of the sample preparation approach used.
The presence of non-viable cells and the analysis of cell death
can be determined using a number of different approaches, as
listed and described in the sections below:
 DNA-binding dyes
 Protein-binding dyes
 Vital dyes
 Plasma membrane changes
 Caspase activation
As for all experimental procedures, it is essential that the rel-
evant literature is sought out and reviewed prior to embarking
on any studies, as this is likely to contain key information on the
parameters that others have identified as being optimal for that
particular application.
8.1 DNA-binding dyes
The principle of identifying dead cells using DNA binding dyes
is based on the concept that these dyes are impermeable to the
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plasma membrane and so cannot enter viable cells having intact
membranes. Viable cells will exclude these dyes and therefore
exhibit little to no fluorescence. Cell viability can therefore be
assessed by incubating samples with a DNA dye such as PI or 7-
AAD; dead cells will stain positively for either of these two nuclear
dyes. It is important to be aware that dyes such as PI and 7-AAD
can be taken up into viable cells over time, and so these stains
should be added immediately (10 min) prior to analysis, and the
staining protocol should be standardized across the experiments.
It is also important to note that DNA binding dyes cannot be used
on fixed or permeabilized cells such as those that would be used
in studies interrogating the expression of intracellular “targets”
using intracellular flow cytometry.
For the analysis, a data acquisition region is placed around the
positively stained cells, and color-eventing or “back gating” on the
PI+ or 7-AAD+ cells present is used to identify most, but not all,
dead cells as exhibiting lower FSC and higher SSC than viable
cells. Although it is possible to gate around the viable cell popu-
lation on the basis of their light scatter profile and use this for all
subsequent samples, even if these samples do not include a viabil-
ity indicator, by far the best method for excluding dead cells from
data analysis is to use a vital DNA dye in all samples. Although
common dyes used in multicolor analyses include PI, 7-AAD, TO-
PRO-3, pyronin Y(G) [PY(G)] and SYTOXۛ, a plethora of options
are now available from a range of commercial suppliers. A note of
caution is that the broad emission spectrum of 7-AAD (600–750
nm at 20% normalized emission maximum) can result in a signif-
icant level of spectral overlap into other detectors and exclude its
use in the context of other fluorochromes such as PE-Cy5, PerCP,
PerCP-Cy5.5 in large multi-parameter panels. Furthermore, it is
quite a “dim” (low quantum efficiency) fluorescent molecule when
compared to PI which is very “bright.” However, the minimal spec-
tral overlap between 7-AAD emission and that of fluorochromes
such as FITC and PE can be useful in some instances. One will
also need a compensation control for these dyes, and this could
be generated by staining cells that have been heat treated (70°C,
30 minutes).
Although these approaches use one of the fluorescent detec-
tion channels and thereby reduce the number of other parameters
that can be interrogated, the issue of viability is an important one
and the integrity of the experimental data and their interpreta-
tion should not be compromised by not including a viability stain
in all experiments. The far-red viability dye DRAQ7TM (Biostatus
Ltd., UK) is another viability dye which can be used in similar
settings to PI and 7-AAD and allows the identification or exclusion
of apoptotic, damaged or dead cells. A particularly useful feature
of DRAQ7TM is that its dual excitation using blue (488 nm) and
red (633/638 nm) lasers and its emission at 650–800 nm allows
multi-beam excitation and the exclusion of dead (DRAQ7+) cells
without “consuming” what could be a vital, and much needed,
additional fluorescent channel [465, 466].
The advantages of the classical DNA-binding dyes are that this
is a well-established approach which involves a short incubation at
the end of the staining procedure, and that the reagents are of low
cost. However, they are limited in their spectral (excitation, emis-
sion) characteristics and a significant disadvantage is that they are
not suitable for experiments which are interrogating intracellular
expression of relevant antigens that require fixation and perme-
abilization. A typical staining protocol involves the following:
1. Add 500 μL of cell suspension (1–2 × 106 cells – unfixed) to a
12 × 75 mm polystyrene tube.
2. Add nuclear staining compound dissolved in PBS [propidium
iodide: 5μL, 200μg/mL, 7-AAD: 4μL, 250μg/mL, TO-PRO-3:
4 μL, 250 μg/mL, or PY(G): 5 μL, 200 μg/mL] to tube.
3. Incubate cells on ice for at least 5 min.
4. Analyze cells by flow cytometry.
8.2 Protein-binding dyes
In some instances, the aim of the analysis will be to determine
and compare the expression of intracellular molecules / proteins,
in which case cells must be fixed and permeabilized in order to
allow the probes and antibodies to enter the cells. The use of
DNA binding dyes is inappropriate in these circumstances. In these
instances, the use of dyes binding to the amine groups of proteins
(amine-binding dyes), not DNA, is recommended.
The identification of non-viable cells under such circumstances
can be achieved using products having varied fluorescence spectral
properties such as the LIVE/DEAD
R©
fixable range of products from
Life Technologies, the eFluorۚ fixable dyes from eBioscience, BioLe-
gend’s Zombie range of fixable dyes, Tonbo biosciences’ Ghost
DyesTM and the Fixation and Dead Cell Discrimination Kit from
Miltenyi Biotec. These dyes covalently react with protein so that
the discrimination is completely preserved following fixation of
the sample. It should be noted that these dyes are membrane
impermeable and so will be internalized only by non-viable cells.
However, the level of fluorescence emitted by viable cells (with
which the dye has had access to only a few amines on the cell
surface), and non-viable cells (in which the dye has had access to
many more amines intracellularly) will be clearly distinguishable.
A word of caution: it is crucial to ensure that staining protocols
are performed in the absence of proteins in the staining buffer, to
which the dye will bind. Experiments can be compensated using
commercially-available amine-reactive beads.
8.3 Vital dyes
A third category of reagent which can be used for determining
cell viability and cell death are the vital dyes. These dyes indi-
cate viability by emitting fluorescence in response to metabolic
activity in cells. Cellular esterases cleave the acetomethoxy group
to yield calcein inside metabolically active cells. “Free” calcein
binds intracellular calcium and fluoresces brightly green. Calcein
AM dyes can be passively loaded into adherent and non-adherent
cells. These cell-permeable esterase substrates serve as viability
probes that measure both enzymatic activity, which is required to
activate their fluorescence, and cell membrane integrity, which is
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required for intracellular retention of their fluorescent products.
Available with blue, violet, and green fluorescence, these dyes
are ideal for short-term staining (signals can be measured within
5 minutes, but once the AM group is cleaved, it can be actively
transported out of the cell within a few hours) of live cells and can
be used in multiplexed flow cytometry experiments. However, as
the fluorescence generated by these dyes is driven by the presence
of metabolic activity, it is not easy to include them in staining
protocols that require fixation and permeabilization.
8.4 Measurement of apoptosis
The above approaches for identifying the induction and presence
of cell death are based on the loss or maintenance of membrane
integrity, and thereby reflect cellular necrosis. They provide lit-
tle insight into the nature of that cell death. In instances where
the induction of cell death is a primary endpoint of the exper-
iment, interrogating changes in the plasma membrane provide
an opportunity to generate insight into the mechanisms that are
involved. By far the most common approach is to determine the
induction of apoptosis (programmed cell death). Apoptosis is a
tightly controlled pattern of cell death which is required for the
maintenance of normal cell growth and development. Defective
apoptosis can result in abnormal development and pathogene-
sis. Understanding cell death mechanism(s) is important as the
mode of cell death (necrosis versus apoptosis) can influence the
pro- and anti-inflammatory responses which cell death can induce.
The importance of this area was recognized by the award of the
2002 Nobel Prize in Physiology or Medicine to Sydney Brenner, H.
Robert Horvitz and John E. Sulston “for their discoveries concern-
ing genetic regulation of organ development and programmed cell
death.”
During early apoptosis, phosphatidylserine (PS) is translocated
from the cytosolic side of the intact plasmamembrane to the extra-
cellular surface. Early apoptotic cells cannot therefore be reliably
identified using approaches that are based on membrane perme-
ability. Annexin V belongs to a family of proteins consisting of
over 160 members, and has high affinity, specificity, and sensi-
tivity for PS. Thus, the binding of Annexin V to cells can be used
as a marker of early apoptosis [467]. In order to rule out “leaky”
necrotic cells, Annexin V staining must always be used in con-
junction with reagents that determine the integrity of the cell
membrane, such as PI or 7-AAD. Of course, such assays cannot be
performed using fixed cells.
The protocol for such assays is relatively straightforward, but
should be undertaken according to the protocol which is provided
by the supplier of the reagents. This is especially important in
the case of Annexin V binding, as all Annexin family members
share the same characteristics of Ca2+-dependent binding to neg-
atively charged phospholipid surfaces. It is essential that the cor-
rect staining buffers are used, as changing or variations in Ca2+ ion
concentrations can have dramatic effects on the staining profiles.
Furthermore, the binding of Annexin V to PS is reversible, and so
samples must be analyzed as soon as possible (typically 1–3 hours
Figure 63. Identifying healthy and apoptotic cells on the basis of
Annexin V staining. The human prostate cancer cell line LNCap was
seeded into 6 well plates and allowed to adhere overnight. The fol-
lowing day, cells were left untreated (A) or incubated for 6 h with 4
μg/mL human recombinant granzyme B [468, 469] (B). After the incuba-
tion period, cells were harvested and processed as described above,
with 105 cells being stained with Alexa-Fluor R© 647 Annexin V (fol-
lowing the manufacturer’s instructions) and propidium iodide (final
concentration 1μg/mL). Cells were analyzed on a Beckman Coulter
GalliosTM flow cytometer. Plotting Annexin V binding on the x-axis
of a two-dimensional dot/density plot and PI/7-AAD on the y-axis
enables the identification of healthy (Annexin VnegativePI/7-AADnegative,
bottom left quadrant), apoptotic (Annexin VpositivePI/7-AADnegative, bot-
tom right quadrant) and late apoptotic / dead (Annexin VpositivePI/7-
AADpositive, top right quadrant) cells. The cells incubated in the pres-
ence of granzyme B showed induction of apoptosis and increased cell
death.
after labelling), using a consistent and reproducible protocol. A
typical experimental protocol producing a typical staining profile
(Fig. 63) involves the following:
1. Wash cells (1 × 105) in Annexin V Binding Buffer (PBS con-
taining 10% v/v FCS, 1.0 mM MgCl2 and 2.5 mM CaCl2).
2. Pellet cells (5 minutes, 400 × g), remove the supernatant,
either by decanting or vacuum aspiration and resuspend cells
in 100 μL of Annexin V Binding Buffer.
3. Incubate cells with an appropriate volume (e.g. 5 μL) of
fluorescently-conjugated Annexin V (e.g. Alexa Fluor R© 647-
Annexin V, Biolegend), vortex mix in order to ensure even
distribution of the stain) for 15 minutes at room temperature
whilst protected from light.
4. Wash cells in Annexin V Binding Buffer and resuspend cells in
250 μL fresh buffer.
5. Transfer cells to 12× 75mmpolypropylene tubes, stored on ice
protected from light before being analyzing by flow cytometry.
6. Immediately prior to analysis, add DNA-binding dye [propid-
ium iodide: 5 μl, 200 μg/mL 7-AAD: 4 μL, 250 μg/mL] to
allow identification, and exclusion, of any non-viable cells.
Although Annexin V staining is probably the most common
approach used for determining apoptosis, other approaches can
also be used. For instance, the TdT-mediated dUTP nick end
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labelling (TUNEL) method involves labelling the ends of DNA
breaks with dUTP using terminal deoxynucleotidyltransferase
(TdT). These labelled breaks can then be detected using an anti-
BrdU antibody. In this case, fixation is required. However, given
that this approach depends on DNA damage rather than staining
actual components of the apoptotic pathway, it can be insensitive.
Another alternative to the Annexin V assay is the Violet Ratio-
metric Membrane Asymmetry Probe, F2N12S from ThermoFisher.
This probe is excitable at 405 nm and detects variations in sur-
face charge associated with PS flipping. Viable cells produce an
orange emission which shifts to green with apoptosis, resulting in
a decreased orange/green emission ratio.
The later stages of apoptosis involve chromatin condensation
and DNA fragmentation, a consequence of which is that the nuclei
of apoptotic cells become smaller than those of viable cells and
display higher fluorescence when labeled with dyes such as UV-
excited Hoechst 33342 (which is available from a number of sup-
pliers) or 405 nm-excited Vybrant
R©
DyeCycle ۛ Violet stains (Ther-
moFisher). When paired with an impermeable dead cell stain, it is
possible to distinguish live, apoptotic and necrotic cell populations
using such chromatin condensation assays.
The loss of mitochondrial membrane potential is another
hallmark of early apoptosis. In cells undergoing apoptosis, the
mitochondria will release cytochrome C and the apoptosis induc-
ing factor—both of which are necessary for caspase activation
(yet another critical step in apoptosis). It is also possible to assess
apoptosis on the basis of mitochondrial membrane polarization
using fluorescent dyes such as JC-1 (5,5′,6,6′-tetrachloro-
1,1′,3,3′-tetraethyl-benzimidazol-carbocyanine) or JC-10 which
can be obtained from a number of different suppliers. As the
mitochondrial potential is lost during the course of apoptosis, the
emission shifts from red to green, thereby resulting in a decreased
red/green fluorescence ratio. The principle of this approach is
that the dye accumulates in healthy mitochondria, in which it
is present as a multimer. Upon disruption of the mitochondrial
membrane, the dye is released, and changes color due to it
transforming into a monomer in the cytoplasm. However, a word
of caution is that some dispute the collapse of the mitochondria
membrane potential as being a critical step in apoptosis.
DiIC1(5) (1,1′3,3,3′3′-hexamethylindocarbocynanine iodide)
is another positively charged dye that accumulates in active mito-
chondria. It is excited at 635 nm, is read in the APC channel and
its fluorescence intensity decreases as membrane potential is lost.
MitoTracker Red CMXRos is another useful mitochondrial probe
which is excited at 488 nm, read in the phycoerythrin (PE) channel
and also shows a decrease of fluorescence as membrane potential
is lost.
A key issue to be aware of is that the sample preparation process
can all lead to preferential loss of apoptotic cells during sample
preparation (i.e. prolonged trypsinization, mechanical or enzy-
matic disaggregation from tissues, centrifugation steps). Remem-
ber to collect cells that have been released into the media when
experimenting with adherent cell cultures. Density gradient sep-
aration of cells can also selectively deplete apoptotic cells due to
differing relative densities.
8.5 Caspase activation
A distinctive feature of the early stages of apoptosis is the acti-
vation of caspase enzymes. The caspases constitute a family of
aspartate-specific cysteine proteases that cleave protein substrates
at specific amino acid residues. This triggers a sequence of cleav-
age events, including the cleavage of other caspases, and generates
a caspase signaling cascade that leads to apoptosis. In mammals,
the “initiator” caspases-2, -8, -9, -10, and -12 are closely cou-
pled to upstream, pro-apoptotic signals, and cleave and activate
downstream effector or “executioner” caspases-3, -6, and -7 that
modify the proteins that ultimately drive apoptosis [470, 471].
In most cases, caspase activation is one of the earliest measur-
able markers of the apoptotic cascade, and precedes the induc-
tion of cell permeability, DNA fragmentation, cytoskeletal col-
lapse, and the flipping of PS. The pivotal and early involve-
ment of caspases in cell death events has prompted the devel-
opment of a number of assays which can be applied alone, or
in conjunction with assays for detecting other aspects of the cell
death process. A number of commercial suppliers provide vali-
dated assays for the detection of apoptosis on the basis of caspase
activation.
Caspase activation assays can involve the intracellular stain-
ing of cell populations using monoclonal antibodies that are spe-
cific for the activated forms of the relevant caspase (Fig. 64),
or can employ small inhibitor peptides conjugated to a fluo-
rophore which specifically target the active site of the chosen
caspase.
As an example, the CellEvent
R©
Caspase-3/7 Green Detection
Reagent from ThermoFisher is a cell-permeable reagent consist-
ing of a four-amino acid peptide (DEVD) conjugated to a nucleic
acid-binding dye. The activation of caspase-3 and caspase-7 pro-
teins enables them to cleave the caspase 3/7 recognition sequence
which is encoded in the DEVD peptide. Cleavage of the recognition
sequence and binding of DNA by the reagent labels the apoptotic
cells with a bright, fluorogenic signal that has absorption/emission
maxima of 511/533 nm. When used together with the SYTOX
R©
AADvancedTM Dead Cell Stain, apoptotic cells can be easily dis-
criminated from live and necrotic cells.
Caspase activity can also be determined using the PhiPhiLux
R©
system, which employs a non-fluorescent substrate for the enzyme
that yields a fluorescent product if the enzyme is active. The
PhiPhiLux
R©
caspase substrates are cell permeable, demonstrate
relatively good caspase specificity, possess high SNRs between
their uncleaved and cleaved forms, and have fluorescence spec-
tral properties that are compatible with other fluorescent probes.
ApoStat (R&D Systems) identifies and quantifies caspase activity
in apoptotic cells by irreversibly labeling cells with a cell per-
meable, FITC-conjugated pan-caspase inhibitor (ApoStat). Any
unbound reagent diffuses out of the cell and is washed away and
an increased fluorescence is indicative of caspase activity. The
CaspGLOWTM staining system detects active caspase-9 in mam-
malian cells using FITC-conjugated LEHD-FMK, a specific inhibitor
of caspase-9 which is cell permeable and irreversibly binds to the
active enzyme.
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Figure 64. Identifying healthy and apoptotic cells
on the basis of activated caspase-3 expression. The
human breast cancer cell line MDA-MB-231 was
seeded into 6-well plates and allowed to adhere
overnight. The next day, cells were left untreated
or incubated for 24 hours with the topoisomerase
I inhibitor camptothecin (4 μg/mL, induces apopto-
sis). After the incubation period, cells were harvested
and stained using the FITC active caspase-3 apopto-
sis kit (BD Biosciences) following the manufacturer’s
instructions and analyzed on a BD Biosciences LSRII
flow cytometer. Cells were identified using FSc and
SSc measurements (A) and the expression of active
caspase-3 determined on the basis of FITC fluores-
cence (B; control sample shown on open histogram
and camptothecin treated shown on grey histogram).
The cells incubated in the presence of camptothecin
showed activation of caspase-3.
Another approach involves the use of a fluorescently labelled
inhibitor peptide that binds to the active site of the caspase or
FLICA
R©
– Fluorescent Labelled Inhibitor Caspase. FLICA
R©
probe-
based assays, which are available from a number of suppliers, are
comprised of an affinity peptide inhibitor sequence, a fluoromethyl
ketone (FMK) moiety that facilitates an irreversible binding event
with the activated caspase enzyme, and a fluorescent tag reporter.
The FLICA
R©
are therefore retained in apoptotic cells, but not in
non-apoptotic cells following washing. Necrotic and late apoptotic
cells can be concurrently identified in green FLICA
R©
-labelled cells
using red fluorescent dyes such as PI or 7-AAD, or the far red
dye DRAQ7TM. The ability to measure three apoptotic phenotypes
in a single assay provides a powerful and comprehensive view
of the apoptotic process, applicable to both suspension cells by
traditional flow cytometry.
The approach selected for measuring cell viability, cell death
and apoptosis will very much depend on the experimental ques-
tion, the supplier of the reagents, and the analysis of the strengths
and weaknesses for each assay. Conventional internet searches
will readily identify the plethora of kits and approaches that can
be used for measuring caspase activation.
8.5.1 Useful resources.
 Chromocyte Limited – Resource for flow cytometry and cell-
based assays (www.chromocyte.com)
 Expert Cytometry – Flow cytometry training (www.exp
ertcytometry.com)
 Purdue University Cytometry Laboratories (www.cyto.
purdue.edu)
 International Society for Analytical Cytology (ISAC, http://isac-
net.org)
 European Society for Clinical Cell Analysis (ESCCA,
www.escca.eu)
 BitesizeBio Flow Cytometry Channel (http://bitesizebio.com/
category/technical-channels/flow-cytometry)
8.6 Cytofluorimetric analysis of mitochondria
Mitochondria are essential mediators of cell metabolism, being
producers and targets of reactive oxygen species (ROS), regulators
of ATP levels and calcium homeostasis, and hubs of the biosyn-
thetic pathways involved in the synthesis of amino acids, lipids and
nucleotides [472]. Mitochondria are present in all cells, including
those that rely mostly on glycolysis rather than on oxidative phos-
phorylation for ATP synthesis. They are very heterogeneous in size,
shape, and number, depending on the metabolic requirement of
the cells, the underlying tissue, and several other factors. Given
their crucial role in cellular and organismal functions, it is not sur-
prising that mitochondrial (mt) dysfunctions have been observed
in a number of genetic and non-genetic diseases, as well as in
cancer and aging [473]. In the vast majority of cases, distinctive
features of mt dysfunction include changes in mtmP, mt mass and
redox potential.
Flow cytometry allows the rapid monitoring of all these param-
eters in intact cells, avoiding artifacts associated with mt isolation
and/or permeabilization, and offering the benefits to work in a
preserved cellular environment [474]. A number of mt-specific
fluorescent probes have been developed, which can be used to
measure mtmP, mt mass, and intra-mt reactive oxygen species
(Table 20) [475].
mtmP is the main component of the proton-motive force, which
is established by protons pumped from the mt matrix to the inter-
membrane space, and combines the mtmP to the mt pH gradient.
This potential varies according to the status of mitochondria, it is
related to their capacity to synthetize ATP, and is a common indi-
cator of cell health. According to the Nernst equation [476], the
mt matrix is negative, thus indicating that hyperpolarized or depo-
larized mitochondria present a more or less negative mt matrix,
respectively. Dyes for measuring mtmP are typically lipophilic
cationic compounds, i.e. positively charged molecules that can
cross membranes without binding them, and accumulate in the mt
matrix in direct proportion tomtmP. Hyperpolarizedmitochondria
accumulate more dye, whereas depolarized mitochondria accu-
mulate less dye. When mtmP is assessed by flow cytometry, two
major recommendations have to be taken into account. First, dye
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Table 20. Main fluorescent probes used to stain mitochondria in intact, living cells
Full name Short name Abs (nm) Em (nm) Fixable
Mitochondrial membrane potential
3,3’-dihexyloxacarbocyanine iodide DiOC6 484 501 No
Rhodamine 123 Rh123 507 529 No
5,5’,6,6’-tetrachloro-1,1’,3,3’-tetraethyl-
benzimidazolcarbocyanine
JC-1 514 529/590 No
3,3’-dimethyl-αlpha-naphthox-
acarbocyanine
iodide
JC-9 522 535/635 No
Tetramethylrhodamine ethyl ester TMRE 549 574 No
Tetramethylrhodamine methyl ester TMRM 548 573 No
MitoTracker Red CMXRos 578 599 Yes
Mitochondrial mass
Nonyl Acridine Orange NAO 495 519 No
Mito ID Red 558 690 Yes
Mitotraker Green FM 489 517 No
Mitotraker Deep Red 633 644 665 Yes
MitoTracker Red 580 581 644 No
Mitochondrial reactive oxygen species
MitoSOX Red mitochondrial superoxide
indicator
MitoSOX 510 580
Mitochondria Peroxy Yellow-1 MitoPY-1 510 528/540
Abs, absorbance; nm, nanometers
concentration should be carefully titrated. High dye concentra-
tions lead to fluorescence quenching, which generates artifacts and
misleading results. Even if quenching threshold varies depending
on the dye, concentrations in the range 1–30 nM should be low
enough to avoid unwanted quenching phenomena [477]. Second,
functional controls must be used to ensure that changes in the
dye signal are interpreted properly and are not caused by other
parallel changes, including those in mt mass. Appropriate controls
are represented by:
1. carbonyl cyanide-4-(trifluoromethoxy)phenylhydrazone
(FCCP), carbonyl cyanide m chlorophenyl hydrazine (CCCP),
and valinomycin, which are uncouplers;
2. oligomycin, an ATP synthase inhibitor
3. nigericin, a K+/H+ ionophore.
While FCCP, CCCP, valinomycin and oligomycin induce depo-
larization, nigericin induces hyperpolarization.
A list of the main fluorochromes used to assay mtmP
in living cells is shown in Table 20. Among them, 3,3′-
dihexyloxacarbocyanine iodide (DiOC6) has been extensively used
in flow cytometric studies [478]. However, DiOC6 activity as
NADH inhibitor, together with its toxicity toward mt respira-
tion, strongly limits the use of this probe [335, 479]. Similarly
to DiOC6, rhodamine 123 (Rh123) was initially used in several
studies [480]. However, Rh123 enters easily into the cells and
rapidly equilibrates, but is not well retained. In addition, in cer-
tain conditions, Rh123 binding to mitochondria can be indepen-
dent of mitochondrial energy status, and this further restricts its
use [335, 481]. Conversely, tetramethylrhodamine ethyl ester
(TMRE) and tetramethylrhodamine methyl ester (TMRM) are
widely used to probe mtmP by flow cytometry [482, 483]. These
dyes are nontoxic, specifically stain polarized mitochondria and
do not display quenching effects [483]. They should be used at
relatively low concentrations, and the analysis can be performed
immediately after staining, even in the absence of wash steps.
Upon excitation at 488 nm, TMRE and TMRM emits at 574 nm.
As monochromatic dyes, the MdFI relative to the proper channel
should be measured for TMRE and TMRM. Typically, an unstained
sample (also known as “blank”) should be prepared, in order to
set the levels of background fluorescence, and subtract this back-
ground fluorescence to fluorescence of the stained sample. When
assayed by TMRE or TMRM, changes in mtmP are thus evaluated
as changes in MdFI of a given sample (Fig. 65).
Carbocyanine dyes, especially 5,5′,6,6′-tetrachloro-1,1′,3,3′-
tetraethyl-benzimidazol-carbocyanine (JC-1), are considered the
most reliable probes for the detection of mtmP. JC-1 has poly-
chromatic fluorescence emission spectra, and allows a ratiometric
semi-quantitative assessment of mt polarization [484, 485]. In the
monomeric state, it emits a green fluorescence (529 nm), whereas
in the aggregate state, which is highly dependent upon mtmP,
it emits an orange-red fluorescence (>590 nm), well detectable
in healthy cells. In the presence of compounds that cause a col-
lapse in mtmP, JC-1 becomes monomer. This means that while in
healthy cells both green and orange-red fluorescence are expected,
cells with depolarized mitochondria display only green fluores-
cence [486]. Considering the shift in fluorescence due to mtmP
changes, the best way to display results is that of indicating the
percentage of cells with high or low mtmP, rather than the ratio
between green and orange-red fluorescence. Since 1993, JC-1
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Figure 65. TMRM and JC-1 staining of CD4+ T cells.
The K+ ionophore valinomycin depolarizes mitochon-
dria of CD4+ T cells, as revealed by the decrease in
TMRM fluorescence, and by the decreased fluores-
cence of JC-1 aggregates and increased fluorescence
of JC-1monomers. Untreated cells (CTRL) are shown in
left panels. For TMRM, unstained sample is also shown
in right panel. Dot plot combining untreated sam-
ple and valinomycin-treated sample is also reported
(lower right panel).
has been reported as a reliable membrane potential indicator for
several cell types and assay conditions [484, 487, 488], and its
compatibility with other fluorescent probes has also been demon-
strated in the design of multi-color panels [489, 490]. However,
the sensitivity of JC-1 toward hydrogen peroxide, its photosensi-
tivity, and the slow rate of equilibration between monomers and
aggregates, could partially limit its use. Other dyes, similar to
JC-1, are also available but are scarcely used JC-9 is characterized
by polychromatic fluorescence emission, with excitation at 522
nm, and emission at 535 or 635, in the monomeric or aggregate
forms, respectively. The green fluorescence of JC-9, characterized
by a different chemical structure respect to JC-1, is essentially
invariant with membrane potential, whereas the red fluorescence
is significantly increased at hyperpolarized membrane potentials.
JC-10 is excited at 490 nm, and emits at 520 nm (monomeric
form) or 590 nm (aggregated form). Compared to JC-1, JC-10 is
characterized by higher water solubility and diffuses out of mito-
chondria in apoptotic and necrotic cells.
Mitochondrial mass can be monitored by using dyes able to
bind specific mt components regardless of mt polarization status.
For this reason, the amount of fluorescence is directly proportional
to mt content. Mito ID and nonyl acridine orange (NAO) bind to
cardiolipin in the inner mt membrane, whereas MitoTracker dyes
react with the thiol groups of cysteine residues present in mt pro-
teins [491, 492]. Some of these dyes, including MitoTracker deep
red 633, also form covalent bonds with mt proteins, thus allow-
ing fixation after cell staining. As described for TMRE and TMRM,
the MdFI relative to the proper channel should be measured for
MitoTracker dyes, and the MdFI of the unstained sample should
be subtracted to the MdFI of the stained one (Fig. 66).
Regarding mt ROS, two fluorescent probes, i.e. MitoSOX red
mitochondrial superoxide indicator (MitoSOX) and mitochondria
peroxy yellow-1 (mitoPY1), have been recently developed to stain
specifically anion superoxide and hydrogen peroxide in mito-
Figure 66. MitoTracker Green staining of different subsets of CD8+ T
cells. Different CD8+ T-cell subsets, i.e., central memory (CM), naı¨ve
(N), effector memory (EM), and terminally differentiated effector mem-
ory (EMRA) were identified according to the expression of CD45RA and
CD197. Among them, the use of MitoTracker Green (MT Green) allows
to determine mt mass, which is clearly different among cell subsets.
chondria, respectively [493–495]. MitoSOX is the mitochondria-
targeted form of hydroethidine. It accumulates into mitochondria
depending on mtmP, and it emits fluorescence upon oxidation
and binding to mitochondrial DNA [496]. As already reported for
other probes, when using MitoSOX and mitoPY1, preparing ade-
quate positive and negative controls is crucial to fully validate
the presence of mt H2O2 in biological systems. Antimycin A or
doxorubicin are best-suited positive controls for MitoSOX stain-
ing, whereas exogenous H2O2 or other molecules that increase
the fluorescence signal of the probe represent proper positive
controls for mitoPY1. Negative controls for MitoSOX staining are
cell-permeable superoxide dismutase mimetics or mt uncouplers,
depending on the cell type. Additional controls can be represented
by antioxidants, such as N-acetylcysteine, or other specific scav-
engers that highly reduce free radical production [497]. MitoSOX
and mitoPY1 have been tested by flow cytometry for selective
quantification of mt anion superoxide and mt hydrogen peroxide
in keratinocytes, endothelial cells, fibroblasts, several cancer cell
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Figure 67. MitoSOX Mitochondrial Red
superoxide indicator andMitochondria Per-
oxyYellow-1 staining of different subsets of
CD8+ T cells. Doublets were excluded from
the analysis of peripheral blood mononu-
clear cells by using FCS-A and FSC-H
(upper left panel); viable cells were selected
according to negativity for annexin-V (ANX-
V) Pacific Blue conjugate and TO-PRO-3
iodide (upper right panel). Then, CD4+
or CD8+ T lymphocytes were selected on
the basis of positivity for a CD4−APC-
H7 mAb or a CD8-PO mAb respectively.
Among these, fluorescence intensity of
MitoSOX Mitochondrial Red Superoxide
Indicator (MitoSOX) and Mitochondria Per-
oxy Yellow-1 (mitoPY) was analyzed.
lines, among others [498–501]. The possible simultaneous use
of MitoSOX and mitoPY1 in the same panel for the analysis of
mt reactive oxygen species in living cells has also been reported
(Fig. 67) [498].
Flow cytometry is undoubtedly a useful tool to assay mt func-
tions in biological samples. Protocols to assay mt parameters can
be applied to several cell models, and are relatively fast, as the
time required to complete staining and data analysis (even in the
case of multi-color panels) rarely exceeds three hours. In addition,
the analysis of several thousands of cells in a few minutes allows
accurate measurements. Nevertheless, as a general rule, the use of
more than one probe, as well as the use of complementary meth-
ods to assess changes in mt membrane potential or mt mass, is
strongly recommended.
9 Phagocytosis
9.1 Background
Phagocytes are essential components of the first defensive line
of the innate immune system. Professional phagocytes include
neutrophils, monocytes, macrophages, dendritic cells, osteoclasts,
and eosinophils [502]. Phagocytosis is, indeed, one of the
most ancient functions of immunity conserved through evolution
[503].
Ingesting and killing of microorganisms involves intrinsic func-
tions of phagocytes as well as complex interactions between
phagocytes, pathogens and plasma factors such as opsonins.
Deficiencies in these functions or interactions are associated
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with increased susceptibility to infection. Defensive phagocyto-
sis involves sequentially chemotactic migration of the phagocytes,
recognition of pathogen determinants, ingestion of microorganism
and, finally, destruction by oxygen-dependent (“oxidative burst”)
and -independent mechanisms [502].
It is important to note that the interaction with extracellular
pathogens may lead to the apoptotic death of phagocytes [504].
On the other hand, phagocyte recognition of apoptotic cells helps
clearance of unwanted self cells from tissues. Phagocytosis of
apoptotic cells prevents the release of cell components that might
otherwise trigger inflammatory response [505]. Phagoptosis, also
called primary phagocytosis, is a form of cell death caused by
phagocytosis and destruction of viable cells. Phagoptosis mediates
turnover of erythrocytes, neutrophils and other cells, and thus is
one of the main forms of cell death in the body. Phagoptosis is trig-
gered by exposure on plasma membrane of “eat-me” signals (such
as phosphatidylserine or calreticulin) and/or loss of “don’t-eat-me”
signals (such as CD47) by viable cells, causing their phagocyto-
sis by phagocytes. Live cells may modify the expression of such
signals as a result of cell stress, damage, activation or senescence
[506].
Also of interest, is the study of phagocytic ingestion of synthetic
nanoparticles in the range of 1 to 100 nm. These particles are
increasingly used in industrial and commercial products [507].
9.2 Flow cytometric assays of phagocytosis: fundamentals
and general applications
Flow cytometry (FCM) has been used for many years to study
phagocytosis [508–514]. Although frequent applications include
the clinical study of human immunodeficiencies and septic condi-
tions [515], phagocytosis assays also serve veterinary [516] and
environmental settings [517], as well as a growing multiplicity of
other experimental settings.
In classical FCM phagocytosis assays, phagocytes are incubated
at 37ºC with fluorescent target particles pre-opsonized with an
appropriate dilution of serum. Phagocytosis is measured as the
mean fluorescence of effector cells and or the percentages of
fluorochrome-positive phagocytes, or serum dilutions at which a
defined endpoint value is calculated. These techniques have intrin-
sic drawbacks, such as quenching of fluorescence upon internaliza-
tion, difficulty distinguishing between adherent and internalized
bacteria inmost cases, or a failure to determine antibody-mediated
phagocytosis [508–514].
Phagocytosis studies benefit from the unique integration of
functional and phenotypic information provided by FCM and the
large availability of phagocytic cell types and targets (both nat-
ural and synthetic) that are suitable for the technical capabili-
ties of FCM [508–514]. In many cases, FCM assays of phagocy-
tosis are available as commercial kits, and may include simul-
taneous assessment of other functional aspects or consequences
of phagocytosis, typically the oxidative burst [515] or apoptosis
[515, 518].
9.3 Critical points in the pre-analytical and analytical
phases of assays
9.3.1 Phagocytic cell types and sample preparation. FCM assays
of phagocytosis and other phagocytic-related functions can be per-
formed on a large variety of primary phagocytic cells, including but
not restricted to peripheral blood monocytes and neutrophils from
humans [515], rats [519], dogs [520], cats [521], cows [522]
or cetaceans [517], human dendritic cells [523], human peri-
toneal [524] or monocyte-derivedmacrophages [525], peritoneal-
or bone-marrow murine macrophages [526], and coelomocytes
from earthworms [527]. In addition, several established cell lines
with phagocytic capacity can be used for experimental studies,
typically the human monocytic cell lines U937 and THP-1 or the
murine macrophage cell lines J774A.1 and RAW 264.7 [528].
When using whole blood samples, heparin is often the choice
anticoagulant, and anticoagulated blood samples should be pro-
cessed within 4 hours of collection. Prolonged storage may lead
to abnormal results. Specimens should typically be maintained at
18–22 °C, and temperatures below 10°C and above 30°C must
be avoided if possible when using whole blood. If cryo-preserved
blood cells are used for assay, it is essential to thaw and use
the cells rapidly. Neutrophils are especially fragile, and can be
activated by endotoxins, excessive agitation or repeated centrifu-
gations, with resultant cell death. Endotoxin-free polypropylene
tubes should be used. Cell clumping after standing at room tem-
perature can be avoided by using the cells promptly or by adding
DNase to the cell suspension [511].
Human PBMCs and neutrophils can be isolated by using dif-
ferent classical procedures, with dextran sedimentation prefer-
able for neutrophil purification and gradient centrifugation by
Histopaque 1077 for monocyte enrichment [529]. In addition,
magnetic separation can be used successfully to isolate functional
primary phagocytic cells based upon immunophenotypic myeloid
cell determinants [154]. Human monocytes are often cultured in
serum-free or serum-supplemented media to create macrophages
or dendritic cells [154].
9.3.2 Phagocytosis targets. A multiplicity of fluorescent biologi-
cal and synthetic micro- or nanoparticles can be used as suitable
targets for phagocytosis with FCM assays reflecting, on the one
hand, the different roles and clinical failures of phagocytosis and,
on the other hand, the diversity of plasma membrane receptors
that mediate phagocytic recognition of microbes, apoptotic cells
or synthetic particles [502].
The best biological targets can be live microorganisms, includ-
ing pathogenic and non-pathogenic bacteria and yeast. Because of
their hazardous nature, pathogens can be inactivated by different
means. However, inactivation by heat killing (e.g. boiling) may
result in loss of cell wall components, which are extremely impor-
tant for phagocyte recognition, thus potentially reducing phago-
cytosis [530]. Inactivation by fixation with 4% paraformalde-
hyde may preserve some pathogen-associated determinants
and improves recognition [531]. Another typical target for
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phagocytosis assays are zymosan particles, prepared from the
cell wall of Saccharomyces cerevisiae and consisting of protein-
carbohydrate complexes [510–512, 532]. FCM assays of phagocy-
tosis can use fluorescent microbeads of different optical properties,
chemical composition and diameter which may be, in addition,
coupled with components relevant for receptor-mediated particle
recognition [511].
Since physiological phagocytosis occurs mainly after binding
of opsonized particles to receptors of the constant fragment of
immunoglobulins (Fc) or complement receptors expressed on
phagocytes, it may be essential to ensure opsonization of phagocy-
tosis targets. Engagement of phagocyte Fc receptors can be done
by pre-incubation of targets with appropriate sera or Immunoglob-
ulin G (IgG) solutions, as well as by coating of fluorescent beads
with IgG antibodies. In this aspect, whole-blood assays of phago-
cytosis have the advantage of not requiring additional steps of
target opsonization.
As rates of phagocytosis are highly dependent on the target-
to-cell ratio, accurate counting of targets and effector phagocytes
and the use of a suitable ratio is important [532]. Target: effector
ratios ranging from 1:1 [532] to 260:1 [533, 534] have been
applied in different assay settings. Similarly, the determination of
the duration of the assay must take into account the difference
of phagocytosis kinetics between synthetic and natural targets,
as well as among different types of biological targets . One-hour
incubation is usually sufficient and typically, phagocytosis assays
require incubation times of 15–30 min [535].
9.3.3 Fluorescent labelling of targets. There are several conve-
nient commercial sources of fluorescently conjugated biological
and synthetic particles [513]. In some cases, such particles
are components of assay kits which can be used in conven-
tional FCM using a suitable laser. For custom labelling of
targets, the most common fluorescent labels are incorporated
as N-hydroxysuccinimide esters, which react covalently with
–NH2 groups [513]. Fluorescein derivatives (e.g. fluorescein,
dicarboxyfluorescein, Oregon GreenTM, dihydrodichlorofluores-
cein) have been popular, but their fluorescence is quenched in
the acidic compartments of phagocytes and, moreover, their
emission wavelength overlaps markedly with green autoflu-
orescence, which is especially present in macrophages and
monocytes [536]. Other fluorophores such as Alexa Fluor R©,
BODIPY R© FL, tetramethylrhodamine and Texas Red R© have
stable, intense emission over a broad pH range (pH 4–9). Most
interestingly, pHrodoTM, a new series of probes with green- or red
fluorescence emission increasing with decreasing pH has been
recently developed [513, 537]. Fluorescent-protein expressing E.
coli can be also suitable for FCM assays [538–540].
9.3.4 Identification of live subpopulations of phagocytic cells by light
scatter and surface immunophenotype. The nucleated phagocytes
in whole blood assays may be distinguished from debris and from
smaller targets (microorganisms and fluorescent beads) by gating
on the granulocyte and monocyte populations using forward and
SSC properties [511, 513]. As phagocytosis may lead to degranu-
lation and, even, apoptosis of phagocytes, especially neutrophils,
it is recommended to include at least a viability marker and even-
tually, appropriate immunophenotypic markers (e.g. CD45, CD14,
CD13, CD15, CD16, CD11b) [541]. It is worth mentioning that the
lymphocyte population in whole blood assays may often serve as
an internal negative control of non-phagocytic cells. In FCM assays
using homogeneous phagocytic populations (e.g. U937, TPH-1,
RAW) and small targets it is recommended to include viability
markers, in order to exclude non-specific attachment of targets
to dead or dying phagocytic cells. In those specialized assays in
which target cells (e.g. apoptotic cells, infected erythrocytes) may
have similar size as phagocyte effectors, it is recommended to
label separately effectors and/or targets using appropriate track-
ing dyes [533, 542].
In all cases, phagocytosis assays involving immunophenotyping
with multicolor cytometry should include the appropriate controls
for fluorescence compensation (single-stained tubes) and gating
(Fluorescence-minus-One, or FMO, controls). This is further dis-
cussed in Section III.1: Compensation.
9.3.5 Distinguishing non-internalized from internalized particles.
In order to accurately assess the phagocytosis process it is essential
to demonstrate that the particles are in fact ingested, and not
adherent to the phagocyte surface nor merely coincident with the
cell in the laser-illuminated area.
While coincidence of phagocytes and targets can be minimized
by running diluted samples at the slower flow rates, quantification
of internalized particles as distinguished from surface adherent
may be approached by different strategies:
1. Comparing the cell-associated fluorescence intensity in condi-
tions avoiding (negative controls) or allowing particle inter-
nalization. Negative controls of this type should include cells
incubated without fluorescent targets (autofluorescence) and
of cells and targets co-incubated at 4°C (Fig. 68) or in the
presence of inhibitors of cytoskeleton rearrangement, as the
commonly used cytochalasins, or other inhibitors of phagocyte
function, such as N-ethylmaleimide [535].
2. Using targets labelled with a dye that is sensitive to quenching
agents (e.g. FITC-, or Calcofluor White can be quenched by
Trypan blue and crystal violet [511–513], while Sytox Green
is quenched by propidium iodide [530]. In this approach, extra
washing steps are necessary to remove the quenching dye, thus
increasing assay time and making the assay prone to artefacts
and cell loss.
3. Using fluorescent targets emitting fluorescence at different
wavelengths at neutral or acidic pH. Probes of this type
include the pHRodoTM series, and the Eos-FP fluorescent
protein. pHRodoTM dye can be used for the labeling of targets,
as it reacts with the primary amino groups on the particle to
yield a covalently linked pH probe, which increases fluores-
cence emission as the pH of its environment becomes more
acidic. The optimal absorption and fluorescence emission
C© 2017 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.eji-journal.eu
Eur. J. Immunol. 2017. 47: 1584–1797 Cytometric parameters 1701
Figure 68. Representative examples of strategies to differentiate between attached and internalized fluorescent bacteria in whole-blood phago-
cytosis assays by conventional flow cytometry (A–C) and imaging flow cytometry (D–F). In both assays, whole-blood samples anticoagulated with
heparin were stained with CD45-APC (A) or CD45-PE (D) antibody and incubated for 30 min at 37ºC (B) or at 4ºC (C) with a suspension of Escherichia
coli (ATCC 11775) transformed by electroporation with a plasmid containing the GFP gene (pMEK91 GFP). The ratio bacteria/leukocytes was 1:4.
Then, samples were lysed with BD FACS Lysing Solution, put on ice and analysed immediately in a BD Accuri C6 conventional flow cytometer (A–C)
or in an Amnis ImageStream 100 multispectral imaging flow cytometer (D-F), both using a 488 nm blue laser. Graphs B and C show the intensity of
GFP fluorescence emission in granulocytes distinguished by higher granularity (SSC) and lower CD45 expression (purple-colored events in graph
A) after incubation of whole blood with GFP-expressing E. coli at 37ºC (graph B) or at 4ºC (graph C). Comparison of B and C shows the difference
between granulocytes with adherent and/or internalized bacteria (74.5% of the population after incubation at 37ºC) and granulocytes with only
adherent bacteria (3.8% of the population after incubation at 4ºC). Graph D shows the features of the main leukocyte populations identified on an
imaging flow cytometer by their light scatter under darkfield illumination (intensity_ SSC) and the expression CD45 (Intensity_CD45-PE). Composite
graphs E and F shows the intracellular localization of GFP bacteria in single cells of the granulocyte subpopulation (gate on NEUTRO, graph D) after
incubation of whole blood with GFP-expressing E. coli at 37ºC. Merged images (BF/GFP) from the brightfield illumination channel (BF) and the green
fluorescence channel (GFP) allow distinguishing cells with external bacteria (graph E) from cells with internalized bacteria (graph F). Numbers on
the BF image in E and F composites indicate the sequential number of the event in the sample run.
maxima of the pHrodo R© Green dye and its conjugates are
approximately 509 nm and 533 nm, respectively, while
pHrodo R© Red excites at 560 nm and emits at 585 nm. Both
pHrodo R© Green and pHrodo R© Red can also be excited with
the 488 nm argon-ion laser installed on most flow cytome-
ters (https://www.thermofisher.com/es/es/home/brands/
molecular-probes/key-molecular-probes-products/phrodo-
indicators.html). Due to the low pH of the phagolysosome,
phagocytized targets can be quantified without interference of
adherent particles [513, 537, 543].
Eos-FP can be transfected into infectious microorganisms.
After UV-irradiation of bacateria, peptide cleavage in Eos-FP
occurs and the transfected bacteria emit green (516 nm)
and orange (581 nm) fluorescent light at 488 nm excita-
tion. Orange fluorescence is sensitive to acidic pH, and the
phagocytosed bacteria stop emitting orange fluorescent light
as soon as the phagosomes fuse with lysosomes. The green
fluorescence is maintained in the phagolysosome until bacte-
rial degradation is completed [539].
4. Applying Imaging FCM. This novel technique of cytometry
combines the statistical power and fluorescence sensitivity of
standard FCM with the spatial resolution and quantitative
morphology of digital microscopy, as it is based on the cap-
ture of images of particles in flow and subsequent pixel-based
image analysis of objects [543]. Imaging FCM allows defining
the intracellular localization of fluorescent targets in phago-
cytes, thus ruling out the need of quenching or blocking steps
(Fig. 68) [544].
9.3.6 Assessing or quantifying phagocytosis kinetics and capacity.
The simplest calculation is the proportion of phagocytosing cells
within the evaluated population, defined as the percentage of
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gated cells with target fluorescence, present in the appropriate
gate (established by morphological, viability and immunopheno-
typic criteria) [511].
Regarding the quantification of ingested fluorescent targets,
calculation may be relatively straightforward if pH-independent
fluorescent particles (biological or synthetic) are used. The mean
number of particles ingested per effector cell can be calculated
by dividing the MFI of the cell population by the fluorescence of
a single, extracellular target [545]. When using targets labeled
with pH-dependent dyes, however, this calculation is inaccurate
and must be modified by subtracting the number of free targets
per phagocyte from the initial number of targets per phagocyte
[511, 512].
An interesting parameter to quantify phagocytosis capacity is
the Phagocytosis Product (PP) parameter [511]. PP is defined as
the percentage of phagocytosing cells multiplied by the number
of targets per phagocytosing cell. PP reflects that the total elimi-
nation of targets from a given assay preparation depends both of
the percentage of phagocytosing cells and the number of targets
ingested by each effector cell [511].
10 Autophagy
10.1 Introduction
Autophagy is a catabolic lysosomal survival pathway for the degra-
dation and turnover of cytoplasmic constituents during times of
nutrient starvation and in response to stress. There are three main
types of autophagy; chaperone-mediated [546], microautophagy
[547] and macroautophagy [548]. The techniques described in
this section detect macroautophagy and hereafter will be referred
to as autophagy.
The catabolic degradation of cellular constituents generates
metabolites, which are reused as sources of energy or synthesis of
new macromolecules. Much less is known about how autophagy
produces cell biological change, but it is known to be an important
player in the regulation of proliferation, cell growth, remodelling
and differentiation in a number of systems [548].
Autophagy is tightly regulated by complex signalling pathways,
key players include AMPK, PI3K, mTOR, ULK1 complex and Vps34
complex. Close to 40 core autophagy genes have been identified
that mediate the completion of a double-membrane autophago-
some, which engulfs unwanted cytosolic material such as aged
and damaged organelles, protein aggregates or pathogens. Subse-
quent fusion of the autophagosome to the lysosome degrades its
cargo (Fig. 69). Autophagy related genes (ATGs) were originally
identified in yeast, but most of these are evolutionary conserved in
higher organisms such as mammals [549]. A key player often used
to quantify autophagy is the ATG8-family member MAP1LC3B
(LC3I). During autophagosome elongation, the cytosolic protein
LC3I is lipidated by conjugation to phosphatidylethanolamine (PE)
to become LC3-II, and thereby inserts into the membrane of the
growing autophagosome.
Many compounds are known to affect the autophagy pro-
cess [550] and are used in its study such as Chloroquine [551],
which inhibits lysosomal acidification, and Bafilomycin A1 [552],
which blocks lysosomal proton transport and leads to inhibition
of lysosomal hydrolases. Both of these block autophagosome-
lysosome degradation and are common inhibitors used to measure
autophagic flux (Fig. 69).
Autophagic flux (or flow through the autophagy pathway) is
used to measure autophagic activity. One such approach is to
measure the rate of protein breakdown by autophagy by arresting
the autophagic process at a given point and recording the time-
dependent accumulation of an organelle or organelle marker. The
most common way to induce this block is to inhibit lysosomal
proteolysis, thus, increasing levels of LC3-II and autophagosomes,
which can be measured.
10.2 Flow cytometry autophagy assays
In recent years autophagy has been successfully measured with
commonly used techniques such as western blot and microscopy
[553]. However, these assays are limiting since a certain number
of cells are needed or cell sorting is required to measure autophagy
in a specific cell type within a mixed cell population. More recently
developed techniques for flow cytometry and imaging flow cytom-
etry opened new possibilities in the field of autophagy. Not only
can primary cells be analyzed, these techniques also allow a higher
throughput and the possibility to look at multiple parameters
simultaneously. As the available antibodies to LC3 do not discrim-
inate between lipidated and non-lipidated LC3, these techniques
rely on detecting punctate LC3 visible by imaging or removing the
non-lipidated form prior to staining [554].
Detection of fused autophagomes also relies on the identifi-
cation of lysosomes, as required for the Amnis R© ImageStream
autophagy assay described later. Lysosomes contain many pro-
teases, which a number of substrates detect the activity of. One
such reagent are the LysoTracker probes (ThermoFisher Scien-
tific) which are hugely selective for acidic organelles. They must
be used at low concentrations (usually 50nM) and only require a
short incubation time (1–5 mins) before imaging otherwise they
induce an increase in lysosomal pH. They can however be fixed
with aldehydes, but the autoflourescence or non specific stain-
ing means their specificity for quantifying lysosomes by flow will
depend on cell type. However, it has had some success in flow
assays with cells showing an increase in signal after treatment
with Chloroquin (an autophagy inducer) [332]. LysoTracker dyes
(ThermoFisher Scientific) are similar, but exhibit a pH depen-
dent increase in fluorescence intensity upon acidification. They
still have the same issue with increasing lysosomal pH with longer
incubation times and nonspecific staining when used for flow
cytometry. Lyso-ID (Enzo) is another acidic organelle-selective dye
but does not increase lysosomal pH over time lending itself to short
and long term tracking of lysosomes. An alternative are lysosome
specific antibodies, such as Lysosomal-associated membrane pro-
tein 1 (LAMP) familymembers. Anti-LAMP1 staining was shown to
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Figure 69. Autophagy pathway showing key mod-
ulators used in detection of autophagy. A double-
membraned elongation vesicle is formed, which elon-
gates to form an autophagsome. During elongation
(left), a cytosolic protein LC3-I is lipidated to LC3-II and
inserts into the membrane of the growing autophago-
some. The autophagosome circularizes, engulfing the
material to be degraded (middle). The autophago-
some then fuses with a lysosome to breakdown the
autophagy vesicle and its contents (right).
give the same results when compared to Lyso-ID in the autophagy
imaging flow cytometry assay discussed below [34].
Autophagy flow cytometry assays include:
(a) Amnis R© ImageStream autophagy assay. The imaging features
of the ImageStream R© (see Section I. 4: Imaging flow cytom-
etry) make it possible to quantify endogenous LC3 puncta
while detecting surface markers. To detect autolysosomes
the co-localization between LC3 and lysosomes using a bright
detail similarity analysis feature can be used [34, 555, 556].
(b) FlowCellect Autophagy LC3 kit (Merck Millipore). Selec-
tive cell membrane permeabilization allows discrimination
between cytosolic non-lipidated LC3-I frommembrane bound
LC3-II by washing out the soluble cytosolic form.
(c) Cyto-ID R© Autophagy detection kit (Enzo).
This is a novel proprietary dye that selectively stains
autophagic vesicles including newly formed double mem-
brane vesicles, autophagsomes and autolysosomes.
10.3 Measuring autophagy in primary cells
Primary cells typically have high basal levels of autophagy and only
show small changes in autophagy after treatments in comparison
to cell lines. It is advisable to choose appropriate controls for each
Table 21. Autophagy inducers for primary immune cells. Treatments
which successfully induced autophagy after 24 hoursa)
Primary cell
type
Autophagy inducer
T cells αCD3/CD28 (highest after 4 days)
B cells IgM, megaCD40L (CD40L construct,
Enzo life sciences)
Monocytes LPS, IFN-γ
Macrophages LPS, IFN-γ
a)This is not an exhaustive list and kinetic experiments have not been
performed.
treatment and experiment since basal autophagy is cell type/state
dependent (Table 21).
Notably, when using any compounds to induce autophagy
the vehicle needs to be considered. DMSO is known to induce
autophagy [557] and should therefore be avoided if pos-
sible. Always include vehicle-treated, “untreated” controls in
experiments. To measure autophagic flux, cells need to be
treated with inhibitors such as Bafilomycin A1 and Chloroquine
(Fig. 70). Both block autophagosome-lysosome fusion allowing
LC3 to accumulate in the autophagosome. Autophagy induc-
ers such as Rapamycin or starvation do not always show dif-
ferences in autophagy levels in primary cells. Generally, it is
wise to test some inducers and inhibitors to find the best
read-out.
Figure 70. Autophagy induction and flux measured with the FlowCellect LC3 kit. Human PBMCS were treated for 24 hours with Bafilomycin A1
(BafA) present for the last two hours. Cells were treated with LPS and gated on CD14+ cells for monocytes, CD3/CD28 beads with CD3+ gating for T
cells and IgM and MegaCD40L with CD19+ gating for B cells. After all treatments cells were stained with the appropriate antibody for detection of
the cell population of interest and for LC3-II using the FlowCellect LC3 kit. This involves staining cells with an anti-LC3 FITC conjugated antibody
that is selectively washed out to only detect membrane bound LC3-II. Data is shown as histograms of LC3-II FITC expression after compensation
and gating on the population of interest.
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One also needs to be aware of off target effects of compounds
used to modulate autophagy. Some may require specific concen-
trations or incubation times [550]. The most widely used inhibitor
3-MA (a target of Vps34) is low potency requiring it to be used
at 10 mM to prevent autophagy at which concentration it can
also affect other kinases including class I PI3K, p38MAPK or
c-Jun kinase therefore affecting many cellular processes, for this
reason 3-MA is not our inhibitor of choice [558]. Bafilomycin A1
is widely used in our laboratory, but one should be aware that it
needs to be used at low concentration for >4 hours or it will also
inhibit the proteasome, endocytic trafficking and other cellular
processes [559].
Another note of caution is when using adherent cells. Caremust
be taken when preparing single-cell suspensions from adhered
cells as this requires disruption and injury of the plasma mem-
brane, which can itself induce autophagy. For some cells we found
Accutase R© induced less autophagy when compared to scraping or
trypsinization. However, different methods should be tested for
the cell type of interest.
The FlowCellect LC3 flow cytometry assay is our assay of
choice. Selective detection of LC3-II gives an enormous advan-
tage to investigate autophagy in primary cells and requires fewer
cells and is significantly quicker than the ImageStream autophagy
assay. It has been described previously that this method must be
used carefully since it includes several washing and permeabi-
lization steps on live cells [560]. To monitor inconsistencies, we
have performed experiments on fresh and frozen cells from sev-
eral healthy donors at multiple time points. We could show that in
our hands the assay was reliable and consistent for different cell
types such as T cell, B cells and monocytes (data not published).
Differences in autophagy levels can be presented in different
ways. Using flow-based techniques make it easy to apply quantifi-
cation of statistical analysis. For the flow cytometry assays after
compensation and gating on the cell population of interest, the
geometric mean of LC3-II fluorescence intensity can be measured.
Basal or induction levels (e.g. Bafilomycin A1 treatment in Fig. 70)
of LC3-II can be quantified or autophagic flux can be calculated
from geometric mean values (treatment-basal / basal). The latter
takes variations in basal autophagy levels into account and allows
comparisons across multiple samples.
However, every technique has its limitations and it is impor-
tant to choose the best one for the experimental question. All
compounds should be titrated and tested carefully.
11 Cytotoxicity
Priming of naive pathogen- or tumor-reactive CD8+ T lymphocytes
(TN) occurs in secondary lymphoid organs (SLOs) where they
undergo clonal expansion and differentiate into effector CD8+ T
(TE) lymphocytes. In the course of their functional maturation,
CD8+ TE acquire the ability to leave SLOs, enter non-lymphoid
organs (NLOs), produce inflammatory cytokines and lyse target
cells displaying appropriate MHC class I-peptide complexes [561,
562]. Some CD8+ TE survive the expansion/effector phase and
convert into long-lived CD8+ memory T lymphocytes (TM). CD8+
TM can be found in SLOs and NLOs where they exert immediate
effector functions upon secondary antigen contact [563, 564].
Peptide-specific target cell lysis is a cardinal feature of cytotoxic
CD8+ TE/TM (CTLs) [564, 565] and its quantification is a valu-
able means to track CD8+ T-cell responses. Traditionally, in vitro
CTL assays relied on the detection of compounds released from
dying target cells. For example, target cells loadedwith radioactive
sodium chromate lose their radioactive label as a result of CTL-
mediated lysis. Hence, the amount of radioactivity in the super-
natant of effector (CTL)/target cell co-cultures directly correlates
with the lytic activity of the respective CTL population [566]. To
achieve suitable effector-to-target cell (E:T) ratios of at least 50:1,
high numbers of CTLs are required for this type of assay. This usu-
ally requires antigen-dependent CTL expansion in vitro, a process
that may alter the composition and/or function of the starting CTL
population.
In order to replace radioactive CTL assays, several flow
cytometry-based techniques were established in the past years.
Their major aim is to visualize the biochemical processes involved
in CTL-mediated target cell lysis.
CTLs induce target cell apoptosis via the Fas/Fas ligand
pathway or the release of cytotoxic granules containing per-
forin and granzymes. Either pathway results in the activation
of caspase-dependent target cell apoptosis. To visualize this pro-
cess, cell-permeable fluorogenic caspase substrates can be used
[567]. They consist of two fluorophores, which are linked by a
caspase-sensitive peptide. Only upon caspase-dependent cleavage
these substrates become activated and can be detected by flow
cytometry [568]. Hence, fluorescence intensities correlate with
CTL-dependent target cell destruction. However, similar to the
chromium release assay, relatively high E:T ratios are required for
this experimental approach.
A more sensitive assay relies on the co-incubation of CTLs with
a mixture of target cells consisting of at least two different pop-
ulations. The first population is loaded with the MHC I-restricted
peptide of interest and stained with one dye (e.g. PKH-26). The
second population is loaded with an irrelevant peptide, stained
with a different dye (e.g. CFSE) and serves as negative con-
trol [569]. Alternatively, different concentrations of the same dye
can be used to stain both target cell populations, which still can be
discriminated based on their differential fluorescence intensities.
The extent of CTL activity is determined by the relative decrease
in the number of labeled target cells loaded with the desired pep-
tide over non-specific target cells after a period of time, usually
5 hours. An example is shown in Fig. 71. A significant advantage
of this assay is its high sensitivity and favorable signal-to-noise
ratio. In most cases this allows the measurement of CTL function
directly ex vivo without prior expansion and at comparably low
E:T ratios.
Target cells may be immune (e.g. splenocytes) or somatic
cells (e.g. epithelial cells or fibroblasts) to more closely resem-
ble the physiological CTL targets. CTLs can be purified from any
organ of interest, either lymphoid or non-lymphoid. Depending
on the research question, purification of total CD8+ T cells or
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Figure 71. Quantification of ex vivo cytotoxicity by influenza-specific CTLs. (A) Seven days after pulmonary infection with influenza A/WSN/33,
untouched flu-specific CTLs in unfractionated bronchoalveolar lavage (Effectors, E) were incubated in vitro with a titrated number of target cells (T).
Targets consisted of an equal mixture of spleen cells loaded with an MHC-I-binding influenza peptide (flu) or an irrelevant MHC-I ligand (control).
Flu peptide-loaded spleen cells were labeled with a higher concentration of Cell Proliferation Dye eFluor 670 than their control counterparts. Five
hours later, the relative frequency of the remaining target cells was quantified by flow cytometry. The exact frequency of flu-specific CTLs can
be determined in parallel by staining with the corresponding MHC-I multimer. (B) Quantification of technical duplicates shown in (A). The % of
flu-specific kill was calculated as: 100 – [100 × (Tflu / Tcontrol)with E / (Tflu / Tcontrol)without E].
antigen-specific CD8+ T cells may be required. In the former case,
the frequency of antigen-specific CTLs can be determined in paral-
lel by MHC/peptide multimer staining to determine CTL frequen-
cies and adjust E:T ratios for different tissue samples. Fig. 71 shows
an example of ex vivo cytotoxicity by influenza-specific CTLs iso-
lated from the broncho-alveolar space of infected mice without
the need of a prior sort for influenza-specific CTLs.
However, if the frequency of antigen-specific CD8+ T cells is
very low, it may be necessary to enrich them prior to the cytotox-
icity assay. In this case, it is not advisable to sort antigen-specific
CD8+ T cells by means of TCR labeling (e.g. by MHC/peptide
multimers) since this may alter their lytic function. If available,
the use of congenically-marked TCR-transgenic (TCRtg) CD8+ T
cells might be useful to circumvent this problem. This allows their
marker-based, TCR-independent enrichment prior to the ex vivo
CTL assay. Hence, direct ex vivo CTL assays have several advan-
tages: (1) they are very sensitive, (2) CTLs may be isolated from
any organ, (3) the type of target cell may be adapted to the nature
of the experiment, (4) E:T ratios can be adjusted to compare
different samples. However, it is important to note that the tis-
sue microenvironment affects CTL activity [570]. Hence, the lytic
potential of tissue-resident CTLs may differ from those purified for
ex vivo CTL assays.
To circumvent this problem, CTL activity can be measured in
vivo [565, 571, 572]. Again, for this approach, at least two target
cell populations are required. One is labeled with the peptide
of interest and e.g. a high concentration of a suitable dye such
as CFSE (CFSEhi population). The control population is loaded
with an irrelevant peptide and a tenfold lower concentration
of CFSE (CFSElo population). Equal numbers of CFSEhi and
CFSElo cells are co-injected into effector mice. After 4–18 hours,
SLOs can be isolated to analyze single-cell suspensions by flow
cytometry (Fig. 72). Similar to the direct ex vivo assay described
above, the relative loss of CFSEhi target cells over CFSElo cells
indicate the extent of CTL-mediated lysis. This method provides
the most sensitive and physiological assessment of CTL activity.
Figure 72 shows an example of influenza-specific CTL activity
in lung-draining mediastinal LNs and non-draining distal LNs in
mice undergoing flu infection.
In vivo CTL assays can also be used to determine the lytic poten-
tial of multiple CTL populations with different specificities in the
same analysis. This requires the simultaneous use ofmore than two
target cell populations. A simple method to achieve this goal is the
use of splenocytes from homozygous CD45.1+/1+ and heterozy-
gous CD45.1+/2+ congenic mice as target cells in CD45.2+/2+
effector mice. Using monoclonal antibodies against CD45.1 and
CD45.2, mixed CD45.1+ target cells can be discriminated from
host cells. Furthermore, the different target cell types can be dis-
tinguished based on their differential CD45.1/.2 expression and
varying CFSE intensities.
Although in vivo CTL assays offer obvious advantages, they are
not suitable for all experimental systems. For example, somatic
cells such as SLO fibroblasts [573], lung epithelial cells [574] or
hepatocytes [575] are often the primary targets of viral infec-
tions. After i.v. injection into mice, however, somatic cells hardly
reach the parenchyma of SLOs or other organs, but are rather
trapped within the lung and liver vasculature ([576] and unpub-
lished observation). Thus, they are of limited use as target cells
for in vivo CTL assays.
The use of naive splenocytes as target cells may help to cir-
cumvent this problem. However, naive splenocytes usually do not
enter NLOs effectively. Hence, the appropriate tissue tropism of
the desired target cell type is a prerequisite for the successful
application of the flow cytometry-based in vivo kill assay. A disad-
vantage of in vivo CTL assays is the fact that E:T ratios cannot be
adjusted. Hence differences in lytic activity may result from differ-
ences in CTL numbers and/or the lytic potential of individual cells.
The quantification of specific CTLs by MHC/peptide multimers in
the respective target organs may be useful to judge whether differ-
ences in target cell lysis rely on differences in CTL number and/or
function.
All assays described so far are suitable to quantify the lytic
action of CTL populations. However, the lytic potential of individ-
ual CTLs cannot be judged. To approach this problem, antibodies
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Figure 72. Quantification of in vivo cytotoxicity by
influenza-specific CTLs. Seven days after pulmonary
infectionwith influenza A/WSN/33, infected and naive
mice received targets cells intravenously. Targets con-
sisted of an equal mixture of spleen cells loaded with
an MHC-I-binding influenza peptide (flu) or an irrele-
vant MHC-I ligand (control). Flu peptide-loaded spleen
cells were labeled with a higher concentration of Cell
Proliferation Dye eFluor 670 than their control coun-
terparts. Four hours later, target cells in lung-draining
mediastinal LNs andnon-draining inguinal (distal) LNs
were quantified by flow cytometry.
directed against e.g. CD107a can be used. This molecule is present
on the membrane of cytotoxic granules and becomes detectable
on the cell surface of degranulating CTLs. CD107a levels correlate
mostly [441], but not always [577, 578], with the lytic potential
of CTLs. Antibodies to CD107a need to be added at 37°C to cap-
ture this rapidly recycling protein. Monoclonal antibodies directed
against CD107a can be combined with MHC/peptide multimers
and cytokine-specific antibodies to determine multiple effector
functions of individual antigen-specific CTLs by flow cytometry.
This method might be helpful to complement the ex vivo and in
vivo CTL assays described above.
12 Reactive oxygen species production with minimal
sample perturbation
12.1 Introduction
Reactive oxygen species (ROS) have been shown to be associ-
ated with oxidative stress [579]. Toxic oxygen free radicals con-
tribute to aging [580], apoptosis [581, 582], and pathological
processes [583] in many clinical disorders, such as cardiac dys-
function and myocyte injury [584, 585]. More recently, ROS have
been also involved in signaling processes [586–589], having a role
as signaling molecules that generate specificity in ROS homeosta-
sis. ROS are generated during mitochondrial oxidative phosphory-
lation or after interacting with xenobiotic compounds [589], and
their rate of production increases under hypoxia or after inhibition
of mitochondrial respiration [590, 591]. The term ROS includes
superoxide anion (O2−), hydrogen peroxide (H2O2), and hydroxyl
radical (HO·) [589]. ROS are formed by the incomplete reduction
of oxygen. ROS are mainly free radicals which many times are not
very reactive and have too short a half-life [588]. Oxygen-derived
free radicals are molecular species with unpaired electrons [592]
and are the product of multiple biological oxidation and reduction
pathways [589].
Although ROS are generated during mitochondrial oxidative
normal metabolism, they are also generated in cellular response
to exogenous compounds, cytokines, and bacterial invasion [593].
ROS including all highly reactive molecules that contain oxygen
are members of important mechanisms of protection against infec-
tions [594]. However, ROS generation can result in cell and tissue
damage, as a result of the interaction with cell membranes, nucleic
acids, proteins and enzymes [588, 595]. Oxidative stress is a con-
sequence of the excessive production of oxygen reactive species
or a decrease in the antioxidant defense [596]. Oxidative stress
causes cytotoxicity through structural and functional alterations,
resulting in the disruption of cell homeostasis [597].
One of the main sources for production of anion superoxide
(O2 ·-) is the electron transport system of mitochondria. Anion
superoxide is the first ROS to be produced after oxygen enters
living cells and this radical may generate many other ROS of dif-
ferent reactivity. Superoxide is produced by one electron reduction
of molecular oxygen, has a short half-life and is little reactive, and
does not result in oxidative attack of polyunsaturated lipids and
DNA. However, defects in superoxide dismutase (SOD), a pow-
erful enzyme that catalyzes the dismutation of superoxide into
O2 and H2O2, can cause membrane damage due to spontaneous
dismutation of O2− into H2O2, resulting in elevated levels of super-
oxide, which can lead to cell membrane damage because of the
accumulation of this oxygen reactive species [598]. Its instabil-
ity is related to the rapid O2 ·- dismutation reaction to hydrogen
peroxide (H2O2) catalyzed by SOD [599].
Hydrogen peroxide is not a free radical but it can give rise to
other ROS. Most ROS are free radicals which cause little damage
due to their short half-life, but they are always reactive. H2O2 is
a molecule much more stable and less reactive than superoxide
anion. However, it can cause cell damage at relatively lower
concentrations when compared with O2− damage [600]. This
hydrosoluble molecule can diffuse across cells and can reach
distant targets to cause damage a long distance from its site of for-
mation [600]. Hydrogen peroxide is formed by O2·- dismutation,
catalyzed by SOD, and an unstable intermediate, hydroperoxyl
radical [601]. However, dismutation can also be spontaneous
or it can also be formed through direct oxygen reduction with
participation of two electrons. Hydrogen peroxide can generate
other ROS with enhanced reactivity, such as the hydroxyl radical
(·OH) [600]. The direct activity of H2O2 can damage cells by cross-
linking sulfhydryl groups and oxidizing ketoacids, causing inacti-
vation of enzymes andmutation of DNA and lipids [600]. Hydroxyl
radical is highly reactive and toxic. With a relatively short half-life,
hydroxyl radical can also react with many biomolecules, including
DNA, proteins, lipids, aminoacids, sugars and metals [600].
Production of ROS by human monocytes was originally
described using the NBTsalt assay [602] or luminol-dependent
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chemiluminescence [603]. Flow cytometry is progressively replac-
ing these assays [604] and has several advantages: it is rapid, sen-
sitive and multiparametric, and allows cell subpopulations to be
studied [605]. However, in many of these cytofluorometric assays,
samples are subjected to manipulation in the form of centrifuga-
tion, washing steps, erythrocyte lysis and, in some cases, fixation
of cells or enrichment of the target cells by means of density gra-
dients [606, 607]. Hence, sample manipulation can give rise to
both cellular depletion and artifactual activation and may result
in inaccurate measurements, especially in those cases where target
cells are the minority.
12.2 Sample preparation and flow cytometry setup for
measuring ROS generation
Ideally, cytofluorometric functional studies on oxidative burst
should be performed in whole blood with minimal sample manip-
ulation (stain, no-lyse, and no-wash) in order to mimic physio-
logical conditions. Studies on minimal sample perturbation can
be achieved with single and multicolor laser instrumentation. We
have developed two no-wash, no-lyse strategies for identifying
leukocytes in whole human blood on the flow cytometer that can
be used for ROS production. One approach (Fig. 73) is to use a
nucleic acid stain to label and analyze only nucleated cells, avoid-
ing anucleate mature red blood RBCs. A series of dyes have low
cytotoxicity, are permeable DNA-specific dyes and can be used
for DNA content cell cycle analysis and stem cell side population
by flow cytometry. Many of these dyes can be excited with UV,
blue or violet 405 nm laser light and can be used for simultaneous
staining with antibodies and dyes suitable for ROS detection. A flu-
orescence threshold is applied to the nucleic acid stain detector to
eliminate the non-nucleated cells from detection by the cytometer
during acquisition.
A second approach using a light scatter threshold (Fig. 74)
exploits the difference in light-absorbing properties between RBCs
and leukocytes. RBCs contain hemoglobin, a molecule that read-
ily absorbs violet laser (405 nm) light, whereas leukocytes and
platelets/debris do not, resulting in a unique scatter pattern when
observing human whole blood in the context of blue (488 nm) and
violet (405 nm) side scatter (SSC). This can be done by switch-
ing to a new filter configuration for the violet laser. The 440/50
fluorescence bandpass filter is replaced with a 405/10 violet side
scatter bandpass filter to allow simultaneous measurement of both
blue and violet side scatter and the differentiation of RBCsand
leukocytes based on light-scattering properties alone. Moreover,
the 495 Dichroic Longpass (DLP) filter should be also replaced
using a new 415 DLP to allow fluorescence detection above 495
nm if desired (Fig. 75).
In this approach, non-nucleated cells are detected by the instru-
ment during acquisition, but excluded by gating during analysis.
Care must be taken when using the method to keep event rates
below instrument limitations for Poisson coincidence. RBC con-
centration in whole blood is on the order of 5 million cells per
Figure 73. Identification of leukocytes in human whole blood using
violet laser and Vybrant DyeCycle Violet stain on the Attune NxT Flow
Cytometer. Leukocytes are outnumbered by red blood cells 700-fold
in whole blood and generally require enrichment by red blood cell lysis
or gradient centrifugation prior to analysis. This strategy exploits the
use of Vybrant R© DyeCycleTM Violet stain (DCV), a low cytotoxicity per-
meable DNA-specific dye that can be used for DNA content cell cycle
analysis and stem cell side population by flow cytometry. DCV thresh-
old levels were set empirically to eliminate from detection the large
amounts of red blood cells that are found in unlysed whole blood. A
proper threshold is shown in a SSC-Height versus DCV-Height dotplot.
DCV can be excited with violet lasers and can be used for simultaneous
staining with antibodies. This protocol is ideally suited to study the
numbers of nucleated cells in unlysed whole blood. Using a gate in this
figure as the parent gate, the three main leukocyte cell populations in
human blood are identified using classic forward and side scatter plots.
microliter so whole blood must be properly diluted (1/100) to
avoid instrument saturation.
Dead cells often give false positive results, as they tend to
bind nonspecifically to many reagents. Therefore, removing dead
cells from your flow cytometry data is a critical step to help ensure
accurate results and analysis. Differentmanufacturers market non-
fixable cell viability assays for flow cytometry to distinguish live
and dead cell populations that are more accurate than forward-
and side-scatter data. For more detail on this control aspect see
Section IV.5: Frozen samples and cell viability. For ROS produc-
tion studies, different dyes can be used on a flow cytometer based
on auto-oxidation, photochemical reactions, mitochondrial res-
piration, cytochrome P450, NADPH oxidase, and other enzymes.
Most of these reagents are photostable fluorogenic probes that can
also be detected by conventional fluorescence microscopy or high-
content imaging and screening. One of the most common cytoflu-
orometric assays uses dihydrorhodamine 123, an uncharged and
nonfluorescent ROS indicator that can passively diffuse across
membranes where it is oxidized to cationic rhodamine 123, which
then localizes in the mitochondria and exhibits green fluores-
cence [608].
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Figure 74. Identification of leukocytes in human whole blood using
violet side scatter on the flow cytometer. Resolution of leukocytes from
red blood cells in whole blood is improved by incorporating violet 405
nm side scatter. Using both violet and blue side scatter allows identi-
fication of leukocytes in whole blood. Using a gate in this figure as the
parent gate the three main leukocyte cell populations in human blood
can be identified using classic forward and side scatter plots.
Designing an experiment to measure ROS production in blood
can be simple and elegant. Blood samples with volumes ranging
from 20 to 40 μL can be used [609]. Figure 76 shows a represen-
tative experiment of resting and activated leukocytes in unlysed
whole blood. Cells were stained with Vybrant DyeCycle Violet
(DCV) stain to discriminate nucleated cells, in combination with
dihydrorhodamine 123 (DHR) PE-CD33, APC-CD11b, and 7-ADD.
Cells were stimulated with PMA dissolved with DMSO and incu-
bated in presence of DHR for 30 min at 37ºC. Subsequently, cells
Figure 75. Use of the Attune NxT No-Wash No-Lyse Filter Kit. The
standard configuration for the 405 nm violet laser optical filter block
is shown in (A) and the same optical filter block using the No-Wash
No-Lyse Filter Kit shown in (B), with changes outlined in red. To use the
filter kit, remove the 440/50 bandpass filter in VL1 slot 1 and place the
405/10 bandpass filter that is placed in the VL1 slot 1in slot 1. Remove
the 495 Dichroic Longpass (DLP) filter in a lot A the 415DLP. The Blank
filter in slot 1A is switched with the 417LP filter in slot 0.
were stained with DCV and PE-CD33 and APC-CD11b antibod-
ies for 20 min at room temperature. Following incubation, blood
was diluted in HBSS and immediately acquired for flow cytometry
measurements. As shown, ROS production can be easily distin-
guished using these markers with a multi-laser flow cytometry
protocol with no color compensation, making support to no-wash
no-lyse strategies as the better choice for phenotypic and func-
tional measurements using freshly drawn blood samples [609].
For more than 15 years, we have used these no-lyse no-wash
methods for ROS production, but also for the detection of rare
cells. ROS production should be studied using this simple and fast
methodology, but also for rare cell detection (Section V.3: Rare
cells—general rules), minimal residual disease studies or human
hematopoetic progenitor cell counting.
Figure 76. Reactive oxygen species produc-
tion. Representative experiment of resting
and activated leukocytes in unlysed whole
blood. Cells were stained with Vybrant Dye-
Cycle Violet stain to discriminate nucleated
cells fro erythrocytes (Excitation/Emission
(nm): 405/437), in combination with dihy-
drorhodamine 123 (Excitation/Emission (nm):
488/530) PE-CD33 (Excitation/Emission (nm):
561/578), APC-CD11b (Excitation/Emission
(nm): 637/660), and 7-ADD (Excitation/Emission
(nm): 488/647). Cells were stimulated with PMA
dissolved with DMSO and incubated in pres-
ence of DHR for 30 min at 37ºC. Subsequently,
cells were stained with DCV and PE-CD33 and
APC-CD11b antibodies for 20 min at room
temperature. Following incubation, blood was
diluted in HBSS and immediately acquired for
flow cytometry measurements.
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13 Intracellular Ca2+ mobilization by means of Indo-1
AM
13.1 Introduction
Ca2+ ions play an essential role as an intracellular messenger in
nearly all cellular systems and regulate a multiplicity of cellular
functions [610]. In the immune system, Ca2+ mobilization induces
direct processes as activation of platelets, degranulation of mast
cells or killing of target cells by cytolytic T cells but it is also an
essential component of the signaling cascades downstream of sev-
eral receptors, such as the B- and T-cell receptor, activating Fc
receptors, chemokine receptors and others, regulating the tran-
scription of target genes and subsequently driving processes such
as proliferation, differentiation and others [611–613], implying
that Ca2+ mobilization has to be considered in many aspects of
immunologic research. Based on patch clamp methods, Ca2+ cur-
rents can be measured very precisely on a single-cell level [614].
Provided that this method is not feasible in many laboratories,
determination of Ca2+ mobilization by means of widely available
flow cytometry may represent an easy alternative, providing rela-
tive values of Ca2+ mobilization on a single-cell level.
13.2 Theory of measuring intracellular Ca2+ mobilization
via Indo-1 AM staining
Indo-1 Acetoxymethyl (AM) is a cell-permeant ratiometric Ca2+
indicator, used to determine intracellular Ca2+ mobilization at
the single-cell level [615]. The dye is excited at 355 nm and there-
fore requires a UV laser. The Indo-1 AM emission peak at 475
nm in the absence of Ca2+ shifts to 400 nm upon binding Ca2+
ions. Therefore, changes in the ratio of Ca2+-bound Indo-1 AM
signal at 475 nm to Ca2+-unbound Indo-1 AM signal at 400 nm
allow the immediate detection of alterations in intracellular Ca2+
concentration (Fig. 77A).
Since mixed populations of cells, as is the case with periph-
eral blood, might respond differently to stimulation, a compar-
ison between defined homogeneous cell populations should be
attempted. This can be achieved by using additional staining for
cell surface markers. Data acquisition by flow cytometry enables
the analysis of various subpopulations (e.g. different B-cell or T-
cell subpopulations) at the same time, provided that Ca2+ mobi-
lization is induced by the same agent or stimulus (such as B-cell
or T-cell receptor stimulation).
Alternative methods for detecting Ca2+ by flow cytometry
include Fluo-3 [616] and its respective analogues, which have
the advantage that they provide sufficient sensitivity and can also
be excited at 488 nm, which is a standard laser wavelength more
readily available than the UV laser wavelength. The advantage
of Indo-1 AM is primarily due to the possibility of measuring it
as a ratiometric assay, which includes the advantages of control-
ling for differential uptake of the dye between different cells and
a lower sensitivity to photobleaching [617]. An additional signifi-
cant advantage of using Indo-1 AM is that the commonly used 488
nm laser remains available for the detection of other surface mark-
ers [615]. Flow cytometers such as the LSR II R© or LSR Fortessa R©
from Becton Dickinson (BD Biosciences, San Jose, CA) or the ZE5
Cell Analyzer from Bio-Rad (Bio-Rad Laboratories, Inc., Hercules,
CA) can be equipped with a UV laser for Ca2+ mobilization exper-
iments using Indo-1. This manuscript will focus on using Indo-1
AM for detection of Ca2+ flux.
13.3 Sample preparation
As for all functional assays, for Ca2+ mobilization control samples
which have ideally undergone the same pre-analytical steps as
the test samples are required. This is especially important when
samples have been shipped or previously frozen. The optimal tem-
perature for the investigation of Ca2+ mobilization, as for all sig-
naling studies, is 37°C. While some facilities or institutes provide
this option by individual solutions, standard instruments are not
equipped with a heatable acquisition chamber to maintain the
samples at a constant temperature of 37°C during the measure-
ment. Strong fluctuations in temperature during cell preparation
and between the different experiments should be avoided, since
this may influence the Ca2+ flux. Although most cell types are
capable of inducing Ca2+ mobilization at room temperature (e.g.
human lymphocytes subpopulations), some cell types are more
sensitive and may need 37°C to run the assay. In most cases
pre-warming of the samples to 37°C improves Ca2+ mobiliza-
tion, but subsequent cooling during the measurement may lead
to changes of the Ca2+ baseline levels in some subpopulations and
may thus render the analysis inaccurate (Fig. 77B). Therefore,
in the absence of an option to run the experiment at a constant
temperature of 37°C we perform the entire process of loading,
staining, washing and measuring the cells at room temperature.
Of note, during cell isolation or preparation (e.g. isolating PBMCs
through Ficoll), labeling and staining, the use of cold PBS and
other media should be avoided. Furthermore, mechanical forces
may induce Ca2+ flux. Therefore, carefully dragging the sample
tubes over a tube rack to mix them during the entire procedure is
better than vigorous shaking or vortexing of the cells.
A density of up to 10 × 106 cells, e.g. PBMCs, is commonly
suspended in cell culture medium such as RPMI/10% FCS, con-
taining 4.5 μM Indo-1 AM in the presence of 0.045% of the deter-
gent Pluronic F-127, in a process known as loading. Loading is
commonly carried out for 45 min at room temperature in the
dark [618]. For cell lines it might be necessary to serum starve
the cells prior to Ca2+ determination, therefore both loading and
washing steps could occur in the absence of FCS, or in the pres-
ence of lower concentrations of FCS. Alternatively, lower concen-
trations of Indo-1 AM, shorter incubation times and the omission
of Pluronic F-127 can be tested, depending on the cell type and
the precise application, leading to changes in the fluorescence
intensity of Indo-1 AM. During the loading procedure the cell
suspension should be mixed every 15 min. After loading is com-
plete, the cells are washed twice with media (300 g, 5 min, at
room temperature), followed by staining for cell surface mark-
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Figure 77. Measuring intracellular Ca2+ mobi-
lization in human B cells in response to anti-
IgM stimulation after labeling with Indo-1
AM by flow cytometry. (A) The shift in Indo-
1 bound to Indo-1 unbound at low intra-
cellular Ca2+ concentrations (grey) and high
intracellular Ca2+ concentrations (black). Ca2+
increase was induced in Indo-1 labeled PBMCs
by addition of ionomycin. (B) The influence of
temperature on Ca2+ baseline levels is demon-
strated by gating on CD19+ B cells (black) and
CD19- non-B cells (grey) after warming to 37°C
prior to the measurement and cooling off dur-
ing the recording over 10 minutes. In B cells
the Indo-1 bound/unbound is progressively
decreasing with the reduction of temperature.
(C) Setting of Indo-1 AM bound versus Indo-
1 AM unbound on x-axis and y-axis respec-
tively. The photomultiplier (PMTs) should be
adjusted so that unstimulated cells occur on a
line about 45° to the y-axis. (D) Gating strategy
for the analysis of Ca2+ mobilization in naı¨ve,
IgM Memory and switched memory B cells
after stimulation with anti-IgM. PBMCs were
labeled with Indo-1 AM and cell surface stain-
ing with CD27, CD19, IgG and IgA After gat-
ing on living Indo-1 bound cells, lymphocytes
were determined. Gating of CD19+ B cells is
followed by differentiation of IgG/IgA-/CD27-
naı¨ve (na) B cells, IgG/IgA-/CD27+ IgM Mem-
ory B cells (M Mem) and IgG/IgA+/CD27+ class
switched B cells (sw). Time versus the ratio of
Indo-1 bound/unbound is shown for the three
subpopulations (lower panels). After baseline
acquisition anti-IgM (arrow) was added induc-
ing a shift of Indo-1 AM bound/unbound in
IgM-expressing naı¨ve and IgM Memory B cells
whereas this ratio is at baseline levels in IgM-
class switched memory B cells. After addi-
tion of ionomycin the ratio of Indo-1 AM
bound/unbound is rapidly increasing in all
subsets. Data were acquired with a BD LSR
FortessaTM and analyzed by FlowJoTM.
ers with fluorescence-conjugated antibodies for 15 min at room
temperature in the dark. After the cell surface staining, the sam-
ples are washed again and resuspended in the respective medium,
RPMI 10% FCS for example. The spectral measurement should
be performed within the next 1—2 h. If datasets from different
days have to be compared, it is recommended to keep the times
between loading and staining and data acquisition the same for
all samples.
Cell culture medium usually contains Ca2+. To differenti-
ate between internal store release (ISR), from the ER into the
cytoplasm, and store-operated Ca2+ entry (SOCE), from the extra-
cellular space into the cell, Ca2+-containing medium has to be
removed by washing and resuspending the cells in Ca2+-free PBS
or other Ca2+-free buffers. Alternatively, EGTA, a chelator related
to EDTA but which preferentially binds Ca2+ ions, can be used. The
transient ISR is detected after the appropriate stimulation, while
subsequent addition of CaCl2 during the measurement reveals the
sustained SOCE.
It is important to make sure that the antibodies used for cell
surface staining do not themselves induce Ca2+ mobilization. This
can be tested by adding the staining antibody to Indo-1 AM loaded
cells and detecting the resulting Ca2+ levels. Since kinetics may
vary, the period of acquisition for these tests should be for at least
10–15 min. If the Ca2+ baseline shifts in response to the staining
antibody that antibody should not be used. To test whether one
of the staining antibodies interferes with binding of the antibody
used for stimulation, the measurement should be compared in the
presence and absence of the respective cell surface antibody.
13.4 Flow cytometer settings
Before acquisition it is important to ensure that the filter combina-
tion is correct, for example for Indo-1 AM bound (FL12 405/10)
and Indo-1 unbound (FL13 520/35 445 LP). Both parameters must
be displayed on a linear scale. It is recommended to view Indo-1
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AM unbound on the y-axis and Indo-1 AM bound on the x-axis.
The photomultiplier (PMT) should be adjusted so that unstim-
ulated cells occur on a line about 45° to the y-axis (Fig. 77C).
A dot plot showing time on the x-axis versus the ratio of Indo-
1 bound/unbound on the y-axis displays the kinetics of Ca2+
mobilization. Ensure that the baseline and the maximal peak upon
stimulation are within the displayed range. If this is not the case
the PMTs must be adjusted. Of note, different cells have different
intracellular Ca2+ levels. For instance, the appropriate PMT set-
tings for B cells would not necessarily fit those for granulocytes or
cell lines, and the PMTs would then need to be reset accordingly.
13.5 Data acquisition
The UV laser should be turned on at least 15 min beforehand to
allow it to stabilize prior to use, since it is highly sensitive andmore
prone to fluctuation than other lasers. To ensure data reproducibil-
ity it is also useful to wait a few seconds after loading the tube,
before recording the events. This will provide a better definition
of the baseline. The flow rate should be kept constant throughout
the measurement at low or intermediate rates. However, if the
population of interest represents only a very small percentage of
the acquired cells, it will be necessary to measure at higher speed
to be able to record enough events per second. After acquisition of
the baseline for 30–45 s, the respective stimulus is added. To allow
for comparison of different data sets this time should be kept con-
stant. Ionomycin is a Ca2+ ionophore, inducing a rapid influx of
Ca2+ ions from the extracellular space into the cytosol. At the end
of measurement ionomycin is added as a loading control, meaning
that in the presence of Ca2+ in the medium and proper labeling of
the cells with Indo-1 AM, cells have to show a maximal increase
of the intracellular Ca2+ concentration, thus an increased ratio
of Indo-1 bound/unbound. Since residual ionomycin can directly
induce Ca2+ mobilization in the subsequent sample it is important
to wash the flow cytometer thoroughly before the next tube is
loaded. While some investigators prefer to use DMSO or special
cleansing solutions, followed by PBS for one minute, running fresh
tubes of PBS twice may also be sufficient to avoid this.
13.6 Analysis
Depending on the required resolution of the information, data
analysis can be performed by using standard acquisition software,
as BD FACSDIVATM (BD Biosciences, San Jose, CA) or others. The
analysis software FCS ExpressTM from De Novo Software (Glen-
dale, CA), FlowlogicTM from Inivai Technologies (Victoria, Aus-
tralia) and FlowJoTM (Treestar Inc., Ashland, OR) offer a “kinetics”
tool to analyze the acquired Ca2+ mobilization data. An example
for anti-IgM-induced Ca2+ mobilization in human B-cell subpopu-
lations analyzed by FlowjoTM is shown in Fig. 77D. Prior to further
gating, Indo-1 AM-negative cells must be excluded. Subsequently,
commonly used gating strategy including FSC/SSC, exclusion of
doublets and gating on the specifically stained subpopulations
is performed. Looking at the respective subpopulations in a dot
plot showing the ratio of Indo-1 AM bound/unbound versus time
gives a better impression than merely looking at the kinetics func-
tion, since Ca2+ kinetics providemultiple read-out parameters. For
example, the mean peak intensity and the time to peak imply the
early phases of Ca2+ mobilization in B cells essential for the induc-
tion of NF-κB and JNK [619]. In contrast, the decline represents
the later phase important for the activation of NFAT [617]. When
analyzing ISR and SOCE separately (see above), specific infor-
mation can be gained on both processes. Of note, the response
of lymphocyte subpopulations is usually less homogeneous than
those from cell lines, for example. The percentages of responding
cells can differ, and the non-responding population will strongly
influence the read out, especially with regard to the mean values.
Thus, we advice to perform an additional analysis of the param-
eters mentioned above, referring to the responding cells only, by
setting the baseline as the threshold and excluding non-responding
cells from further analysis.
14 mRNA
The quantification of mRNA production is key to understanding
the immediate responses of cells to changes in the environment
and it also facilitates the comprehension of signaling pathways.
The response to stimuli can be very heterogeneous in different cell
types or even within the same cell population. Several techniques
have been traditionally developed to quantify mRNA, such as RT-
qPCR, Northern blot analysis, nuclease protection assays and fluo-
rescence in situ hybridization (FISH) but none of them allows com-
plex high-throughput single-cell analysis. This section will intro-
duce a novel flow cytometry technique based on FISH that allows
for the simultaneous quantification of mRNA species, intracellular
and cell surface proteins on a single-cell level [620–622].
14.1 Introduction
The immune system comprises of a heterogeneous population
of cell types, each of them bearing specialized functions. Upon
stimulation, a cell-specific immediate response can be detected at
the mRNA level that can trigger the production of specific pro-
teins, for example, the production of antiviral cytokines upon
viral infection [620]. Until recently, the simultaneous detection
of specific nucleic acid sequences in combination with intracellu-
lar proteins and cell-type specific markers on a single-cell basis
had been restricted to microscopy, granting the analysis of a few
hundred cells. FISH is an example of such a method, although
high-throughput acquisition is not applicable. Flow cytometric
analysis of nucleic acids, especially RNA species, including mRNA,
micro RNA (miRNA) and long non-coding RNA (lncRNA) targets,
would allow the high-throughput acquisition of several million
cells on a single-cell basis. PrimeFlowTM RNA Assay (Affymetrix,
eBioscience) makes use of branched DNA technology (bDNA)
to measure the expression levels of up to three RNA targets of
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Figure 78. PrimeFlowTM RNA Assay procedure. Steps 1–3 reproduced with permission from Thermo Fisher Scientific C© 2016.
interest, using a conventional flow cytometer and, therefore allows
for the simultaneous detection of further antigens. Specifically,
the technique is based on an initial surface staining, followed by
permeabilization and two fixation steps. Probes specific for the
RNAs of interest hybridize to their target sequences with high
stringency and the signal is increased by serial of amplification
steps. Using bDNA technology, a tree-like structure is built to
achieve signal amplification. Pre-amplifier molecules, the trunk
of the tree, directly bind to the pairs of primers. Subsequently,
multiple amplifier molecules hybridize to a single pre-amplifier
molecule, as the tree branches. Finally, as tree leaves, multiple
label probe molecules that are conjugated to a label dye, bind to
an amplifier molecule (Fig. 78).
14.2 Sample preparation
The use of healthy cells is critical for optimal results, since han-
dling of less viable cells will consequently lead to an increase in
cell lysis during assay performance, and thus, decrease sensitiv-
ity detection. For cell lines, it is highly recommended to use cells
in an exponential growth phase and to avoid overconfluent or
overly concentrated cells. One main advantage of this assay is
the simultaneous staining of cell surface antigens such as lineage
markers and the binding of probes to RNAs of interest, allowing
for the discrimination between different cell types. After staining
for cell surface markers, one permeabilization and two fixation
steps are required. Permeabilization allows for the intracellular
staining of antigens, whereas fixation warrants that surface and
intracellular antigens, as well as the target RNA, are immobilized
and stable. The first generation of the flow cytometry-based in situ
hybridization assay was based on methanol fixation, which lim-
ited the number of suitable fluorochromes for surface staining to
only methanol-resistant fluorochromes and was not recommended
for parallel intracellular protein staining. Indeed, methanol-based
permeabilization buffers, due to their dehydrating effects, may
lead to protein denaturation and antibody-epitope loss, causing a
signal intensity decrease. However, the second generation assay
has overcome this limitation by avoiding the use of methanol as
a fixative. Unfortunately, the use of the improved fixatives largely
diminishes the detection of fluorescent proteins such as GFP. If
their detection is required as an experimental readout, antibodies
directed against fluorescent proteins should rather be used. Dur-
ing the assay procedure, RNase inhibitors and storage solutions
included in the kit are integrated into the protocol to assure the
stability and integrity of the target RNAs for up to 3 days, allow-
ing for sample collection and batching. In addition, the increased
stability allows for the usage of the samples not only for flow
cytometry, but also for direct visualization by a confocal micro-
scope after the application of the cells to an object slide.
14.3 Acquisition
The detection of RNA species with PrimeFlowTM RNA Assay
is based on hybridization and branched DNA technology. In a
first hybridization step, specifically designed probes targeting
the desired RNA sequences are co-incubated with the already
fixed and stained cells. The probes are a key component to the
whole process and they need to be accurately designed to avoid
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non-specific binding to other RNAs. The number of oligonu-
cleotide pairs in a designed set of probes strongly depends on
the target RNA size and the desired accuracy of discrimination
between different gene isoforms. A typical set of probes consists
of 20–40 oligonucleotide pairs, but if there is a need for isoform
discrimination or the target RNA is small, the amount of specific
oligonucleotide pairs might be reduced to a minimum of eight.
In order to mediate signal amplification, cells are serially incu-
bated with PreAmplifier and Amplifier molecules, which build
up a branched tree (Fig. 78). A last incubation step adds label
probes conjugated to a fluorescent dye such as type 1/AF647, type
4/AF488 and type 6/AF750 to the amplification tree, enabling the
detection of the signal with a conventional flow cytometer. A novel
fluorochome was recently included, type 10/AF568, to increase
the choice and combination of colors. Of those types, AF647 gives
the strongest signal, and should be used for low-expressed RNAs
or RNAs with unknown expression levels. AF488 and AF568 are
considered as signals of medium intensity and AF750, giving the
lowest signal, should be used for highly expressed RNA targets.
However, fixation steps in the protocol induce an increase of the
cell autofluorescence, leading to higher background fluorescence
in the FITC, PE and other channels after excitation with the blue
488 nm laser. Therefore, it is recommended to avoid the use of
type 4 probe sets to detect low expressed targets. According to the
manufacturer’s instructions, an 8 000–16 000-fold amplification of
the RNA transcript is achieved after optimal assay performance.
Importantly, type-1, -4, -10 or -6 single-stained samples (ideally
with the housekeeping control) have to be used to set the voltages
while performing the sample compensation at the flow cytometer.
It is not recommended to use APC, FITC, PE-CF594 or APC-Cy7
stained beads or samples for compensation purposes, since the
fluorescence signal will be different.
14.4 Technical guidelines
To control for the background expression levels for each of the
probe types, a control sample should be stained with the full anti-
body panel and included to the sample run. This is a crucial step
in order to determine the autofluorescence and the background
signal of the cells. One sample has to be performed with an inter-
nal RNA control targeting a housekeeping RNA to ensure that the
whole protocol was properly performed. In case of low signal res-
olution of the signal, a few technical improvements can be added
to the protocol (see Section VII.14.5: step-by-step protocol). For
instance, background levels can be diminished in certain samples
with extra washing steps between different incubations. In the
case of low expression levels of the target RNA or if the amount of
oligonucleotide pairs used is reduced, increasing the signal may
be desired. This can be achieved by longer incubation times of
target probes, PreAmplifier, Amplifier and label probe. As an extra
step to increase the signal, increasing the amount of target probes
during 3 hours of incubation significantly ameliorates the signal
of the target RNA detection without increasing the background
expression levels.
14.5 Step-by-step protocol
PrimeFlowTM RNA Assay can be performed in a conventional lab-
oratory equipped with a CO2 incubator, capable of stably main-
taining 40ºC+/− 1ºC, and a flow cytometer supplied with a 488 nm
and a 633 nm laser.
Day 1. Cell-surface, intracellular staining and target probe
hybridization
The washing buffer should be pre-warmed at room tempera-
ture.
1. Centrifuge at 500 × g for 5 min in polystyrene flow cytometry
tubes 1–5 × 106 cells. Authors have the experience of using
fewer cells but if the target mRNA is expressed at a low level,
the total sensitivity of the assay will drop.
2. Decant the supernatant and resuspend cells in the cell-surface
antibody master mix at a final volume of 100 μL with staining
buffer (SB: PBS + 2% FBS). Incubate in the fridge for 30 min.
Note: This step can be avoided if there is no need for surface
antigen staining.
3. Wash by adding 1 mL of SB per tube and centrifuge at 500 ×
g for 5 min.
4. Prepare the Fixation 1 buffer: mix equal parts of Buffer 1A and
1B: volume/sample: 1 mL.
Note: The buffer is foamy, so prepare at least for 1–2 samples
extra.
5. Discard supernatant, gently resuspend the pellet and add 1 mL
of Fixation Buffer 1 to the sample.
6. Incubate for 30 min at 4°C.
7. Centrifuge at 600 × g for 5 min. During centrifugation, pre-
pare the Permeabilization Buffer. Resuspend the Perm Buffer
at a 1/10 ratio with distilled autoclaved water and add RNase
inhibitor 1 and 2 at 1/1 000 and 1/100 ratio, respectively. The
amount of buffer per sample needed is 3 mL.
Note: The buffer is foamy, so prepare at least for 1–2 samples
extra.
8. Discard supernatant and resuspend in 1 mL of Perm Buffer.
Centrifuge at 800 × g for 5 min.
9. Repeat step 8.
10. Discard supernatant and add the required amount of intracel-
lular antibody and incubate for 30 min at 4°C.
Note: This step can be avoided if there is no need for intracellular
antigen staining.
11. Wash with 1 mL Perm Buffer by centrifuging for 5 min at 800
× g. Prepare Fixation Buffer II in bulk (you will need 1 mL per
sample) at 1× concentration by combining PrimeFlow RNA
Fixation Buffer 2 (8×) with Wash Buffer.
12. Discard supernatant and resuspend the pellet carefully by
inverting. Incubate for 60 min at room temperature in the
dark.
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Note: The protocol can be stopped at this step. The cells can be
incubated overnight in the dark in Fixation Buffer II at 4°C.
13. Transfer the samples into the 1.5 mL tubes provided in the kit
and centrifuge them at 800 × g for 5 min.
14. Thaw Target Probes at room temperature and pre-warm Target
Probe diluent to 40°C in the incubator.
15. Aspirate the supernatant carefully, leaving the last 100 μL of
each sample. Add 1 mL of Wash Buffer, mix by inverting and
centrifuge at 800 × g for 5 min.
16. Repeat step 14.
Note 1: The remaining volume in the 1.5 mL tube should be as
close as possible to 100 µL, since all the following steps take in
account this exact volume. Utilize the markings in the 1.5 mL
tubes.
Note 2: The protocol can be stopped at this step. In the wash step,
add RNase Inhibitor 1 to Wash Buffer at a 1/1 000 concen-
tration and store the samples overnight in the dark at 4°C.
17. Prepare each Target Probe at a 1/20 dilution in Target Probe
diluent (5 μL of Target Probe and 95 μL of Target Probe
diluent) and mix the solution by pipetting up and down. Vol-
ume/sample: 100 μL of one Target Probe. Prepare for 1 extra
sample.
Note 1: If you are combining more than one Target Probe in a
sample, please adjust the final volume to 100 µL.
Note 2: For some low-expressed RNA targets and to increase the
final signal, the authors have experience using lower dilutions
of Target Probes, up to 1/4 dilution per sample (20 µL of
Target Probe and 80 µL of Target Probe diluent).
18. Add directly to each cell suspension 100 μL of the prepared
solution of Target Probe. Mix by vortexing briefly, place the
tubes in a special metal heat block and incubate for 2 h at
40°C in the special incubator. Mix by inverting samples after 1
h.
Note 1: To increase the signal, up to 3 h incubations can be
performed.
Note 2: The traffic of the incubator has to be minimized. The
temperature must be controlled to maintain stably 40°C ±
1 °C. If you have more than three samples, first put the tubes
in the metal heat block in the hood and then place the whole
system in the incubator.
19. Wash by adding 1 mL of Wash Buffer, inverting to mix and cen-
trifuging at 800× g for 5 min. Prepare Wash Buffer with RNase
Inhibitor 1 at 1/1 000 dilution (see step 16). Volume/sample: 1
mL, but the buffer is foamy, so prepare at least for 1–2 samples
extra. This buffer has to be used fresh.
20. Aspirate the supernatant carefully, leaving the last 100 μL of
each sample. Resuspend gently the cell pellet. Add 1 mL of
Wash Buffer with RNase Inhibitor 1, mix by inverting and cen-
trifuge at 800 × g for 5 min.
21. Aspirate the supernatant carefully, leaving the last 100 μL of
each sample. Resuspend gently the cell pellet.
Note: For the manageability of the whole procedure, the protocol
should be stopped at this step. The cells can be kept overnight
in the dark at 4°C.
Day 2. Signal amplification
22. Prewarm at 40°C (in the incubator) PreAmpMix, AmpMix and
Label Probe diluent.
23. Prewarm at room temperature all samples (in the dark) and
Wash Buffer.
Note: Authors leave the samples for 10 min at room temperature.
24. Add directly into the cell suspension 100 μL of warm PreAmp
Mix and mix gently by short vortex.
25. Incubate at 40°C (in the incubator) for 1.5 h.
Note 1: Do not open the incubator during this step to maintain
the 40°C temperature.
Note 2: To increase the signal, up to 2 h incubation can be per-
formed.
26. Wash by adding 1 mL of Wash Buffer, inverting to mix and
centrifuging at 800 × g for 5 min. Aspirate the supernatant
carefully, leaving the last 100 μL of each sample. Resuspend
gently the cell pellet.
27. Repeat step 26 two extra times.
28. Add directly into the cell suspension 100 μL of warm Amp Mix
and mix gently by short vortex.
29. Incubate at 40°C (in the incubator) for 1.5 h.
Note 1: Do not open the incubator during this step to maintain
the 40°C temperature.
Note 2: To increase the signal, up to 2 h incubation can be per-
formed.
30. Thaw Label Probes on ice in the dark during this incubation
step.
31. Wash by adding 1 mL of Wash Buffer, inverting to mix and
centrifuging at 800 × g for 5 min. Aspirate the supernatant
carefully, leaving the last 100 μL of each sample. Resuspend
gently the cell pellet.
32. Repeat step 31 two extra times.
33. Prepare 100 μL/sample of Label Probe by diluting it at 1/100
in warm Label Probe diluent (10 μL of Label Probe in 90 μL of
Label Probe diluent). Add directly into the cell suspension 100
μL of warm Label Probe and mix gently by short vortex.
Note: If you prepare the label probes in advance during step 32,
be sure to maintain them at 40°C.
34. Incubate at 40°C (in the incubator) for 1 h.
Note 1: Do not open the incubator during this step to maintain
the 40°C temperature.
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Note 2: To increase the signal, up to 1.5 h incubation can be
performed.
35. Wash by adding 1 mL of Wash Buffer, inverting to mix and
centrifuging at 800 × g for 5 min. Aspirate the supernatant
carefully, leaving the last 100 μL of each sample. Resuspend
gently the cell pellet.
36. Repeat step 35 once more.
37. Add 1 mL of Storage buffer (provided in the kit) or Staining
buffer (SB, PBS + 2% FBS), invert to mix and centrifuge at 800
× g for 5 min. Aspirate the supernatant carefully, leaving the
last 100 μL of each sample. Resuspend gently the cell pellet.
38. Add 100 μL of Storage buffer or SB and transfer each sample
to a polystyrene FACS tube and measure samples in a flow
cytometer.
Note: You may keep the samples at 4°C and store them up to 3
days before analyzing them on a flow cytometer.
14.6 Limitations
Although the stability and the number of applications have
improved, the technique still harbors some limitations. Currently,
the protocol allows for the simultaneous detection of only three
RNAs of interest, restricting the study of complex interactions. In
addition, the expression levels of the RNA targets are the major
pitfalls toward a successful application, as rare expression events
might not be detectable with this assay. The sequence specificity is
absolutely necessary to allow for correct binding of the probes to
the target sequence. Minor sequence variations as well as splicing
variants will not be detected, and therefore can restrict the use
of this technique. As pointed out previously, the size of the tar-
get RNA is also critical to design a specific set of probes that will
confer an optimal signal.
14.7 Conclusion
In conclusion, PrimeFlowTM RNA Assay opens up new options
in studying complex cellular interactions, especially if specific
antibodies for the target proteins are not commercially avail-
able [620–624]. This assay also offers high-throughput screening
of certain conditions, with the possibility of simultaneously mea-
suring mRNA and protein expression even from the same target
in a specific cell type on a single-cell basis.
15 Transcription factors
15.1 Introduction
Cell functionality and differentiation are all controlled by tran-
scription factors within cells that regulate gene expression. As
these factors are generally proteins, they may be detected using
an antibody directed against some specific epitope within the
protein. In this way, detection of transcription factors is in essence
no different from detecting proteins on the surface of the cell.
However, as the proteins of interest will be located within the
cell, either in the cytoplasm, within a cellular sub-compartment
or in the nucleus, cells must be permeable to allow access of the
antibody to its binding site. As the factors need to be preserved
in their sub-cellular location and in their physiological condition
at the time of sampling, any fixation must be very rapid and
pervasive.
Detection of transcription factors by flow cytometry thus
requires careful planning, with attention paid to several specific
questions that will dictate the best protocols to follow. The
most important of these questions is, “Will surface staining (i.e.
phenotyping) be necessary to identify the cells of interest?”
The answer to this question is critical, as it will dictate the
best way to prepare the cells, allowing the antigens access to the
intracellular compartment and their target. It will also impact the
choice of fluorochromes used because different fixation methods
can have dramatic impact on the fluorescent molecules [625]. The
two most common fixation reagents are alcohols and aldehydes,
each having their strengths and drawbacks.
Alcohols, such as ethanol and methanol, or acetone, are
dehydrating fixatives which both coagulate proteins (fixation)
and create holes in the lipid membrane (permeabilization).
Many of the cyclins and phospho-specific proteins are readily
detectable post-alcohol fixation [626]. Unfortunately, alcohol
fixation adversely affects fluorescent proteins such as GFP, which
will be affected by alcohol fixation in such a way that it will no
longer be fluorescent after conformational changes or may even
leach out of the cell [627].
Alcohol fixation will also adversely affect commonly used
fluorochromes including PE, PerCP and APC, making these
fluorochromes a poor choice for surface staining. Small cyclic
ring fluors such as FITC, the Alexa Fluor R© and the cyanine dyes
are more resistant to alcohol fixation. Surface markers may
also be stained post-fixation if the protein structure, or at least
the specific recognized sequence is unaltered by the chemical
process of fixation. If no evidence is available, this may have to
be determined empirically.
Aldehyde fixation is performed usually with formaldehyde in
the range 1–4% [628]. Aldehydes are cross-linking fixatives so
they lock protein structure in place by forming cross-links between
lysine residues, forming methylene bridges. This generally means
antibodies will still recognize their epitope. However, formalde-
hyde on its own is not a good permeabilizing agent and it would
normally be combined with a detergent—this is the basis of many
Fix and Perm kits that are on the market (although the exact com-
position of commercial kits is often not common knowledge due to
Intellectual Property policies). A range of detergents is available
such as Triton X-100, lysolecithin, Nonidet-P40 and saponin. The
choice may depend on localization of the protein. Transcription
factors tend to be nuclear and the use of a stronger detergent
such as Triton X-100 (generally around 0.1%) is a good choice as
it can permeabilize both the plasma and the nuclear membrane.
Saponin on the other hand is not a good permeabilizing agent
for nuclear factors due to its more “gentle” and reversible nature
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Figure 79. Typical sequential gating analysis performed on samples of cycling cells stained for DNA content and intra-nuclear histone modifi-
cations. Asynchronously proliferating Jurkat cells were harvested, processed and stained exactly as outlined in Section VII.15.3: Example generic
protocol for intranuclear antigen – pH3. 1. A bi-variate plot showing FSC-A (X axis) versus SSC-A (Y axis) with a polygonal gate set to include “intact
cells” and exclude debris (low FSC-A/SSC-A). 2. A bi-variate plot showing the area of the DNA signal (PI) on the X axis versus the height of the same
parameter on the Y axis. A gate has been set to include single events and exclude events that are likely doublets based on a breakdown in the
linear relationship between area versus height. 3. A second step of doublet exclusion using the width of the SSC signal pulse (Y axis) versus the
FSC-A signal (X axis). 4. A plot of PI DNA area signal (X axis) versus the area signal for the phospho-serine H3 residue 28 modification as revealed
by an AF488 tagged monoclonal antibody (Y axis). Data is shown for cells that have been left untreated (left panel) and cells treated for 16 hours
with 0.1 μM Nocodazole as a positive biological control for staining. Unt, Untreated; Noc, Nocodazole.
and has often seen more use in cytokine staining. However, it
should also be noted that cytokine staining is also compatible
with detergents such as NP-40 (see also Section IV.6: Cell fixation
and permeabilization for flow cytometric analyses) [629].
It is important to note, as with any flow cytometry protocol,
the exclusion of dead cells is critical for analysis. Commonly
used viability dyes such as PI or 7-aminoactinomycin D (7AAD)
rely on an intact membrane for differentiation of live versus
dead cells (see Section IV.5: Frozen samples and cell viability).
When targeting intracellular markers by flow, the use of fixable
amine-reactive dyes must be used (see also Section IV.6: Cell
fixation and permeabilization for flow cytometric analyses) [323].
These dyes still allow for the discrimination of dead and live cells
from live even after the fixation and permeabilization processes.
As fixation chemically alters the cells, it will also change
to some extent the autofluorescence of the cell. Changes in
morphology may be seen as alterations in light scatter patterns
in a flow cytometer. Again, alcohols will have a more dramatic
effect. Conversely, alcohols do not cause, in general, a change in
levels of background autofluorescence which may be important
if a low level specific signal is expected. If an aldehyde is used,
fixation should be brief and cells should be stored in a phosphate
buffer prior to staining as aldehydes, especially glutaraldehyde,
will cause an increase in autofluorescent background.
Reagent manufacturers each sell specific buffers and kits for
staining of specific transcription factors, often with proprietary
reagents, but these buffers have been designed to allow detection
of nuclear antigens without comprising surface antigen detection.
Some of these kits will have separate fixation and permeabiliza-
tion steps, while others will be in a single solution. The choice of
which kit or reagents to use is often dictated by the intracellular
target, so reading of the technical specification of the given
antibody is critical.
The location of the target may also influence the fluorochrome
used to label the antibody. Fluorochromes such as PE, APC
and PerCP and their tandems are large proteins which add
considerably to the molecular weight and size of the antibody.
This means that to detect a nuclear protein, a harsher permeabi-
lization/fixation regime may be needed which may also lead to
selective loss of small molecules from the cell. But it may also
mean that the comparatively larger fluorochrome will restrict
access of the antibody to the nucleus altogether.
A good example of detection of a transcription factor is FoxP3,
which is expressed by the regulatory subset of T cells (Treg
cells) [630]. This is a nucleus-located protein and as with most
transcription factors, can influence gene expression up or down.
Dysregulation of FoxP3 has been implicated in the etiology of sev-
eral autoimmune disorders. As the protein is specifically expressed
by cells also expressing CD3, CD4 and CD25, these antigens must
also be detected using fluorescently labeled antibodies. Many
reports in the literature also use CD127 as a further marker of the
Treg-cell subpopulation [631]. A typical protocol for detection
of FoxP3 cells is described below, in section VII.15.2: Example
general protocol: FoxP3. It should however be mentioned again
that FoxP3 staining tends to use kits containing proprietary
buffers. As such we have also included a “generic” protocol for
performing intra-nuclear staining that has been used successfully
on a range of transcription factors and intra-nuclear targets. In
the example provided in Fig. 79, staining for DNA content using
PI combined with the detection of histone H3 phosphorylation on
serine residue 28 [632] is shown. The design of any multicolor
flow cytometry panel is critical to the success of the identification
of the specific sub-population. The choice of fluorochromes will be
influenced by the cytometer available but should be determined
by dye characteristics, spectral overlap, and antigen expression
and density (for further detail see Section III.1: Compensation).
Importantly, the design should allow the critical analyte, in this
case the FoxP3 expression, to be measured in the channel with
the brightest fluorochrome or the least spillover and/or data
spreading (for further detail see Section III.1: Compensation).
In conclusion, there is not a universal protocol applicable to all
transcription factors, which can be expressed in different cellular
locations (see Table 22); the type of fixation, the length of fixa-
tion, the type of permeabilization, the choice of fluorochromes,
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Table 22. Most common transcription factors measured by flow cytometry. For more information about them http://www.uniprot.org/uniprot/
Transcription factors Cell type Cellular location
AHR Liver, Treg and Th17 cells Cytoplasm
Aiolos B, T and NK cells Nucleus
AIRE Dendritic cells, lymph node, lymphoid
stromal cells, and monocytes
Perinuclear region (??)
BATF B and T cells Nucleus
Bcl-6 B cells and CD4+ T follicular helper cells and
memory T cells
Nucleus
β Catenin Several non-immune tissues, B, T, and
hematopoietic stem cells
Cytoplasm / nucleus
Blimp1 B, T, dendritic and some NK cells Cytoplasm
c-Maf Neural, ocular and hematopoietic systems Nucleus
c-Rel Treg, mature T cells Cytoplasm / nucleus
E4BP4 NK, NKT, and dendritic cells Nucleus
Egr1 B, T and myeloid cells Cytoplasm / nucleus
Egr2 (B), T and NKT cells Cytoplasm / nucleus
Eomesodermin / TBR2 NK and T cells Nucleus
Eos T cells and nervous system Transmembrane
FoxJ1 Ciliated epithelial cells, naive B and T cells Nucleus
FoxP3 CD4+CD25+ regulatory T cells (Treg cells),
and CD4+CD25− cells
Cytoplasm / nucleus
Gata-3 Central nervous system, kidney, mammary
glands, skin, and T cells
Nucleus
Helios / IKZF2 T and hematopoietic stem cells Nucleus
IκB-zeta Macrophages, monocytes, B and T cells Nucleus
IRF4 Macrophages, B and T cells Cytoplasm / nucleus
Nanog Blastocyst, embryonic stem cells, and
embryonic germ cells
Nucleus
NFkB Almost all cell types Cytoplasm / nucleus
NFAT T cells Cytoplasm / nucleus /
transmembrane
Notch1 Thymocytes, bone marrow hematopoietic
stem cells, T and NK cells
Cytoplasm / Golgi/ nucleus /
transmembrane
Notch2 Activated peripheral T cells, bone marrow
and thymocytes,
Cytoplasm / Golgi/ nucleus /
transmembrane
Notch3 CNS, some thymocyte subsets, vascular
smooth muscle, and T cells
Cytoplasm / Golgi/ nucleus /
transmembrane
Notch4 CD8+ splenic dendritic cells, endothelial cells,
and macrophages
Cytoplasm / Golgi/ nucleus /
transmembrane
Nurr77 Thymocytes and T cell Cytoplasm / nucleus
OCT3/4 Embryonic stem and induced pluripotent
stem (iPS) cells
Nucleus
Pax5 Hematopoietic cells, B cells Nucleus
PLZF CD4 and CD8+ T cells, gamma delta T cells
and NK.
Cytoplasm / nucleus
RORγ Heart, kidney, liver, lung, muscle, and
CD4+CD8+ thymoycte cells
Nucleus
Runx1 / AML1 Hematopoietic, myeloid, B and T cells Cytoplasm / nucleus
Sox2 Embryonic stem cells and neural cells Cytoplasm / nucleus
T-bet B cells and CD4+ T-cell lineage Nucleus
ThPOK Hematopoietic cells, skin, heart, smooth
muscle, and liver, invariant natural killer T
(iNKT) cells and gamma delta T cells
Nucleus
TOX Thymocytes, T lymphocytes, NK cells, and
lymphoid tissue-inducer (LTi) cells
Nucleus
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the staining protocol, including incubation times of antibody
staining, must all be optimized. The principle advantage of flow
cytometry in this area is the ability to multiplex an assay, and by
using multiple analytes be able to very specifically define subsets
of interest — this will only be limited by the cytometer available.
One downside of flow cytometry is the lack of morphological
information and inability to specifically localize the fluorescence
within the cell. If this is important then imaging using either
fluorescence microscopy, confocal microscopy or imaging flow
cytometry should be considered.
15.2 Example general protocol: FoxP3
15.2.1 Reagents for intranuclear staining.
Staining buffer: PBS + 2% FCS (0.5% sodium azide optional)
FIXATION buffer: PBS + 4% formaldehyde (made from a 16%
solution obtained from Polysciences cat no: 18814-20 (make
up 1 week prior))
PERM buffer: PBS + 2% FCS + 0.1% Triton X-100
15.2.2 Staining.
1. After harvesting cells, resuspend cells in PBS without protein.
Added protein will interfere with step 2.
2. Stain cells with live/dead fixable according to vendor’s proto-
cols. Typical protocol requires 20 min incubation at room tem-
perature.
3. Wash cells and resuspend in PBS containing protein (Staining
Buffer — SB).
4. Stain cells with appropriately labeled and properly titrated
antibodies. Typical protocol requires 20–30 min incubation on
ice in the dark.
5. Wash cells and resuspend in fixation buffer. Typical protocol
will involve 1 mL of reagent with a 30–60 min incubation at
4°C.
6. Wash with SB.
7. Resuspend cells in SB and add appropriately labeled and prop-
erly titrated FoxP3 antibody. Typical protocol requires incuba-
tion for 60 min at room temperature.
8. Wash cells in SB and resuspend in appropriate volume before
analysis on flow cytometer.
Note: Do not forget to treat all controls including compensation,
fluorescence minus one (FMO), reference, positive and negative
controls the same way!
15.2.3 Data acquisition. Gating protocol should include steps:
1. Remove doublets (using pulse geometry gating, e.g. FSC-height
versus FSC-Area).
2. Remove dead cells (viability dye dim/negative).
3. Identify lymphocytes (based on forward and side scatter
parameters).
4. Subset lymphocytes into T cells (based on CD3 and CD4 expres-
sion).
Once those cells are identified, a dot plot of CD25 versus FoxP3
can be generated. Since Treg cells are a minor percentage of cells
(around 2–4% of mature CD4+ T cells [633]), it is critical to
use FMO controls to help identify the appropriate cells of interest
(Fig. 80).
15.3 Example generic protocol for intranuclear antigen —
pH3
15.3.1 Staining (adapted from [632]). Staining is done in a 96-
well U- or V-bottom plate.
1. Count cells from culture/primary sample and resuspend at 10
million cells per mL, aliquot 100 μL per well (106 viable cells
per sample for staining). Spin down plate at 350 × g for a
minimum of 3 min at room temperature. Flick SN and vortex
plate to re-suspend. These will be the conditions for all wash
steps.
2. Optional: Stain for Live/dead and surface markers prior to fix-
ation. Follow manufacturer’s recommendations for live/dead
staining. Make up Ab cocktail in staining buffer at optimized
dilutions. Add 100 μL per well per million cells and incubate
for optimized time (1 h minimum).
3. Add 100 μL of Staining buffer per well and spin down as in
step 2. Add 200 μL of fresh Staining buffer and spin down
again.
4. Resuspend cells in 100 μL of PBS only and pipette up and
down to ensure cells are fully in suspension. Then add 100
μL of 4% Fixation buffer to final concentration of 2%. The
pre-suspension in PBS minimizes the formation of cell clumps
during the fixation process. Leave at room temperature for a
minimum of 60 min.
5. Spin down cells and treat as in step 1.
6. Resuspend pellet in 100 μL of PERM buffer using a P200
pipette. Incubate tubes at room temperature for exactly 5 min
(stagger addition of PERM buffer if needed).
7. Add 100 μL of Staining buffer to each well in staggered fashion
to end permeabilization step. Spin down and process as in step
2.
8. Add 100 μL of primary Ab cocktail and mix in PBS + 2% FCS.
Incubate at RT for optimized time (usually 1–2 h).
9. Add 100 μL of Staining buffer and spin down and process as
in step 2. Repeat this wash step with 200 μL fresh Staining
buffer.
10. If necessary, incubate cells with secondary Ab cocktail mix for
the optimized time (usually a minimum of 30 min) at RT in
the dark.
11. Wash the cells, as outlined in step 2, twice in fresh Staining
buffer.
Final resuspend volume should be 200–400 μL of Staining buffer.
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Figure 80. FoxP3 staining to detect T-regulatory cells (example gating). Human PBMCs were stained following standard protocols followed by
fixation and permeabilization as per the protocol (above). There are several ways of identifying T-regulatory cells. In this example, the following
gating strategy was applied to identify CD4+ T-regulatory cells: 1. Flow stability gating (Time vs Side Scatter)—to ensure the instrument had good
stable flow over the run of the sample. 2. Doublet gating (Forward Scatter height vs area)—removal of doublets based on pulse geometry gating. 3.
Scatter gating (Forward vs Side Scatter)—to remove debris and events off-scale. 4. Dump and Viability—removal of dead cells and non-T cells.5.
CD3 (T-cell) gate—gating to identify the CD3+ subset. 6. T-cell subsetting (CD4 vs CD8) — further subsetting of the CD3+ cells to identify CD4+. 7.
T-reg gating (CD25 vs FoxP3)—identification of T-regulatory cells Clones used FoxP3 PCH101, CD25 M-A3251. The final gate was set based on the
FMO controls. As shown, the event file started with 507471 events, and the percentage of cells in each gate are identified on each plot, resulting
in approximately 3 000 cells in the final gate.
16 Measurement of signal transduction pathways by
flow cytometry
16.1 Introduction
The large majority of proteins involved in the regulation of cell sig-
naling, survival, and growth regulation are intracellular. This sec-
tion covers the technical aspects of intracellular antigen staining
for flow cytometry, using activation and simultaneous monitor-
ing of multiple pathways in human peripheral blood monocytes
as a practical example. The approaches we use for cell fixation
and permeabilization that optimize intracellular labeling while
preserving light scatter and phenotypic markers are presented in
the section on cell fixation and permeabilization (Section IV.6:
Cell fixation and premeabilization for flow cytometric analyses).
Although more demanding than cell surface staining, mastery of
intracellular cytometry enables the study of fundamental regula-
tory mechanisms of normal and abnormal cell biology, many of
which remain under-explored.
Signaling pathways typically relay instructions from outside the
cell to the nucleus, where an appropriate genetic program such as
DNA synthesis or enhanced cell survival is executed in response
to inputs from growth factors, cell-cell contacts, or ECM inter-
actions. The biochemical basis of signal transduction involves the
addition (by kinases) and removal (by phosphatases) of phosphate
groups from the amino acids serine, threonine, and tyrosine that
contain –OH side chains. Phosphorylation alters the charge dis-
tribution, hence the conformation, of proteins. Typically this acti-
vates the catalytic site of an enzyme, although some phosphoryla-
tions are inhibitory, inactivating the kinase function of the protein.
Individual proteins involved in signal transduction are arranged
in pathways, where an incoming phosphorylation activates the
kinase activity, allowing it to pass the phosphorylation signal on
to the next signaling element. There are other key cellular path-
ways that similarly result in different types of post-translational
C© 2017 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.eji-journal.eu
1720 Andrea Cossarizza et al. Eur. J. Immunol. 2017. 47: 1584–1797
Figure 81. “Canonical” pathways for LPS activation of multiple signaling pathways in peripheral blood monocytes via TLR-4 (adapted from Guha
and Mackman [635] and reproduced with permission). Inhibition of PI3K (right) by Ly294002 or GDC-0941) or of MEK 1/2 (left) by U0126 is also
illustrated here. Also shown, in monocytes, activation of the ribosomal S6 protein is predominantly through activated ERK.
protein modifications, including methylation, hydroxylation,
acetylation, ubiquitination, etc., and the basic fixation and perme-
abilizkation technique described in Section IV.6: Cell fixation and
permeabilization for flow cytometric analyses, has been used to
study some of these [634].
Signal transduction is clearly a complex area of biology.
Although it is likely that the major signaling pathways in mam-
malian cells have now been identified, basic research into how
these are regulated and interconnected continues at a rapid pace.
The complexity of signal transduction pathways allows for multi-
ple activating and inhibitory inputs, and for networking between
pathways. Considering that signal transduction is essential for the
survival of multicellular organisms, this is to be expected.
Derangements in signal transduction are extremely common in
human cancers, and appear to play a major role in the develop-
ment and progression of both solid and hematological malignan-
cies. Similarly, signal transduction pathways play a pivotal role in
multiple aspects in both the development of the immune system,
and in regulating responses to antigenic challenges.
16.2 Sample preparation for signal transduction analysis
The analysis of phospho-epitope expression in clinical samples
(whole blood, bone marrow, body fluids) is complicated by the
need to lyse RBCs, while at the same time preserving surface
immunophenotypic markers as well as light scatter. For this, we
have developed a technique which starts with fixation of the entire
cell suspension, ensuring that phospho-epitopes are stabilized as
soon as possible, followed by red cell lysis using Triton X-100 (Sec-
tion IV.6: Cell fixation and permeabilization for flow cytometric
analyses). As discussed there, some epitopes (e.g. phosphorylated-
STAT proteins) require an additional methanol “unmasking” step
for optimization of their expression [175]. We have also used
this technique for the analysis of signaling in bone marrow sam-
ples [172, 173].
16.3 Activation of signal transduction pathways regulating
acute inflammatory responses
Like most signaling pathways, the MAP kinase (Membrane Acti-
vated Protein kinase) pathways are arranged in cascades in which
one member becomes catalytically active following phosphoryla-
tion by its upstream activating kinase. The activated upstream
kinase is able to pass on the signal by phosphorylating its down-
stream substrate. This complexity allows multiple levels of feed-
back regulation, and interconnections involving pathways that are
critical to the normal maintenance of tissues. There are three MAP
kinase pathways that in mammals have very distinct functions,
although they are highly conserved in evolution. The ERK path-
way, often simply called the “MAP kinase pathway” is involved
in growth factor stimulation, whereas the SAPK/JNK (Stress-
Activated Protein Kinase/c-JUN N-terminal Kinase) and p38 MAP
kinase pathways are more sensitive to other environmental cues
including osmotic stress and heat shock.
In the innate immune response, the bacterial endotoxin
LPS induces the activation of multiple signaling pathways
(“pan-kinase” activation) which leads to an inflammatory response
in monocytes.
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As shown in Fig. 81, LPS activation of signaling pathways in
peripheral blood monocytes is somewhat unique, in that it results
in the activation ofmultiple signaling pathways, including all three
major MAP kinases, PI3 Kinase>AKT, and NFκB pathways. NFκB
andMAP kinase activation induces the production of inflammatory
and other cytokines. These pathways have widespread effects on
cell function, which together coordinate the host response to acute
bacterial infection.
Although the original canonical signaling maps indicated that
LPS activates ERK in monocytes via the “classical” Ras>Raf path-
way [635], in monocytes one pathway for LPS activation of ERK
is via TPL-2, a MAPKKK, which is sequestered in one of the forms
of IκB, is phosphorylated/activated by IKK, and released from the
complex by proteasomal degradation of IκB. Phosphorylated TPL-
2 subsequently phosphorylates/activates its downstream target,
MEK 1/2, which then activates/phosphorylates ERK 1/2 [636].
Signaling pathways are complex, and a specific pattern or path-
way seen in one type of cell does not predict the same pattern
or pathway in all cells. Therefore, it may be important to study a
broad set of specific signaling proteins/modifications for compre-
hensive understanding of signaling pathways in a specific cell type.
16.4 Kinetics
In studying the activation (and inactivation) of signaling path-
ways, it is critical to include multiple time-points within the exper-
iment. For example, the phosphorylation of ERK in human bone
marrow CD34+ cells (at 37°C incubation) reaches a peak and
returns to unstimulated cell levels in less than 10 min [172], indi-
cating that the dephosphorylation of P-ERK occurs rapidly in this
cell population.
16.5 Kinase and phosphatase inhibitors
Specific (or relatively specific) kinase inhibitors are very useful
when analyzing pathways downstream from a signaling “node.”
For example, U0126 binds to MEK1/2 and prevents it from
phosphorylating (activating) its downstream partner ERK1/2 (see
Fig. 81). Adding U0126 to a whole blood sample will block activa-
tion of ERK1/2 and activation of any downstream target such as
ribosomal S6 protein (in monocytes). In addition, by comparing
the level of a target phospho-epitope expressed in cells exposed
to an inhibitor with that of untreated cells, it is possible to reveal
background or constitutive levels of activation of a specific kinase
and its downstream partners. In Fig. 82, whole blood was treated
(here for 4 min) at 37 °C with LPS alone, or with UO126 (MEK
inhibitor) or with Ly294002 (PI3 kinase inhibitor). In the presence
of UO126, activation of both ERK 1/2 and the downstream S6
ribosomal protein are inhibited. Also shown here, the PI3 kinase
inhibitor Ly294002 (we have also used the more specific PI3K
inhibitor GDC-0941 with similar results) likewise inhibits activa-
tion of both ERK 1/2 and S6 at this time point. Neither inhibitor
changes the responses for p38 or SAPK/JNK, although PI3K inhi-
bition does prevent AKT activation (see below). These results are
consistent with a model in which ERK 1/2 can be activated (in
human monocytes) via PI3k>AKT. However, a better understand-
ing of the responses and inhibitions of specific pathways requires
monitoring the responses to different stimuli over time.
As shown in Fig. 82, after appropriate inhibitor and LPS
treatment, cells were fixed and permeabilized using formalde-
hyde/Triton X-100, and subsequently stained using antibodies to
phospho-ERK 1/2 (p44/42 MAPK), phospho-S6 ribosomal pro-
tein, plus CD14 and CD45 to identify monocytes (not shown in
figure) and eliminate debris from the analysis. Figure 82 demon-
strates several key points mentioned above. LPS activates the ERK
pathway rapidly, and only the monocytes showing maximal lev-
els of ERK phosphorylation also show phosphorylation of S6 (top
left). U0126 inhibition of ERK activation (top right) inhibits the
activation of both ERK and S6. It should be noted that the “canoni-
cal” pathway usually shown in signaling documents indicates that
S6 is activated by PI3K>AKT [637]. The data shown in Fig. 82
are consistent with the concept that activation of ribosomal S6
protein is via the ERK pathway in human peripheral blood mono-
cytes, highlighting the need to carefully investigate the appropri-
ate upstream activation pathways. Finally, both the activation of
ERK and S6 are inhibited (at this time point) by the PI3 kinase
inhibitor Ly294002, consistent with the concept that ERK activa-
tion in human peripheral bloodmonocytes can also be via AKT (not
the “canonical” RAS>RAF pathway, bottom left) [635]. At first,
these data seem inconsistent with the comment above that ERK
activation in monocytes is via TPL-2 [636]. However, as shown
below (Figure 84), there are two separate signaling pathways
activating ERK, one through PI3 kinase (early ERK activation),
the other through NFkB.
Signaling pathways (particularly phosphorylation/
dephosphorylation) in normal cells are frequently activated
and then rapidly inactivated. Inactivation of a kinase involves
dephosphorylation of the target phosphorylated amino acid(s)
by a phosphatase. One of the predictions of this model is that
inactivation of a phosphatase should result in maintaining the
effects of an activated kinase for longer time periods [638].
16.6 Simultaneous monitoring of multiple signaling
pathways in the context of response kinetics
The results shown above in Fig. 82 can be interpreted to indi-
cate that both ERK and AKT pathways are activated by LPS. While
this conclusion is correct, the use of different pathway inhibitors
in conjunction with detailed kinetic analyses reveals important
details of the specific pathways that are activated in human periph-
eral blood monocytes by LPS.
Using the same logic that is commonly used to understand
complex biological systems (e.g. hematopoietic cell differentia-
tion and lineage reconstruction in bone marrow), for simultane-
ous measurement of multiple signaling targets, we routinely mea-
sure multiple signaling targets in each sample. As in all complex
immunophenotyping experiments, attention to details is essential
in the design and execution of these types of experiments. For
example, large fluorophores such as PE or APC should only be
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Figure 82. LPS activation of the ERK pathway in human peripheral blood monocytes. Samples were pre-incubated with the indicated inhibitors
for 60 min at 37oC before the addition of LPS to all samples. After 4 min incubation with LPS, all samples were fixed using formaldehyde and
permeabilized using Triton X-100 (see Section IV.6: Cell fixation and permeabilization for flow cytometric analyses, for details on fixation and
permeabilization steps). Only monocyte responses are shown here, based on CD45 and CD14 gating (not shown here).
used for nuclear localizing target phospho-epitopes after running
preliminary experiments to ensure the antibody-conjugate can get
to the target. Similarly, tandem dyes (PE-Cy5) should be used
with caution, with appropriate controls to ensure integrity of the
tandem at the time of the assay.
As an illustration of simultaneous measurement of four dif-
ferent signaling targets, Fig. 83 demonstrates the whole blood
analysis of LPS-stimulated human peripheral blood using CD14-
PE-Cy7 to detect monocytes, plus P-p38 (MAPK)-Alexa Fluor R©
488, P-AKT-PE, P-ERK- Alexa Fluor R© 647, and P-S6-PacBlue.
These results demonstrate that the majority of monocytes
(shown in red) are positive for all four phospho-epitopes at 10
min incubation with LPS. As also shown in Fig. 83, the analysis of
each phospho-epitope response includes an evaluation using side
scatter (SS), demonstrating that in this donor, only the mono-
cytes show significant activation of these phospho-epitopes (in
many donors, the granulocytes also show a positive P-p38 pop-
ulation following LPS activation, not seen here). However, the
details of the individual signaling pathway responses can only be
appreciated using both multiple time points for LPS activation and
the simultaneous use of specific pathway inhibitors. As shown in
Fig. 84, looking at the kinetics of both P-ERK and P-AKT activation
simultaneously over a 15 min period of LPS activation shows two
different peaks of P-ERK expression (upper response in red in both
panels): one extremely rapid, peaking at 2–4 min (left panel),
the second peaking at 8–10 min (at 37°C incubation). In most
(though not all) normal human donors we see both peaks, while
in a minority of donors we only see the “later” P-ERK. In a sample
pre-treated with the PI3K inhibitor (here GDC-0941, right panel),
only the “early” (2–4min) P-ERK response is inhibited. In contrast,
pre-treatment with U0126 (as shown in Fig. 82) inhibits both the
early and the late P-ERK peak, indicating that the first peak goes
through PI3K, but requires P-MEK. The second peak of activation
of P-ERK actually goes through IKK>IκB>TPL-2 [636]. Consistent
with this concept, we have demonstrated that the “second” P-ERK
peak is inhibited by proteasome inhibitors, such as MG-132 (inhi-
bition of proteasomal destruction of IκB prevents the release of
TPL-2, preventing it from activating MEK).
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Figure 83. Simultaneousmeasurement of four different signaling targets. Human peripheral blood was incubated with LPS for 10minutes at 37oC.
Here, each of the measured phospho-epitopes is shown versus side scatter, with the CD-14pos monocytes in red.
The kinetics of AKT activation (Fig. 84) demonstrate a peak at
4–8 min (left panel, lower response in orange) with a sustained
response for the time period measured here. As shown in the
right panel of Fig. 84, GDC-0941 causes complete inhibition of
AKT activation, a useful internal control which strengthens the
concept that the “early” ERK activation is through PI3K>AKT.
These data also suggest that there is a constitutive activation of
AKT in peripheral blood monocytes, which is inhibited by PI3
Kinase inhibitors (GDC-0941).
16.7 Sample protocol for LPS activation of human whole
blood
This same approach can be used to study the impact of specific
signaling pathway inhibitors to determine which downstream sig-
naling pathways are affected. Overall, monitoring signal transduc-
tion pathways in stimulated whole blood (and other similar types
of samples) offers a unique way to test and validate antibodies,
specific agonists, or antagonists, using a relevant biological sys-
tem. In addition, this approach can be used to monitor the activity
of targeted therapies (inhibitors) in vivo, or to monitor the prior
exposure of individuals to LPS/Endotoxin [639].
16.8 Materials
1. 4.0–5.0 mL human whole blood collected into K2EDTA or
sodium heparin, stored at room temperature until tested. The
blood sample must be used as soon as possible in order to pre-
serve appropriate signaling capabilities. Sample testing should
(ideally) begin within 1–4 h of collection.
2. Directly conjugated antibodies to phospho-epitopes (e.g. Cell
Signaling Technology, Danvers, MA) and cell surface-specific
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Figure 84. Kinetics of LPS activation of the AKT and ERK pathways in peripheral blood monocytes. Whole blood samples were pre-treated with
the PI3K inhibitor GDC-0941 (right panel), or vehicle controls (left panel), followed by activation with LPS for 0 to 15minutes at 37oC. P-AKT (orange,
lower line in both panels) and P-ERK (red, upper line in both panels). Note that in the GDC-0941 treated sample (right), the P-ERK peak seen in the
untreated sample is missing (arrow, right panel).
conjugates are necessary. We generally use multiple (gener-
ally 4) phospho-epitope specific antibodies in each tube, using
lower molecular weight fluorophores (e.g. Alexa Fluor R© 488,
or 647, Pacific Blue) for staining nuclear or ribosomal targets,
and PE or APC for cytoplasmic targets. The same guidelines
must be used here for the selection of fluorophore-antibody
pairs for phospho as for other targets (e.g. use “bright” con-
jugates for non-abundant targets and “dim” conjugates with
abundant targets).
(a) CD14-PC7
(b) CD45-KrO
(c) P-ERK-Alexa Fluor R© 647 [T202/Y204], also known as P-
p44/42 MAPKP
(d) P-S6-Pacific Blue [Ser235/236]
(e) P-AKT-PE [Ser 473]
(f) P-p38 MAPK-Alexa Fluor R© 488
16.9 Reagents
1. LPS from E. coli 0127:B8; dilute to 50 μg/mL in PBS; store this
working dilution at 4°C; stable for up to 6 months.
2. Triton X-100, 10% aqueous solution; prepare working solution
by diluting 116μL stock with 10mL PBS; store stock and work-
ing solution at room temperature; working dilution is stable for
1 month.
3. Appropriate pathway inhibitors (e.g. U0126 MEK>ERK, GDC-
0941 PI3K>AKT, bortuzamib for proteasome inhibitor), as nec-
essary.
4. Formaldehyde, 10% (methanol-free); store at room tempera-
ture in the dark.
5. Albumin solution from bovine serum; store at 4°C.
6. PBS (calcium- and magnesium-free).
7. Wash Buffer: 4% BSA in PBS; filtered through 0.22 μm sterile
filter.
8. Deionized water (for Triton X-100 dilution)
16.10 Procedure: Whole blood fixation and permeabilization
protocol for kinetics and use of inhibitors
Before starting this procedure, prepare an experiment worksheet
to aid in the critical timing steps (see sample Worksheet presented
in Table 23). The experiment described below is for time points of
up to 10 min of LPS activation. LPS is added to the tube(s) with
the longest incubation time first (here, 10 min), followed by stag-
gered LPS addition for shorter incubation times. For experiments
adding specific signaling pathway inhibitors (not outlined here),
whole blood samples are incubated at 37°Cwith inhibitor(s) for an
appropriate time (generally 30–60 min, depending on the specific
inhibitor) before the addition of LPS.
1. Label the appropriate number of 75 mm polypropylene test
tubes for the experiment. There will be one control tube for
each cell surface antibody-conjugate, and appropriate control
tubes for each phospho-epitope (remember that the compen-
sation control for each phospho-epitope target should express
maximal levels of each target).
For phospho-epitopes requiring methanol treatment, have a
50% methanol solution ready for use in the freezer and right
before use, remove from freezer and place into an ice bucket.
See Section IV.6: Cell fixation and permeabilization for flow
cytometric analyses, for details.
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Table 23. Worksheet for timed addition of reagents for 15 minute (max) LPS activation of whole blood
Time of addition Time of addition Time of addition
Tube no. Tube label LPS Formaldehyde Triton X-100
1 LPS 15′ 0:00 15:00 25:00
2 LPS 10′ 5:10 15:10 25:10
3 LPS 8′ 7:20 15:20 25:20
4 LPS 6′ 9:30 15:30 25:30
5 LPS 4′ 11:40 15:40 25:40
6 LPS 2′ 13:50 15:50 25:50
7 Unstimulated control 16:00 26:00
8 CD14-PC7/CD45-KrO only 16:10 26:10
Unstimulated control: Vortex and put into 37°C water bath at 14:00
CD14-PC7/CD45-KrO only: Vortex and put into 37°C water bath at 14:10
Blood samples: 100 μL
Addition of LPS: 2 μL of 50 μg/mL PBS; final concentration 100 ng per 100 μL blood
Addition of formaldehyde: 65 μL of 10% solution: final concentration 4%
Addition of 0.1% Triton X-100: 1 mL of 0.1% Triton X-100/PBS
2. Just before use, mix blood by inverting vacutainer tube sev-
eral times, then transfer blood into a 50 mL conical tube.
Mix blood while aliquoting samples into 75 mm tubes from
step 1.
3. Pipette 100 μL of blood sample into the bottom of each appro-
priately labeled tube. Use a cotton-tipped applicator to remove
any blood from the side of the tube.
4. Add 100 ng LPS (2 μL of working dilution) to the first of the
designated stimulation tubes and mix by shaking tube. Place
that tube into the water bath and start a stopwatch. At the
appropriate time interval, add LPS to the next tube, vortex
and place it into the water bath. Continue for all tubes in the
stimulation part of the experiment.
5. Continue to use the staggered start to place the 37°C “no LPS”
control tube and the CD14-only tube into the water bath (last
tubes to be placed into the 37°C water bath.
6. At the 10minmark, remove the first tube in the timed sequence
from the water bath and add 65μL of 10% formaldehyde to the
tube. Immediately mix well by shaking tube and place it into
a tube rack. Continue adding 65 μL of formaldehyde to each
tube in the timed sequence, mixing between each one. Note:
This is a critical step. Formaldehyde stops the LPS activation
and fixes the cell.
7. Incubate each tube for a total of 10 min at room temperature.
8. After exactly 10 min of incubation in formaldehyde at room
temperature, pipette 1 mL of Triton X-100 solution into each
tube at the appropriate time interval, vortex well and return
tube to rack. After Triton is added to the last tube, vortex all
tubes, place into the 37°C bath and set timer for 15 min.
(a) After 15 min, inspect tubes for complete RBC lysis (clear
non-turbid red color). If lysis is incomplete, continue incu-
bation for a maximum of 15 additional min.
(b) If lysis is still incomplete, centrifuge, decant supernatant,
loosen pellet by vortexing, resuspend with 1 mL of Triton
working solution and incubate in 37°C bath for up to 30
min to obtain maximal RBC lysis.
9. Remove tubes from the water bath, dab on paper towel to
remove water from the bottom of the tubes and place in rack.
Add 1 mL of cold (4°C) wash buffer (4% BSA/PBS) to each of
the tubes, and then vortex all tubes well.
10. Centrifuge all tubes at 500 × g for 4 min. Remove supernatant.
Vortex each tube to loosen pellet.
11. Resuspend pellet by adding 1 mL of cold (4°C) wash buffer
(4% BSA/PBS) to each of the tubes, and then vortex all tubes
well.
12. Centrifuge all tubes at 500 × g for 4 min. Remove supernatant.
Vortex each tube well to loosen pellet
For phospho-epitopes that require 80% methanol treatment to
“unmask” (e.g. P-STATs)
 Add 1 mL of cold (4°C) 80% methanol while vortexing.
NOTE: This is critical to reduce cell aggregation. Place
the tube on ice.
 After the last tube, set timer and incubate for 10 min.
 At the end of the incubation, centrifuge all tubes at 500
× g for 4 min. Remove supernatant. Vortex each tube
well to loosen up the pellet. Pipette 2 mL of cold (4°C)
wash buffer (4% BSA/PBS) to each tube.
 Centrifuge all tubes at 500 × g for 4 min.
 Remove supernatant. Note: not necessary to loosen up
the pellet before the addition of antibody cocktail
13. Add antibodies (concentrations and volumes previously
defined) and cold wash buffer to a final volume of 100μL. (Pre-
pare a cocktail containing all desired antibodies. This ensures
that the antibody concentration for each tube is “identical.”) All
antibodies should be diluted in PBS/4% BSA (protease free).
14. Incubate all tubes at room temperature for 30 min in the dark.
15. At the end of the incubation, add 2 mL of cold (4°C) wash
buffer (4% BSA/PBS) to each tube.
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16. Centrifuge all tubes at 500 × g for 4 min. Remove as much of
the supernatant as possible, exercising care to preserve the cell
pellet. Vortex each tube well to loosen up the pellet.
17. Resuspend the cells in 350 μL of 0.5% paraformaldehyde in
PBS, and store at 4°C in the dark, until sample can be analyzed.
Samples in 0.5% paraformaldehyde are stable for 24 h.
17 Lymphocyte metabolism through functional dyes
17.1 Introduction
The aim of this section is to provide rapid and simple protocols to
measure lymphocyte metabolism. We briefly layout general path-
ways and the relevance of some selected pathways for lymphocyte
biology before going into methodological detail. Lymphocytes
upregulate glycolysis and mitochondrial oxidative phospho-
rylation (OxPhos) during their activation [640]. Metabolic
reprogramming differs between B cells and T cells, and also
within regulatory T-cell subsets [640]. For instance, na¨ıve murine
splenic CD4+ T cells upregulate glycolysis and glucose uptake
and reveal a strongly enhanced ratio of glycolysis versus OxPhos
upon anti CD3/CD28 stimulation. In contrast, B cells upregulate
both glycolysis and OxPhos upon LPS or anti-B-cell receptor
stimulation, and maintain the glycolysis/OxPhos ratio of resting
B cells [641]. Although OxPhos ensures efficient ATP production
under aerobic conditions, mitochondria also contribute cytosolic
biosynthetic precursors such as acetyl-CoA and pyrimidines, and
are responsible for the production of ROS and cell death by
the intrinsic apoptosis pathway [472]. Glycolysis does also take
place under aerobic conditions and can be an actively induced
program to meet the cells’ energy demand, for instance in cancer
cells [642], and also in certain lymphocyte subtypes [640].
Counterintuitively, during hypoxia, which is encountered by
lymphocytes in the bone marrow and the thymus [643, 644], ROS
production by complex III of the respiratory chain, which usually
contributes to OxPhos, has also been observed [645]. The three
cellular ROS species are superoxide anions (·O2-) which are the
precursors of hydrogen peroxide (H2O2) and hydroxyl radicals
(·OH). ROS at high levels can cause oxidative stress to cells by
either directly inducing single- and double-stranded DNA breaks
or by oxidizing fatty acids, amino acids in proteins or enzymatic
co-factors [646]. At low levels and under normoxic conditions ROS
do, however, represent important cellular signaling molecules.
For instance, in stem cells, ROS act as second messenger to
ensure cycling of the cells [646]. The ROS species involved in
intracellular signaling is H2O2 as it has a long half-life and diffuses
easily [646]. Numerous proteins are redox sensors. For instance,
the oxidation of cysteine inactivates PTEN or Akt, which are
critically involved in B cell development [646]. Bach2, involved
in antibody class switch recombination, is a redox-sensitive tran-
scription factor [647]. Thus, metabolismmay reflect the activation
status and predict the fate of an immune cell. In fact, anergic B
cells are metabolically less active than na¨ıve B cells, and even less
than hyperactive B cells from B-cell activating factor of the TNF
family (BAFF) transgenic mice [641]. These selective examples
show that immune cell metabolism comprises ROS, glycolysis and
mitochondrial activity, which intersect with signaling pathways.
The gold standard to measure glycolytic and mitochondrial
activities in real time is via extracellular flux analysis using a
SeahorseTM device. However, this experimental setup requires
access to such a device and a substantial amount of cells (2
× 106 per single experiment), which might be difficult to achieve,
especially when looking at rare lymphocyte subsets. To perform
a quick first screen or to analyze complex cell populations with-
out enrichment and purification, such as bone marrow, rapid flow
cytometric techniques can provide first clues of whether a given
treatment, genetic deletion or a cytokine alters glucose uptake,
mitochondria or generation of ROS.
17.2 Experimental design
We describe here the use of cell permeable functional dyes
(see Table 24) to measure basic parameters such as (1)
glucose uptake (6-NBDG; 6-(N-(7-nitrobenz-2-oxa-1,3-diazol-4-
yl)amino)-2-deoxyglucose), (2) mitochondrial mass (MitoTracker
Green/Red FM), (3) mitochondrial membrane potential (mtmP)
(DIOC6; 3,3′-dihexyloxacarbocyanine iodide; TMRE; tetramethyl-
rhodamine), (4) ROS (DCFDA; 2′-7′-dichlorodihydrofluorescein
diacetate). We found it feasible to choose one color filter for
all dyes (FL1/green emission; 6-NBDG; MitoTracker Green FM,
DIOC6, DCFDA) to analyze complex cell populations, such as bone
marrow. This has the advantage that one single, titered cocktail of
antibodies can be combined with each functional dye to analyze
glucose uptake, mitochondrial mass, mtmP and ROS. Of course,
the same strategy can be applied to use dyes with a different emis-
sion (MitoTracker Red FM, TMRE) and different MitoTracker dyes
can be combined [647].
17.2.1 Measurement of mitochondrial mass and activity. Mito-
Tracker Green FM labels mitochondrial proteins via mildly thiol-
reactive chloromethyl moieties within the dye. MitoTracker Green
FM diffuses through the plasma membrane and is then taken up
by active mitochondria, irrespective of their mtmP. Once inside,
the dye cannot be washed out of the cells again. MitoTracker
Green FM is used to semi-quantify mitochondrial mass using
standardized conditions for cell numbers, dye concentration and
incubation time. This also holds true for the other cell perme-
able dyes. Increased MitoTracker FM staining can either signify
more or larger mitochondria or more structured mitochondria,
i.e. increased protein content providing more reaction targets for
the dye, and henceforth refers to the total mitochondrial mass of
a cell. In contrast to MitoTracker Green FM, the lipophilic and
cationic fluorescent dye DiOC6 specifically accumulates in mito-
chondria in relation to their mtmP at low concentrations [648]. It
has to be noted that loss of mtmP is a marker for early apoptotic
cells [649]. Thus, care has to be taken to gate on non-apoptotic
cells if alterations of mtmP that are not related to apoptosis are to
be analyzed by DiOC6 or TMRE.
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Table 24. List of cell permeable dyes described in Chapter VII: Cytometric parameters, along with solvents, working concentrations and storage
conditions
Solution Suppliera) Solvent (Stock) Working concentration Storage
6-NBGD Life Technologies (#N23106) dH2O (100 mM) 300 μM –20°C
DCFDA Thermo Fisher (#D399) DMSO (100 mM) 1 μM –20°C
DIOC6 Sigma-Adrich (#318426) EtOH (40 μM) 1–40 nM –20°C
MitoTracker Green FM Cell Signalling (#9074S) DMSO (1 mM) 5–10 nM –20°C
MitoTracker Red FM Thermo Fisher (#M22425) DMSO (1 mM) 50–100 nM –20°C
TMRE Life Technologies (#T668) MeOH or DMSO (20 μM) 20 nM –20°C
a)Some chemicals such as DCFDA or DiOC6 can also be obtained from other suppliers.
17.2.2 Measurement of ROS. In lymphocytes, the major source
of ROS are the two respiratory chain complexes I and III. The fluo-
rogenic dye DCFDA detects cellular ROS irrespective of its origin.
Inside a cell, DCFDA is first deacetylated but does not emit fluores-
cence until oxidized by ROS into DCF (2′,7′′dichlorofluorescein).
Of note, the probe is not selective for a particular ROS species
[650] but elicits a broad specificity particularly in the presence of
other oxidizing enzymes and factors like Fe2+ [651, 652]. See also
Section VII.12 Reactive oxygen species production with minimal
sample perturbation.
17.2.3 Measurement of glucose uptake. The fluorescent glucose
analogue 6-NBDG is used to directly track uptake of this monosac-
charide sugar into cells. By incubating cells in glucose-freemedium
supplemented with 6-NBDG, the analogue is taken up instead of
glucose and accumulates in the cells. The specificity of this assay
can be verified by competitively adding glucose. It has to be noted
that this assay does not directly measure glycolysis, i.e. pyruvate
or lactate production, as it is restricted to measure glucose uptake.
17.2.4 Caveats and their solutions. A problem is, especially when
measuring the organelle content of a cell, such as mitochondria,
that fluorescence intensity correlates with cell size. Therefore, we
firstly recommend choosing median fluorescence intensity (MdFI,
more robust against outliers) over MFI. Secondly, it is recom-
mended to normalize MdFI to cell volume by adjusting MdFI to
the cubic value of FSC pulse width (that is, [FSC pulse width]3),
which is the preferable parameter to evaluate cell size rather than
the height or area of FSc or SSc [653].
Other critical issues are concentration and incubation time. In
particular, DiOC6 can also be maintained in cells by membrane
potentials of other organelles, such as ER. Therefore, it has to be
kept at the recommended low concentrations (low nM range). The
specificity of dyes mirroring mtmP (DiOC6, TMRE) can easily be
verified by adding micromolar concentrations of the protonophore
Carbonyl cyanide 3-chloro phenyl hydrazine (CCCP), even in real
time (Fig. 85). By titrating CCCP, this assay can be used to test
the stability of mtmP of different cell types or under different
environmental or genetic conditions [654]. As mentioned above,
care has to be taken to gate on viable cells.
To validate the desired specificity andworking concentration of
DCFDA, positive controls and negative controls can be included.
For instance, we used ammonium peroxodisulfate (APS; 0.001-
0.1%), a radical starter, to assess the dynamic range of DCFDA.
DCFDA oxidation can vice versa be blocked by the addition of
vitamin C (mM Range) to the assay (Fig. 86). For further reading
on this issue we recommend Ref. [650].
Taken together, results obtained with the methods described
here can provide first indications of the very basal metabolic and
oxidative status of a given cell population. They may nevertheless
be helpful to decipher complexmechanisms, such as antibody class
switch recombination [647].
17.3 Sample preparation
The cell permeable functional dyes that can be used are detailed
in Table 24.
1. desired single cell preparation
2. staining medium (in the case of lymphocytes): OptiMEM with-
out any additives or glucose-free DMEM
3. flow cytometry buffer (2% FCS in PBS, 0.02% NaN3; for mea-
surement of mtmP, NaN3 should be omitted)
4. antibodies for staining of surface antigens for cellular subsets
17.4 Acquisition and analysis
17.4.1 MitoTracker, ROS and mtmP.
 Resuspend cells at 1–3 × 106/mL in 100–300 μL medium
without supplements (serum will cause unspecific MitoTracker
staining).
 Incubate for 30 min at 37°C, 5% CO2 with 100 nMMitoTracker
Green FM or 1–40 nM DiOC6 (titer down as far as possible) or
1 μM DCFDA.
 Wash cells once in the same medium.
 Stain for surface antigens with fluorescent antibodies in
medium for 20 min at 4°C in the dark.
 Wash cells with 500 μL flow cytometry buffer, resuspend in
250 μL of the same buffer and analyze by flow cytometry.
 To adjust the mitochondrial activity to the volume of the cells,
normalize data to the cubic value of FSC pulse width (that is,
[FSC pulse width]3) of the different samples. Important note:
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Figure 85. Analysis of the sensitivity of mtmP toward CCCP in real time. Splenic B cells of a C57Bl/6 mouse were left unstained or stained
with TMRE (tetramethylrhodamine). Live cells were analyzed by flow cytometry for 40 seconds, then medium or carbonyl cyanide 3-chloro
phenyl hydrazine (CCCP; 100 μM) were added and cells were analyzed for another 120 seconds. For comparison, TMRE-stained and CCCP-
treated apoptotic/necrotic cells are shown in the lower panel. Apoptotic/necrotic cells reveal a lower and irregular TMRE fluorescence and are not
responsive to CCCP treatment anymore, indicating a collapse of mtmP. MFI, mean fluorescence intensity. Data were acquired with a BD FACS
Calibur and analyzed by FlowJo software.
in certain cytometric softwares, recording FSC pulse width may
have to be activated before acquisition.
17.4.2 6-NBDG.
 Wash cells once and resuspend in glucose-free DMEM with 300
μM 6-NBDG for 30 min at 37°C, 7.5% CO2 (1–3 × 106/mL)
 Wash cells with 500 μL flow cytometry buffer, resuspend in
250 μL of the same buffer and analyze by flow cytometry
VIII. Cytometric phenotypes
1 Differentiation stages of T cells
1.1 Differentiation stages of human T-cell differentiation
The body is under constant threat of pathogen attack. Microbes
and viruses lurk in the environment and are evolutionary adapted
to seize every opportunity to invade the system. The network of
cells that make up the immune system works tightly together
to protect against foreign invaders. If pathogens manage to get
through the body’s physical barriers the first line of immuno-
logical defense is made up of innate immune cells. Innate cells
are rapidly activated by pathogen-associated molecules in a non-
antigen specific way. As a consequence, innate cells can react
equally well to a variety of pathogens. Simultaneously, innate cell
activation also paves the way for the second line of immunological
defense by presenting antigen processed peptides, which primes
the adaptive phase of the T-cell response. After priming in the
secondary organs, T cells migrate to the affected tissue where
they execute cytotoxicity and other effector functions. In addi-
tion, antigen-specific T-cell memory is formed. T-cell immunity is
complex and there are an increasing number of subsets defined
by differentiation stage, function and cellular location. In the last
decades flow cytometry proved itself to be the key technology to
study heterogeneity among human T-cell subsets. However, as the
Figure 86. Testing the specificity of DCFDA. Splenocytes of a C57Bl/6 mouse were stained with DCFDA (2′,7′-dichlorodihydrofluorescein diacetate).
0.01% ammonium peroxodisulfate (APS) or 0.01% APS together with 0.5 mM vitamin C were added or cells were left untreated. Viable cells
(lymphocyte gate, left) were analyzed in a BD Gallios flow cytometer. Data were analyzed with Kaluza software.
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Figure 87. Gating of CD4+ and CD8+ T cells in peripheral blood. Lymphocytes are identified on based of the forward (FSC) and side (SSC) scatter.
Single cells are discriminated from doublets by plotting the pulse width and height against each other for both the SSC and FSC. CD3+ T cells
are gated and excluded from apoptotic cells by viability dye. Including dead cells can result in large errors because of their property to bind
nonspecifically to antibody conjugates. Although not applied here, in the same channel other cell types may be excluded by using a DUMP
channel, meaning a channel that contains all cellular markers in one color that should be excluded e.g. antibodies against CD14 (monocytes),
CD19 and CD21 (B cells). Peripheral blood ratios of CD4+ and CD8+ T cells vary from donor to donor. A normal CD4:CD8 ratio is between 1 and 2.
Low frequencies of double negative CD3+CD4−CD8− cells are common and contain populations of NKT cells.
options for multi-color flow cytometry panel design emerged due
to technical innovation, this went hand-in-hand with the increas-
ing complexity to define T-cell subsets. As new T cell subsets are
defined at increasing rates, it is virtually impossible to be complete.
Hence in this section we will review the best-established cellular
markers that can be measured to shed light on these complexities.
1.1.1 A four-dimensional model to address CD8+ T-cell differenti-
ation stages. Conventional human T cells are a subpopulation
of lymphocytes that can be characterized by the expression of
a T-cell receptor (TCR), through which they can recognize pep-
tides presented in the context of HLA-molecules. The conventional
TCR is composed of a transmembrane alpha- and beta-chain het-
erodimer that is embedded in the cell membrane in combination
with the CD3 protein complex. In the thymus, T cells mature and
develop into two main cell lineages of CD4+ and CD8+ single pos-
itive T cells that are released as naive cells into the circulation
(Fig. 87). The lack of expression of any of these markers iden-
tifies a third lineage of T cells in the periphery. These so called
double-negative T cells (DN) are a legitimate component of the
immune system but remain poorly understood [655]. In response
to antigen exposure, naive T cells (TN) start to proliferate and
differentiate rapidly into large numbers of effector and memory
precursor T cells. Following pathogen clearance the majority of
effector cells die while the memory precursor cells develop into
long-lived memory T cells [656, 657]. Although the precise model
of T-cell differentiation has not been fully deciphered, twomodels,
progressive versus asymmetric differentiation, are currently dis-
cussed that explain how T cells diversify into effector and memory
subsets. Despite this discussion a consensus was reached about
markers that define na¨ıve and memory T-cell subsets [658].
Markers that can be used to phenotypically differentiate TN,
effector, and memory cells are two isoforms of the CD45 family.
While TN express the CD45RA molecule, both the central memory
(TCM) and the effector type RA- (TE RA-) cells preferentially express
CD45R0. Another marker that can be used to identify TN and a
fraction of memory cells is the L-selectin CD62L which guides T
cells to the lymph nodes. Expression of this marker can only be
honestly assessed using freshly isolated cells, as cryopreservation
results in a profound decrease of CD62L expression [659]. Several
markers are proposed in combination with CD45RA/R0 to pre-
cisely define phenotypically different T-cell subsets. Among these
markers is CD27, a member of the TNF receptor family which pro-
motes survival of T cells, CCR7, a chemokine receptor which medi-
ates LN homing, and the co-stimulatory molecule CD28, which is
required for T-cell activation and survival [660–663] (Fig. 88).
Monoclonal antibodies directed against these markers are widely
available and conjugated to plenty of different fluorescent dyes
which enables broad application in various multi-color phenotyp-
ing panels.
The four-dimensional model to address T-cell differentia-
tion stages starts with TN (CD27+CD28+CCR7+CD45RA+). After
priming TN differentiate through early-differentiated (CD27+
CD28+CCR7−CD45RA−), early like (CD27−CD28+CCR7−CD45
RA−) and intermediately differentiated (CD27+CD28−CCR7−
CD45RA−) T cells to give rise of TE RA+ (CD27−CD28−CCR7−
CD45RA+), TE RA- (CD27−CD28−CCR7−CD45RA−) and TCM
(CD27+CD28+CCR7+CD45RA−) cells. TE RA- are memory cells
that in contrast to TCM lack constitutive expression of CCR7. In
healthy individuals without any clinical signs of viral infection,
from now on referred to as steady state, na¨ıve and early differen-
tiated type form the most abundant circulating CD8+ T-cell sub-
sets. In humans that are chronically infected with Cytomegalovirus
(CMV) or HIV the effector type RA+ also contributes substantially
to the CD8+ T cell compartment composition. Similar phenotypic
heterogeneity exists in the CD4+ T cell compartment although
subdivisions of differentiation stage based on the expression of
CD28 and CCR7 are not generally recognized. However, although
effector type CD4+ T cells are virtually absent during steady state,
increasing evidence suggests that cytolytic CD4+ T cells play an
important role during infections and these cells are appreciated to
lack CD28 expression [664, 665].
1.1.2 The use of adhesion and chemokine receptor expression to
address CD4+ T-cell differentiation. To date, the most appreci-
ated model to define CD4+ T-cell differentiation stages relies on
the differential expression of adhesion and chemokine receptors
(Fig. 89A). Like CD8+ TN, CD4+ TN can be recognized by the
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Figure 88. A four-dimensional model to address T-cell differentiation stages. At least seven stages of T-cell differentiation can be distinguished
for peripheral blood derived CD8+ T cells by using the markers; CD45RA, CD27, CD28 and CCR7.
mutual expression of CD45RA and CD27 combined with a bright
CCR7 staining. Below we describe a model by which 8 different
antigen-experienced CD4+ T cell subsets can be distinguished.
Type 1 helper (TH1) cells are critical for cell-mediated immunity
as they produce vast amounts of the anti-viral IFN gamma (IFN-γ)
(Fig. 89B). TH1 cells can be identified by the expression of CXCR3
which guides these cells to the infected tissues. Other chemokine
receptors expressed by TH1 are CCR5 and CXCR6 [666]. While
TH1 cells are critical for cell-mediated immunity, CD4+ TH2 cells
are required to support activation of other leucocytes such as B
cells and are associated with the production of the cytokines IL-4,
IL-5, and IL-13 (Fig. 89B). TH2 cells are enriched in the CCR4
positive fraction and can be further distinguished by the vari-
able co-expression of other chemokine receptors including CCR3,
CCR6, CCR8 ad CCR10 [667]. Caution is required when using
CCR4 as expression is shared by TH17 and TH22 cells. Differentia-
tion of T cells into TH1 and TH2 subsets is controlled in a biphasic
model by the transcription factors T-bet and GATA binding pro-
tein 3 (GATA3) [668, 669]. T-bet has been shown to antagonize
GATA-3, the master regulator differentiation and maintenance of
TH2 cells [670]. In recent years, TH subsets have been identi-
fied that differ from the traditional TH1 and TH2 subsets by the
preferential production of IL-9 (TH9), IL-17 (TH17) and IL-22
(TH22) (Fig. 89B); multiple functions have been attributed to
the IFN regulatory factor 4 (IRF4) driven TH9 cells that express
CCR6, CXCR3 and CCR3 [671], and the pro-inflammatory TH17
cells play an important role in pathogen clearance of extracellular
pathogens at barrier sites. In humans TH17 cells can be identified
by the mutual expression of CCR6 and CD161 [672]. The TH17
lineage can be further devided into more or less cytotoxic sub-
sets based on the selective expression of CXCR3 (TH17/TH1) and
CCR4, respectively [673]. Several studies have demonstrated that
a fraction of TH17 can also secrete IFN-γ besides IL-17 [673–675]
(Fig. 89B). These cells are generally refered to as TH17/TH1 cells.
More recently a third subset of TH17 was characterized that har-
bored regulatory T cell features. These cells can be identified
by the production of IL-10, which is also produced by conven-
tional TREG cells (Fig. 89B) [676]. Differentiation of TH17 cells is
driven by the expression of RAR-related orphan receptor gamma
t (RORγt) which is controls IL-17 transcription [677]. In addi-
tion, the skin-homing TH22 cells appeared to be regulated by the
aryl hydrocarbon receptor (AHR) transcription factor and can be
identified by the mutual expression of CCR6, CCR4 and CCR10
[678, 679]. Finally, a decade ago a specific subset of TH cells was
C© 2017 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.eji-journal.eu
Eur. J. Immunol. 2017. 47: 1584–1797 Cytometric phenotypes 1731
Figure 89. Adhesion, chemokine and cytokine receptor expression identify up to eight functional subsets within the human CD4+ memory pool.
Peripheral blood derived CD4+ T cells can be divided between naı¨ve, cytotoxic and 8 different T-helper subsets based on the surface expression
of (A) CCR4, CCR6, CXCR3, CXCR5, CX3CR1, CD28 and CD161 and (B) production of IFN-γ, IL-4, IL-10, IL-17, IL-21 and IL-22. For detection cells were
stimulated with Ionomycin and PMA in the presence of BFA and MN.
discovered that resided in B-cell areas of follicular regions in sec-
ondary lymphoid tissues. Consequently, these cells were named
follicular helper cells TFH and are identified by the constitutive
expression of the chemokine receptor CXCR5. Since their discov-
ery multiple TFH have been characterized, both in tissue and cir-
culation that can be distinguished based on the expression of pro-
grammed cell death protein 1 (PD-1), CXCR3, CCR6 and the secre-
tion of IL-21 (Fig. 89B) [680]. TFH differentiation is orchestrated
by the transcription factor B-cell lymphoma 6 (BCL6) and regulates
the activation of B cells in germinal centers and are therefore cru-
cial for the induction of humoral immune responses [681]. Finally,
CD4+ T cells can also directly mediate viral clearance and suppress
tumor growth through cytotoxic function. Loaded with cytotoxic
molecules such as Granzyme B and perforin these cells can be
identified by the surface expression of the Fractalkine receptor
CX3CR1 and the lack of CD28 (Fig. 89A) [665].
1.1.3 T-cell differentiation during acute infection. In multiple
well established models of acute infection, expression of the
IL-7 receptor α-chain (CD127) is used to discriminate between the
short-lived effector cells (SLEC) and the memory-precursor effector
cells (MPEC) [682]. Although mice and human differ significantly
in life span and pathogen encounter, immune cell gene expression
demonstrated high similarities [683, 684]. In humans, the com-
bined use of these markers is less established and combinations
of different markers have been used to define T-cell differentia-
tion during acute infections. In combination with the cell-surface
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Figure 90. Effector CD8+ T-cell differentiation during acute infection using KLRG1 and CD127. In humans four different effector populations can
be identified during acute infection based on the expression of KLRG1, CD127, CD45RA, and CD27.
markers CD45RA and CD27, the human equivalent of MPEC cells
can be identified by an increased expression of CD127 that goes
hand-in-hand with a decreased expression of the killer cell lectin-
like receptor G1 (KLRG1) (Fig. 90). In addition, the human equiv-
alent of SLEC can be identified by the selective expression of
KLRG1. In contrast to the bi-phasic model in mice, the majority
of the human effector CD8+ T-cell compartment consists of dou-
ble positive effector cells (DPEC). In addition, low number of early
effector cells can be identified that lack both CD127 and KLRG1
expression. Although in mice and humans, phenotypically similar
effector T-cell populations can be identified during an acute infec-
tion, it remains to be elucidated to what degree these populations
are functionally comparable.
1.1.4 Transcriptional regulation of T-cell differentiation. The rela-
tionship between phenotype and function has been subject of
much investigation. Although the association between the above
mentioned surface markers and T-cell function are mostly well
established, ultimately not all phenotypically similar T cells share
the same cell fate and effector response. The emerging complex-
ity among T-cell subsets and their potential to elicit a plethora
of effector functions require a more thorough characterization of
each subset that would reflect its function. The actual regulator
of T-cell development and function is the circuitry of transcrip-
tion factor expression. Complex interactions of transcription fac-
tors drive expression of target genes that ultimately determine T-
cell functionality and many use opposing mechanisms to counter-
regulate each other [685]. Multi-color flow cytometry is the pre-
ferred method of choice to detect low frequent T-cell subsets with
differential transcription factor expression within heterogeneous
T-cell populations. As these factors bind to DNA they are concen-
trated in the nucleus. To allow antibodies to reach their nuclear
epitopes T cells need to be fixated and permeabilized. There is a
variety of commercial kits and procedures available to accommo-
date these stainings. Permeabilization may induce cell shrinkage
and loss of surface marker staining intensity and protocols should
therefore be validated and optimized. Generally the FSC and SSC
voltage are amplified for intracellular protein staining.
The CD8+ T-cell lineage is enriched for cytolytic cells (CTL)
that are very effective in direct lysis of infected target cells. Dur-
ing chronic infections CTL like cells can also be detected among
the CD4+ lineage. These cells can be recognized by the expres-
sion of Granzyme B (GZMB) and Perforin which are stored in
acidic lysosomes (Fig. 91A). Differentiation of CTL, but also TH1
differentiation was demonstrated to be regulated by expression
of the T-box transcription factor Tbx21 (T-bet) [686]. While
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Figure 91. T-cell subsets as identified by intracellular cytokine and transcription factor staining. Peripheral blood derived CD3+ T cells are divided
between CTL and TH cells. (A) CTL can be identified by the mutual expression of GZMB and Perforin. (B) CTL but also TH1 cells can be identified in
the CD8 and CD4 lineage by the expression of T-bet and further divided by the expression of Eomes. (C) Hobit expression strongly correlates with
T-bet expression in CD8+ T cells. (D) Treg cells can be identified among the CD25 positive CD4+ T cells by the expression of FoxP3 and Helios.
T-bet drives terminal differentiation of effector T cells, expression
of a second T-box transcription factor, Eomesodermin (Eomes),
enables TH1 cells to generate memory with a certain degree of
redundancy (Fig. 91B) [663, 687]. Recently, the zinc finger pro-
tein ZNF683 (Hobit) was identified as a transcriptional regulator
of CD8+ and CD4+ effector type T cells in humans [688] and the
lack of CD28 (Fig. 89A) [665]. Expression of Hobit strongly cor-
relates with T-bet and regulates production of IFN-γ (Fig. 91C).
To prevent immune-mediated pathology by ongoing effector func-
tion and unrestricted expansion of CTL and TH1 cells, the stim-
ulatory activities of these subsets are counterbalanced by natural
and induced Tregs. These suppressor cells are CD4+ T cells, exert
their modulatory function by direct interaction with target cells, by
the secretion of immunosuppressive cytokines such as TGFβ and
IL-10 and by increasing the consumption of IL-2. Two lineages of
Treg cells can be distinguished in humans. Both express the IL-2
receptor alpha chain (CD25) and the transcription factor forkhead
box 3 (FoxP3) and can be distinguished by the expression of the
transcription factor Helios [630, 689, 690] (Fig. 91D). Although in
mice the expression of Helios is used to identify natural and periph-
eral induced Treg cells, that developed in the thymus or periphery,
respectively [691], this model is controversial in humans.
1.1.5 T-cell differentiation and effector function. To define spe-
cific T-cell subsets on basis of cytokine production usually in vitro
stimulation is required. Since cytokines are not preformed, their
levels are typically low in resting cells. Accumulation of cytokines
within the ER is achieved by adding an inhibitor of protein trans-
port to stimulated cells. The two most frequently used inhibitors
are Monensin (MN) and Brefeldin A (BFA). The choice of protein
transport inhibitor is very important as they can have differential
effects on surface and intracellular protein expression after stim-
ulation. For example, BFA will help to maximize the capture of
TNF-α, IFN-γ and IL-17 but blocks the surface expression of the
T-cell activation marker CD69 (Fig. 92A). In addition, MN max-
imizes the detection of the T-cell degranulation marker CD107
(Fig. 92B). After polyclonal stimulation of T cells cytokines are
produced with different kinetics. For most cytokines a stimulation
and accumulation period of 4–6 h is optimal. However for several
cytokines such as IL-10 and IL-12 the production kinetics are rela-
tively slow and up to 24 h stimulation may be required for optimal
detection. As both MN and BFA are toxic, exposure of stimulated
cells should be limited. Consequently, for the longer stimulations
(>6 hours) MN and BFA may be added during the last 4–6 h. MN
was demonstrated to be less toxic and can be added for periods up
to 24 h. When there is no prior knowledge regarding the specific
cytokines that will be produced by the stimulated T cells, expres-
sion of activation induced markers can be considered. Both CD4+
and CD8+ T cells depict CD69 and HLA-DR expression as early as
4 h after stimulation. Other markers like the CD8+ biased 4-1BB
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Figure 92. Detection of cytokine production and degranulation after stimulation of T cells. Peripheral blood T cells were stimulated for 4 hours
with Ionomycin and PMA or medium control in the presence of BFA and MN. (A) Stimulated CD8+ and CD4+ T cells were stained for expression of
IFN-γ and IL-2. (B) TNF-α production was captured in combination with degranulation of stimulated CD8+ T cells as detected by capture of CD107.
(CD137) and the CD4+ T-cell biased CD40L (CD154) peak at 24
h after stimulation. One problem with defining T-cell phenotypes
after stimulation is the internalization of TCR and the CD4 and
CD8 coreceptors. This will result in a decreased staining intensity
for CD4, CD8 and especially CD3 which makes it more difficult
to define T cells. By either staining the cells before stimulation
or by intracellular staining of these markers, this problem can be
circumvented.
1.1.6 Protocol.
1. Freezing PBMC
1.1 Isolate PBMC from heparinized blood or buffy coat by
using ficoll or lymphoprep according to manufacturer’s
protocol.
1.2 Collect the PBMC in 50 mL tubes.
1.3 Add washing medium up to 50 mL and centrifuge for 10
min at 500 × g at RT.
1.4 Aspirate supernatant, resuspend pellet in 50 mL washing
medium and centrifuge for 10 min at 250 × g at RT.
1.5 Aspirate supernatant, resuspend pellet in 35 mL washing
medium and centrifuge for 10 min at 250 × g at RT.
1.6 Resuspend in 1–2 mL of thawing medium and put on ice.
1.7 Count cells and adjust concentration to 10—25 × 106
cells/mL.
1.8 Prepare a similar amount of freezing medium and put on
ice.
1.9 Make sure your cells, cryovials and freezing medium are
cold before freezing.
1.10 Add drop by drop, while gently shaking, 1 mL of freezing
medium for every mL of cell suspension.
1.11 Transfer 2 mL of the cell suspension to each vial.
1.12 Freeze the cryovials by using a Mr. Frosty (Nalgene), Cool-
Cell (Corning) or a freezing apparatus at −80°C for a
period of four to 24 h.
1.13 Store the vials until further use in liquid nitrogen.
2. Thawing PBMC
2.1 Thaw the vials by gently shaking in a 37°C water bath,
until little ice remains.
2.2 Transfer the contents of the vial to a 50 mL tube.
2.3 Add drop by drop, while gently shaking, 18 mL of cold
thawing medium.
2.4 Let the cell suspension rest for 20 min and centrifuge for
10 min at 500 × g.
2.5 Aspirate supernatant, resuspend pellet in 50 mL washing
medium and centrifuge for 10 min at 250 × g at 4°C.
2.6 Aspirate supernatant, resuspend pellet in desired volume
of flow cytometry buffer (for surface and intracellular stain-
ings) or culture medium (for stimulations) and count cells.
3. Surface staining
3.1 Transfer up to 2 × 106 PBMC to a 96-well round buttom
plate (Greiner BioOne).
3.2 Centrifuge the plate at 390 × g at 4°C for 3 min.
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3.3 Aspirate supernatant and resuspend cells by gently vortex-
ing the plate.
3.4 Add 30 μL flow cytometry buffer containing a pretitrated
appropriate amount of tetramer for each well (prepare 1×
extra).
3.5 Incubate for 30 min at 4°C, shaking, protected from light.
3.6 Meanwhile prepare surface staining (including the
live/dead exclusion dye) in a total volume of 30 μL flow
cytometry-buffer for each well (prepare 1× extra).
3.7 Add 30 μL surface staining mix, without washing the cells,
directly into the well and incubate for a further 30 min at
4°C, shaking, protected from light.
3.8 Add 150 μL flow cytometry buffer and centrifuge at 390 ×
g at 4°C for 3 min.
3.9 Resuspend cells by gently vortexing the plate.
3.10 Add 100 μL flow cytometry buffer, and analyze by flow
cytometry cell sorting in the desired format, or continue
with the intracellular staining protocol.
Note: Always use appropriately titrated antibodies and
tetramers, which is usually not the concentration sug-
gested by the supplier. The ins and outs of titrating
antibodies can be found in the publication of Lamore-
aux et al. [421].
4. Intracellular stainings of transcription factors and cytolytic
molecules
4.1 After surface staining add 200 μL Fixa-
tion/Permeabilization buffer.
4.2 Gently resuspend the cells by pipetting up and down three
times.
4.3 Incubate for 20 min at 4°C, shaking, protected from light.
4.4 Centrifuge for 5 min at 700 × g at 4°C.
4.5 Aspirate supernatant and resuspend cells in 200 μL flow
cytometry buffer and centrifuge for 5 min at 700 × g at
4°C.
4.6 Aspirate supernatant and resuspend cells by pipetting up
and down 3 times in 50 μL of the intracellular staining
mix prepared in Permeabilization Buffer.
4.7 Incubate 30 min at 4°C, shaking, protected from light.
4.8 Add 150 μL Permeabilization Buffer to each well and cen-
trifuge for 5 min at 700 × g at 4°C.
4.9 Aspirate supernatant and resuspend cells in 200 μL Per-
meabilization Buffer and centrifuge for 5 min at 700 × g at
4°C.
4.10 Aspirate supernatant and resuspend cells in 100 μL flow
cytometry buffer and analyze by flow cytometry cell sorting
in the desired format.
5. Cytokine staining
5.1 Transfer PBMC into suspension culture flasks (690 190,
Greiner) at 1 × 106 cells/mL in culture. medium (flask
standing upright, or 45° tilted depending on volume) and
rest them overnight in a 37°C 5% CO2 incubator.
5.2 Transfer cells to a 15 mL tube and centrifuge for 10 min
at 500 × g at RT.
5.3 Aspirate supernatant, resuspend cells and add 1 mL of
culture medium.
5.4 Count the cells and adjust concentration to 10–20 × 106
cells/mL.
5.5 Add 100 μL control mix to the correct wells of a non-
tissue culture treated 96-well round bottom plate (3788,
Corning).
5.6 Add 100 μL stimulation mix to the correct wells of the
96-well plate.
5.7 Then add 100 μL cell suspension.
5.8 Incubate for 4 h in a 37°C 5% CO2 incubator.
5.9 Put plate on ice for 15 min after incubation.
5.10 Centrifuge plate for 5 min at 700 × g at 4°C.
5.11 Aspirate supernatant, resuspend cells in 200 μL flow
cytometry buffer and centrifuge plate again for 5 min at
700 × g at 4°C.
5.12 Aspirate supernatant, resuspend cells in 50 μL flow cytom-
etry buffer containing a pretitrated appropriate amount of
surface staining mix.
5.13 Incubate for 30 min at 4°C, shaking, protected from light.
5.14 Add 150 μL flow cytometry buffer and centrifuge at 700 ×
g at 4°C for 3 min.
5.15 Aspirate supernatant and add 100 uL of Cytofix/Cytoperm
reagent (554722, BD Biosciences) to each well and resus-
pend by pipetting 3 times up and down.
5.16 Incubate for 20 min at RT protected from light.
5.17 Add 100 μL flow cytometry buffer and centrifuge at 700 ×
g at 4°C for 3 min.
5.18 Aspirate supernatant and add 50 μL intracellular staining
mix prepared in 1× perm/wash and resuspend by pipetting
3 times up and down.
5.19 Incubate for 30 min at 4°C, shaking, protected from light.
5.20 Add 150 μL 1× perm/wash to each well and centrifuge for
5 min at 700 × g at 4°C.
5.21 Aspirate supernatant, add 200 μL 1× perm/wash to each
well and centrifuge for 5 min at 700 × g at 4°C.
5.22 Aspirate supernatant and resuspend cells in 100 μL flow
cytometry buffer and analyze by flow cytometry cell sorting
in the desired format.
Note: protocol adapted from Lamoreaux et al. [421].
6. Monoclonal antibodies
6.1 Surface staining:
BD Biosciences: CD4 BUV 395 (SK3), CD45RA BV421 (HI100),
CCR7 BUV395 (150503), CD45RA BV650 (HI100), CXCR5
Alexa Fluor R© 488 (clone RF8B2), CD25 APC (clone 2A3)
CD161 FITC (DX12).
eBioscience: CD3 PE (UCHT1), KLRG1 AF488 (clone 13F12F2),
CD4 PerCP-eFluor 710 (clone SK3), CD127 PE-Cy7 (clone
eBioRDR5), CD27 APC-eFluor 780 (clone O323), CD107a
FITC (clone H4A3)
Biolegend: CD27 APC-Fire 750 (O323), CCR6 Alexa Fluor R© 647
(clone G034E3), CCR7 BV421 (clone G043H7), CX3CR1
FITC (clone 2A9-1), CCR4 BV421 (L291H4), CD28 Alexa
Fluor 700 (CD28.2), CD127 BV650 (A019D5).
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R&D Systems: CXCR3 PE (clone 49801)
Sanquin: CD28 FITC (15E8)
6.2 Live/dead exclusion dyes: Live/dead fixable dyes (Ther-
mofisher) or Fixable viability dye (eBioscience); we here
use Fixable viability dye eFluor 506 (eBioscience).
6.3 Intracellular stainings:
BD Biosciences: IL-4 PE (3010.211), IFNγ BUV395 (B27),
granzyme B Alexa Fluor R© 700 (clone GB11), IL-2 PE (clone
5344.111), IL-10 BV650 (JES3-9D7), TNF-α Alexa Fluor R©
700 (clone MAb11), Perforin BV421 (clone B-D48), Hobit
(clone 5A);
eBioscience: IL-21 eFluor 660 (eBio3A3-N2), Eomes PerCP-
eFluor 710 (WD1928), Helios PE-Cy7 (22F6), IFN-γ APC-
eFluor 780 (clone 4S.B3), FoxP3 PE (clone PCH101), T-bet
PE-Cy7 (clone 4B10)
Biolegend: IL-17A BV421 (BL168), IL22 PE (BG/IL22), Anti-
IgM PE (clone ma-69)
7 Flow cytometer
7.1 All experiments were performed on a LSR Fortessa
flow cytometer with a 365 nm, 405 nm, 488 nm,
561 nm and 640 nm configuration (BD Bioscience).
Filters: 379/34(365) for BUV395; 530/30(488) for
FITC or AF488; 665LP(488) for PerCP-eFluor 710;
450/50(405) for BV421; 525/50(405) for BV510, V500
and Fixable viability dye eFluor 506; 660/20(405)
for BV650; 710/40(405) for BV711; 800/50(405) for
BV785; 585/15(561) for PE; 780/60(561) for PE-Cy7;
675/20(640) for APC or AF647; 730/45(640) for AF700;
780/60(640) for APC-eF780 and APC-FIRE 750.
8 Media and buffers:
Thawing medium:
IMDM
20% (v/v) FCS
0.00036% (v/v) 2-ME
Freezing medium (after addition of DMSO use within 1 h):
IMDM
20% (v/v) FCS
20% (v/v) DMSO
0.00036% (v/v) 2-ME
Washing medium:
HBSS
5% (v/v) FCS
10% (v/v) TRIS-HCL pH 7.0 (as extra buffering)
Culture medium:
RPMI
10% (v/v) FCS
Flow cytometry buffer:
Phosphate buffered saline (PBS)
0.5% (w/v) BSA
0.01% (w/v) sodium azide
2mM EDTA pH 8.0 (to prevent clots)
Fixation/Permeabilization buffer (FOX-P3 kit eBioscience)
75% Fixation/Permeabilization Diluent (cat. 00-5223)
25% Fixation/Permeabilization Concentrate (cat. 00-5123)
Permeabilization Buffer (FOX-P3 kit eBioscience)
90% Fixation/Permeabilization Diluent (cat. 00-5223)
10% Permeabilization Buffer (10×) (cat. 00-8333)
Stimulation mix:
Culture medium
2 μg/mL Ionomycin
20 ng/mL PMA
20 μg/mL BFA
2.8 μLl/mL GolgiStop (BD Bioscience)
Controlmix:
Culture medium
20 μg/mL BFA
2.8 μL/mL GolgiStop (BD Bioscience)
1× perm/wash:
10% 10×perm/wash (554723 BD Biosciences)
90% ddH2O
1.2 Differentiation stages of murine T-cell differentiation
Flow cytometry and cell sorting have been instrumental to unravel
the basic principles of T-cell differentiation. The combined results
of analyzing human samples and experimental animal models has
given us great insights about thymic selection of T cells, induction
of T-cell responses and the generation of long lived T-cell memory.
Although for the most part the same mechanisms apply to the
differentiation of T cells in humans andmice as the primary animal
model in T-cell biology, there are also fundamental differences
in the way T cells are analyzed. In this section, we will provide
guidelines for the analysis of murine T-cell differentiation and
highlight differences in terminology and analysis of human and
murine T cells.
1.2.1 T cells: Of mice and men. In our environment we encounter
different microorganisms, pathogens and foreign substances every
day. These agents trigger and shape our immune system constantly
during our life. This includes an enormous range of potential
antigen exposure including non-persistent and persistent latent
viruses, bacteria, vaccinations, neoplastically transformed cells, as
well as the flora of our individual microbiota. The current life
expectancy of 70+ years in the western world leaves a lot of time
to perturb the immune system from its original na¨ıve state. In
contrast, most lab mice are used 8–12 weeks after birth and are
bred and maintained in clean areas under specific pathogen free
conditions (SPF) with minimal exposure to foreign materials. Con-
sequently the phenotype of CD8 T cells of SPF mice is more similar
to CD8 T cells found in neonatal humans [692].
These disparities lead to a different starting point of analysis.
Mice at steady state without experimental induction of immune
responses contain a largely na¨ıve immune system without current
infections, whereas even in healthy adult humans we find an expe-
rienced immune system under constant attack. However, the use
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of lab animals enables us to selectively induce disease states and
study the T-cell response at defined synchronized time points. To a
limited degree this is also possible in human clinical studies that,
e.g., monitor the immune response following vaccination [693,
694] or primary infection after organ transplantation [695]. This
longitudinal view on T-cell responses is generally more common
in murine T-cell biology and has formed definitions of terminology
that are distinct from the ones used in human T-cell biology.
1.2.2 Flow cytometric analysis of T-cell differentiation in mice. T-
cell precursors differentiate in the thymus into mature na¨ıve CD4+
or CD8+ T cells depending on the affinity of their T-cell receptor
(TCR) for MHCI or MHCII presented peptides. In flow cytometry
mature CD4+ and CD8+ T cells can be identified by gating on
lymphocytes according to scatter, exclusion of doublets and dead
cells and gating on CD3+ cells and CD4 or CD8 single positive cells
(Fig. 93). Mature na¨ıve T cells are defined by the high expres-
sion of CD62L, which enables migration to secondary lymphoid
organs, and low expression of CD44. After infection or immu-
nization an immune response is induced and na¨ıve T cells are
primed. During this first phase of activation after antigen exposure
na¨ıve T cells proliferate, differentiate into effector cells specialized
for the type of pathogen encountered and acquire higher expres-
sion of CD44 and lose CD62L expression. CD127 and KLRG1 are
classical markers to distinguish between short-lived effector cells
(SLEC, CD127−KLRG1+) and T cells with higher memory poten-
tial (MPEC, CD127+KLRG1−) during the effector phase of CD8+
T cells. After the peak of infection (7–14 days), the T-cell response
contracts and T-cell memory begins to be formed. Within the
CD44 high memory T cells, CD62L distinguishes between CD62L+
central memory (CM) and CD62L−effector memory (EM) cells
(Fig. 94). These memory subsets are maintained in lymphoid and
peripheral tissues and provide protection in case of rechallenge
with the same pathogen. In contrast to human T cells, where next
to CM and EMT cells long lived quiescent effector cells or CD45RA-
expressing effector memory cells can be found during steady state,
in mice a temporal definition of T-cell differentiation state is used.
In this case, effector T cells are present during early infection to
ensure pathogen clearance and then following successful resolu-
tion of the immune response, antigen specific memory T cells are
generated and maintained.
Several methods are used to analyze and follow T-cell immune
responses in mice. Antigen specific cells can be detected by MHC
tetramers/multimers, analysis of dividing cells using BrdU or
the proliferation-associated marker Ki67, functional assays like
cytokine/activation marker expression ex-vivo or after restimula-
tion as well as using transfer of TCR transgenic T cells. Moreover,
animal studies allow for directed breeding and genetic manip-
ulation, which can introduce features such as congenic markers
and reporter genes that find broad application in flow cytomet-
ric analysis of murine T cells. For example, allelic variations of
the cell surface molecules CD90 (Thy-1) and CD45 (Ly-5), which
can be distinguished with selective antibodies, are used to track
adoptively transferred T cells in recipients. Additionally fluores-
cent molecules such as GFP are not only used to follow transferred
cells but also as reporters for deletion or expression of genes in
genetically modified mice.
1.2.3 T cell in tissues. The location plays a big role for the main-
tenance and functional capacity of T cells. Analysis of human T
cells is largely confined to blood, whereas in murine experimen-
tal models lymphoid organs like the spleen are generally used
for the investigation of T cells differentiation. Also other tissues
like skin, intestine and bone marrow are more easily available in
mice and accordingly they are a more frequently used subject of
investigation.
Next to the circulating T cells, which form the majority of
T cells in lymphoid organs like the spleen, lymphoid organs as
well as peripheral tissues like the bone marrow, lung and intes-
tine contain tissue resident memory T cells (Trm). Trm are non-
circulating T cells that form a first line of defence at barrier tissues
and a privileged reservoir of memory T cells in the bone mar-
row. CD69 expression is maintained by Trm in the absence of
antigen, is functionally important for the residency of Trm and
consequently a commonly used marker for Trm. Trm in epithelial
and neuronal tissues might also express CD103, the α-chain of the
αEβ7 integrin, and CD49a, the α-chain of the α1β1 integrin (VLA-
1) [696]. CD103 is also expressed by a subset of na¨ıve T cells,
which makes the usage of CD44 or CD62L essential to discrimi-
nate Trm and na¨ıve T cells. Furthermore, it cannot be excluded
that Trm that lack expression of CD69 or CD103 exist. Addition-
ally, in vivo labeling provides information about the location of
T cells. Intravenous injection of antibodies directed against CD4,
CD8 or pan-T-cell markers such as CD90 and CD45, can be used to
distinguish between the labeled cells in circulation and unlabeled
T cells in tissues [697].
1.2.4 Analyzing T-cell subsets by flow cytometry. During the
defence against pathogens, an immune response is elicited, result-
ing in expansion of pathogen-specific T cells that are equipped
with a specialized set of effector functions, transcription factors,
cytokine- and chemokine receptors. CD4 T cells can be divided
into multiple lineages including Th1, Th2, Th9, Th17, Th22, Treg
and Tfh cells. Recent results suggest that the generated specialized
CD4 T subsets are not separate lineages but a continuum of mixed
functional capacities [698]. Also for CD8 T cells Tc1, Tc2, Tc9
and Tc17 cells are described [699]. However, as Tc1 cells are the
primarily generated CD8 T-cell type in most used murine infection
models, it is more common to distinguish between CM, EM and
Trm CD8 T cells. Here, we will describe how to use flow cytometry
to distinguish CD4 and CD8 T-cell subsets based on transcription
factors, chemokine receptors and effector molecules.
1.2.5 T-cell subsets in flow cytometry: Transcription factors. Each
CD4 T-cell subset expresses its own master transcription factor,
which controls the expression of downstream effector molecules
that are essential for their function. The first Th subsets described
were Th1 and Th2 cells [700]. Th1 cells are vital in the defence
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Figure 93. Gating on CD4 and CD8 T cells. Lymphocytes are identified based on their forward (FSC) and side (SSC) scatter. Single cells are
discriminated from doublets by plotting the pulse width and height against each other for the FSC. In order to exclude non-specific binding of
antibodies by dead cells, non-viable cells are excluded using a viability dye and live CD3+ stained cells are gated on. The majority of CD3+ T cells
should either be CD4 or CD8 single positive, however, depending on the organ analysed, there may be either double positive or double negative
cells.
against viral infections, while Th2 cells protect against parasitic
infections, but also mediate much of the pathology associated
with allergic reactions. Th1 cells are primed via the cytokines
IL-12 [701] and IFN-γ [702], resulting in expression of their mas-
ter transcription factor T-bet [703]. Th2 cells, primed by IL-4
[704, 705], are regulated by the master transcription factor GATA-
3 [668]. Th17 cells are a more recently described subset of Th
cells. They were originally described in mice as being pathogenic
in murine models of autoimmune disease [706, 707], but they
have also been shown to be protective against certain pathogens
Figure 94. Discriminating naive, effector and memory T cells. Naive T cells can be distinguished from activated and memory T cells based on
their low expression of CD44 and high expression of CD62L. In this example, live CD8+CD3+ T cells have been gated on and antigen specific T cells
can be further distinguished from endogenous T cells using tetramer staining. The majority of CD8 T cells during the effector phase of an immune
response typically upregulate CD44 and downregulate CD62L. In the memory phase of an immune response, T cells retain high expression of CD44
and can be either CD62L positive or negative.
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Figure 95. Using transcription factors or chemokine receptors to identify CD4 subsets. Subsets of CD4 T cells can be identified based on their
expression ofmaster transcription factors. Surfacemarkers such as CD4, CD3 and viability dyes are typically stained on the surface before washing,
fixing and permeabilizing the cells to allow the transcription factor antibodies to bind in the nucleus. Th1 cells are identified by expression of
T-bet, Th17 cells by RORgt, Treg cells by FoxP3 and Tfh cells by Bcl6 expression. Chemokine receptor staining can also be used to distinguish CD4
Th subsets. Examples shown include Th1 cells which express the chemokine receptor CXCR3 and Tfh cells which express CXCR5.
including fungal infections [708]. Their master transcription fac-
tor is RORγt [677], and the subset was named Th17 due to
expression of the inflammatory cytokine IL-17 [709]. Th9 and
Th22 cells are relatively newly described subsets of CD4 Th cells
which produce IL-9 or IL-22, respectively. Th22 cells are regu-
lated by expression of the transcription factor Ahr [710], while
Th9 cells do not appear to be regulated by an individual transcrip-
tion factor, but rather a combination of factors such as IRF4 and
PU.1 [710, 711]. Follicular T helper cells (Tfh) and their cross-talk
with B cells stimulate the production of high affinity antibodies in
germinal center reactions. Tfh cells are controlled by the tran-
scription factor Bcl6 [712] and express surface markers such as
ICOS to interact with B cells. Finally, a regulatory subset of Th
cells exists which is necessary to keep inflammatory processes in
check. These cells are known as regulatory T cells (Treg) and are
regulated by their transcription factor FoxP3 and expression the
IL-2Ra chain, CD25, which is normally upregulated on T cells after
activation [630, 689].
The majority of antigen experienced CD8 T cells in experimen-
tal murine models are of Tc1 type. The effector/ memory differ-
entiation of CD8 T cells is coordinated by a network of transcrip-
tion factors and favour either effector differentiation (Tbet, ID2,
BLIMP1) or memory differentiation (EOMES, BCL-6, ID3) [685].
Additionally, Blimp and Hobit (homolog of Blimp1 in T cells)
mediate the development of Trm [713].
Staining of transcription factors for flow cytometry has been
made possible through the production of staining buffers which
efficiently permeabilize the nucleus of cells (Fig. 95). The fix-
ation and permeabilization prevents further functional assays.
Functional assays based on transcription factor expression have
become available through the development of transgenic fluores-
cent reporter mice.
1.2.6 T-cell subsets in flow cytometry: Effector function and expres-
sion of chemokine receptors. During their primary activation, T
cells start to express chemokine receptors, surface molecules and
secrete cytokines that are necessary for their effector function
(Figs. 95 and 96).
CD4 T cells characteristically express the co-stimulatory
molecule CD40L after activation [429], which is crucial for most
of their helper functions [714, 715]. The classical effector cytokine
produced by Th1 cells is IFN-γ [700], which is vital in the defence
against viral and intracellular bacterial pathogens. Th1 cells also
express key effector molecules which are directly downstream of
T-bet expression, such as the chemokine receptor CXCR3 [716]
(Fig. 95) which is thought to help to guide these cells into inflamed
tissues, where they fight against infection. Th2 cells produce IL-4,
IL-5 and IL-13 and express the chemokine receptor CCR4, which
helps them to migrate out of the blood and into tissues such
as the skin to mediate their actions [717]. Th17 cells, as their
name suggests, produce IL-17 and express the chemokine recep-
tor CCR6 [718]. While these cells can be pathogenic when acti-
vated against self-antigens, they also provide protection against
fungal infections. In addition to the cell contact mediated actions
of Tfh, these cells also produce cytokines including IL-21 to help
mediate B-cell activation in germinal centre immune responses.
Moreover, the expression of the chemokine receptor CXCR5 is
vital in the positioning of Tfh out of the T-cell zone and into B-cell
follicles which allows their interaction with activated B cells [719]
(Fig. 95).
Antigen experienced CD8 T cells largely have the capacity to
produce IFN-γ and/or TNF-α and in this respect mainly overlap
with Th1 cells. Next to the direct effect of these cytokines on the
target cells, they also support the recruitment of other immune
cells. A subset of CD8 T cells is able to perform CD40L-mediated
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Figure 96. Effector molecules produced by T cells. T-
cell subsets produce cytokines according to the subset
to which they have been polarized toward. To ana-
lyze production of cytokines in vitro, cells are restim-
ulatedwith either antigen orwith PMAand ionomycin,
together with brefeldin A. Th1 cells produce IFN-γ, Th2
cells produce IL-4 and Th17 cells produce IL-17. Anti-
gen specific CD8 T cells at the effector and memory
phase after infection can also be identified based on
their cytokine expression, in these examples, IFN-γ,
TNF-α, IL-2 and CD107a are used.
helper like functions [720], however the development of cytotoxic
functions and the directed killing of infected or malignant cells is
the main effector function of the majority of activated CD8 T
cells. The cytotoxic function of CD8 T cells is typically achieved
via the release of cytotoxic granules containing Granzymes and
Perforin, or via expression of FasL, which can induce apoptosis of
Fas expressing cells.
The production of these effector molecules by T cells can be
analyzed in a number of ways. Generally, T cells are stimulated
in vitro by polyclonal (PMA/Iono, aCD3) or antigen specific stim-
ulation (pathogen lysates, proteins, peptides). Cells are treated
with protein transport inhibitors such as brefeldin A or mon-
ensin during the stimulation period to allow accumulation of
cytokines and surface molecules like CD40L within the cell. As
these inhibitors are toxic, it is important to limit the time of cell
exposure. Typically, 4–6 h are used. For CD8 T cells, degranula-
tion is an important effector function. When cytotoxic granules
are released toward the target cell surface, lysosomal markers like
CD107a/b become detectable at the cell surface. As extracellular
expression of CD107a/b is transient during degranulation due to
recycling of the granules, staining for CD107a has to be performed
during T-cell stimulation. T cells also contain pre-stored effector
proteins, such as the cytotoxic molecules Granzymes and Perforin
that are produced by effector CD8 T cells and can be detected by
intracellular staining without the need for stimulation. Addition-
ally, in vitro or in vivo killing assays with fluorescently labelled and
peptide loaded target cells are used to assess the antigen specific
CD8 T-cell response and their cytotoxic potential.
The detection of effector functions by flow cytometry can be
used to gain information about the properties of specific T-cell
subsets, but it is also utilized to enumerate antigen-specific T-cell
responses. For this purpose, effector functions that are present in
the majority of the T cells after antigen-specific activation with
protein or peptides are used, such as CD40L expression for CD4 T
cells and IFN-γ expression or degranulation via CD107a for CD8
T cells in infections.
1.2.7 Conclusions. Although mice might not represent humans
on all levels, the use of inbred mice with predefined HLA
molecules, experimental immunization/infection with defined
antigens, the possibility for genetic, in vitro and in vivo manipula-
tion of cells and the easier access to tissues other than peripheral
blood enables us to answer many T-cell biological questions. Mice
with defined microbiota or mice exposed to a broader range of
natural pathogens might complement the knowledge build on SPF
mice. Due to the vast amount of cell biological and flow cytometri-
cal tools for the analysis of T-cell responses, the analysis of experi-
mental murine models will continue to be instrumental to unravel
basic principles and functional mechanisms of T-cell biology.
2 B cells and their subsets
B cells represent the antibody-producing cells developing from
na¨ıve B cells to antibody-secreting plasma cells. The stages of B-
cell development share a lot of common features between the
human and rodent immune system. In this section, we focus on
human B cells and their peripheral subpopulations in particular.
After PBMC preparation or lysing whole blood, lymphocytes
should be gated according to their scatter properties and by exclu-
sion of doublets and dead cells from the analysis (Fig. 97A, B). In
order to detect plasma cells simultaneously, the initial FSC/SSC
gating should be larger and not limited to a conventional lympho-
cyte gate [721].
To identify B cells among the remaining cells, the B-cell spe-
cific markers CD19 and/or CD20 serve as specific surface markers
(Fig. 97). CD19 is a B-cell surface molecule expressed at the time
of immunoglobulin heavy chain rearrangement [722], CD20 is
expressed by all mature B cells beyond the pro B-cell stage in the
bone marrow and disappears on the surface of mature plasma cells
[723, 724]. For further discrimination of developmental stages
in B-cell maturation, combinations of additional markers such as
CD27, CD38, CD23, CD77 and expression of surface immunoglob-
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Figure 97. Gating strategy for the identification of B cells. (A) Lymphocytes are identified by their scatter properties. (B) Exclusion of doublets. (C)
Cells positive for markers in the “dump” channel, and DAPI stained dead cells are excluded. (D) B cells are identified by their expression of CD19
and CD20 including CD20low plasmablasts. (E) B-cell subsets are discriminated by CD27 and CD20: naive B cells are CD27− CD20+; memory B cells
CD27+ CD20+ and plasmablasts CD27++ and CD20low.
ulins are used (Table 25). Immature CD19+ B cells in the bone
marrow express high levels of CD38 and variable levels of CD20
and IgM, which increase with their further differentiation [725].
CD38++ CD20++ immature B cells express IgM and IgD, leave the
bone marrow and become CD38++ CD24++ CD10+ transitional
B cells [725]. Na¨ıve B cells express IgM and IgD and are CD27−
and CD38−; they comprise about 60% of B cells in the peripheral
blood [726, 727]. After antigen encounter and T-cell help, mem-
ory B cells and antibody-secreting plasma cells are generated in the
germinal center reaction. Human memory B cells can be identified
Table 25. Phenotypic differentiation of B-lineage cell subsets based on their characteristic expression of surface markersa)
B cell population (CD19+) Phenotype/subphenotype
Transitional
T1+T2 CD24++CD38++CD10+CD27−IgM++
Naı¨ve
Resting CD24+/−CD38+/−CD27−IgM++/+IgD++CD21+CD95−
Activated CD24−CD38−CD27−IgM++IgD++CD21−CD9+MTG+
Memory (Ki-67-)
Pre-switched IgM+IgD+/−CD27+CD1c+
Switched IgG/IgA+CD27+CD21+
Atypical memory i) double negative IgD−CD27−
ii) activated double negative IgD−CD27−CD95+
iii) Syk++ IgD+/−CD27−CD95+/−CD21+/−CD38−MTO-Syk++
iv) tissue-resident IgM/IgG/IgA+CD27−FcRL4+
Marginal zone
Spleen IgD+IgM+CD27++CD21++CD1c+
Circulating IgD+IgM+CD27+CD1c+
Antibody secreting cells
Circulating plasmablasts CD38++CD27++CD138−Ki-67+
Plasma cells CD38++CD27++CD138−Ki-67+
Bone marrow i) CD19+ plasma cells CD19+CD38++CD27++CD138+Ki-67−
ii) CD19− plasma cells CD19−CD38++CD27++CD138+Ki-67−
a)Intracellular expression of the spleen tyrosine kinase Syk represents an intracellularly expressed protein, while the expression of the ABCB1
transporter is required to excrete mito tracker orange (MTO) which serves a functional discrimination of naı¨ve and memory subsets.
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Figure 98. B-cell subsets. (A) Further B-cell subsets
can be discriminated by the expression of IgD together
with CD27. IgD+ CD27− cells are the naive B cells (Q3).
The CD27-expressing subsets are different types of
memory B cells: the IgD+ CD27+ cells are non-switched
memory B cells (Q2) and the IgD– CD27+ cells are
switched memory B cells (Q1). The double-negative
(IgD– CD27– B cells is heterogeneous and also contains
memory B cells. (B) CD95 expression in B cells of a
healthy donor. Quadrant Q6 shows activated CD27+
CD95+ memory B cells and Q7 activated CD27– CD95+
naive B cells.
by the expression of CD27 andmutated immunoglobulin VDJ gene
rearrangements [726, 728]. In the peripheral blood, between 30
and 40 % of circulating B cells express CD27 [726, 729]. Plasma
cells carry distinct FSC and SSC characteristics, express high lev-
els of CD27 and lack the expression of CD20 but are also highly
positive for CD38 and partially CD138++ [721]. A CD19− plasma
cell population is uniquely enriched in the bone marrow [730].
When gating on B cells using CD19, CD3+ T cells and
CD14+ monocytes need to be excluded. If these cells are not of
further interest, one can assign them in a so called “dump chan-
nel” with CD3 and CD14 mAbs together with other markers for
cells that should be excluded from subsequent analyses, e.g. CD16
mAb/CD56 mAb for NK cells. One approach frequently taken is
to gate on CD3− CD14− 4′,6-Diamidino-2-Phenylindole (DAPI)−
cells (Fig. 97C) and, in a subsequent step, on CD19+ and CD20+/−
cells (Fig. 97D). This gating permits a reliable identification of
CD20+ B cells and additionally of CD20low plasmablasts.
For the analysis of B-cell subsets, a classical combination using
CD27 and CD20 of CD19+ B cells has been established. Using
CD27, a number of B-cell subsets can be identified independent
of the expressed Ig subclasses. As a result, CD27− CD20+ na¨ıve B
cells, CD27+ CD20+ memory B cells (mBCs) and CD27++ CD20low
plasmablasts can be identified (Fig. 97E). While the distribution
of these subsets can vary between different diseases with slight
variations [731], it has been demonstrated that CD27 can serve
as a reliable marker for human healthy controls memory B cells,
since CD27-expressing B cells differentiate timely into antibody-
secreting cells after stimulation and carry somatic mutations in
their immunoglobulin V regions [726, 728].
An alternative staining protocol of CD20+/CD19+ B cells has
applied co-staining of CD38 and IgD together with CD77 and CD23
to mark differentiation stages of B cells in human tonsils [732].
CD23 is an Fcε receptor and associated with activation of B cells. It
was found to be co-expressed with IgM and IgD in the tonsil and in
peripheral blood but not with IgA and IgG and hence is lost during
isotype class-switching [733]. CD77 is strongly expressed by ger-
minal center B cells and can be used to differentiate centroblasts
from centrocytes [732, 734]. In this protocol, naive IgD+ CD38− B
cells are separated by CD23 into Bm1 (CD23−) and Bm2 (CD23+)
B cells. IgD− CD38+ germinal center B cells can be further dis-
criminated into CD77+ centroblasts (Bm3) and CD77− centrocytes
(Bm4). IgD− CD38− B cells comprise the memory compartment
(Bm5).
The expression of IgD could be used as marker to further dis-
criminate certain na¨ıve and memory B-cell populations (Fig. 98).
CD19+ CD20+ B cells can be separated in a CD27 versus IgD dot
plot (Fig. 98A). In this regard, na¨ıve B cells express IgD and are
CD27−. Further quadrants represent different subsets of memory
B cells: in detail, CD27+ IgD+ are memory B cells which mostly
express high levels of IgM and carry somatic mutations of their
V(D)J rearrangements, whereas CD27+ IgD− memory B cells are
class-switched and also carry somatic mutations [726]. Interest-
ingly, the CD27− IgD− B-cell subset appears to be very heteroge-
neous. It has been shown that it contains a memory B-cell subset
expressing CD95 with an activated phenotype (Fig. 98B), which is
especially enhanced in patients with systemic lupus erythematosus
(SLE) and correlated with disease activity and serologic abnor-
malities, whereas healthy donors only show minor frequencies
of CD95+ cells [735]. Among other disturbances, B cells lacking
expression of the complement receptor CD21, which is part of a
signaling complex, together with CD19 have been reported to be
expanded in patients with SLE [736, 737].
3 Antibody-secreting cells (plasmablasts and plasma
cells)
Antibody-secreting cells (ASCs) in humans and rodents are
terminally differentiated B cells [738] and can be characterized
by the intracellular staining of immunoglobulins (Igs). After
the fixation of cells to permeabilize the cell membrane, ASCs
can be further analyzed according to their isotype [721, 739]
or the antigen-specificity of the antibody they generate and
secrete [740, 744]. The intracellular staining of Igs is considered
as gold standard for the detection of ASCs. The intracellular
immunoglobulin staining is incompatible with cell viability. In
mice, this limitation can be circumvented by using a Blimp1:GFP
(green fluorescent protein) reporter mouse [741]. Surface
markers can be used in mice without the Blimp1 reporter allele.
No surface marker uniquely specific for ASCs currently exists.
Surface markers that are often used to identify ASCs, such as
CD38 and CD138, are also expressed on other B-cell lineage and
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Figure 99. Flow cytometric analysis of
murine ASC derived from spleen and bone
marrow. (A) ASCs were detected by surface
staining of CD138 and intracellular stain-
ing of kappa. ASCs were further character-
ized by surface expression of MHC class II
and intranuclear BrdU, which was incor-
porated into the DNA of proliferating cells
after administration via the drinking water.
Non-proliferating BrdU low ASCs express
less MHC class II, which characterizes long-
lived plasma cells while proliferating BrdU
high and MHC class II high cells indicate
newly generated plasmablasts (PBs). The
intracellular staining of IgG and IgM allows
the differentiation of ASC with regard to
the antibody isotype that they generate.
The cells were derived from a NZB/W F1
mouse that represents a model of lupus. (B)
Identification of ASCs in an antigen-specific
manner in Balb/c mice three days after
a booster immunization with ovalbumin
(OVA). Anti-OVA ASCs were enumerated by
intracellular staining with OVA conjugated
with FITC. Almost all splenic anti-OVA
are BrdU positive proliferating plasmablasts
(PBs) three days after secondary immuniza-
tion with OVA. The majority of bone mar-
row ASCs including those with intracellular
OVA staining do not express BrdU charac-
terizing them as long-lived plasma cells.
non-B-cell lineage cells. In mice, CD138 staining is frequently
used for analyzing splenic ASCs, while intracellular Ig staining
is required for the detection of bone marrow ASCs since other
B-cell subpopulations express CD138. In addition to the isotype
that ASCs secrete the antibody reactivity of the cells can be
detected by staining with the labeled antigen (Fig. 99). Combined
staining of surface markers can lead to a better identification of
splenic and bone marrow ASCs in mice such as CD138, TACI,
B220 and CD19 [742] or CD138 and Sca-1 [743]. In humans,
circulating ASCs can be analyzed as CD20-/CD19+/CD27bright
cells (Fig. 100) [721] or CD19+/CD27bright/CD38bright cells [745].
Very recently, a lamprey monoclonal antibody reacting with a
unique epitope of the CD38 ectoenzyme was shown to be highly
specific for ASCs. The antibody recognizes ASCs in tonsils, spleen,
bone marrow and peripheral blood from healthy individuals and
on most multiple myelomas [209].
A staining pattern consisting of CD20low/CD138+/CD31+
was recently described; it detects bone marrow ASCs in rhesus
macaques, a model which is frequently used for the evaluation
of human vaccines. This panel also stains human bone marrow
ASCs [746].
It has become an important issue to distinguish between newly
generated plasmablasts and mature plasma cells. Plasmablasts are
proliferating cells that are able to migrate toward a chemokine
gradient to the bone marrow and inflamed tissues, where they
becomemature andmay become long-lived plasma cells. Although
the chemokine receptors CXCR3 and CXCR4 are expressed on all
ASCs only the plasmablasts have the migratory capability [738].
In preclinical mice models the incorporation of the nucleotide
analogue BrdU (bromodeoxyuridine, administered via drinking
water) into the DNA of proliferating plasmablasts allows, together
with a plasma cell marker, the clear differentiation between BrdU
positive plasmablasts and BrdU negative long-lived plasma cells
(Fig. 99) [740, 747]. As an alternative to BrdU, EdU (5-ethynyl-
2′-deoxyuridine) can be used (see Section VII.7: DNA synthesis,
cell cycle, and proliferation) [748]. Since the incorporation of
nucleotide analogues is not possible in studies of human cells,
markers indicative of plasmablasts and long-lived plasma cells,
Figure 100. Flow cytometric analysis of cir-
culating peripheral blood ASC derived from
an active SLE patient. PBMCs were gated
for CD19+ cells excluding CD3+/CD14+/CD16+
cells. ASCs highly express CD27 and are neg-
ative for CD20. The majority of ASCs express
HLA-DR, which characterizes newly gener-
ated plasmablasts. PBMCs: peripheral blood
mononuclear cells, mB: memory B cells, nB:
naive B cells.
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Figure 101. Identification of murine circulating splenic NK cells. Representative gating strategy to identify circulating NK cells from the spleen
of 6-week-old C57BL/6 mice. NK cells were gated as viable (LD–) B220– CD3– NK1.1+ DX5+. Among NK1.1+ DX5+ NK cells expression of CD27 and
CD11b defines different stages of NK cell maturation. Expression profile of the key transcription factors Eomes and T-bet in splenic NK1.1+ DX5+
NK cells is shown on the right.
such as MHC class II molecules and Ki-67 can be used. It was
demonstrated that plasmablasts express more MHC class II
molecules on their surface [740]. MHC class II expression was
therefore used to distinguish between circulating plasmablasts and
mature plasma cells in SLE patients (Fig. 100) [749]. An expan-
sion of circulating plasmablasts was identified in patients with
active autoimmune diseases such SLE [721, 749] and Takayasu
arteritis [750]. The secondary immunization e.g. with tetanus
toxoid leads to an increase of circulating plasmablasts as well. In
contrast, the appearance of these tetanus specific plasmablasts
(enumerated by intracellular staining with a recombinant C
fragment of the tetanus toxin conjugated with digoxigenin) in the
peripheral blood is subject to a time limit on days 6 and 7 after
the immunization [744]. Another option is the nuclear staining
of the proliferation marker Ki-67 in plasmablasts [751].
Recently, it was shown that bonemarrow plasma cells are more
heterogeneous than thought. In bone marrow there is a CD19-
negative plasma cell population expressing intracellular IgG, and
its characterization suggests that it represents the real long-lived
plasma cells contributing to the humoral memory [739, 752].
4 Innate lymphoid cells
During the past years, an emerging family of CD45+ innate lym-
phoid cells (ILCs) has been described. CD45+ ILCs lack rear-
ranged antigen receptors as well as lineage (Lin) markers typically
expressed on T cells, B cells or dendritic cells (DCs) [753]. The ILC
family includes previously identified innate lymphocytes, such as
NK cells, and novel cell populations, namely ILC1, ILC2 and ILC3,
classified according to the expression of surface markers, tran-
scription factors and effector cytokines, in analogy to the CD4+ T
helper (Th) subsets Th1, Th2 and Th17 [753, 754]. NK cells and
ILC1 (also named group 1 ILCs) express NKp46 (or also NK1.1 in
B6 mice) and the T-box transcription factor T-bet (Tbx21); group
1 ILCs produce IFN-γ in response to IL-12 and IL-18 or activating
receptor engagement, thus contributing to the response against
viruses and intracellular pathogens [755–758]. ILC2 express GATA
binding protein-3 (GATA3), produce IL-13 and IL-5 in response to
IL-25, IL-33, and Thymic stromal lymphopoietin (TSLP) and con-
tribute to the defense against helminthic infections as well as to the
pathogenesis of allergic inflammation [759]. ILC3 express retinoic
acid receptor (RAR)-related orphan receptor RORγt, and produce
IL-17 and/or IL-22 in response to IL-1β and IL-23 or activating
receptor engagement. ILC3 include fetal lymphoid tissue-inducer
(LTi) cells and post-natally expanding ILC3; LTi are required for
the prenatal development of lymph nodes and Peyer’s patches,
while ILC3 contribute after birth to defense against extracellular
pathogens, containment of commensals, epithelial tissue home-
ostasis and regulation of inflammatory disorders, such as inflam-
matory bowel disease (IBD) and psoriasis [760].
NK cells have been largely investigated in mouse spleen and
human peripheral blood (PB), where they mainly represent circu-
lating lymphocytes. Splenic circulating mouse NK cells are defined
as CD3− CD19− NK1.1+ DX5 (CD49b)+ and are characterized,
in addition to T-bet and IFN-γ production, by cytotoxic capacity
and expression of Eomesodermin (Eomes) (Fig. 101) [758, 761].
Instead of NK1.1, which is not expressed in all mouse strains,
staining of NKp46 can be used. Among splenic NK cells, expres-
sion of CD27 and CD11b defines distinct stages of maturation,
with CD27− CD11b+ cells being themoremature subset (Fig. 101)
[762–764].
In humans, circulating PB-NK cells are defined as Lin− CD56+
cells expressing T-bet and Eomes (Fig. 102). Human PB-NK cells
can be distinguished according to the level of CD56 expression into
CD56bright (CD16low) and CD56dim (CD16+) NK cells [765] and
further dissected according to the expression of CD57 (Fig. 102)
(or CD62L) into distinct maturation stages, with CD57+ (CD62L−)
NK cells being more terminally differentiated [766–768]. Further
characterization of NK cells is described in Section VIII.5: Natural
killer (NK) cells.
In addition to circulating NK cells, several ILC populations have
been identified [757, 758, 769–781], which are largely tissue res-
ident [758, 782]. In mice, small intestinal (SI) lamina propria
(LmP), all ILCs, namely NK cells, ILC1, ILC2 and ILC3 have been
described [757, 783]. In Fig. 103 a gating strategy for murine ILCs
derived from SI LmP is shown; however, it should be stressed that
ILC populations are not equally distributed in all organs and dis-
play some tissue-specific phenotypic differences. Combination of
intranuclear staining of master transcription factors, namely T-bet
(expressed on ILC1, NK cells and a subset of murine ILC3), Eomes
(NK cells), RORγt (ILC3) and GATA3 (ILC2) together with NKp46
and CD127 (IL-7Rα) (Fig. 103) or CD90 (not shown) enables
identification of ILC subsets in all organs analyzed. Among SI LmP
CD45+ Lin− cells, NKp46 (or NK1.1) can be expressed not only
on NK cells but also on ILC1 and a subset of ILC3. Thus staining
of transcription factors is helpful to dissect their identity. It has
been proposed that SI LmP NK cells can be defined as NKp46+
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Figure 102. Identification of human circulating PB-NK cells. Representative gating strategy to identify human CD3− CD56bright, CD56dim CD57−,
and CD56dim CD57+ NK cell populations after pre-gating on viable CD14− CD19− human PBMCs. Expression profile of the key transcription factors
Eomes and T-bet in these NK cell subsets is shown on the right.
RORγt− T-bet+ Eomes+ cells, while ILC1 are NKp46+RORγt− T-
bet+ Eomes− cells [757] (Fig. 103). However, a population of
cytotoxic NKp46+ RORγt− T-bet+ Eomes+ intraepithelial ILC1 has
been also described [780]. Moreover, the analysis of NK cells/ILC1
in different mouse compartments revealed a high degree of phe-
notypic and functional complexity [758, 761], suggesting that dis-
tinction between ILC1 and NK cells might be more challenging.
ILC2 and ILC3 are enriched among SI LmPCD45+ Lin− CD127+
lymphocytes and can be identified after intranuclear staining of
GATA3 and RORγt as GATA3hi RORγt− ILC2 and of GATA3lo
RORγt+ ILC3 (Fig. 103) [783, 784]. Surface markers such as ST2
(IL-33R), CD25, ICOS or KLRG1 have also been commonly used to
identify ILC2 [776, 777, 783]. As previously mentioned, expres-
sion of these markers slightly varies in different compartments.
SI LmP RORγt+ ILC3 can be dissected into three major sub-
sets according to NKp46 and CD4 expression (Fig. 103), namely
CD4+ ILC3, which functionally and phenotypically resemble fetal
LTi and preferentially produce IL-17 and IL-22; NKp46+ ILC3,
which expand post-natally, co-express RORγt and T-bet and pro-
duce IL-22 and IFN-γ; and CD4− NKp46− ILC3, which actually
represent a heterogeneous population of CCR6+ cells (related
to LTi) and CCR6− ILC3, co-expressing RORγt and T-bet, simi-
lar to NKp46+ ILC3 [785–787]. As it has been shown that ILC3
can be plastic in vivo, and down-regulate RORγt expression while
acquiring ILC1/NK-cell features such as T-bet expression and IFN-
γ production, the use of RORγt fate mapping (RORγtfm) can be
helpful to distinguish ex-ILC3 (RORγtfm+ RORγt− T-bet+) from
ILC1 [787, 788]. Although this distinction is conceptually impor-
tant, ex-ILC3 functionally behave similar to ILC1/NK cells.
In humans, ILCs have been documented in several tissues (and
more recently also in PB), although the most extensive character-
ization has been performed in tonsils, where all ILC subsets have
been described [770, 779–781, 789–791]. In tonsils, magnetic
depletion of CD3+ T cells is recommended for better detection of
ILCs, due to their low frequency. After pre-enrichment and fur-
ther gating on lineage negative cells, staining of CD94 and CD127
enables the identification of NK cells, as CD94+/lo CD127neg/lo
CD56+ cells, which express high levels of T-bet and Eomes, and of
other ILCs enriched among Lin− CD127hi CD94− cells (Fig. 104).
It has been proposed that staining of CD117 (the receptor for
stem cell factor, c-kit) and CRTH2 (prostaglandin D2 receptor
chemoattractant receptor-homologous molecule expressed on T
helper type 2 cells) facilitates identification of ILC3 and ILC2
in tonsils. ILC3 are enriched among CD117+ CRTH2− cells and
express RORγt, while lacking T-bet and Eomes [771, 781]. ILC2
are enriched among CD117-/lo CRTH2+ cells and express GATA-
3, while lacking T-bet and Eomes (Fig. 104) [779, 781]. Among
Lin− CD127hi CD94− CD117− CRTH2− cells, a population of ILC1
Figure 103. Identification of murine SI LmP ILCs. Representative gating strategy of ILCs derived from the small intestinal (SI) lamina propria LmP
of 6-week-old C57BL/6 mice. Mononuclear cells (MCs) were prepared as previously described [796]. Cells were gated as viable (LD–), B220– CD11c–
Gr-1– F4/80– FcεR1α– (Lin–) CD45+ TCRβ– TCRγδ– and either as NKp46+ (grey gate, A) T-bet+ Eomes– ILC1, Eomes+ T-bet+ NK cells or as CD127+
(black gate, B) GATA3+ RORγt– ILC2 and RORγt+ GATA3lo ILC3 which can be further separated according to NKp46 and CD4 expression (B).
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Figure 104. Identification of human tonsil ILCs. Representative gating strategy (upper panel) and expression of transcription factors (lower panel)
of human ILCs derived from tonsillectomy. After magnetic depletion of CD3+ cells, cells were gated as viable (LD–), CD3– CD14− CD19− FcεRIα−
CD123− CD11c− CD141− (Lin−) and either CD94+/lo CD127−/lo CD56+ NK cells; CD94− CD127hi CD117+ CRTH2− ILC3; CD94− CD127hi CD117+/lo
CRTH2+ ILC2; or CD94− CD127hi CD117− CRTH2− NKp44− CD56− ILC1.
has been described which lacks NKp44 and CD56 and is enriched
in the SI LmP of patients affected with inflammatory bowel dis-
eases [781]. This population displays only low amount of T-bet
protein expression (Fig. 104). In line with mouse data, additional
populations of NK cells/ILC1 subsets with different phenotypic
characteristics have been described in human tissues, including
tonsils [780, 790, 792–794], making the selection of markers for
the identification of NK cells/ILC1 quite challenging.
Notably, the resolution of transcription factor staining in
humans is not as good as in murine tissues and, therefore, com-
bined staining of the above mentioned surface markers is highly
recommended in order to reliably gate on different human ILC sub-
sets. However, as for their murine ILC counterparts, tissue-specific
differences of surface markers should be taken into account, as it
has been shown for expression of CRTH2 for lung ILC2 [791]. A
selection of additional markers shown to be expressed by human
and/or mouse ILC subsets is depicted in Table 26.
4.1 Materials and methods
Cell isolation: Written informed consent was obtained from all
patients prior to sample acquisition and experiments have been
approved by the Ethics Committee of the Charite´ Medical Univer-
sity, Berlin (EA2-078-16, EA1/149/1). Human PBMCs were iso-
lated from buffy coats by density gradient centrifugation using
Ficoll-Paque PLUS (GE Healthcare). Mononuclear cells (MCs)
from human tonsils were isolated from patients undergoing tonsil-
lectomy as previously described [795]. After density gradient cen-
trifugation using Ficoll-Paque PLUS, ILCs were enriched by using
magnetic cell depletion of CD3+ T cells with CD3 microbeads and
LD columns (Miltenyi) according to the manufacturer’s instruc-
tions. For isolation of murine circulating splenic MCs, spleen was
mashed through a 70 μm strainer in the presence of PBS/BSA. Cell
suspensionwas centrifuged for 10min at 350× g, supernatant was
aspirated and erythrocytes were lysed. For isolation of murine SI
LmP MCs a previously described protocol was used [796]: Resid-
ual fat tissue, Peyer’s Patches and feces were removed, and the
intestine was cut open longitudinally and washed with PBS. After
clearing, tissue was cut into pieces of 1 cm length and digested
with a lamina propria dissociation kit (Miltenyi), according to the
manufacturer’s instructions. Lymphocytes were further enriched
on a 40%/80% Percoll gradient.
Flow cytometry: Phenotypic analysis of human lymphocytes
was performed using the following antibodies reactive to human
surface or intracellular antigens: eFluor780 Fixable Viability Dye,
APC-eFluor780 CD14 mAb (61D3), CD19 mAb (HIB19), CD3
mAb (SK7), CD123 mAb (6H6), eFluor660 or FITC anti-Eomes
(WD1928), PE-Cy7 anti-T-bet (eBio4B10), PerCP-eF780 Strep-
tavidin (eBioscience); APC -Vio770 CD141 mAb (AD5-14H12),
anti-FcεRIα (CRA1), and CD11c mAb (MJ4-27G12), Fitc CD127
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Table 26. Selection of important markers for flow cytometry analysis of mouse and human ILC
Mouse Human
NK cells CD127+ ILC1 ILC2 NCR− ILC3 NCR+ ILC3 NK cells CD127+ ILC1 ILC2 NCR− ILC3 NCR+ ILC3
Marker
CD127 − + + + + lo/− + + + +
CD117 lo/− − +/− − lo lo/− − +/− + +
CD25 − lo + + ND +/− lo + +/− lo
IL-23R − lo/− − + + lo +/− lo + +
IL-17RB − − + − − − lo/− + ND −
ST2 − − + − − − ND + ND −
IL-1R1 − lo ND + + +/− lo/− lo + +
CCR6 − − − +/− − − + + + +
RANKL lo/− ND ND + + − ND ND + +
CRTH2 ND ND ND ND ND − − + − −
ICOS − ND + + + − + + + +
NK1.1/CD161 + + − − lo/− +/lo + + + +
CD56 NA NA NA NA NA + − − +/− +/−
CD94 +/− ND +/− − +/− +/− − − − −
CD16 +/− ND − − − +/− − − − −
NKp30 NA NA NA NA NA + ND +/lo +/− +
NKp44 NA NA NA NA NA +a − − − +
NKp46 + + − − + + − − − +
Ly49/KIR +/− lo − − − +/− − − − −
CD57 NA NA NA NA NA +/− ND ND ND ND
CD27 +/− + − − − +/− + − − −
CD11b +/− − − ND ND +/− ND ND ND ND
Perforin + lo − − − + − − − −
Transcription factors
T-bet + + − +/− + + + − − −
Eomes + − − − + + − − − −
RORγt − − − + + − − –/lo + +
GATA3 lo lo + lo lo lo lo + lo lo
Cytokines
IFNγ + + –/lo –/lo –/lo + + − − −
IL-22 − − lo + + − − lo lo/− +
IL-17 − − − +/− − − − − + −
IL-13 − − + − − lo − + − lo
IL-5 − − + − − − − + − −
+ indicates high expression, – indicates no expression, +/– indicates bimodal expression, lo indicates low expression, + a indicates expression on
activated cells, ND indicates not determined, NA indicates not applicable according to published reports [756–759, 762–764, 766–768, 770–781, 783–
788, 796].
mAb (MB15-18C9), PE anti-T-bet (REA102) or anti-GATA-3
(REA174), APC anti-RORγt (REA278), PE-Vio770 NKp44 (2.29),
biotin anti-CRTH2 (REA598) (Miltenyi Biotec); Zombie Aqua
Fixable Viability Dye, BV605 CD117 mAb (104D2), BV510
CD14 mAb (M5E2), and CD19 mAb (HIB19), PE-Cy5 CD3 mAb
(UCHT1), PE-Dazzle594 CD56 mAb (HCD56), Pacific Blue CD57
mAb (HCD57) (BioLegend); Pacific Blue CD94 mAb (XA185)
(conjugated in house).
Phenotypic analysis of murine lymphocytes was performed
using the following antibodies reactive to murine surface or
intracellular antigens: anti-FcγReceptor (2.4G) in-house produc-
tion, eFluor780 Fixable Viability Dye, APC-eFluor780 anti-FcεRIα
(MAR-1), PerCP-Cy5.5 anti-TCRβ (H57-597), PerCP-eFluor710
anti-TCRγd (GL-3), Alexa Fluor R© 488 anti-Eomes (Dan11mag),
eFluor 450 anti-CD11β (M1/70) from eBioscience; APC-Vio770
anti-B220 (RA3-6B2), PE anti-GATA3 (REA174), PE anti-DX5
(DX5) from Miltenyi, APC-Cy7 anti-CD11c (N418), APC-Cy7
anti-Gr-1 (RB6-8C5), APC-Cy7 anti-F4/80 (BM8), BV785 anti-
CD127 (A7R34), BV605 anti-NKp46 (29A1.4), PE-Cy7 anti-CD4
(RM4-5), Alexa Fluor R© 647 anti-T-bet (4B10), PE-Cy7 anti-CD27
(LG.3A10), BV650 anti-NK1.1 (PK136) all from BioLegend; V500
anti-CD45 (30F11) and BV421 anti-RORγt (Q31-378) from BD.
Staining for transcription factors was performed using the
Foxp3 Transcription Factor Staining Buffer Set (eBioscience)
according to manufacturer’s instructions and cells were immedi-
ately analyzed. Flow cytometric analysis was performed by using
BD Fortessa employing FACSDiva Software (BD Biosciences), and
data were analyzed by using FlowJo software (FlowJo, LLC).
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5 Natural killer (NK) cells
Natural killer (NK) cells were described over 40 years ago as
cells capable of killing tumor cells without prior sensitization.
They are lymphoid cells derived from hemopoietic stem cells
(HSCs) [797] and belong to the innate immunity cell family.
In contrast to T and B cells, NK cells do not express receptors
encoded by rearranging genes and they play a major role in innate
immunity as both effector and regulatory cells, participating in
the first line of defence against pathogens and tumors. Notably,
NK-cell-susceptible tumors are primarily those lacking or express-
ing insufficient amounts of MHC class I molecules (missing-
self hypothesis) [798]. Another requirement for NK-cell-mediated
tumor cell killing is the surface expression of a series of differ-
ent stress-induced structures [799]. The NK cell function appears
to complement the cytolytic T cell–mediated MHC-I-dependent
activity [800].
The recognition ofMHC class-I is mediated by a family of recep-
tors termed Killer Ig-like receptors (KIRs), by the NKG2A/CD94
heterodimer and by LIR-1 (CD85j). In particular, NKG2A/CD94,
expressed early during the process of NK cell maturation, recog-
nizes the non-classical HLA-E molecule [801, 802] while KIRs,
expressed at later stages of NK cell maturation, recognize allelic
determinants of HLA-A -B or -C [803, 804]. Other non-HLA-related
inhibitory receptors including Siglec7 (CD328), PD1 (CD279) and
IRP60 (CD300a) may be expressed at the surface of NK cells (see
Table 27). In most instances, the NK receptors that mediate their
activation upon binding to target cells are non-HLA-specific and
recognize cell stress-induced molecules. These receptors include
NKp30, NKp44 and NKp46 (which constitute the natural cytotoxi-
city [NCR] family), NKp80, 2B4 (CD244) and NKG2D [805–807].
Of note, activating isoforms of KIRs also exist [808]. While
inhibitory KIRs are characterized by immune-receptor tyrosine-
based inhibition motif (ITIM) domains in their long intracytoplas-
mic tail, the various activating receptors bear a short intracyto-
plasmic tail and are associated with signalling polypeptides con-
taining immune-receptor tyrosine-based activating motifs (ITAM)
domains [809].
Among peripheral NK cells, two major subsets have been
identified on the basis of the cell surface density of CD56
molecules (neural cell adhesion molecule, N-CAM). CD56bright
(CD3−CD56++CD16−/+) represent approximately 10% of the
circulating PB NK cells while they prevail in secondary lym-
phoid organs (liver, synovial fluid and decidua). CD56dim
(CD3−CD56+/− CD16++) cells are largely predominant (90%)
in PB NK cells. They derive from CD56bright NK cells, as revealed
by different studies in vitro (differentiation from HSC) and in vivo
after HSC transplantation [810, 811].
5.1 CD56bright NK cells
All CD56bright, in contrast to CD56dim, NK cells express both high
(CD25) and intermediate (CD122/CD132) affinity IL-2 recep-
tors and c-Kit (CD117), rendering them highly susceptible to
IL-2–induced cell proliferation [812, 813]. Moreover, CD56bright
NK cells express high levels of both CD62L [814] and CXCR3
which, together with the surface expression of CCR7, dictates their
preferential homing into secondary lymphoid organs [815–817].
Notably, although under resting conditions, CD56bright NK cells are
poorly cytotoxic, they may acquire cytolytic activity comparable
to that of CD56dim cells upon stimulation with cytokines, such as
IL-2, IL-12, IL-15.
While CD56bright NK cells express CD94/NKG2A (i.e. the recep-
tor for HLA-E) they lack KIRs. Regarding activating NK receptors,
CD56bright cells express higher levels of NKp46 and NKp30 than
CD56dim cells, while CD56bright cells lack or express low amounts
of CD16.
5.2 CD56dim NK cells
CD56dim NK cells under resting conditions express granules con-
taining perforin and granzymes, and display cytolytic activity.
Until recently, CD56dim NK cells were mainly associated with cyto-
toxicity while cytokine production was thought to be confined to
the CD56bright subset. However, more recently, it has been shown
that, upon stimulation via activating receptors, CD56dim NK cells
rapidly release cytokines such as IFN-γ- and TNF-α (even more
efficiently than CD56bright cells) and chemokines such as MIP-1β
and MIP-1α [818, 819].
In contrast to CD56bright NK cells, the CD56dim population is
phenotypically heterogeneous. Thus, as shown in Fig. 105, NKG2A
versus KIR expression allows three distinct subsets that recapitu-
late the consecutive steps of PB NK cell maturation to be distin-
guished. The “maturing” population (NKG2A+KIR−) is character-
ized by the NKG2A+/KIR− phenotype, similar to that of CD56bright
cells, while the “mature” population expresses the NKG2A−KIR+
phenotype. An intermediate step of maturation is identified by
the “double positive” NKG2A+KIR+ cells [820, 821]. The unidi-
rectional nature of NK cell differentiation is further supported by
the presence of CD57 on the surface of the “terminally differenti-
ated” NK subset. When compared with the CD57-negative coun-
terpart, the NKG2A−KIR+CD57+ population shows a decreased
surface expression of NKp30 and NKp46, and a reduced prolifera-
tive potential, possibly as the result of downmodulation of IL-2Rβ
(CD122) and IL-18Rα (CD218a) [768, 821].
In CMV-positive healthy donors it is possible to find an addi-
tional subset of mature cells that expresses CD57 and the acti-
vating HLA-E-specific receptor NKG2C dimerizing with CD94
[822]. This subset appears to contain cells endowed with an
adaptive/memory-like capability (i.e. clonal expansion, prompt
response to restimulation and epigenetic modification including
that of the intracytoplasmic FcεRγ chain) [823–825]. Recent data
have shown that, in CMV positive individuals, a fraction of CD57
positive cells may also express PD-1 [826].
The recruitment of CD56dim NK cells to inflamed peripheral tis-
sues is driven by several chemokines and homing receptors includ-
ing, for example, CXCR1, CX3CR1 and in certain subsets CD62L
and CXCR3low also [815].
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Table 27. NK cell phenotypes
(Continued)
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Figure 105. NK cells can be first gated on the basis of their surface level of CD56 expression and lack of CD3. The CD56bright NK subpopulation is
positive for NKG2A, negative for KIRs while CD16 can be either negative or dimly expressed (as shown). NKG2A and KIR surface expression allows
three subpopulations of CD56dim NK cells, namely “maturing” (NKG2A+KIR−), “double positive” (NKG2A+KIR+) and “mature” (NKG2A−KIR+), to
be identified. Among the mature population, CD57 molecule is expressed on the, so-called, “terminally differentiated” NK cells. In CMV positive
donors, a percentage of this latter population can also express NKG2C representing the so called “memory NK cells.” Recently it has been
demonstrated that in CMV positive individuals a fraction of the NKG2C subset can also express PD1.
5.3 NK cells present in decidua
During the first trimester of pregnancy, NK cells represent themain
lymphoid population (50–70%) in human decidua where they
bear a unique phenotypic and functional profile. Their phenotypic
features resemble to an extent those of CD56bright PB NK cells;
however, in addition to the NKG2AhighNKp30highNKp46high surface
phenotype, they also display characteristics of CD56dim NK cells
including high expression of KIR and lytic granules. Of note, in
contrast to PB NK cells, the 2B4 (CD244) receptor on decidual
NK cells displays a strong inhibitory (and not activating) activity,
similar to that seen in NK cell precursors [827], that renders this
population poorly cytolytic [828, 829]. Moreover, in contrast to
PB NK cells, decidual NK cells release a unique set of cytokines,
including IL-8 (CXCL8), VEGF, CXCL12 (stromal-derived factor–1
[SDF-1α]), and IFN-γ–inducing protein 10 (IP-10, CXCL10), that
play a pivotal role in tissue remodelling (i.e. placenta development
processes) and neo-angiogenesis [831].
5.4 NK cells present in lymph nodes
In normal conditions, NK cells are present in lymph nodes
where they occupy the T-cell areas [830]. They are consistently
CD56brightCD16negKIRneg and lack perforin and granzymes. In con-
trast to PB CD56bright NK cells, lymph node NK cells do not express
CCR7 or CD62L. Concerning the NCR family, lymph node NK cells
express low levels of NKp46 and may lack NKp30. Remarkably,
however, upon IL-2 activation, lymph node NK cells may express
KIRs and CD16, and upregulate NCR [831, 832].
5.5 Protocols and stainings
All the protocols for T cells described in Section VIII.1: Differentia-
tion stages of T cells, can be applied to the analysis of NK cells, and
NK cell characterization is also described in Section VIII.4: Innate
lymphoid cells. Regarding the effector function and expression of
chemokine receptors, that which is already described for T cells is
also true for NK cells. Here we will suggest a series of conjugated
monoclonal antibodies that are commonly used for the surface
staining of NK cells.
Beckman Coulter: CD3 APC-Alexa Fluor R© 750 (UCHT1, IgG1)
CD158a PE (EB6B, IgG1), CD158b PE (GL183), CD158e PE
(Z27, IgG2a), CD159a PE-Cy7 (Z199 IgG2b), NKp30 (Z25, IgG1),
NKp44 (Z231, IgG1) NKp46 (BAB281, IgG1), NKp80 (MA152,
IgG1) NKG2D (ON72, IgG1).
Becton Dickinson: CD16 BV510 (3G8, IgG1), CD56 BV650
(NCAM16.2, IgG2b), CD57 BV421 (NK-1, IgM), CD158b (CH-L,
IgG2b).
Miltenyi: PD1 PE (PD1.3.1.3, IgG1), NKG2C VioBright FITC
(REA205, Ig1).
R&D System: NKG2C Alexa Fluor R© 700 (134591, IgG2a).
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Figure 106. Schematic illustrating the tripartite orga-
nization of the mononuclear phagocyte system. Clas-
sical tissue macrophages are established before birth
and with few exceptions, self-maintain throughout
adulthood. Classical DCs are short-lived and continu-
ously replaced from dedicated BM-derived precursor
cells. Monocytes reside in the blood circulation and
are recruited to tissues on demand where they give
rise to cells with macrophage or DC features (for fur-
ther details see [843]).
6 Mononuclear phagocytes
6.1 Introduction
Mononuclear phagocytes belong to the myeloid immune cell lin-
eage and comprise monocytes, macrophages and dendritic cells
(DCs), which collectively play critical, but distinct roles in tis-
sue homeostasis and immunity. The “mononuclear phagocyte con-
cept” [833] was originally based on the assumption that the main-
tenance of tissue-resident macrophages and DCs relies on constant
replenishment by blood monocytes. However, short-lived classi-
cal DCs (cDCs) are now known to originate from distinct DC-
committed precursors that arise in the bone marrow [834, 835].
Adult tissue macrophage compartments, on the other hand, are
established before birth and, with few notable exceptions, these
cells subsequentlymaintain themselves through longevity and self-
renewal [836, 837] independent from monocytic input, as shown
by fate mapping studies. According to their distinct ontogeny,
monocytes, macrophages and cDCs can therefore be regarded as
distinct cellular entities [838], despite the fact that these cells dis-
play considerable overlap with respect to phenotype and function
(Fig. 106).
Monocytes are circulating in the blood and comprise in mam-
mals two main subsets, which in mice have been defined as
CX3CR1int CCR2+ CD62L+ CD43lo Ly6Chi and CXCR1high CCR2−
CD62L− CD43hi Ly6Clo cells [839]. Monocytes develop in the BM
from commonmonocyte precursors (cMOP) [840] that themselves
derive from the monocyte/macrophage-DC precursors (MDP)
[841, 842]. Murine Ly6Chi monocytes, and their human coun-
terpart, classical CD14+ monocytes, are short-lived, and poised
to home to sites of inflammation [843], where they can give rise
to monocyte-derived DC (MoDC, also called “inflammatory DC”)
or macrophages (Table 28). Murine Ly6Clo cells are in steady
state progeny of Ly6Chi monocytes, display more extended half-
lives [844] and are “patrolling” cells specialized in surveillance of
vascular integrity [845].
Macrophages are strategically positioned throughout the body
tissues, where they ingest and degrade dead cells, debris and
foreign material, and orchestrate inflammatory processes [846].
Recent studies show that tissue macrophages form, aside from
being immune sentinels, also integral components of their respec-
tive host tissue [837]. Distinct tissue macrophage compartments,
such as brain microglia and liver Kupffer cells, develop locally and
independently from each other. This entails their specialization in
response to local environmental cues to contribute to the devel-
opment and specific function of their tissue of residence. Factors
that govern tissue macrophage specialization are emerging [837].
Moreover, tissue specialization is prominently reflected in discrete
gene expression profiles of macrophages, including selected sur-
face markers (Table 28), as well as epigenetic signatures reporting
actual and potential enhancer usage [847].
Dendritic cells have unrivaled potential to stimulate T cells
and form a critical interface between innate and adaptive immu-
nity [835]. As immune cell sentinels, cDCs are specialized in
the sensing of pathogen challenges and cancer, translating the
latter into peptide form for T cells. In addition, cDCs provide
critical information on the original antigen context to trigger
a diverse spectrum of appropriate protective responses and T-
cell polarization. cDCs generally display a short half-life and
are constantly replenished from dedicated BM precursors in a
strictly Flt3L-dependent manner [834]. cDCs can be divided into
functionally distinct subsets, including cells specialized for cross-
presentation, which are characterized by expression of surface
markers, such as XCR1 and the αEβ7 integrin CD103, and a less
well-defined population negative for these markers. Both sub-
populations can be found in lymphoid tissue, including spleen,
lymph nodes and BM, as well as most non-lymphoid tissue
(Table 28).
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Table 28. Selected commonly used surface markers for murine mononuclear phagocytes
Phenotype Selected references
Monocytes
classical CD115+ CX3CR1int CCR2+ CD62L+ CD43lo Ly6Chi [836, 839, 851]
non-classical CX3CR1hi CCR2+ CD62L+ CD43hi [836, 839, 851]
Macrophages
Kupffer cells (liver) CD11b+ F4/80+ CD68+/–, Clec4F+ [837, 852, 853]
microglia (brain) CX3CR1hi CD45int CD11b+ F4/80+ Siglec+ [854, 855]
intestinal lamina propria macrophages CD64+ CX3CR1+ CD11c+/– F4/80+ CD11b+ (lamina propria) [856–860]
Dendritic cells
lymphoid organ CD11c+ MHCII+ CD24+/– XCR1+/– [834, 835]
non-lymphoid organ (intestine) CD11c+ CD103+/– MHCII+ CD24+/– CD11b+/– [835, 861, 862]
Given the limited availability of known robust surface markers
and considerable overlap of their expression among mononuclear
phagocytes, the phenotypic discrimination of these cells is chal-
lenging. The integrin CD11c for instance, was long considered spe-
cific for mouse DCs, but its expression is shared by macrophages
in lung and gut, as well as Ly6Clo monocytes, and even certain
lymphocytes [848]. Emerging unbiased approaches to the study
of mononuclear phagocytes, including massive parallel single-cell
RNA-seq (MARS-seq) [849], might help to molecularly define sub-
sets and provide new markers that can be used in flow cytometry
to allow future better definition of functional entities within this
cellular compartment.
Below we provide guidelines for the flow cytometric analysis
of mononuclear phagocyte populations of selected lymphoid and
non-lymphoid tissues (i.e. spleen, gut, brain), as well as the blood.
Collectively, these protocols highlight the fact that analysis of tis-
sue resident mononuclear phagocytes requires protocols, which
have been adjusted to the respective tissues, including extended
digests, or cell fractionations prior to the flow cytometric anal-
ysis. Of note, classical fluorescence-based flow cytometric anal-
ysis of mononuclear phagocytes can be complemented by mass
spectometry-based CyTOF analysis (see Section I.5: Mass cytome-
try), which allows for a considerable extension of simultaneously
used parameters [191, 850].
For additional information on the ever-growing number of
sub-populations of mononuclear phagocytes in specific we refer
to http://www.immgen.org, [863] and [864] (skin) and [865]
(lung). For markers of the respective corresponding human cells
we refer to the following recent review articles: [835, 864]
6.2 Materials
General reagents
 Dulbecco’s Phosphate Buffered Saline without calcium and
magnesium (PBS −/−)
 Dulbecco’s Phosphate Buffered Saline with calcium and mag-
nesium (PBS+/+)
 Staining medium: PBS −/− with 2% heat-inactivated Fetal
Calf/Bovine Serum (FCS/FBS) and 1 mM EDTA.
 Delicate cell-strainer (80 μm).
 Flow cytometry tubes suitable for reading in the flow cytometry
cell sorting machine of use (for example, “Polystyrene Round
Bottom Test Tube” 5 mL, Cat# 352052, by BD Falcon).
 All antibodies described in these protocols are available at Biole-
gend.
General comments
 Adult mice, such as C57BL/6, typically 6–10 weeks old are
commonly used.
 Antibodies should be tested and titrated to determine ideal
conditions for staining.
 Staining volume for the samples should be 20 μl for up to 2 ×
106 cells, 50 μl for up to 5 × 106 cells, etc.
 Incubation with antibodies should be performed at 4oC (or on
ice) in dark. In the majority of cases 10–20 minutes should be
sufficient.
 The volume of staining buffer, in which to suspend the cells
before reading in the flow cytometry cell sorting machine varies
according to cell numbers. Initially suspend 1 × 106 cells in 100
μL of staining buffer and dilute if necessary.
6.2.1 Staining of mouse blood monocytes.
1. Anti-coagulant such as Heparin (for example “Heparin sodium
salt from porcine intestinal mucosa,” Cat# H3393 by Sigma-
Aldrich).
2. Ficoll for isolation of lymphocytes and removal of erythrocytes
by gradient (for example “Ficoll-Paque PLUS,” Cat# 17-1440-
03 by GE healthcare); alternatively, erythrocytes can be lysed
using ACK buffer (a solution of 0.15M NH4C, 0.01M KHCO3
is made by dissolving of 8 g of NH4Cl and 1 g of KHCO3
(Merck, Germany) in 1 L of DDW. The solution is then divided
into 50 mL aliquots and stored at –20°C). ACK treatment
retains neutrophils, which are largely depleted using the Ficoll
gradient.
3. Staining antibodies (clones indicated within brackets): CD45
mAb (30-F11), CD11b mAb (M1/70), CD115/CSF-1R mAb
(AF598), anti-Ly-6C (HK1.4).
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Figure 107. Flow cytometric analysis of murinemyeloid
blood cells. Neutrophils are defined by high sideward
scatter (not shown) and expression of Ly6G. Monocytes
are defined as CD115hi cells and can be further subdi-
vided into classical (Ly6Chi; red) and patrolling mono-
cytes (Ly6Clo; blue) (for further details see [850]).
6.2.2 Staining of mouse intestinal macrophages and DCs.
1. [Recommended] Repeater pipette/dispenser (for example
“Repeater M4” Cat# 4982000322 by Eppendorf) and suit-
able tips (for example, “Combitips Advanced” Cat# depends
on pipette, by Eppendorf).
2. Solution 1: 5 mL/sample (up to 300 g of tissue) of Hanks’
Balanced Salt Solution (HBSS) with 10% heat-inactivated
FCS/FBS, 2.5 mM EDTA and 1 mM DTT (for example “DL-
Dithiothreitol (DTT),” Cat# D9779 by Sigma-Aldrich). Divide
5 mL per 50 mL tube.
3. Solution 2: 5 mL/sample of PBS +/+ with 5% heat-inactivated
FCS/FBS, 1 mg/mL Collagenase VIII (for example, “Collage-
nase type VIII,” Cat# C2139 by Sigma) and 0.1 mg/mL DNase
I (for example “DNase I” Cat# 10104159001 by Roche). Divide
5 mL per 50 mL tube.
4. Cell strainers: crude (<100 μm) and delicate (80 μm).
5. Staining antibodies (clones indicated within brackets): CD45
mAb (30-F11), CD64/FcγRI mAb (X54-5/7.1), CD11c mAb
(N418), CD103 mAb (2E(7)), CD11b mAb (M1/70), anti-
Ly-6C (HK1.4). Additional markers, which can be used: anti-
F4/80 (BM8), ant-XCR1 (ZET), anti-Sirpα/CD172a (p84).
6.2.3 Staining of mouse splenic DCs.
1. 1 mL syringes.
2. Collagenase D (for example “Collagenase D,” Cat#
11088858001 by Roche)
3. Red blood cell lysis buffer (for example “Red Blood Cells Lysis
Buffer,” Cat# 11814389001 by Roche).
4. Staining antibodies (clones indicated within brackets): CD45
mAb (30-F11), CD11b mAb (M1/70), CD11c mAb (N418),
anti-I-Ab / MHC-II (AF6-120.1), anti-SIRPα (P84), anti-XCR1
(ZET).
6.2.4 Staining of mouse brain macrophages.
1. 24-well plate for incubation of homogenized brains.
2. Collagenase D solution: 1 mL/brain of Hanks’ Balanced
Salt Solution (HBSS) with Bovine Serum Albumin (BSA), 1
mg/mL of collagenase D (for example, “Collagenase D,” Cat#
11088858001 by Roche) and DNase I (for example “DNase I”
Cat# 10104159001 by Roche).
3. Percoll for isolation of mononuclear cells (for example “Per-
coll,” Cat# 1644 by Sigma)
4. Staining antibodies (clones indicated within brackets): CD45
mAb (30-F11), CD11bmAb (M1/70), anti-Ly-6G (1A(8)), anti-
Ly-6C (HK1.4).
6.3 Sample preparation
6.3.1 Sample preparation of murine blood monocytes.
1. Extract blood (for techniques see [866]) and immediately
transfer to a tube containing the company-recommended
amount of anti-coagulant. Note: if more than 300 μL of blood
are extracted, consider dividing the sample.
2. Carefully load the blood-anti-coagulant mixture onto 1 mL
room-temperature Ficoll in a flow cytometry tube.
3. Centrifuge at room temperature, 925 g without breaks for 15
minutes.
4. Collect the ring between the phases, transfer to a new, clean
tube and wash with staining buffer. (Alternatively, perform
ACK lysis by incubation with 1 mL of hypotonic ACK buffer
for 2 minutes at room temperature (RT). Lysis is stopped by
dilution of the ACK buffer with PBS−/− (10-fold volume at
least).
5. Centrifuge at 4oC, 375 g for 6 minutes. Collect and discard
supernatant.
6. Re-suspend the pellet in staining buffer with the antibodies.
Incubate in dark at 4oC.
7. Wash with staining buffer, centrifuge at 4oC, 375 g for 6 min-
utes. Collect and discard supernatant.
8. Re-suspend in staining buffer, filter with delicate cell strainer
into a new, clean flow cytometry tube and read sample in flow
cytometry cell sorting machine.
# Gating: Blood monocytes are defined by gating on
CD45+/CD11b+/CD115+ cells. The monocytes subsets are
revealed as Ly-6C positive and negative cells (Fig. 107).
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Figure 108. Flow cytometric analysis of colonic
mononuclear phagocytes. Classical DCs are
defined as CD11chi cells (red), which can be fur-
ther subdivided into three subsets according to
their CD103 and CD11b expression. Monocyte-
derived intestinal macrophages are defined as
CD64+ CD11c low-int CD11b+ cells (blue) (for fur-
ther details see [850]).
6.3.2 Sample preparation of mouse intestinal macrophages/DCs.
1. Remove desired part of the intestine, i.e. colon, ileum etc.
2. Flush out fecal content by washing the lumen of the intes-
tine with PBS −/−, either with a regular pipette or a repeater
pipette/dispenser with suitable tip.
3. Open the intestine longitudinally and cut into short pieces of
0.5 cm in 5 mL/sample of solution 1.
4. Incubate at 37oC shaker at 300rpm for 30 minutes to remove
mucus and epithelial cells.
5. Vortex hard for 10 seconds and filter suspension through
a crude cell strainer. Collect the pieces and transfer to 5
mL/sample of solution 2.
6. Incubate in 37oC shaker at 300 rpm for 20 minutes (small
intestine) or 40 minutes (large intestine) to extract cells from
lamina propria, i.e. the connective tissue underlying the epithe-
lium.
7. Vortex hard for 30 seconds until tissue is dissolved (incubate
again for 5–10 minutes if tissue did not dissolve well) and filter
through crude cell strainer. Wash with PBS−/− and centrifuge
at 4oC, 375 g for 6 minutes.
8. Re-suspend the pellet in staining buffer with the antibodies.
Incubate in the dark at 4oC.
9. Wash with staining buffer, centrifuge at 4oC, 375 g for 6 min-
utes. Collect and discard supernatant.
10. Re-suspend in staining buffer, filter with delicate cell strainer
into a new, clean flow cytometry tube and read sample in flow
cytometry cell sorting machine.
# Gating: intestinal DCs are defined as CD45+ CD64− CD11c+
CD103+/− CD11b+/− cells. Intestinal macrophages are CD45+
CD64+ CD11b+ Ly-6C− cells.
Infiltrating monocytes (under conditions of gut inflammation) are
CD45+ CD64+ CD11b+ Ly-6C+ cells. For further details please
see [850] (Fig. 108).
6.3.3 Sample preparation of mouse splenic DCs.
1. Isolate spleen and inject it with 1 mL of PBS+/+ containing 1
mg/mL of collagenase D using 1 mL syringe.
2. Incubate at 37oC for 30 minutes.
3. Filter cell suspension using an 80 μm cell-strainer and cen-
trifuge at 4 oC, 375 g for 5 minutes.
4. Remove erythrocytes using red blood cell lysis buffer accord-
ing to manufacturer’s protocol. If not indicated in protocol,
centrifuge at 4oC, 375 g for 6 minutes and discard the super-
natant.
5. Re-suspend the pellet in staining buffer with the antibodies.
Incubate in dark at 4oC.
6. Wash with staining buffer, centrifuge at 4oC, 375 g for 6 min-
utes. Collect and discard supernatant.
7. Re-suspend in staining buffer, filter with delicate cell strainer
into a new, clean flow cytometry tube and read sample in flow
cytometry cell sorting machine.
# Gating: splenic classical DCs are defined as CD45+ CD11c+
MHC-II+ cells. BATF3-dependent CD8α-expressing classical
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Figure 109. Flow cytometric analysis of splenic DCs. Classical CD11chi MHCII+ DCs can be further subdivided into two main subsets according to
CD11b and XCR1 expression (for further details, see [850]).
DCs are XCR1+ (blue) and the other populations are CD11b+
(red) (Fig. 109).
6.3.4 Sample preparation of mouse brain macrophages.
1. For the analysis of non-parenchymal and parenchymal CNS
macrophages, as well as monocyte-derived macrophages that
arise during neuro-inflammation from monocyte infiltrates,
perfuse mice with ice-cold PBS −/− and isolate brains.
2. Homogenize brains and incubate with 1 mL/brain of collage-
nase D solution at 37oC for 30 minutes.
3. Filter cell suspensions using an 80 μm cell-strainer and cen-
trifuge at 4oC, 975 g for 5 minutes.
4. Resuspend the pellet in 3 mL/brain 40% Percoll and centrifuge
in room temperature, 975G without breaks for 15 minutes.
Collect and discard supernatant.
5. Wash in staining buffer, centrifuge at 4oC, 375 g for 6 minutes.
Collect and discard supernatant.
6. Re-suspend the pellet in staining buffer with the antibodies.
Incubate in dark at 4oC.
7. Wash with staining buffer, centrifuge at 4oC, 375 g for 6 min-
utes. Collect and discard supernatant.
8. Re-suspend in staining buffer, filter with delicate cell strainer
into a new, clean flow cytometry tube and read sample in flow
cytometry cell sorting machine.
# Gating: microglia are defined as Ly-6G−/CD11b+/CD45low cells.
Monocytes are Ly-6G−/CD11b+/CD45high/Ly-6Chigh. Other
brain macrophages are Ly-6G−/CD11b+/CD45high/Ly-6Clow
(Fig. 110).
7 Granulocytes
7.1 Sample preparation
Successful flow cytometry analysis requires viable single-cell sus-
pensions. Granulocytes are sensitive cells which can rapidly die or
aggregate upon inappropriate treatment (extended incubation on
density gradients, harsh physical treatment). Therefore, it is nec-
essary to use optimized protocols for the dissociation of different
tissues to prepare cell suspensions for flow cytometry. The easi-
est way to obtain granulocytes for analysis is to use whole blood
and perform lysis of erythrocytes. This can be achieved by several
methods (e.g. short hypotonic water lysis, ammonium chloride
treatment or commercially available RBC lysis buffers).
7.2 Discrimination by FSC/SSC
Differential light scattering of cells depending on the size andmor-
phology is useful to discriminate subsets of cells. The side scatter
(SSC) is considered to be an indicator for the internal structure of
the cell (e.g. nuclear morphology) and the forward scatter (FSC)
reflects cellular size. Since neutrophils and eosinophils have a
multilobulated nucleus, they exhibit a high SSC signal. However,
eosinophils show a slightly higher signal in this parameter. The
nuclear morphology of basophils is less complex and therefore
they are found among the lymphocyte population and cannot be
distinguished in such a manner (Fig. 111A).
Changes in SSC and FSC may also represent other morpho-
logical features of various cellular processes (e.g. phagocytosis,
C© 2017 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.eji-journal.eu
Eur. J. Immunol. 2017. 47: 1584–1797 Cytometric phenotypes 1757
Figure 110. Flow cytometric analysis of CNS macrophages. Neutrophils are excluded according to their Ly6G expression. Microglia are defined
as CD45int CD11b+ cells (red). Monocytes (blue) and monocyte-derived macrophages (green) are defined as CD45hi CD11b+ Ly6C+ and Ly6C− cells,
respectively.
cell death). These changes can also be detected in this fashion as
described below in this section.
7.3 Discrimination using specific antibodies
To detect either human or murine granulocytes it is useful to start
with a staining for CD45 to define white blood cells, accompanied
by simultaneous staining for CD11b. These two markers, together
with FSC and SSC features, are enough to roughly identify granu-
locytes from whole blood preparations.
Human neutrophils are the most abundant cell type within
the granulocyte family. They can be easily distinguished from
other granulocytes by their positivity for both CD15 and CD16.
Eosinophils are positive for CD15, but do not express CD16. Addi-
tional staining for CCR3 and Siglec-8 allows a specific detection of
eosinophils. Basophils neither express CD15 nor CD16, therefore
staining with anti-FcεRIα identifies them in the CD15neg/CD16neg
population (Fig. 111B).
Murine neutrophils and eosinophils are CD11b positive and
exhibit an intermediate to low expression of Ly6C. Neutrophils are
detected as Ly6G positive cells, whereas eosinophils are identified
by their expression of CCR3 and Siglec-F. Basophils also show
positivity for CD11b, but have only a low expression of Ly6C.
They can be further identified by the expression of CD200R3 and
CD49d (Fig. 111C). For details see Table 29.
7.4 LIVE/DEAD analysis of granulocytes
Especially in the context of studying inflammatory infiltrates, it is
sometimes necessary to determine whether neutrophils are viable.
During the resolution of inflammation, neutrophils undergo apop-
tosis, mediate anti-inflammatory and immunosuppressive effects,
and secrete factors that prevent the additional influx of neu-
trophils.
Granulocyte apoptosis can be detected by a combination of
propidium iodide (PI) and fluorophore-conjugated annexin A5
(AxA5). PI is a DNA-intercalating substance that only enters cells
that have lost their membrane integrity (necrotic cells and NETotic
cells). AxA5 binds to phosphatidylserine (PS) exposed by cells
undergoing apoptosis (Fig. 112A). See Section VII.8: Cell death,
for further information.
1. If granulocytes have been purified prior to the live/dead analy-
sis, no antibody staining is needed. However, if more than one
cell type is present, the cell death staining should be supple-
mented with an antibody combination, allowing the identifica-
tion of granulocytes as mentioned above.
2. Minimal manipulation of the cells is essential for the quality of
the cell death staining. The initial cell suspension, i.e. a peri-
toneal lavage or whole blood, should be depleted of erythro-
cytes, centrifuged at 300 g for 10 min and then resuspended in
a small volume of HBSS including calcium andmagnesium and
supplemented with 2% FCS. Usually, cell suspensions of 1 ×
106 cells per milliliter are required for antibody and apoptosis
staining. Optimal results are achieved using a staining solution
containing PI (100 ng/mL) and AxA5 (1μg/mL). Homogenous
staining can be assured by gentle tapping of the tube.
3. The cells should be stained for 30minutes at room temperature
in the dark.
4. After incubation, the sample is immediately subjected to anal-
ysis by flow cytometry. No additional washing steps are recom-
mended, since they can lead to the loss of subcellular apoptotic
particles and to the degeneration of apoptotic cells.
Modern flow cytometers allow the simultaneous use of mul-
tiple fluorophores. If such an instrument is available, the classi-
cal apoptosis staining, deploying AxA5-conjugates and PI, can be
supplemented with two additional dyes (e.g. Hoechst33342 and
1,1′,3,3,3′,3′-hexamethylindodicarbo-cyanine iodide (DilC1(5)),
which would allow a more detailed characterization of cell death.
This staining takes into account the condition of the nucleus and
the mitochondrial membrane potential respectively, and can also
be deployed for live-cell imaging [867, 868].
7.5 Measuring phagocytic uptake of microparticles by
granulocytes
Neutrophils show a strong capacity to take up particulate matter.
When confronted with nanoparticles or small-sized monosodium
urate crystals, neutrophils engulf these particles. Since such
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Figure 111. Discrimination of granulo-
cyte subpopulations. Human or murine
whole blood was subjected to hypotonic
water lysis to remove erythrocytes prior
to antibody staining. Cells were incu-
bated with antibodies for 30 min at
4°C (human) or on ice (murine) in the
dark. Stained cells were acquired using a
BeckmanCoulter GalliosTM FlowCytome-
ter and analyzed by Beckman Coulter
Kaluza R© Flow Analysis Software 1.3. (A)
Human cells are displayed in a SSC ver-
sus FSC dot plot to show the location
of eosinophils (green, high SSC), neu-
trophils (blue, high SSC), and basophils
(red, low SSC). (B) Human cells were
stained with antibodies against CD45,
CD11b, CD15, CD16, CCR3, Siglec-8 and
FcεRIα. CD45+/CD11b+ cells were gated
on CD15 versus CD16 to distinguish gran-
ulocyte subpopulations. CD15+/CD16+
cells were determined as neutrophils,
CD15+CD16− were further designated as
eosinophils by their expression of Siglec-
8 and CCR3, and the CD15−/CD16− pop-
ulation was depicted in a FcεRIα versus
CCR3 plot to identify the double posi-
tive basophil fraction. (C) CD45+ murine
cells were gated on CD11b/Ly6C to dis-
play the CD11b+/Ly6int population which
was further analyzed using Ly6G to iden-
tify neutrophils (blue). CD11b+/LyCneg-low
cells were gated on Siglec-F versus
CD200R3 and were subsequently ana-
lyzed for expression of additional cell
subset markers. CD200R3− cells express-
ing Siglec-F and CCR3 were designated
as eosinophils (green) and Siglec-F− cells
were marked as basophils (red) sup-
ported by their expression of CD200R3
and CD49b.
materials cannot be easily conjugated with fluorophores, one has
to rely on other methods to monitor their uptake. Soluble dyes,
such as Lucifer Yellow, can be added together with the “prey par-
ticle” and will be co-ingested during phagocytosis. In addition, the
uptake of particulate matter tends to increase the complexity of
the phagocyte. As shown in Fig. 112B, the increase in SSC and
in Lucifer Yellow strongly correlates. Observation of either one
represents a feasible method for addressing such questions.
Table 29. Selection of most important markers for flow cytometry analysis of granulocytes
Cell type Mouse Human
Basophil CD45pos, CD11bpos, Ly6Clow, CD200R3pos, CD49bpos,
FcεRIαpos
CD45pos, CD11bpos, CD15neg, CD16neg, CCR3pos,
FcεRIαpos, CD203pos, CD117neg
Eosinophil CD45pos, CD11bpos, Ly6Clow/int, Siglec-Fpos, CCR3pos,
FcεRIαpos
CD45pos, CD11bpos, CD15pos, CD16neg, Siglec-8pos,
CCR3pos, FcεRIαpos
Neutrophil CD45pos, CD11bpos, Ly6Cint, Ly6Gpos CD45pos, CD11bpos, CD15pos, CD16pos, CD66bpos
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Figure 112. Apoptosis detection and uptake of nanoparticles in purified human granulocytes. Human granulocytes were purified by density gradi-
ent centrifugation with Lymphoflot. Erythrocyte contaminations were depleted by hypotonic water lysis. Human granulocytes were resuspended
in RPMI-1640 supplemented with 50 U/mL penicillin/streptomycin, 2 mM glutamine and 10% heat-inactivated fetal calf serum and 25 mM HEPES
at a concentration of 2 × 106 cells/mL. (A) Granulocytes were cultivated at 37°C/CO2 for indicated time points and stained according to the protocol
included in this article. Subsequently, they were subjected to analysis on a Beckman Coulter CytoFLEXTM Flow Cytometer. Evaluation of data was
performed with the Beckman Coulter software CytExpert 1.2. During apoptosis, granulocytes shrink and increase in granularity, as indicated by
a decrease in FSC and an increase in SSC. Viable cells (V) first start to expose AxA5-FITC and become apoptotic (A), before they lose their plasma
membrane integrity and become necrotic as indicated by PI-positivity (N). Note that in the N-gate the population high in PI reflects cells without the
loss of nuclear content. In contrast, the population low in PI reflects cells with a subG1 DNA content, which is considered a hallmark of apoptosis.
(B) 20 μg/ml micro monosodium urate crystals and 250 μg/mL Lucifer Yellow were added to the granulocytes and the suspension was incubated
at 37°C/CO2 for the time points indicated. Subsequently, analysis was performed on a Beckman Coulter GalliosTM flow cytometer. Evaluation of
data was performed with the Beckman Coulter Kaluza R© Flow Analysis Software 1.3. The increase in Lucifer Yellow (see arrow; in red) is restricted
to the population of cells which increase in granularity. Therefore, the simultaneous increase in Lucifer Yellow and SSC can be used to monitor
the uptake of nanoparticles by granulocytes.
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7.6 Pitfalls of flow cytometry analysis of granulocytes
 Neutrophil release from the bone marrow follows a circadian
rhythm [869]. To ensure the highest comparability, neutrophils
from different donors should be isolated roughly at the same
time.
 When flow cytometric analysis is performed, proper arrange-
ments are necessary to prevent neutrophil adhesion. Neu-
trophils show a tendency to adhere under serum free condi-
tions, to glass or adhesive plastic surfaces and especially fast in
response to stimulation. Supplementation of culturemedia with
10% fetal calf serum or 1% bovine serum albumin counteracts
neutrophil adhesion to surfaces.
 Neutrophils have a very limited life time. They undergo full
blown apoptosis in less than 24 h. In addition, several stimuli
induce the formation of neutrophil extracellular traps. Although
it is possible to detect NETs as material with very high SSC, flow
cytometry is not robust enough to quantify NETs.
 Furthermore, NETs tend to aggregate and form material which
cannot be collected by standard needles.
 Phagocytic uptake of particles alters themorphology of a variety
of cell types. It is therefore not advisable to identify granulocyte
populations only by SSC.
 Activation of leukocytes is usually accompanied by shedding
or membrane renewal consequently changing their phenotype
(e.g. CD16 downregulation).
 Live/dead stainings deploying AxA5 must be performed in the
presence of at least 2 mM calcium, since binding of AxA5 to
phosphatidylserine in the membrane is calcium-dependent.
8 Bone marrow stromal cells
8.1 Introduction
The bone marrowmicroenvironment is composed of multiple stro-
mal cell populations involved in the formation and regeneration of
the skeleton and in the regulation of hematopoiesis. Bone marrow
stromal cells are thought to originate from mesenchymal stem
and progenitor cells (MSPCs) [870, 871] and have been shown
to support hematopoietic stem cell (HSC) functions through their
expression of adhesionmolecules and their secretion of HSCmain-
tenance factors [872]. Recent technological advances allowed the
identification of distinct perivascular stromal cell populations that
constitute the HSC niche and are responsible for maintaining
either quiescent or proliferative HSCs at the steady state or after
stress [873–876]. Cell surface markers have been suggested to
label bone marrow stromal cells but many of these markers are
based on the expression of cultured stromal cells [877] as opposed
to freshly isolated stroma [878–880]. Therefore, the identification
and isolation of bonemarrow stromal cells by flow cytometry using
standardized cell preparation criteria are critical for their applica-
tion in regenerative medicine and the understanding of their role
in the HSC niche.
8.2 Materials
8.2.1 Animals.
 Adult mice such as C57BL/6 (8–12 weeks old)
8.2.2 Reagents.
 Collagenase type IV (Gibco, Cat #17104019)
 Dispase (Gibco, Cat #17105-041)
 PBS 10X (Fisher Scientific, Cat #BP665-1)
 EDTA (Sigma, Cat #E5134)
 Ammonium chloride (Sigma, Cat #A4514)
 Potassium bicarbonate (Fisher Scientific, Cat #P235)
 BSA (Sigma, Cat #BP1600-100)
 DAPI (Sigma, Cat #D9542)
 Anti-Mouse CD45 antibody (30-F11, Biolegend)
 Anti-Mouse Ter119 antibody (Ter-119, Biolegend)
 Anti-Mouse CD31 antibody (390, Biolegend)
 Anti-Mouse CD51 antibody (RMV-7, eBioscience)
 Anti-Mouse PDGFRα antibody (APA5, eBioscience)
8.2.3 Solutions.
 HBSS (Corning, Cat #21-023-CV)
 Flow cytometry buffer (PBS 1X, EDTA 2 mM, BSA 0.1%)
 RBC lysis buffer (NH4Cl 0.17M, KHCO3 0.01 M, EDTA 0.1 mM)
 Digestion buffer (Collagenase IV 2 mg/mL, Dipase II 1 mg/mL
in HBSS)
 DAPI (0.05 μg/mL in flow cytometry buffer)
8.2.4 Equipment.
 1 mL syringe with 21G x 1 needle (for femurs) or 25 G x 5/8
needle (for tibias)
 100 uM cell strainer (Falcon, Cat #08-771-19)
 CD45 microbeads, mouse (Miltenyi Biotec, Cat #130-052-301)
 MACS
R©
LS column (Miltenyi Biotec, Cat #130-042-401)
 QuadroMACS
R©
separator (Miltenyi Biotec, Cat #130-090-976)
 Flow cytometry cell sorter (at least 5 colors and equipped with
UV laser)
8.3 Procedure
The stromal fraction of the bone marrow is highly heterogeneous
and includes MSPCs that possess tri-lineage differentiation into
osteoblasts, adipocytes and chondroblasts [871]. In order to iso-
late MSPCs and stromal cells from the bone marrow, extraction
of an intact bone marrow plug is necessary as opposed to the
standard crushing or flushing technique used for hematopoietic
cells [881]. Sequential digestion of the bone marrow plug allows
the recovery of MSPCs that can be measured by colony-forming
units-fibroblasts (CFU-F) activity, which ismostly absent in flushed
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Table 30. Antibodies for bone marrow stromal cells
Antibody Clone Company
CD45 30-F11 Biolegend
Ter119 Ter-119 Biolegend
CD31 390 Biolegend
CD51 RMV-7 eBioscience
PDGFRα APA5 eBioscience
bone marrow. Femurs or tibias from mice are cut below the
metaphysis and the intact bone marrow plug is gently flushed
out with digestion buffer containing collagenase type IV and dis-
pase. Bone marrow plugs are sequentially digested three times for
10 min at 37°C and the supernatant is collected between diges-
tions and pooled into a tube containing ice-cold flow cytome-
try buffer to stop further digestion, which may result in a loss
of cell viability or detection of cell surface markers. The single-
cell suspension containing bone marrow stromal cells can then
be pelleted, subjected to red blood cell lysis and filtered using
100 μm cell strainer. For cell sorting, enrichment for stromal cells
can also be obtained by incubating bone marrow digested cells
with CD45 mAb-conjugated microbeads (for further details see
Section II.1.2.1: Magnetic beads coupled to antibodies). After 10
min incubation at 4°C, the cell suspension is washed and applied
onto a MACS
R©
LS column, resulting in the elution of an enriched
fraction of bone marrow stromal cells. In order to analyze stro-
mal cells by flow cytometry, antibody staining is performed using
antibodies (Table 30) that allow exclusion of hematopoietic cells
(CD45, Ter119), as well as the identification of endothelial cells
(CD31). Finally, stained cells are washed and resuspended in a
buffer containing a viability dye such as DAPI to exclude dead
cells.
8.4 Gating strategy
In adult mice (8–12 weeks old), the bone marrow stromal frac-
tion is commonly defined as CD45− Ter119− CD31− cells (triple-
negative cells or TNCs) and represents 0.3–1.0% of total digested
live cells, using the above-mentioned digestion conditions. There-
fore, it is important that antibody titration is performed prior
to staining in order to exclude any hematopoietic (CD45+ or
Ter119+) or endothelial cells (CD45− Ter119− CD31+). To ana-
lyze MSPCs, the first gate is drawn around TNCs and then MSPCs
can be identified by their expression of both CD51 and PDGFRα
(CD45− Ter119− CD31− PDGFRα+ CD51+) [879]. Under these
conditions, the frequency of MSPCs is typically around 5–15% of
TNCs (Fig. 113); however, depending on the gating for TNCs, the
efficiency of the digestion as well as the method used in isolating
bone marrow cells the MSPC frequency can vary. Indeed, previ-
ous studies showed that MSPCs can also be isolated by digesting
crushed bones which includes bone stromal cells that are probably
phenotypically and functionally distinct [875, 878, 879].
Genetic models can also be used in order to label stromal
cells, for example mice expressing GFP under the Nestin promoter
have been shown to label MSPCs [882] where 60% of Nestin-GFP
stromal cells overlap with the CD45− CD31− Ter119− PDGFRα+
CD51+ and leptin receptor expressing cells [879]. MSPCs defined
as CD45− CD31− Ter119− PDGFRα+ Sca1+ can be harvested from
digested crushed bones although they exhibit little overlap (5%)
with bone marrow Nestin-GFP cells, suggesting that bone mar-
row MSPC activity, unlike that of bone, may not be contained in
the bone marrow CD45− CD31− Ter119− PDGFRα+ Sca1+ cell
fraction [879]. Expression of fluorescent proteins in stromal cells
can also be achieved through the use of reporter mice, which
can be useful for labeling stromal cell populations or performing
lineage-tracing studies that can be analyzed by flow cytometry cell
sorting [874–876, 882–886].
9 Hematopoietic stem cells
9.1 Introduction
Hematopoietic stem cells (HSCs) are rare, self-renewing progeni-
tors giving rise to all lineages of blood cells. Moreover, HSCs are
Figure 113. Gating strategy for bone marrow stro-
mal cells. Live single cells are separated using
CD45, Ter119 and CD31 markers. Cells were then
gated for TNCs (CD45− Ter119− CD31−) and MSPCs
were analyzed using CD51 and PDGFRα (CD45−
Ter119− CD31− PDGFRα+ CD51+).
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Figure 114. Phenotypic characterization of mouse HSCs in BM in vivo. (A) LT-pHSCs were identified as Lin–c-Kit+Sca-1+
Thy1.1loFlk2−CD34−CD201highCD150+CD48– cells [911]. (B) Alternatively, LT-pHSCs that are endowed with Hoechst dye efflux properties were
identified as side population (SP) cells and further purified as Lin–c-Kit+Sca-1+ cells.
capable of long-term production of all blood cell types in primary
irradiated recipients in transplantations, as well as self-renewal,
such that the cells can be transplanted to secondary hosts to give
rise to long-term multilineage repopulation [887–889].
The balance of HSC quiescence, self-renewal and differenti-
ation strongly depends on the interaction of HSCs with their
niche [890–892]. In the developing embryo HSCs reside in the
fetal liver that has not yet formed a niche allowing longevity of
the cells [893]. From E 17.5 the bone marrow is colonized by
HSCs, the BM remains the main hematopoietic niche through-
out adult life [894, 895]. In adults, the most primitive HSCs are
thought to localize to the most hypoxic microenvironments in the
BM, the hypoxic stem cell niche, resulting in the maintenance of
the primitive phenotype and cell cycle quiescence to avoid HSC
senescence [644, 896].
Mouse HSCs can be isolated by flow cytometry, based on
surface-marker expression. The first step in the isolation of
mouse HSCs from BM usually consists of removing mature
cells that express “lineage” (Lin) antigens specific to terminally
differentiated blood cells, including F4/80+/Mac1+ monocytes
and macrophages, Gr1+ granulocytes, CD11c+ dendritic cells,
CD4+/CD8+/CD3+ T cells, CD5+CD19+B220+ B cells, NK1.1+
NK cells and Ter119+ erythrocytes. These antigens are absent on
HSCs. HSCs are then further enriched as lineage-negative (Lin–)
cells that express combinations of cell surface markers. Commonly
used markers include Thy1.1, c-Kit and Sca1. Thus, multipotent
hematopoietic progenitors have been purified as Lin−Thy1.1loc-
Kit+Sca-1+ cells that make up <0.1% of nucleated BM cells
[897–900]. Although this population contains all multipotent pro-
genitors in mice, it is still heterogeneous, containing transiently
reconstituting multipotent progenitors in addition to long-term
reconstituting HSCs.
Fortunately, there are differences in surface-marker expres-
sion between long-term self-renewing HSCs and transiently
reconstituting multipotent progenitors, which permit the inde-
pendent isolation of these progenitor populations. One strat-
egy involves sorting of so-called “SLAM” cells [901–903] as
a Lin–c-Kit+Sca-1+Thy1.1loCD150+CD48– population contain-
ing mainly long-term self-renewing HSCs, the Lin–c-Kit+Sca-
1+Thy1.1loCD150+CD48+ population containing mainly tran-
siently self-renewing multipotent progenitors, and the Lin–c-
Kit+Sca-1+Thy1.1loCD150−CD48+ population containing mainly
non-self-renewingmultipotent progenitors, followed by transplan-
tation analyses. These three distinct populations vary with each
stage in the progression toward lineage commitment in their
frequency, engraftment-kinetics, self-renewal potential, cell-cycle
status, gene expression, and lineage distribution of the mature
cells they can generate in vivo.
However, SLAM-defined cells themselves are still heteroge-
neous populations in which HSCs represent, at most, 20% of all
cells. Further enrichment of HSCs can be achieved by the purifi-
cation of SLAM-defined cells that express high levels of CD201
(EPCR) and low levels of CD34 and Flk2 [904, 905]. Thus, long-
term self-renewing pluripotent HSCs (LT-pHSCs) are enriched as
Lin–c-Kit+Sca-1+Thy1.1loFlk2−CD34−CD201highCD150+CD48–
bone marrow cells (Fig. 114A; Table 31). Although transiently
reconstituting multipotent progenitors are enriched in the CD34+
fraction, no evidence indicates that they can be purified based on
CD34 expression.
In addition, other markers such as AA4.1 or Aldehyde dehy-
drogenase permit the purification of HSCs, but they have not been
shown to permit the simultaneous purification of transiently recon-
stituting multipotent progenitors [906].
Finally, HSCs can be isolated due to their hypoxia-induced
high expression of the multidrug transporter proteins MDR1 and
ABCG2, thus, cells that retain only low levels of DNA dyes, such
as Rhodamine-123 (Rho123) and Hoechst 33342. Rho123lo or
Hoechstlo cells (“side population,” SP cells), and that are Lin–c-
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Table 31. Selection of most important markers for flow cytometry analysis of mouse BM hematopoietic stem cells
Cell type Mouse Human
Long-term self-renewing
pluripotent hematopoietic
stem cells (LT-pHSC)
Negative:
F4/80, Mac1, Gr1, CD11c, CD4, CD8,
CD3, CD5, CD19, B220, NK1.1, Ter119
Negative:
CD1c, CD14, CD15, CD16, CD20, CD41,
CD11c, CD56, CD203c, CD235a,
BDCA2, Ter119
Thy1.1low, Flk2, CD34, CD48 CD38, CD45RA
Rho123low / Hoechstlow Rho123low / Hoechstlow
Positive: Positive:
c-Kit, Sca1, CD201high, CD150 CD34, CD90
Figure 115. Phenotypic characterization of human pHSCs in
the peripheral blood in vivo. LT-pHSCs were identified as
Lin–CD34+CD38–CD90+ cells, and MPPs as Lin–CD34+CD38+CD90− cells
[911].
Kit+Sca-1+ are nearly pure populations of long-term reconstitut-
ing HSCs [907, 908] (Fig. 114B; Table 31).
Nevertheless, all of these purified HSCs are still heterogeneous
population of cells regarding their functionality. It is believed that
myeloid-biased HSCs express higher levels of CD150 and efflux
Hoechst 33342 more efficiently than lymphoid-biased HSCs. They
also exhibit higher self-renewal ability as demonstrated by serial
transplantation of BM cells from primary recipients into secondary
hosts.
In contrast, the most important marker of primitive human
hematopoietic cells is the cell surface protein CD34. Most human
HSCs are CD34+, as demonstrated by xenotransplantation assays
and clinical transplants performed with purified CD34+ cells from
different hematopoietic tissues. However, CD34 expression alone
does not provide an accurate measure of HSCs and immature
progenitors, and additional markers are required to identify and
isolate the most primitive hematopoietic cells [909].
As described for mouse cells, human HSCs do not express
Lin antigens and Lin−CD34+ cells can then be separated by
sub-fractionating using markers that are differentially expressed
on primitive and more differentiated cells. The most com-
mon markers include CD38 and CD45RA, which are absent
or only weakly expressed on primitive cells, and CD90,
which is expressed at higher levels on primitive cells than
on differentiated cells (Fig. 115; Table 31). As few as 10
Lin−CD34+CD38−CD45RA−CD90+ peripheral blood cells have
been shown to engraft the BM of immunodeficient mice and gen-
erate human lymphoid and myeloid cells for at least 12 weeks
after transplantation, thus, are identified as LT-pHSCs [910]. Puri-
fied Lin−CD34+CD38−CD45RA− cells that lack CD90 expression
can also contribute to long-term repopulation in immunodeficient
mice, but more cells are required to achieve engraftment and the
cellular output per transplanted stem cell is lower. This suggests
that HSCs in the CD90- subset represent a less primitive cell subset
than their CD90+ counterparts.
9.2 Materials
9.2.1 Staining of mouse BM.
1. Adult mice such as C57BL/6, typically, 6- to 10-week-old mice
are used for the isolation of HSCs.
2. Staining medium: Phosphate Balanced Salt Solution (1xPBS)
with 2% heat-inactivated calf serum.
3. Nylon screen (40 μm nylon mesh) to filter the cells after isola-
tion.
4. 10-mL syringes with 25-gauge needles to flush marrow out of
femurs and tibias.
5. Use 15-mL tubes to stain BM cells. Note that cells must be
transferred to 6-mL Falcon tubes for fluorescence-activated
cell-sorting.
Antibodies described in this protocol are available from eBio-
science and BioLegend.
6. Lineage-marker antibodies: anti-Mac1 (M1/70), anti-Gr1
(RB6-8C5), anti-Ter119 (TER-119), CD19 mAb (1D(3)), anti-
B220 (RA3-6B2), CD5 mAb (53-7.3), CD3ε mAb (145-2C11),
CD11c mAb (N418), CD4 mAb (GK1.5), CD8 mAb (53-6.7),
anti-NK1.1 (PK136). Note that all antibodies should be titrated
before use, and used at dilutions that brightly stain antigen-
positive cells without nonspecifically staining antigen-negative
cells.
7. Anti-Thy-1.1 (19XE5), anti-Flk2 (A2F10), CD201 mAb (RCR-
16), anti-Sca-1 (D7), anti-c-kit (2B(8)), CD150 mAb (TC15-
12F12.2), CD34 mAb (RAM34), CD48 mAb (HM48-1).
8. SP buffer (PBS, 2% FCS, 2 mM HEPES buffer; GIBCO, Life
Technologies), Hoechst 33342 (5 μg/mL, Molecular Probes,
Life Technologies).
9. A viability dye such as propidium iodide (PI) or 7-
aminoactinomycin D (7-AAD).
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9.2.2 Staining of human peripheral blood.
1. For the purification of 2–40 × 103 circulating human
hematopoietic precursor cells from 90 mL of peripheral blood,
PBMCs were obtained by Ficoll-Paque density gradient cen-
trifugation.
2. Lineage-marker antibodies: CD1c mAb (AD5-8E7, Miltenyi
Biotec), CD3 mAb (UCHT1, Beckman Coulter), CD11c mAb
(Bu15, Beckman Coulter), CD14 mAb (RMO52, Beckman
Coulter), CD15 mAb (HI98, BioLegend), mAb CD16 (3G8,
Beckman Coulter), CD20 mAb (2H7, BioLegend), CD41 mAb
(SZ22, Beckman Coulter), CD56 mAb (C218, Beckman Coul-
ter), CD203c mAb (NP4D6, BioLegend), CD235a mAb (KC16,
Beckman Coulter), anti-BDCA2 (AC144, Miltenyi Biotec).
3. CD34 mAb (8G12, BD Biosciences), CD38 mAb (HIT2, Biole-
gend) and CD90 mAb (5E10, Biolegend).
4. A viability dye such as propidium iodide (PI) or 7-
aminoactinomycin D (7-AAD).
A flow cytometry cell sorter with at least four-color capability,
for example a FACS ARIA (BD Biosciences) should be used.
10 Tumor cells
10.1 Introduction
Tumor, also called cancer, cells are derived from healthy, non-
transformed cells of either hematopoietic, epithelial, endothelial,
neuroectodermal ormesenchymal origin, resulting from a sophisti-
cated process of malignant transformation. Therefore, the respec-
tive origin of a tumor cell implicates the markers suitable for its
flow cytometric characterization. The hematopoietic marker pan-
CD45, which was originally defined as leukocyte common antigen
(LCA), can be used for the discrimination of hematopoietic tumor
cells such as leukemias and lymphomas with CD45 epitopes being
present in all splice variants that can be utilized to stain all cells
of hematopoietic origin including hematopoietic progenitor cells
(HCS, see Section VIII.9: Hematopoietic stem cells [912]). As a
consequence, pan-CD45 represents a useful marker for the dis-
crimination of hematopoietic malignancies from solid tumor cells.
The classification of leukemias and lymphomas is guided by
flow cytometry that has been harmonized, standardized and
successfully integrated into clinical routine for immunophenoty-
ing [913]. The EuroFlow (www.euroflow.org) consortium, rep-
resented and headed by Jacques M. van Dongen, has designed
panels for n-dimensional flow cytometric immunophenotyp-
ing of normal, reactive and malignant leukocytes, and devel-
oped novel computerized evaluation procedures for the char-
acterization and quantification of human hematopoietic malig-
nancies. The EuroFlow guidelines represent the gold stan-
dard of immunophenotyping of hematopoietic malignancies
(http://euroflow.org/usr/pub/pub.php). For research laborato-
ries working on leukemias or lymphomas in rodents or man, it
is important to mention that virtually all hematopoietic malig-
nancies are accompanied by a disturbed distribution of the lym-
phocyte subsets in peripheral blood. Therefore, detailed knowl-
edge of the “normal” distribution of leukocytes in healthy donors,
human or mouse, is instrumental for the analysis of the influ-
ence of malignant cells on hematopoiesis and immune function.
“The ONE Study” group guided by Birgit Sawitzki has established
an advanced flow cytometry panel for humans in order to define
the distribution of the most important T-cell, B-cell, NK-cell and
monocyte, dendritic cell subsets in healthy individuals in order
to be able to compare these in the future with the distribution
of patients undergoing solid organ transplantation accompanied
by cellular therapy using suppressor cell populations [914]. The
International Society for Advancement of Cytometry (Cytocon-
ference, http://cytoconference.org/2016/Home.aspx), the CIP
consortium (CIMT immunoguiding program) of the Can-
cer Immunotherapy Consortium (CIMT, http://www.cimt.eu/
workgroups/cip/proficiency), the International Clinical Cytome-
try Society (ICCS, http:// www.cytometry.org/web/index.php),
the Federation of Clinical Immunology Societies (FOCIS,
http://www.focisnet.org/index.php) represent other initiatives
with the aim to harmonize and standardize protocols for
immunophenotyping primarily of human peripheral blood, but
also of tissue-derived immune cells as well as parenchymal cells
such as tumor cells. The tremendous efforts of these consortia to
establish guidelines, protocols and tools for the quantification of
leukocytes, tumor cells and immune responses will be instrumen-
tal not only for research projects but also for future clinical studies,
in particular with immunological endpoints.
10.2 Material, solutions, and antibodies
Solid tumor cell lines are available in collaboration with research
groups, by several vendors and the ATCC (american type tissue
collection, https://www.lgcstandards-atcc.org/). Recommended
antigens for staining of human solid tumor cells for flow cytom-
etry cell sorting are listed in Table 32. The staining procedures
are identical to the general recommendations for indirect surface
marker staining, direct surface marker staining and intracellular
staining protocols, respectively, summarized in Section VII.2: Sur-
face parameters and Section VII.3: Intracellular parameters.
10.3 Preparation of tissue, staining of samples and gating
strategy
The staining protocols for human or murine tumor cell lines or
tumor cells derived from fresh tumor tissue after enzymatic diges-
tion follow the general recommendations summarized in Section
VII.2: Surface parameters and Section VII.3: Intracellular param-
eters of this guideline. With respect to human or murine tumor
tissue digestion, the same protocols can be applied as summa-
rized in Section IV.3: Preparation of single-cell suspensions, using
collagenase, hyaluronidase and DNAse. These three enzymes are
known not to affect surface expression of the molecules listed
in Tables 32 and 33, respectively. After digestion and Ficoll
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Table 32. Collection of surface molecules for flow cytometry cell sorting staining of human solid tumor cells
Antigen Molecules / synonyms Antibody / clone (selection)
MHC class I complex HLA class I, all HLA-A, -B, -C alleles W6/32, HC10
beta2- microglobuline, β2m HB28, B2M-01, 2M2
MHC class II HLA-DR; HLA-DQ; HLA-DP L243; TU¨169, SK10; B7/21
NKG2D ligands MICA; MICB; ULBP1; ULBP2; ULBP3 MAB1300; MAb1599; MAB1380; MAB1289; MAB1517
ICAM-1 CD54 9H21L19; LB-2
VCAM CD106 51-10C9
Ep-CAM CD326 EBA-1, 9C4, 22HCLC
VE-cadherin CD144 BV13, 55-7H1, BV9
E-cadherin CD234 36/E-cadherin, 5HCLC, 67A4
EGFR HER1 EGFR.1, H11, 199.12,
PDGFR CD140a (alpha chain) AlphaR1, 16A1,
CD140b (beta chain) 28D4, 18A2, Y92,
c-Met HGFR 3D6, ebioclone97
pan-cytokeratin pan-cytokeratin C-11, PAN-CK
cytokeratin 18 CK18 CK2, C-04, DC10, AE1, E431-1
cytokeratin 8 CK8 K8.8, 5D3, C-43, M20
CD99 TU¨12, 3B2/TA8, EPR3096,
density centrifugation, single-cell suspensions can be frozen as
living cells or analyzed immediately using the flow cytometry cell
sorting staining protocols presented in Section IV.3: Preparation
of single-cell suspensions.
10.3.1 Direct and indirect staining of surface molecules expressed by
adherent tumor cells.
1. Cultured adherent tumor cells are detached and singularized
by washing with 5 mL PBS followed by treatment with 0.05%
trypsin/ 0.02% EDTA solution (1 mL per T25 culture flask) for
2-5 minutes, gentle shaking and detachment by adding 5 mL
medium (RPMI1640 + 5% heat-inactivated FBS).
2. Cell count of the single-cell suspension is determined using
trypan blue solution for discrimination of dead cells.
3. 1–2× 105 cells for each antibody are pelleted by centrifugation
(800 g, 5 min) in flow cytometry tubes and resuspended (15
sec vortex).
4a. For indirect staining, unlabeled monoclonal antibody or iso-
type control mAb solutions (50 μL, 5 μg/mL) are added to
the single-cell suspensions for 30 min at 4°C. After washing
Table 33. Collection of surface molecules for flow cytometry cell sorting staining of murine solid tumor cells
Antigen Molecules / synonyms Antibody / clone (selection)
MHC class I complex MHC class I all H-2 molecules M1/42
H-2K; H-2D; H-2L Kd+Dd (ab131404); Dd (ab25590); Kb (ab93364);
beta2-microglobuline, β2m S19.8
MHC class II I-A, I-E M5/114.15.2
NKG2D ligands Rae-1, H60, MULT1 (Rae-1g (CX1); H60 (MAB1155); MULT1 (5D0)
ICAM-1 CD54 YN1/1.7.4
VCAM CD106 429
Ep-CAM CD326 G8.8
VE-cadherin CD144 ab33168, MC13.3
E-cadherin CD234 DECMA-1, M168
EGFR HER1 EP38Y,
PDGFR CD140a (alpha chain) APA-5
CD140b (beta chain) APB-5
c-Met HGFR ebioclone7, EP1454Y
pan-cytokeratin pan-cytokeratin C-11, ab9377, AE1/AE3
cytokeratin 18 CK18 6—19
cytokeratin 8 CK8+CK18 EP1628Y
CD24 J11d, M1/69, 30-F1
CD34 RAM34, MEC14.7, MAB6518
CD44 IM7,
CD133 13A4, 315-2C11,
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twice with 500 μL flow cytometry buffer (PBS, 1 % FBS, 0.1
% Na-azide), and vortexing, FITC-, PE-, APC- or pacific blue-
labeled goat-anti mouse antibody solutions (100 μL of dilu-
tions between 1:100 and 1:200) are added for 30 min at 4°C
in the dark.
4b. For direct staining, cells are resuspended in 50 μL flow cytom-
etry buffer and 1–5 μL of directly labeled (titrated) mAb are
added for 30 min at 4°C in the dark.
5. After two washing steps, cells are resuspended in 150 μL flow
cytometry buffer if measured immediately or in flow cytome-
try fixation buffer (PBS, 1% FCS, 1% paraformaldehyde) and
stored at 4°C until measurement.
6. For live/dead exclusion, 1–2μL propidium iodide (PE channel)
or 7AAD (PerCP channel) solutions are added directly before
measurement which is only suitable without prior fixation.
10.3.2 Detection of circulating tumor cells in peripheral blood and
bone marrow. The detection of circulating tumor cells in periph-
eral blood and bone marrow, respectively, has clinical relevance
for several forms of carcinomas and sarcomas in terms of dis-
ease staging and treatment response [915]. Although molecular
methods such as real-time PCR of tumor-specific mRNA expressed
by carcinoma, sarcoma or melanoma tumor cells etc., recently
called “real time liquid biopsy,” have a higher sensitivity com-
pared to flow cytometry, this technique is still valid for the quan-
tification and characterization of circulating cancer cells. Under
non-malignant conditions, cells of epithelial, mesenchymal or neu-
roectodermal origin cannot be detected in blood or bone marrow
aspirates. However, the process of metastasis formation is asso-
ciated with dissemination of malignant cells through the blood
stream and bone marrow. Therefore, disseminating cancer cells
are detectable in these compartments but at very low frequencies
close to the detection limit. Hence, enrichment techniques such as
antibody-based magnetic positive or negative selection are used
to increase sensitivity of detection. For the quantification of tumor
cells, the direct or indirect staining protocol outlined in Section
VII.9.3.1: Phagocytic cell types and sample preparation, is com-
bined with the marker pan-CD45 for the exclusion of leukocytes.
As discussed inmore detail in the following paragraphs, the epithe-
lial markers Ep-CAM (CD326) or CK18 are suitable markers for
the detection of carcinoma cells. For sarcomas, the mesenchymal
marker (CD99) is recommended and growth factor receptors like
c-Met or PDGFR are appropriate for melanoma cell detection.
Alterations to the protocol noted in VIII.10.3.1 Direct and indi-
rect staining of surface molecules expressed by adherent tumor
cells.
5a. At step 5, stained tumor cells are resuspended in 50 μL flow
cytometry buffer and directly labeled pan-CD45 antibody (2-5
μL) is added for 30 min at 4°C in the dark;
5b. After two washing steps, cells are resuspended in 150 μL flow
cytometry buffer if measured immediately or in flow cytome-
try fixation buffer (PBS, 1% FCS, 1% paraformaldehyde) and
stored at 4°C until measurement.
10.4 Specific recommendations for human and murine solid
tumors
10.4.1 Characterization of solid tumors. In contrast to leukemias
and lymphomas, solid tumor cells are classified according to their
originating cell type, i.e. tumor cells derived from (i) epithelial
cells are defined as carcinoma cells, from (ii) mesenchymal cells
are defined as sarcoma cells, from (iii) neuroendocrine tumors
are defined by originating from endocrine glands and (iv) neu-
roectodermal tumors are defined by originating from neuroecto-
dermal cells of the skin or brain. This classification is identical
for all species, e.g. humans, non-human primates, dogs, cats, and
rodents. Although many solid tumor cells can express a variety
of tumor-associates antigens (TAA) including cancer-testis (CT),
carcinoembryonal (CEA) and neo-antigens, most of these antigens
are not suitable for flow cytometric characterization of tumor
cells, either due to their poor expression, intracellular localiza-
tion or simply the lack of specific antibodies [916, 917]. There-
fore, the characterization of solid tumor cells relies on surface
markers associated with their tissue origin, in combination with
exclusion markers for hematopoietic cells such as pan-CD45. Of
note, loss or downregulation of major histocompatibility (MHC)
or human leukocyte antigen (HLA) class I molecules due to the
mutation or deletion of beta-2-microglobulin (ß2m) represents
one of the major tumor escape strategies in vivo by human tumors
as well as murine tumor models. Thus, class I (mouse H-2) or
HLA class I (human) surface staining by flow cytometry is highly
recommended for all immunological experiments with solid tumor
cells [918]. In addition toHLA class Imolecules, ligands for NK-cell
receptors, NKG2D ligands (NKG2DL) are important for the defi-
nition of the sensitivity of tumor cells toward NK-cell recognition
and elimination [919]. The expression of MHC class I molecules by
tumor cells determines the recognition by CD8+ cytotoxic T cells
with specificity for MHC/peptide complexes derived from tumor-
associated antigens. In contrast, MHC class I molecules, human
HLA-C in particular, serve as inhibitory ligands for NK cells by spe-
cific binding to inhibitory receptors of the killer-immunoglobulin–
like (KIR) and C-type lectin (CD94/NKG2A) receptors, respec-
tively. This negative signaling is balanced by positive signals of
activating NK cell receptors that recognize expression of partic-
ular ligands on the surface of tumor cells. For example, NKG2D
(CD314) belongs to the receptors expressed by NK and T cells that
are conserved between humans, non-human primates and rodents.
In order to investigate the immunogenicity of tumor cells, it is
therefore, recommended to determine the surface expression of
NKG2D ligands on human or mouse tumor cells. Details of ligands
andmonoclonal antibodies are given in Tables 32 (human) and 33
(mouse). Moreover, these ligands for T-cell and NK-cell receptors
can also be targeted by oncogenic signaling ofmutatedMAP kinase
signaling [920]. Surface expression of adhesion molecules such
as ICAM-1, and VCAM should also be included in the flow cyto-
metric characterization of solid tumor cells due to their increased
expression upon development of metastases in human tumors and
mousemodels and, thus, their relevance for T-cell and NK-cell acti-
vation, as well as formation of metastases. Besides these surface
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molecules, which are commonly expressed by non-malignant as
well as malignant cells of both hematopoietic and parenchymal
origin, solid tumor cells should be also characterized by markers
of their tissue origin. Splice variants of CD44, especially CD44v6,
have a long-standing and controversial history as potential “tumor
stem cell” markers, together with the hematopoietic stem cell
markers CD34, CD133 with a recent revival of CD24 as potential
prognostic marker for some carcinomas [921, 922]. A selection
of the most relevant human cancers, grouped into carcinomas,
sarcomas, neuroectodermal tumors and their tumor biology, “the
hallmarks of cancer,” is given in this short section with the respec-
tive recommendation for their flow cytometric characterization.
10.4.2 Solid tumors: Human carcinomas. Carcinomas, i.e.
epithelial tumors, represent the most frequent human cancers
[923] and their malignant transformation is often based on “driver
mutations” in growth factor receptors, receptor tyrosine kinases,
in particular, as well as their downstream signaling pathways.
For the identification of carcinoma cells, epithelial markers such
as cytokeratin (CK) 18 and 8 are useful although they have to
be detected by intracellular staining procedures [924]. In addi-
tion, epithelial cells express selectively growth factors like epider-
mal growth factor receptor (EGFR), platelet-derived growth fac-
tor receptor (PDGFR), fibroblast growth factor receptor (FGFR),
Her-2, c-Met and others [925]. These surface receptors often
directly contribute to tumorigenesis by carrying “tumor-driving
mutations” in their signaling domains; providing constitutive pro-
liferative signals independently from the availability of growth
factors. Therefore, these receptors can be useful for the identifica-
tion and characterization of tumor cells in terms of their growth
factor receptor repertoire. Importantly, the intracellular protein
vimentin serves as specific marker for the discrimination from
fibroblasts.
Some of the most frequent human carcinomas are listed here
with their originating epithelial cell type (Table 34).
10.4.3 Solid tumors: Human sarcomas. Mesenchymal tumors,
i.e. sarcomas [932], develop from tissue cells originating from
mesenchymal progenitors and manifest primarily in soft tissue
such as fat, muscle, tendons, nerve or connective tissue cells, blood
and lymph vessels or fibroblasts (Table 35). The family of Ewing
osteosarcomas comprises a severe form of juvenile sarcoma with
manifestations preferentially in bone, bone marrow and organs
such as lung or rarely kidney. For the flow cytometric detection
of Ewing sarcoma cells in peripheral blood of patients, CD99,
the MIC2 gene product, normally expressed by osteoclasts and
leukocytes, has been proposed in the absence of the pan-leukocyte
marker CD45 [933]. Kaposi’s sarcoma represents a virally induced
form of sarcoma mediated by the human herpesvirus 8 (HHV8)
also called Kaposi’s sarcoma-associated herpesvirus. The viral
HHV8 genome contributes to the pathophysiology and tumorigen-
esis by its manipulation ofmechanisms regulating viral latency and
lytic replication [934]. For bone and soft tissue sarcomas, dysreg-
ulation of the Hippo signaling pathway has been shown to affect
several surface receptors including EGFR, E-cadherin, CD44 and
tight junctions indicating that oncogenic signaling can impinge on
the stability of these surface receptors as markers for sarcoma cells
[935].
10.4.4 Solid tumors: Human neuroectodermal tumors. Neuroec-
todermal tumors, i.e. malignant cells derived from neuroectoder-
mal cells, belong to less prevalent but life-threatening cancers
such as melanoma (black skin cancer) and several forms of brain
cancer (Table 36). In malignant melanoma, melanocytes origi-
nating from neuroectodermal cells acquire “driver” mutations in
components of the MAK kinase signaling, most frequently in the
BRaf kinase with the highest prevalence of the BRafV600E mutation
or the upstream NRas GTPase [936]. Although these mutations
cannot directly be utilized for the flow cytometry of melanoma
cells, their mutation status may have an impact on the recogni-
tion by T cells and NK cells [937, 938]. Several forms of brain
cancers are derived from neuroectodermal cells including some
the most aggressive brain tumors like glioblastoma with malig-
nant cells derived from glial cells [939]. Besides their poor MHC
expression, glioblastoma cells utilize a broad selection of immune
evasion strategies that are in part responsible for their aggressive
nature and the resulting poor survival of glioma patients [940].
Other forms of brain tumors are represented by astrocytomas, a
group of differentially graded variants, i.e. diffuse, polycystic and
anaplastic astrocytoma with different degrees of aggressiveness.
Due to the lack of reliable surface markers, molecular charac-
terization, i.e. expression profiling, is currently used for a more
detailed classification at the level of gene profiles, signaling path-
ways, and regulatory networks. Despite these molecular analyses,
the cellular origin is still controversially discussed ranging from
stem cell-like precursors to neuronal stem cells [941].
10.5 Characterization of murine tumor cells
For the flow cytometric characterization of murine tumor cells,
both hematopoietic tumors like mouse leukemias and lymphomas,
and solid tumors like carcinomas of the mouse breast, liver or
colon, melanomas or sarcomas, the same recommendations can
be applied as outlined for human tumor cells. Since the numerous
mouse tumor models cannot be discussed here comprehensively,
only general remarks are provided regarding flow cytometry of
murine tumor cells. Mouse solid tumor cells are also classified into
carcinomas, sarcomas and neuroectodermal tumors, respectively,
depending on their originating tissue. Therefore, the same sur-
face molecules can be utilized for their characterization by flow
cytometry, which are listed in Table 33, showing a selection of
known monoclonal antibodies for mouse antigens and the pro-
tocols do not differ from the general protocols of direct, indirect
surface and intracellular staining (Section VII.2: Surface parame-
ters and Section VII.3: Intracellular parameters). The recent clin-
ical advances in immunotherapy of human solid tumors could
only be achieved using sophisticated preclinical mouse models.
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Table 34. Overview of the most frequent human carcinomas
Carcinoma tissue Most frequent form of carcinoma Originating cell Ref
Lung cancer Non-small cell lung cancer (NSCLC) Type I / II alveolar epithelial cells [923]
Breast cancer Mammary carcinoma Epithelial cells of the milk duct [926]
Colon cancer Colorectal carcinoma (CRC) Epithelial cells of inner mucosal layer [923]
Prostate cancer Prostate carcinoma Epithelial basal cells of the prostate [927]
Liver cancer Hepatocellular carcinoma (HCC) Hepatocytes [923]
Stomach cancer Stomach carcinoma Epithelial cells transformed by H. pylori [923]
Cervical cancer Cervical carcinoma Cervical epithelial cells after HPV infection [928]
Oesophagus cancer Oesophagus carcinoma Epithelial cells lining the oesophagus [929]
Bladder cancer Bladder carcinoma Transitional epithelium of the bladder wall [930]
Pancreatic cancer Pancreatic carcinoma Endocrine ductal epithelial cells [931]
Kidney cancer Renal cell carcinoma (RCC) Proximal tubular epithelial cells [923]
Ovarian cancer Ovarian carcinoma Ovarian tubal-type epithelium [923]
Squamous cancer Squamous cell carcinoma Epithelial cells of skin or glands [923]
Since the early days of transplanted tumor cells into immunodefi-
cient mice, numerous elegant mouse models with spontaneously
developing tumors based on germline or inducible mutations
have been developed in the past decade [942]. More recently,
humanized mouse models with severely immunodeficient mice,
reconstituted with human peripheral or even hematopoietic stem
cells, have gained tremendous insight into immune recognition
of human tumor cells, escape mechanisms and opened the door
for new therapeutic approaches that finally made their way into
clinical application [943].
10.6 Solid tumors: General hallmarks of cancer
The various alterations involved in this process of malignant trans-
formation are elegantly summarized in “Hallmarks of cancer – the
next generation” by Hanahan and Weinberg [944]. In order to
become a tumor cell, the basic cellular mechanisms regulating
contact inhibition, proliferation (e.g. Hayflick limit), sensitivity
toward cell death like apoptosis, necrosis, necroptosis, ferroptosis
etc. as well as cellular senescence, energy metabolism, have to be
targeted and dysregulated to favor an unlimited survival strategy
of the malignant cell. With respect to the cancer microenviron-
ment, in particular for solid tumors, angiogenesis and immunity
have to be high-jacked in order to guarantee supplementation of
nutrition simultaneously with independence from the availability
of exogenous growth factors on one hand, and to allow evasion
of immune recognition on the other hand. A lot of these mecha-
nisms can be detected using flow cytometry and the most relevant
examples are summarized in Section VI: Evaluation and data han-
dling, startingwith surface expression of hematopoietic, epithelial,
endothelial and neuroectodermal markers for the classification of
tumor cells according to their cellular origin. The malignant trans-
formation can be studied using flow cytometry by the quantifi-
cation of cell cycle, proliferation, signaling pathways, apoptosis,
necrosis and other cell death pathways such as autophagy. Asmen-
tioned before, immune evasion strategies such as downregulation
or loss of MHC class I molecules and simultaneous expression of
ligands for inhibitory receptors like the PD-1 ligand PD-L1 (B7-
H1) or B7-H4 undermines tumor-specific immune responses by
an induction of T-cell unresponsiveness, anergy and, eventually,
T-cell death. Therefore, flow cytometric analysis of the surface
receptor expression of these ligands is important for the determi-
nation of the immunogenicity of tumor cells, ideally assessed in
parallel to non-transformed “healthy” tissue cells. Taken together,
the detailed knowledge regarding the repertoire of growth fac-
tor receptors as well as ligands for immune receptors, primarily
provided by flow cytometry, is instrumental for the improvement
Table 35. Overview of the most frequent human sarcomas
Sarcoma tissue Mesenchymal tumor Originating cell Ref.
Ewing sarcoma Ewing’s sarcomas (bone, bone marrow, lung, kidney) Soft tissue cell of the respective organ [933, 935]
Kaposi’s sarcoma Soft tissue sarcoma Induced after infection with HHV-8 [934]
Table 36. Overview of the most frequent human neuroectoderma tumors
Tumor tissue Neuroectodermal tumor Originating cell Ref.
Black skin cancer Malignant melanoma Melanocytes of the skin [936–938]
Brain cancer Glioblastoma, glioma Glial cells of the brain [939, 940]
Brain cancer Astrocytoma Astrocytes of the brain [941]
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of existing and the development of novel therapeutic strategies
against all types of cancers [945].
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